U.S. patent application number 12/800046 was filed with the patent office on 2011-01-20 for inhibitors of interleukin-1 beta converting enzyme.
This patent application is currently assigned to Vertex Pharmaceuticals Incorporated. Invention is credited to Guy W. Bemis, Julian M. C. Golec, David J. Lauffer, David J. Livingston, Michael D. Mullican, Mark A. Murcko.
Application Number | 20110015371 12/800046 |
Document ID | / |
Family ID | 23846915 |
Filed Date | 2011-01-20 |
United States Patent
Application |
20110015371 |
Kind Code |
A1 |
Bemis; Guy W. ; et
al. |
January 20, 2011 |
Inhibitors of interleukin-1 beta converting enzyme
Abstract
The present invention relates to novel classes of compounds
which are inhibitors of interleukin-1.beta. converting enzyme. The
ICE inhibitors of this invention are characterized by specific
structural and physicochemical features. This invention also
relates to pharmaceutical compositions comprising these compounds.
The compounds and pharmaceutical compositions of this invention are
particularly well suited for inhibiting ICE activity and
consequently, may be advantageously used as agents against
interleukin-1 mediated diseases, including inflammatory diseases,
autoimmune diseases and neurodegenerative diseases. This invention
also relates to methods for inhibiting ICE activity and methods for
treating interleukin-1 mediated diseases using the compounds and
compositions of this invention.
Inventors: |
Bemis; Guy W.; (Arlington,
MA) ; Golec; Julian M. C.; (Swindon, GB) ;
Lauffer; David J.; (Stow, MA) ; Mullican; Michael
D.; (Needham, MA) ; Murcko; Mark A.;
(Holliston, MA) ; Livingston; David J.;
(Newtonville, MA) |
Correspondence
Address: |
ROPES & GRAY LLP
PATENT DOCKETING 39/361, 1211 AVENUE OF THE AMERICAS
NEW YORK
NY
10036-8704
US
|
Assignee: |
Vertex Pharmaceuticals
Incorporated
Cambridge
MA
|
Family ID: |
23846915 |
Appl. No.: |
12/800046 |
Filed: |
May 5, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11901843 |
Sep 18, 2007 |
7772366 |
|
|
12800046 |
|
|
|
|
09886773 |
Jun 21, 2001 |
7288624 |
|
|
11901843 |
|
|
|
|
09430822 |
Oct 29, 1999 |
6420522 |
|
|
09886773 |
|
|
|
|
08465216 |
Jun 5, 1995 |
6103711 |
|
|
09430822 |
|
|
|
|
08440898 |
May 25, 1995 |
5847135 |
|
|
08465216 |
|
|
|
|
08405581 |
Mar 17, 1995 |
5656627 |
|
|
08440898 |
|
|
|
|
08261452 |
Jun 17, 1994 |
5756466 |
|
|
08405581 |
|
|
|
|
Current U.S.
Class: |
530/330 ;
530/331; 546/271.7; 546/293; 548/333.5; 548/537 |
Current CPC
Class: |
C07D 487/04 20130101;
C07K 5/0812 20130101; C07K 5/0202 20130101; C07K 5/06052 20130101;
C07D 243/08 20130101; C07D 263/56 20130101; A61K 38/00 20130101;
C07D 413/04 20130101; C07D 243/12 20130101 |
Class at
Publication: |
530/330 ;
546/293; 546/271.7; 530/331; 548/333.5; 548/537 |
International
Class: |
C07K 5/10 20060101
C07K005/10; C07D 213/76 20060101 C07D213/76; C07D 413/12 20060101
C07D413/12; C07K 5/08 20060101 C07K005/08; C07D 233/90 20060101
C07D233/90; C07D 207/34 20060101 C07D207/34 |
Claims
1-18. (canceled)
19. An ICE inhibitor comprising: (a) a scaffold of formula I:
##STR00201## wherein: each X is independently C or N; Z is CO or
SO.sub.2; W.sub.1 is a straight chain comprising 1-3 covalently
bound members independently selected from the group consisting of
C, N, S and O, said covalent bonds between said members being
independently saturated or unsaturated and said chain comprising
two ends which are covalently bound to two different X atoms
through bonds r; W.sub.2 is a straight chain comprising 3-5
covalently bound members independently selected from the group
consisting of C, N, S and O, said covalent bonds between said
members being independently saturated or unsaturated and said chain
comprising two ends which are covalently bound to two different X
atoms through bonds r; each bond labeled r is independently a
single or a double bond; H is a first hydrogen bonding moiety and Z
is a second hydrogen bonding moiety, each of said moieties being
capable of forming a hydrogen bond with a different backbone atom
of ICE, said backbone atom being selected from the group consisting
of the carbonyl oxygen of Arg-341, the amide --NH-- group of
Arg-341, the carbonyl oxygen of Ser-339 and the amide --NH-- group
of Ser-339; (b) a first and a second moderately hydrophobic moiety,
said moieties each being covalently bound to said scaffold and each
being capable of associating with a separate binding pocket of ICE
when the inhibitor is bound thereto, said binding pocket being
selected from the group consisting of the P2 binding pocket, the P3
binding pocket, the P4 binding pocket and the P' binding pocket;
and (c) an electronegative moiety comprising one or more
electronegative atoms, said atoms being attached to the same atom
or to adjacent atoms in the moiety and said moiety being covalently
bound to said scaffold and being capable of forming one or more
hydrogen bonds or salt bridges with residues in the P1 binding
pocket of ICE.
20-48. (canceled)
49. A compound represented by the formula: ##STR00202## wherein:
X.sub.1 is CH or N; g is 0 or 1; each J is independently selected
from the group consisting of --H, --OH, and --F, provided that when
a first and second J are bound to a C and said first J is --OH,
said second J is --H; m is 0, 1, or 2; T is --Ar.sub.3, --OH,
--CF.sub.3, --CO--CO.sub.2H, --CO.sub.2H or any bioisosteric
replacement for --CO.sub.2H; R.sub.1 is selected from the group
consisting of the following formulae, in which any ring may
optionally be singly or multiply substituted at any carbon by
Q.sub.1, at any nitrogen by R.sub.5, or at any atom by .dbd.O,
--OH, --CO.sub.2H, or halogen, and in which any saturated ring may
optionally be unsaturated at one or two bonds: ##STR00203##
##STR00204## ##STR00205## R.sub.20 is selected from the group
consisting of: ##STR00206## ##STR00207## and wherein each ring C is
independently chosen from the group consisting of benzo, pyrido,
thieno, pyrrolo, furano, thiazolo, isothiazolo, oxazolo, isoxazolo,
pyrimido, imidazolo, cyclopentyl, and cyclohexyl; R.sub.3 is: --CN,
--CH.dbd.CH--R.sub.9, --CH.dbd.N--O--R.sub.9, --CO--R.sub.13, or
##STR00208## each R.sub.4 is independently selected from the group
consisting of: --H, --Ar.sub.1, --R.sub.9, -T.sub.1-R.sub.9, and
--(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9, each T.sub.1 is
independently selected from the group consisting of: --CH.dbd.CH--,
--O--, --S--, --SO--, --SO.sub.2--, --NR.sub.10--,
--NR.sub.10--CO--, --CO--, --O--CO--, --CO--O--, --CO--NR.sub.10--,
--O--CO--NR.sub.10--, --NR.sub.10--CO--O--,
--NR.sub.10--CO--NR.sub.10--, --SO.sub.2--NR.sub.10--,
--NR.sub.10--SO.sub.2--, and --NR.sub.10--SO.sub.2--NR.sub.10--;
each R.sub.5 is independently selected from the group consisting
of: --H, --Ar.sub.1, --CO--Ar.sub.1, --SO.sub.2--Ar.sub.1,
--R.sub.9, --CO--R.sub.9, --CO--O--R.sub.9, --SO.sub.2--R.sub.9,
##STR00209## R.sub.6 and R.sub.7 taken together form a saturated
4-8 member carbocyclic ring or heterocyclic ring containing --O--,
--S--, or --NH--, or R.sub.7 is --H and R.sub.6 is --H, --Ar.sub.1,
--R.sub.9, or --(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9, each R.sub.9
is a C.sub.1-6 straight or branched alkyl group optionally singly
or multiply substituted by --OH, --F, or .dbd.O and optionally
substituted with one or two Ar.sub.1 groups; each R.sub.10 is
independently selected from the group consisting of --H or a
C.sub.1-6 straight or branched alkyl group; each R.sub.13 is
independently selected from the group consisting of --Ar.sub.2 and
--R.sub.4, each Ar.sub.1 is a cyclic group independently selected
from the set consisting of an aryl group which contains 6, 10, 12,
or 14 carbon atoms and between 1 and 3 rings, a cycloalkyl group
which contains between 3 and 15 carbon atoms and between 1 and 3
rings, said cycloalkyl group being optionally benzofused, and a
heterocycle group containing between 5 and 15 ring atoms and
between 1 and 3 rings, said heterocycle group containing at least
one heteroatom group selected from --O--, --S--, --SO--,
--SO.sub.2--, .dbd.N--, and --NH--, said heterocycle group
optionally containing one or more double bonds, said heterocycle
group optionally comprising one or more aromatic rings, and said
cyclic group optionally being singly or multiply substituted by
.dbd.O, --OH, perfluoro C.sub.1-3 alkyl, or -Q.sub.1; each Ar.sub.2
is independently selected from the following group, in which any
ring may optionally be substituted by -Q.sub.1: ##STR00210##
Ar.sub.3 is a cyclic group selected from the set consisting of a
phenyl ring, a 5-membered heteroaromatic ring, and a 6-membered
heteroaromatic ring, said heteroaromatic rings comprising 1-3
heteroatom groups selected from --O--, --S--, --SO.sub.7,
--SO.sub.2--, .dbd.N--, and --NH--, said cyclic group optionally
being singly or multiply substituted with .dbd.O, --OH, halogen,
perfluoro C.sub.1-3 alkyl, or --CO.sub.2H; each Q.sub.1 is
independently selected from the group consisting of --Ar.sub.1,
--R.sub.9, -T.sub.1-R.sub.9, and
--(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9, provided that when
--Ar.sub.1 is substituted with a Q.sub.1 group which comprises one
or more additional --Ar.sub.1 groups, said additional --Ar.sub.1
groups are not substituted with Q.sub.1; each X is independently
selected from the group consisting of .dbd.N--, and .dbd.CH--; each
X.sub.2 is independently selected from the group consisting of
--O--, --CH.sub.2--, --NH--, --S--, --SO--, and --SO.sub.2--; each
X.sub.3 is independently selected from the group consisting of
--CH.sub.2--, --S--, --SO--, and --SO.sub.2--; each X.sub.4 is
independently selected from the group consisting of --CH.sub.2--
and --NH--; each X.sub.5 is independently selected from the group
consisting of ##STR00211## X.sub.6 is CH or N, provided that when
X.sub.6 is N in the R.sub.1 group labeled (o) and X.sub.5 is CH and
X.sub.2 is CH.sub.2 the ring of the R.sub.1 group labeled (o) must
be substituted by Q1 or benzofused; each Y is independently
selected from the group consisting of --O-- and --S--; each Z is
independently CO or SO.sub.2, each a is independently 0 or 1, each
c is independently 1 or 2, each d is independently 0, 1, or 2, and
each e is independently 0, 1, 2, or 3.
50-51. (canceled)
52. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00212##
53. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00213##
54. (canceled)
55. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00214##
56. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00215##
57. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00216##
58. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00217##
59. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00218##
60. (canceled)
61. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00219##
62. (canceled)
63. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00220##
64. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00221##
65. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00222##
66. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00223##
67. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00224##
68. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00225##
69. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00226##
70. The compound according to claim 49 or 80, wherein R.sub.1 is:
##STR00227##
71-79. (canceled)
80. A compound represented by the formula: ##STR00228## wherein:
X.sub.1 is --CH; g is 0 or 1; each J is independently selected from
the group consisting of --H, --OH, and --F, provided that when a
first and second J are bound to a C and said first J is --OH, said
second J is --H; m is 0, 1, or 2; T is --OH, --CO--CO.sub.2H,
--CO.sub.2H, or any bioisosteric replacement for --CO.sub.2H;
R.sub.1 is selected from the group consisting of the following
formulae, in which any ring may optionally be singly or multiply
substituted at any carbon by Q.sub.1, at any nitrogen by R.sub.5,
or at any atom by .dbd.O, --OH, --CO.sub.2H, or halogen; any
saturated ring may optionally be unsaturated at one or two bonds;
and wherein R.sub.1 (e) and R.sub.1 (y) are optionally benzofused;
##STR00229## ##STR00230## ##STR00231## R.sub.20 is selected from
the group consisting of: ##STR00232## ##STR00233## wherein each
ring C is independently chosen from the group consisting of benzo,
pyrido, thieno, pyrrolo, furano, thiazolo, isothiazolo, oxazolo,
isoxazolo, pyrimido, imidazolo, cyclopentyl, and cyclohexyl;
R.sub.3 is: --CN, --CH.dbd.CH--R.sub.9, --CH.dbd.N--O--R.sub.9,
--(CH.sub.2).sub.1-3-T.sub.1-R.sub.9, --CJ.sub.2-R.sub.9,
--CO--R.sub.13, or ##STR00234## each R.sub.4 is independently
selected from the group consisting of: --H, --Ar.sub.1, --R.sub.9,
-T.sub.1-R.sub.9, and --CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9; each
T.sub.1 is independently selected from the group consisting of:
--CH.dbd.CH--, --O--, --S--, --SO--, --SO.sub.2--,
--NR.sub.10--CO--, --CO--, --O--CO--, --CO--NR.sub.10--,
--NR.sub.1o-CO--NR.sub.10--, --NR.sub.1o-SO.sub.2--, and
--NR.sub.10--SO.sub.2--NR.sub.10--; each R.sub.5 is independently
selected from the group consisting of: --H, --Ar.sub.1,
--CO--Ar.sub.1, --SO.sub.2--Ar.sub.1, --CO--NH.sub.2,
--SO.sub.2--NH.sub.2, --R.sub.9, --CO--R.sub.9,
--SO.sub.2--R.sub.9, ##STR00235## R.sub.6 and R.sub.7 taken
together form a saturated 4-8 member carbocyclic ring or
heterocyclic ring containing --O--, --S--, or --NH--; or R.sub.7 is
--H and R.sub.6 is --H, --Ar.sub.1, --R.sub.9,
--(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9, or an .alpha.-amino acid
side chain residue; each R.sub.9 is a C.sub.1-6 straight or
branched alkyl group optionally singly or multiply substituted by
--OH, --F, or .dbd.O and optionally substituted with one or two
Ar.sub.1 groups; each R.sub.10 is independently selected from the
group consisting of --H or a C.sub.1-6 straight or branched alkyl
group; each R.sub.13 is independently selected from the group
consisting of --Ar.sub.2, --R.sub.4 and ##STR00236## each Ar.sub.1
is a cyclic group independently selected from the set consisting of
an aryl group which contains 6, 10, 12, or 14 carbon atoms and
between 1 and 3 rings, a cycloalkyl group which contains between 3
and 15 carbon atoms and between 1 and 3 rings, said cycloalkyl
group being optionally benzofused, and a heterocycle group
containing between 5 and 15 ring atoms and between 1 and 3 rings,
said heterocycle group containing at least one heteroatom group
selected from --O--, --S--, --SO--, --SO.sub.2--, .dbd.N--, and
--NH--, said heterocycle group optionally containing one or more
double bonds, said heterocycle group optionally comprising one or
more aromatic rings, and said cyclic group optionally being singly
or multiply substituted by --NH.sub.2, --CO.sub.2H, --Cl, --F,
--Br, --I, --NO.sub.2, --CN, .dbd.O, --OH, -perfluoro C.sub.1-3
alkyl, ##STR00237## each Ar.sub.2 is independently selected from
the following group, in which any ring may optionally be singly or
multiply substituted by -Q.sub.1 and -Q2: ##STR00238## each Q.sub.1
is independently selected from the group consisting of --Ar.sub.1,
--O--Ar.sub.1, --R.sub.9, -T.sub.1-R.sub.9, and
--(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9; each Q2 is independently
selected from the group consisting of --OH, --NH.sub.2,
--CO.sub.2H, --Cl, --F, --Br, --I, --NO.sub.2, --CN, --CF.sub.3,
and ##STR00239## provided that when --Ar.sub.1 is substituted with
a Q.sub.1 group which comprises one or more additional --Ar.sub.1
groups, said additional --Ar.sub.1 groups are not substituted with
Q.sub.1; each X is independently selected from the group consisting
of .dbd.N--, and .dbd.CH--; each X.sub.2 is independently selected
from the group consisting of --O--, --CH.sub.2--, --NH--, --S--,
--SO--, and --SO.sub.2--; each X.sub.3 is independently selected
from the group consisting of --CH.sub.2--, --S--, --SO--, and
--SO.sub.2--; each X.sub.4 is independently selected from the group
consisting of --CH.sub.2-- and --NH--; each X.sub.5 is
independently selected from the group consisting of ##STR00240##
X.sub.6 is ##STR00241## each Y is independently selected from the
group consisting of --O--, --S--, and --NH; each Z is independently
CO or SO.sub.2; each a is independently 0 or 1; each c is
independently 1 or 2; each d is independently 0, 1, or 2; and each
e is independently 0, 1, 2, or 3; provided that when R.sub.1 is
(f), R.sub.6 is an .alpha.-amino acid side chain residue, and
R.sub.7 is --H, then (aa1) and (aa2) must be substituted with
Q.sub.1; also provided that when R.sub.1 is (o), g is 0, J is --H,
m is 1, R.sub.6 is an .alpha.-amino acid side chain residue,
R.sub.7 is --H, X.sub.2 is --CH.sub.2--, ##STR00242## and R.sub.3
is ##STR00243## or --CO--R.sub.13, when R.sub.13 is:
--CH.sub.2--O--CO--Ar.sub.1, --CH.sub.2--S--CO--Ar.sub.1,
--CH.sub.2--O--Ar.sub.1, --CH.sub.2--S--Ar.sub.1, or --R.sub.4 when
--R.sub.4 is --H; then the ring of the R.sub.1(o) group must be
substituted with Q.sub.1 or benzofused; and provided that when
R.sub.1 is (w), g is 0, J is --H, m is 1, T is --CO.sub.2H, X.sub.2
is O, R.sub.5 is benzyloxycarbonyl, and ring C is benzo, then
R.sub.3 cannot be --CO--R.sub.13 when: R.sub.13 is
--CH.sub.2--O--Ar.sub.1 and Ar.sub.1 is
1-phenyl-3-trifluoromethyl-pyrazole-5-yl wherein the phenyl is
optionally substituted with a chlorine atom; or when R.sub.13 is
--CH.sub.2--O--CO--Ar.sub.1, wherein Ar.sub.1 is
2,6-dichlorophenyl.
81-124. (canceled)
Description
[0001] This patent application is a divisional of U.S. patent
application Ser. No. 11/901,843, filed Sep. 18, 2007, which is a
divisional of U.S. patent application Ser. No. 09/886,773, filed
Jun. 21, 2001, now U.S. Pat. No. 7,288,624, which is a divisional
of U.S. patent application Ser. No. 09/430,822, filed Oct. 29,
1999, now U.S. Pat. No. 6,420,522, which is a divisional of U.S.
patent application Ser. No. 08/465,216, filed Jun. 5, 1995, now
U.S. Pat. No. 6,103,711, which is a divisional of U.S. patent
application Ser. No. 08/440,898, filed May 25, 1995, now U.S. Pat.
No. 5,847,135, which is a continuation-in-part of U.S. application
Ser. No. 08/405,581, filed Mar. 17, 1995, now U.S. Pat. No.
5,656,627, which is a continuation-in-part of U.S. patent
application Ser. No. 08/261,452, filed Jun. 17, 1994, now U.S. Pat.
No. 5,756,466.
TECHNICAL FIELD OF THE INVENTION
[0002] The present invention relates to novel classes of compounds
which are inhibitors of interleukin-1.beta. converting enzyme
("ICE"). The ICE inhibitors of this invention are characterized by
specific structural and physicochemical features. This invention
also relates to pharmaceutical compositions comprising these
compounds. The compounds and pharmaceutical compositions of this
invention are particularly well suited for inhibiting ICE activity
and consequently, may be advantageously used as agents against
interleukin-1 ("IL-1") mediated diseases, including inflammatory
diseases, autoimmune diseases and neurodegenerative diseases. This
invention also relates to methods for inhibiting ICE activity and
methods for treating interleukin-1 mediated diseases using the
compounds and compositions of this invention.
BACKGROUND OF THE INVENTION
[0003] Interleukin 1 ("IL-1") is a major pro-inflammatory and
immunoregulatory protein that stimulates fibroblast differentiation
and proliferation, the production of prostaglandins, collagenase
and phospholipase by synovial cells and chondrocytes, basophil and
eosinophil degranulation and neutrophil activation. Oppenheim, J.
H. et al, Immunology Today, 7, pp. 45-56 (1986). As such, it is
involved in the pathogenesis of chronic and acute inflammatory and
autoimmune diseases. IL-1 is predominantly produced by peripheral
blood monocytes as part of the inflammatory response and exists in
two distinct agonist forms, IL-1.alpha. and IL-1.beta.. Mosely, B.
S. et al., Proc. Nat. Acad. Sci., 84, pp. 4572-4576 (1987);
Lonnemann, G. et al., Eur. J. Immunol., 19, pp. 1531-1536
(1989).
[0004] IL-1.beta. is synthesized as a biologically inactive
precursor, pIL-1.beta.. pIL-1.beta. lacks a conventional leader
sequence and is not processed by a signal peptidase. March., C. J.,
Nature, 315, pp. 641-647 (1985). Instead, pIL-1.beta. is cleaved by
interleukin-1.beta. converting enzyme ("ICE") between Asp-116 and
Ala-117 to produce the biologically active C-terminal fragment
found in human serum and synovial fluid. Sleath, P. R., et al., J.
Biol. Chem., 265, pp. 14526-14528 (1992); A. D. Howard et al., J.
Immunol., 147, pp. 2964-2969 (1991). Processing by ICE is also
necessary for the transport of mature IL-11 through the cell
membrane.
[0005] ICE is a cysteine protease localized primarily in monocytes.
It converts precursor IL-11 to the mature form. Black, R. A. et
al., FEBS Lett., 247, pp. 386-390 (1989); Kostura, M. J. et al.,
Proc. Natl. Acad. Sci. USA, 86, pp. 5227-5231 (1989). ICE, or its
homologues, also appears to be involved in the regulation of cell
death or apoptosis. Yuan, J. et al., Cell, 75, pp. 641-652 (1993);
Miura, M. et al., Cell, 75, pp. 653-660 (1993); Nett-Fiordalisi, M.
A. et al., J. Cell Biochem., 17B, p. 117 (1993). In particular, ICE
or ICE homologues are thought to be associated with the regulation
of apoptosis in neurogenerative diseases, such as Alzheimer's and
Parkinson's disease. Marx, J. and M. Baring a, Science, 259, pp.
760-762 (1993); Gagliardini, V. et al., Science, 263, pp. 826-828
(1994).
[0006] ICE has been previously described as a heterodimer composed
of two subunits, p20 and p10 (20 kDa and 10 kDa molecular weight,
respectively). These subunits are derived from a 45 kDa proenzyme
(p45) by way of a p30 form, through an activation mechanism that is
autocatalytic. Thornberry, N. A. et al., Nature, 356, pp. 768-774
(1992). The ICE proenzyme has been divided into several functional
domains: a prodomain (p14), a p22/20 subunit, a polypeptide linker
and a p10 subunit. Thornberry et al., supra; Casano et al.,
Genomics, 20, pp. 474-481 (1994).
[0007] Full length p45 has been characterized by its cDNA and amino
acid sequences. PCT patent applications WO 91/15577 and WO
94/00154. The p20 and p10 cDNA and amino acid sequences are also
known. Thornberry et al., supra. Murine and rat ICE have also been
sequenced and cloned. They have high amino acid and nucleic acid
sequence homology to human ICE. Miller, D. K. et al., Ann. N.Y.
Acad. Sci., 696, pp. 133-148 (1993); Molineaux, S. M. et al., Proc.
Nat. Acad. Sci., 90, pp. 1809-1813 (1993). Knowledge of the primary
structure of ICE, however, does not allow prediction of its
tertiary structure. Nor does it afford an understanding of the
structural, conformational and chemical interactions of ICE and its
substrate pIL-11 or other substrates or inhibitors.
[0008] ICE inhibitors represent a class of compounds useful for the
control of inflammation or apoptosis or both. Peptide and peptidyl
inhibitors of ICE have been described. PCT patent applications WO
91/15577; WO 93/05071; WO 93/09135; WO 93/14777 and WO 93/16710;
and European patent application 0 547 699. However, due to their
peptidic nature, such inhibitors are typically characterized by
undesirable pharmacologic properties, such as poor oral absorption,
poor stability and rapid metabolism. Plattner, J. J. and D. W.
Norbeck, in Drug Discovery Technologies, C. R. Clark and W. H.
Moos, Eds. (Ellis Horwood, Chichester, England, 1990), pp. 92-126.
This has hampered their development into effective drugs.
[0009] Accordingly, the need exists for compounds that can
effectively inhibit the action of ICE, for use as agents for
preventing and treating chronic and acute forms of IL-1 mediated
diseases, including various cancers, as well as inflammatory,
autoimmune or neurodegenerative diseases.
SUMMARY OF THE INVENTION
[0010] The present invention provides novel classes of compounds,
and pharmaceutically acceptable derivatives thereof, that are
useful as inhibitors of ICE. These compounds can be used alone or
in combination with other therapeutic or prophylactic agents, such
as antibiotics, immunomodulators or other anti-inflammatory agents,
for the treatment or prophylaxis of diseases mediated by IL-1.
According to a preferred embodiment, the compounds of this
invention are capable of binding to the active site of ICE and
inhibiting the activity of that enzyme.
[0011] It is a principal object of this invention to provide novel
classes of inhibitors of ICE. These novel classes of ICE inhibitors
are characterized by the following structural and physicochemical
features: [0012] a) a first and a second hydrogen bonding moiety,
each of said moieties being capable of forming a hydrogen bond with
a different backbone atom of ICE, said backbone atom being selected
from the group consisting of the carbonyl oxygen of Arg-341, the
amide --NH-- group of Arg-341, the carbonyl oxygen of Ser-339 and
the amide --NH-- group of Ser-339; [0013] b) a first and a second
moderately hydrophobic moiety, said moieties each being capable of
associating with a separate binding pocket of ICE when the
inhibitor is bound thereto, said binding pocket being selected from
the group consisting of the P2 binding pocket, the P3 binding
pocket, the P4 binding pocket and the P' binding pocket; and [0014]
c) an electronegative moiety comprising one or more electronegative
atoms, said atoms being attached to the same atom or to adjacent
atoms in the moiety and said moiety being capable of forming one or
more hydrogen bonds or salt bridges with residues in the P1 binding
pocket of ICE.
[0015] It is also an object of this invention to provide a method
for identification, design or prediction of ICE inhibitors
comprising the steps of:
[0016] a) selecting a candidate compound of defined chemical
structure comprising at least two hydrogen bonding moieties, at
least two moderately hydrophobic moieties and one electronegative
moiety comprising one or more electronegative atoms attached either
to the same atom or to adjacent atoms in the electronegative
moiety;
[0017] b) determining a low-energy conformation for binding of said
compound to the active site of ICE;
[0018] c) evaluating the capability of said compound in said
conformation to form at least two hydrogen bonds with the
non-carbon backbone atoms of Arg-341 and Ser-339 of ICE;
[0019] d) evaluating the capability of said compound in said
conformation to associate with at least two of the binding pockets
of ICE selected from the group consisting of the P2 binding pocket,
the P3 binding pocket, the P4 binding pocket and the P' binding
pocket;
[0020] e) evaluating the capability of said compound in said
conformation to interact with the P1 binding pocket of ICE; and
[0021] f) accepting or rejecting said candidate compound as an ICE
inhibitor based on the determinations and evaluations carried out
in the preceding steps.
[0022] It is a further object of this invention to provide novel
classes of ICE inhibitors represented by formulas:
##STR00001##
ABBREVIATIONS AND DEFINITIONS
Abbreviations
TABLE-US-00001 [0023] Designation Reagent or Fragment Ala alanine
Arg arginine Asn asparagine Asp aspartic acid Cys cysteine Gln
glutamine Glu glutamic acid Gly glycine His histidine Ile
isoleucine Leu leucine Lys lysine Met methionine Phe phenylalanine
Pro proline Ser serine Thr threonine Trp tryptophan Tyr tyrosine
Val valine.
DEFINITIONS
[0024] The following terms are employed herein:
[0025] The term "active site" refers to any or all of the following
sites in ICE: the substrate binding site, the site where an
inhibitor binds and the site where the cleavage of substrate
occurs. The active site is characterized by at least amino acid
residues: 173, 176, 177, 178, 179, 180, 236, 237, 238, 239, 244,
248, 283, 284, 285, 290, 338, 339, 340, 341, 342, 343, 344, 345,
348, 352, 381, 383, using the sequence and numbering according to
Thornberry et al., supra.
[0026] The terms "P binding pocket", "S subsite", "S pocket", and
the like, refer to binding subsites, or portions of the substrate
binding site on the ICE molecule. The amino acid residues of the
substrate are given designations according to their position
relative to the scissile bond, i.e. the bond which is broken by the
protease. The residues are designated P1, P2, etc., for those
extending toward the N-terminus of the substrate and P1', P2',
etc., for those extending toward the C-terminus of the substrate.
The portions of an inhibitor which correspond to the P or P'
residues of the substrate are also labeled P1, P1', etc., by
analogy with the substrate. The binding subsites of the ICE
molecule which receive the residues labeled P1, P1', etc., are
designated S1, S1', etc., or may alternately be designated "the P1
binding pocket", "the P1' binding pocket", etc. [I. Schechter and
A. Berger, "On the Size of the Active Site in Proteases", Biochem.
Biophys. Res. Commun., vol. 27, pp. 157-162 (1967).]
[0027] The terms "P2 binding pocket" or "S2 subsite" of the ICE
active site are equivalent and are defined as the space surrounded
by amino acid residues Pro-290, Val-338 or Trp-340.
[0028] The terms "P3 binding pocket" or "S3 subsite" of the ICE
active site are equivalent and are defined as the space surrounded
by amino acid residues Pro-177, Arg-178, Thr-180, Arg-341 or
Pro-343.
[0029] The terms "P4 binding pocket" or "S4 subsite" of the ICE
active site are equivalent and are defined as the space surrounded
by amino acid residues His-342, Met-345, Val-348, Arg-352, Asp-381,
Arg-383 or Trp-340.
[0030] The terms "P1 binding pocket" or "S1 subsite" of the ICE
active site are equivalent and are defined as the space surrounded
by amino acid residues Arg-179, His-237, Gln-283, or Arg-341.
[0031] The terms "P' binding pocket" or "S' subsite" of the ICE
active site are equivalent and are defined as the space surrounded
by amino acid residues Phe-173, Ile-176, His-237, Gly-238, Ile-239,
Cys-244 or His-248.
[0032] The term "hydrophobic" refers to a moiety which tends not to
dissolve in water and is fat-soluble. Hydrophobic moieties include,
but are not limited to, hydrocarbons, such as alkanes, alkenes,
alkynes, cycloalkanes, cycloalkenes, cycloalkynes and aromatic
compounds, such as aryls, certain saturated and unsaturated
heterocycles and moieties that are substantially similar to the
side chains of hydrophobic natural and unnatural .alpha.-amino
acids, including valine, leucine, isoleucine, methionine,
phenylanine, .alpha.-amino isobutyric acid, alloisoleucine,
tyrosine, and tryptophan.
[0033] The term "moderately hydrophobic" refers to a hydrophobic
moiety in which one or two carbon atoms have been replaced with
more polar atoms, such as oxygen or nitrogen.
[0034] The term "heterocycle" or "heterocyclic" refers to a stable
mono- or polycyclic compound which may optionally contain one or
two double bonds or may optionally contain one or more aromatic
rings. Each heterocycle consists of carbon atoms and from one to
four heteroatoms independently selected from a group including
nitrogen, oxygen, and sulfur. As used herein, the terms "nitrogen
heteroatoms" and "sulphur heteroatoms" include any oxidized form of
nitrogen or sulfur and the quaternized form of any basic nitrogen.
Heterocycles defined above include, for example, pyrimidinyl,
tetrahydroquinolyl, tetrahydroisoquinonlinyl, purinyl, pyrimidyl,
indolinyl, benzimidazolyl, imidazolyl, imidazolinoyl,
imidazolidinyl, quinolyl, isoquinolyl, indolyl, pyridyl, pyrrolyl,
pyrrolinyl, pyrazolyl, pyrazinyl, quinoxolyl, piperidinyl,
morpholinyl, thiamorpholinyl, furyl, thienyl, triazolyl, thiazolyl,
.beta.-carbolinyl, tetrazolyl, thiazolidinyl, benzofuranoyl,
thiamorpholinyl sulfone, benzoxazolyl, oxopiperidinyl,
oxopyrrolidinyl, oxoazepinyl, azepinyl, isoxazolyl,
tetrahydropyranyl, tetrahydrofuranyl, thiadiazolyl, benzodioxolyl,
benzothienyl, tetrahydrothiophenyl and sulfolanyl. Further
heterocycles are described in A. R. Katritzky and C. W. Rees, eds.,
Comprehensive Heterocyclic Chemistry The Structure, Reactions,
Synthesis and Use of Heterocyclic Compounds, Vol. 1-8, Pergamon
Press, NY (1984).
[0035] The term "cycloalkyl" refers to a mono- or polycyclic group
which contains 3 to 15 carbons and may optionally contain one or
two double bonds. Examples include cyclohexyl, adamantyl and
norbornyl.
[0036] The term "aryl" refers to a mono- or polycyclic group which
contains 6, 10, 12, or 14 carbons in which at least one ring is
aromatic. Examples include phenyl, naphthyl and biphenyl.
[0037] The term "heteroaromatic" refers to a mono- or polycyclic
group which contains 1 to 15 carbon atoms and from 1 to 4
heteroatoms, each of which is selected independently from a group
including sulphur, nitrogen and oxygen, and which additionally
contains from 1 to 3 five or six membered rings, at least one of
which is aromatic.
[0038] The term "alpha-amino acid" (.alpha.-amino acid) refers to
both the naturally occurring amino acids and other "non-protein"
.alpha.-amino acids commonly utilized by those in the peptide
chemistry arts when preparing synthetic analogues of naturally
occurring peptides, including D and L forms. The naturally
occurring amino acids are glycine, alanine, valine, leucine,
iso-leucine, serine, methionine, threonine, phenylalanine,
tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid,
asparagine, glutamic acid, glutamine, .gamma.-carboxyglutamic acid,
arginine, ornithine and lysine. Examples of "non-protein"
alpha-amino acids include hydroxylysine, homoserine, homotyrosine,
homo-phenylalanine, citrulline, kynurenine, 4-amino-phenylalanine,
3-(2-naphthyl)-alanine, 3-(1-naphthyl)-alanine, methionine sulfone,
t-butyl-alanine, t-butylglycine, 4-hydroxyphenylglycine,
aminoalanine, phenylglycine, vinylalanine, propargyl-glycine,
1,2,4-triazolo-3-alanine, 4,4,4-trifluoro-threonine, thyronine,
6-hydroxytryptophan, 5-hydro-xytryptophan, 3-hydroxykynurenine,
3-aminotyrosine, trifluoromethyl-alanine, 2-thienylalanine,
(2-(4-pyridyl)ethyl)-cysteine, 3,4-dimethoxy-phenylalanine,
3-(2-thiazolyl)-alanine, ibotenic acid,
1-amino-1-cyclopentane-carboxylic acid,
1-amino-1-cyclohexanecarboxylic acid, quisqualic acid,
3-trifluoromethylphenylalanine, 4-trifluoro-methylphenylalanine,
cyclohexylalanine, cyclo-hexylglycine, thiohistidine,
3-methoxytyrosine, elastatinal, norleucine, norvaline,
alloisoleucine, homoarginine, thioproline, dehydroproline,
hydroxy-proline, isonipectotic acid, homoproline,
cyclohexyl-glycine, .alpha.-amino-n-butyric acid,
cyclohexylalanine, aminophenylbutyric acid, phenylalanines
substituted at the ortho, meta, or para position of the phenyl
moiety with one or two of the following: a (C.sub.1-C.sub.4) alkyl,
a (C.sub.1-C.sub.4) alkoxy, halogen or nitro groups or substituted
with a methylenedioxy group; .beta.-2- and 3-thienyl-alanine,
.beta.-2- and 3-furanylalanine, .beta.-2-, 3- and 4-pyridylalanine,
.beta.-(benzothienyl-2- and 3-yl)alanine, .beta.-(1- and
2-naphthyl)alanine, O-alkylated derivatives of serine, threonine or
tyrosine, S-alkylated cysteine, S-alkylated homocysteine,
O-sulfate, O-phosphate and O-carboxylate esters of tyrosine,
3-sulfo-tyrosine, 3-carboxy-tyrosine, 3-phospho-tyrosine, 4-methane
sulfonic acid ester of tyrosine, 4-methane phosphonic acid ester of
tyrosine, 3,5-diiodotyrosine, 3-nitro-tyrosine, .epsilon.-alkyl
lysine, and delta-alkyl ornithine. Any of these .alpha.-amino acids
may be substituted with a methyl group at the alpha position, a
halogen at any aromatic residue on the .alpha.-amino side chain, or
an appropriate protective group at the O, N, or S atoms of the side
chain residues. Appropriate protective groups are disclosed in
"Protective Groups In Organic Synthesis," T. W. Greene and P. G. M.
Wuts, J. Wiley & Sons, NY, N.Y., 1991.
[0039] The term ".alpha.-amino acid side chain residue" refers to a
chemical moiety which is attached to the .alpha.-carbon of an
alpha-amino acid.
[0040] The term "bioisosteric replacement for --CO.sub.2H" refers
to group which may substitute for a carboxylic acid group in
bioactive molecules. Examples of such groups are disclosed in
Christopher A. Lipinski, "Bioisosteres in Drug Design" Annual
Reports In Medical Chemistry, 21, pp. 286-88 (1986), and in C. W.
Thornber, "Isosterism and Molecular Modification in Drug Design"
Chemical Society Reviews, pp. 563-580 (1979).
[0041] The term "association" is used in reference to a condition
of proximity between an inhibitor or portions thereof to an ICE
molecule or portions thereof wherein the juxtaposition is
energetically favored by electrostatic or van der Waals
interactions.
[0042] The term "hydrogen bond" refers to a favorable interaction
that occurs whenever a suitable donor atom, X, bearing a proton, H,
and a suitable acceptor atom, Y, have a separation of between 2.5
.ANG. and 3.5 .ANG. and where the angle X--H--Y is greater than 90
degrees. Suitable donor and acceptor atoms are well understood in
medicinal chemistry (G. C. Pimentel and A. L. McClellan, The
Hydrogen Bond, Freeman, San Francisco, 1960; R. Taylor and O.
Kennard, "Hydrogen Bond Geometry in Organic Crystals", Accounts of
Chemical Research, 17, pp. 320-326 (1984)).
[0043] The term "salt bridge" refers to the non-covalent attractive
interaction between a positively charged moiety (P) and a
negatively charged moiety (N) when the distance between the centers
of mass of P and N is between 2 and 6 Angstroms. In calculating the
center of mass, atoms which may contain a formal charge and atoms
immediately adjacent to these are included. For example, a salt
bridge may be formed between the positively charged guanidinium
side chain of an arginine residue and the negative charged
carboxylate side chain of a glutamate residue. Salt bridges are
well understood in medicinal chemistry (L. Stryer, Biochemistry,
Freeman, San Francisco, (1975); K. A. Dill, "Dominant Forces in
Protein Folding", Biochemistry, 29, No. 31, pp. 7133-7155,
(1990)).
[0044] The term "center of mass" refers to a point in
three-dimensional space which represents a weighted average
position of the masses that make up an object.
[0045] The terms "backbone chain" and "backbone" refer to the
portion of a polypeptide which comprises the repeating unit
--CO--CH--NH--.
[0046] The term "scaffold" refers to a structural building block
which forms the basis of an ICE inhibitor according to this
invention. Various moieties and functional groups are intended to
be appended to the scaffold. The scaffolds of this invention are
thus depicted having open valences. Various scaffolds of ICE
inhibitors according to this invention include the portions:
##STR00002##
In those scaffolds, the NH and CO or SO.sub.2 moieties represent a
first and a second hydrogen bonding moiety, said moieties each
being capable of forming a hydrogen bond with a backbone atom of
ICE, said backbone atom being selected from the group consisting of
the carbonyl oxygen of Arg-341, the amide --NH-- of Arg-341, the
carbonyl oxygen of Ser-339 and the amide --NH-- of Ser-339.
[0047] The term "substitute" refers to the replacement of a
hydrogen atom in a compound with a substituent group. In the
present invention, those hydrogen atoms which form a part of a
hydrogen bonding moiety which is capable of forming a hydrogen bond
with the carbonyl oxygen of Arg-341 of ICE or the carbonyl oxygen
of Ser-339 of ICE are excluded from substitution. These excluded
hydrogen atoms include those which comprise an --NH-- group which
is alpha to a Z or a --CO-- group and are depicted as --NH-- rather
than an X group or some other designation in the following
diagrams: (a) through (t), (v) through (y), and (I) through
(VIID).
[0048] The term "straight chain" refers to a contiguous unbranching
string of covalently bound members, i.e. atoms, which form a
portion of a ring. The straight chain and the ring of which it
forms a part may be substituted, but these substituents are not a
part of the straight chain.
[0049] The term "K.sub.i" refers to a numerical measure of the
effectiveness of a compound in inhibiting the activity of a target
enzyme such as ICE. Lower values of K.sub.i reflect higher
effectiveness. The K.sub.i value is a derived by fitting
experimentally determined rate data to standard enzyme kinetic
equations (see I. H. Segel, Enzyme Kinetics, Wiley-Interscience,
1975).
[0050] The term "minimize" refers to the systematic altering of the
atomic geometry of a molecule or molecular complex so that any
further minor perturbation of the atomic geometry would cause the
total energy of the system as measured by a molecular mechanics
force-field to increase. Minimization and molecular mechanics
force-fields are well understood in computational chemistry [U.
Burkert and N. L. Allinger, Molecular Mechanics, ACS Monograph 177,
American Chemical Society, Washington, D.C. 1982 pages 59-78].
[0051] The term "strain energy" is used in this application to
refer to the difference between the free conformation energy of a
compound and the bound conformation energy of that compound when
bound to ICE. The strain energy can be determined by the following
steps: Evaluate the energy of the molecule when it has the
conformation necessary for binding to ICE. Then minimize and
reevaluate the energy--this is the free conformation energy. The
strain energy for binding of a potential inhibitor to ICE is the
difference between the free conformation energy and the bound
conformation energy. In a preferred embodiment, the strain energy
of an inhibitor of the present invention is less than about 10
kcal/mol.
[0052] The term "patient" as used in this application refers to any
mammal, especially humans.
[0053] The term "pharmaceutically effective amount" refers to an
amount effective in treating or ameliorating an IL-1 mediated
disease in a patient. The term "prophylactically effective amount"
refers to an amount effective in preventing or substantially
lessening IL-1 mediated disease in a patient.
[0054] The term "pharmaceutically acceptable carrier or adjuvant"
refers to a non-toxic carrier or adjuvant that may be administered
to a patient, together with a compound of this invention, and which
does not destroy the pharmacological activity thereof.
[0055] The term "pharmaceutically acceptable derivative" means any
pharmaceutically acceptable salt, ester, or salt of such ester, of
a compound of this invention or any other compound which, upon
administration to a recipient, is capable of providing (directly or
indirectly) a compound of this invention or an anti-ICE active
metabolite or residue thereof.
[0056] Pharmaceutically acceptable salts of the compounds of this
invention include, for example, those derived from pharmaceutically
acceptable inorganic and organic acids and bases. Examples of
suitable acids include hydrochloric, hydrobromic, sulfuric, nitric,
perchloric, fumaric, maleic, phosphoric, glycolic, lactic,
salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric,
methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic
and benzenesulfonic acids. Other acids, such as oxalic, while not
in themselves pharmaceutically acceptable, may be employed in the
preparation of salts useful as intermediates in obtaining the
compounds of the invention and their pharmaceutically acceptable
acid addition salts. Salts derived from appropriate bases include
alkali metal (e.g., sodium), alkaline earth metal (e.g.,
magnesium), ammonium and N--(C.sub.1-4 alkyl).sub.4.sup.+
salts.
[0057] This invention also envisions the "quaternization" of any
basic nitrogen-containing groups of the compounds disclosed herein.
The basic nitrogen can be quaternized with any agents known to
those of ordinary skill in the art including, for example, lower
alkyl halides, such as methyl, ethyl, propyl and butyl chloride,
bromides and iodides; dialkyl sulfates including dimethyl, diethyl,
dibutyl and diamyl sulfates; long chain halides such as decyl,
lauryl, myristyl and stearyl chlorides, bromides and iodides; and
aralkyl halides including benzyl and phenethyl bromides. Water or
oil-soluble or dispersible products may be obtained by such
quaternization.
[0058] The ICE inhibitors of this invention may contain one or more
"asymmetric" carbon atoms and thus may occur as racemates and
racemic mixtures, single enantiomers, diastereomeric mixtures and
individual diastereomers. All such isomeric forms of these
compounds are expressly included in the present invention. Each
stereogenic carbon may be of the R or S configuration. Although
specific compounds and scaffolds exemplified in this application
may be depicted in a particular stereochemical configuration,
compounds and scaffolds having either the opposite stereochemistry
at any given chiral center or mixtures thereof are also
envisioned.
[0059] The ICE inhibitors of this invention may comprise ring
structures which may optionally be substituted at carbon, nitrogen
or other atoms by various substituents. Such ring structures may be
singly or multiply substituted. Preferably, the ring structures
contain between 0 and 3 substituents. When multiply substituted,
each substituent may be picked independently of any other
substituent as long as the combination of substituents results in
the formation of a stable compound.
[0060] Combinations of substituents and variables envisioned by
this invention are only those that result in the formation of
stable compounds. The term "stable", as used herein, refers to
compounds which possess stability sufficient to allow manufacture
and administration to a mammal by methods known in the art.
Typically, such compounds are stable at a temperature of 40.degree.
C. or less, in the absence of moisture or other chemically reactive
conditions, for at least a week.
DETAILED DESCRIPTION OF THE INVENTION
[0061] In order that the invention herein described may be more
fully understood, the following detailed description is set
forth.
[0062] We have discovered that compounds possessing the following
novel combination of features are surprisingly effective ICE
inhibitors:
[0063] a) a first and a second hydrogen bonding moiety, each of
said moieties being capable of forming a hydrogen bond with a
different backbone atom of ICE, said backbone atom being selected
from the group consisting of the carbonyl oxygen of Arg-341, the
amide --NH-- group of Arg-341, the carbonyl oxygen of Ser-339 and
the amide --NH-- group of Ser-339;
[0064] b) a first and a second moderately hydrophobic moiety, said
moieties each being capable of associating with a separate binding
pocket of ICE when the inhibitor is bound thereto, said binding
pocket being selected from the group consisting of the P2 binding
pocket, the P3 binding pocket, the P4 binding pocket and the P'
binding pocket; and
[0065] c) an electronegative moiety comprising one or more
electronegative atoms, said atoms being attached to the same atom
or to adjacent atoms in the moiety and said moiety being capable of
forming one or more hydrogen bonds or salt bridges with residues in
the P1 binding pocket of ICE.
[0066] Preferably, any moderately hydrophobic moiety associating
with the P2 binding pocket of ICE does so in such a way that:
[0067] a) the distance from the center of mass of the moderately
hydrophobic moiety in the P2 binding pocket to the carbonyl oxygen
of Arg-341 of ICE is between about 7.1 .ANG. and about 12.5 .ANG.;
[0068] b) the distance from the center of mass of the moderately
hydrophobic moiety in the P2 binding pocket to the amide nitrogen
of Arg-341 of ICE is between about 6.0 .ANG. and about 12 .ANG.;
and [0069] c) the distance from the center of mass of the
moderately hydrophobic moiety in the P2 binding pocket to the
carbonyl oxygen of Ser-339 of ICE is between about 3.7 .ANG. and
about 9.5 .ANG..
[0070] Preferably, any moderately hydrophobic moiety associating
with the P3 binding pocket of ICE does so in such a way that:
[0071] a) the distance from the center of mass of the moderately
hydrophobic moiety in the P3 binding pocket to the carbonyl oxygen
of Arg-341 of ICE is between about 3.9 .ANG. and about 9.5 .ANG.;
[0072] b) the distance from the center of mass of the moderately
hydrophobic moiety in the P3 binding pocket to the amide nitrogen
of Arg-341 of ICE is between about 5.4 .ANG. and about 11 .ANG.;
and [0073] c) the distance from the center of mass of the
moderately hydrophobic moiety in the P3 binding pocket to the
carbonyl oxygen of Ser-339 of ICE is between about 7.0 .ANG. and
about 13 .ANG..
[0074] Preferably, any moderately hydrophobic moiety associating
with the P4 binding pocket of ICE does so in such a way that:
[0075] a) the distance from the center of mass of the moderately
hydrophobic moiety in the P4 binding pocket to the carbonyl oxygen
of Arg-341 of ICE is between about 4.5 .ANG. and about 7.5 .ANG.;
[0076] b) the distance from the center of mass of the moderately
hydrophobic moiety in the P4 binding pocket to the amide nitrogen
of Arg-341 of ICE is between about 5.5 .ANG. and about 8.5 .ANG.;
and [0077] c) the distance from the center of mass of the
moderately hydrophobic moiety in the P4 binding pocket to the
carbonyl oxygen of Ser-339 of ICE is between about 8 .ANG. and
about 11 .ANG..
[0078] Preferably, any moderately hydrophobic moiety associating
with the P' binding pocket of ICE does so in such a way that:
[0079] a) the distance from the center of mass of the moderately
hydrophobic moiety in the P' binding pocket to the carbonyl oxygen
of Arg-341 of ICE is between about 11 .ANG. and about 16 .ANG.;
[0080] b) the distance from the center of mass of the moderately
hydrophobic moiety in the P' binding pocket to the amide nitrogen
of Arg-341 of ICE is between about 10 .ANG. and about 15 .ANG.; and
[0081] c) the distance from the center of mass of the moderately
hydrophobic moiety in the P' binding pocket to the carbonyl oxygen
of Ser-339 of ICE is between about 8 .ANG. and about 12 .ANG..
[0082] More preferably, all of the above associative conditions are
met in the compounds of this invention.
[0083] The practitioner skilled in the art will appreciate that
there are a number of means to design the inhibitors of the present
invention. These same means may be used to select a candidate
compound for screening as an ICE inhibitor. This design or
selection may begin with selection of the various moieties which
fill binding pockets.
[0084] There are a number of ways to select moieties to fill
individual binding pockets. These include visual inspection of a
physical model or computer model of the active site and manual
docking of models of selected moieties into various binding
pockets. Modeling software that is well known and available in the
art may be used. These include QUANTA [Molecular Simulations, Inc.,
Burlington, Mass., 1992], SYBYL [Molecular Modeling Software,
Tripos Associates, Inc., St. Louis, Mo., 1992], AMBER [S. J.
Weiner, P. A. Kollman, D. A. Case, U. C. Singh, C. Ghio, G.
Alagona, and P. Weiner, J. Am. Chem. Soc., vol. 106, pp. 765-784
(1984)], or CHARMM [B. R. Brooks, R. E. Bruccoleri, B. D. Olafson,
D. J. States, S Swaminathan, and M. Karplus, J. Comp. Chem. vol. 4,
pp. 187-217 (1983)]. This modelling step may be followed by energy
minimization with standard molecular mechanics forcefields such as
CHARMM and AMBER. In addition, there are a number of more
specialized computer programs to assist in the process of selecting
the binding moieties of this invention. These include: [0085] 1.
GRID (Goodford, P. J. A Computational Procedure for Determining
Energetically Favorable Binding Sites on Biologically Important
Macromolecules. J. Med. Chem., 28, pp. 849-857 (1985)). GRID is
available from Oxford University, Oxford, UK. [0086] 2. MCSS
(Miranker, A.; Karplus, M. Functionality Maps of Binding Sites: A
Multiple Copy Simultaneous Search Method. Proteins: Structure,
Function and Genetics, 11, pp. 29-34 (1991)). MCSS is available
from Molecular Simulations, Burlington, Mass. [0087] 3. AUTODOCK
(Goodsell, D. S.; Olsen, A. J. Automated Docking of Substrates to
Proteins by Simmulated Annealing. PROTEINS: Structure, Function and
Genetics, 8, pp. 195-202 (1990)). AUTODOCK is available from the
Scripps Research Institute, La Jolla, Calif. [0088] 4. DOCK (Kuntz,
I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A
Geometric Approach to Macromolecule-Ligand Interactions. J. Mol.
Biol., 161, pp. 269-288 (1982)). DOCK is available from the
University of California, San Francisco, Calif.
[0089] Once suitable binding moieties have been selected, they can
be assembled into a single inhibitor. This assembly may be
accomplished by connecting the various moieties to a central
scaffold. The assembly process may, for example, be done by visual
inspection followed by manual model building, again using software
such as Quanta or Sybyl. A number of other programs may also be
used to help select ways to connect the various moieties. These
include: [0090] 1. CAVEAT (Bartlett, P. A.; Shea, G. T.; Telfer, S.
J.; Waterman, S. CAVEAT: A Program to Facilitate the
Structure-Derived Design of Biologically Active Molecules. In
"Molecular Recognition in Chemical and Biological Problems,"
Special Pub., Royal Chem. Soc., 78, pp. 182-196 (1989)). CAVEAT is
available from the University of California, Berkeley, Calif.
[0091] 2. 3D Database systems such as MACCS-3D (MDL Information
Systems, San Leandro, Calif.). This area has been recently reviewed
by Martin (Martin, Y. C. 3D Database Searching in Drug Design. J.
Med. Chem., 35, pp. 2145-2154 (1992)). [0092] 3. HOOK (available
from Molecular Simulations, Burlington, Mass.).
[0093] In addition to the above computer assisted modeling of
inhibitor compounds, the inhibitors of this invention may be
constructed "de novo" using either an empty active site or
optionally including some portions of a known inhibitor. Such
methods are well known in the art. They include, for example:
[0094] 1. LUDI (Bohm, H. J. The Computer Program LUDI: A New Method
for the De Novo Design of Enzyme Inhibitors. J. Comp. Aid. Molec.
Design., 6, 61-78 (1992)). LUDI is available from Biosym
Technologies, San Diego, Calif. [0095] 2. LEGEND (Nishibata, Y.,
Itai, A., Tetrahedron, 47, 8985 (1991)). LEGEND is available from
Molecular Simultations, Burlington, Mass. [0096] 3. LeapFrog
(available from Tripos associates, St. Louis, Mo.).
[0097] A number of techniques commonly used for modeling drugs may
be employed (For a review, see: Cohen, N. C.; Blaney, J. M.;
Humblet, C.; Gund, P.; Barry, D. C., "Molecular Modeling Software
and Methods for Medicinal Chemistry", J. Med. Chem., 33, pp.
883-894 (1990)). There are likewise a number of examples in the
chemical literature of techniques that can be applied to specific
drug design projects. For a review, see: Navia, M. A. and Murcko,
M. A., "The Use of Structural Information in Drug Design", Current
Opinions in Structural Biology, 2, pp. 202-210 (1992). Some
examples of these specific applications include: Baldwin, J. J. et
al., "Thienothiopyran-2-sulfonamides: Novel Topically Active
Carbonic Anhydrase Inhibitors for the Treatment of Glaucoma", J.
Med. Chem., 32, pp. 2510-2513 (1989); Appelt, K. et al., "Design of
Enzyme Inhibitors Using Iterative Protein Crystallographic
Analysis", J. Med. Chem., 34, pp. 1925-1934 (1991); and Ealick, S.
E. et al., "Application of Crystallographic and Modeling Methods in
the Design of Purine Nucleotide Phosphorylase Inhibitors" Proc.
Nat. Acad. Sci. USA, 88, pp. 11540-11544 (1991).
[0098] Using the novel combination of steps of the present
invention, the skilled artisan can advantageously avoid time
consuming and expensive experimentation to determine enzymatic
inhibition activity of particular compounds. The method also is
useful to facilitate rational design of ICE inhibitors and
therapeutic and prophylactic agents against IL-1-mediated diseases.
Accordingly, the present invention relates to such inhibitors.
[0099] A variety of conventional techniques may be used to carry
out each of the above evaluations as well as the evaluations
necessary in screening a candidate compound for ICE inhibiting
activity. Generally, these techniques involve determining the
location and binding proximity of a given moiety, the occupied
space of a bound inhibitor, the deformation energy of binding of a
given compound and electrostatic interaction energies. Examples of
conventional techniques useful in the above evaluations include:
quantum mechanics, molecular mechanics, molecular dynamics, Monte
Carlo sampling, systematic searches and distance geometry methods
(G. R. Marshall, Ann. Rev. Pharmacol. Toxicol., 27, p. 193 (1987)).
Specific computer software has been developed for use in carrying
out these methods. Examples of programs designed for such uses
include: Gaussian 92, revision E.2 (M. J. Frisch, Gaussian, Inc.,
Pittsburgh, Pa. .COPYRGT.1993); AMBER, version 4.0 (P. A. Kollman,
University of California at San Francisco, .COPYRGT.1993);
QUANTA/CHARMM [Molecular Simulations, Inc., Burlington, Mass.
.COPYRGT.1992]; and Insight II/Discover (Biosysm Technologies Inc.,
San Diego, Calif. .COPYRGT.1992). These programs may be
implemented, for instance, using a Silicon Graphics Indigo 2
workstation or IBM RISC/6000 workstation model 550. Other hardware
systems and software packages will be known and of evident
applicability to those skilled in the art.
[0100] Different classes of active ICE inhibitors, according to
this invention, may interact in similar ways with the various
binding pockets of the ICE active site. The spatial arrangement of
these important groups is often referred to as a pharmacophore. The
concept of the pharmacophore has been well described in the
literature (D. Mayer, C. B. Naylor, I. Motoc, and G. R. Marshall,
J. Comp. Aided Molec. Design vol. 1, pp. 3-16 (1987); A. Hopfinger
and B. J. Burke, in Concepts and Applications of Molecular
Similarity, M. A. Johnson and G. M. Maggiora, ed., Wiley
(1990)).
[0101] Different classes of ICE inhibitors of this invention may
also use different scaffolds or core structures, but all of these
cores will allow the necessary moieties to be placed in the active
site such that the specific interactions necessary for binding may
be obtained. These compounds are best defined in terms of their
ability to match the pharmacophore, i.e., their structural identify
relative to the shape and properties of the active site of ICE.
[0102] The ICE inhibitors of one embodiment of this invention
comprise a first and a second hydrogen bonding moiety, a first and
a second moderately hydrophobic moiety, and an electronegative
moiety which comprise or are covalently bound to one of the
following scaffolds:
##STR00003##
[0103] The ICE inhibitors of another embodiment (A) of this
invention are those of formula .alpha.:
##STR00004##
wherein:
[0104] X.sub.1 is CH or N;
[0105] g is 0 or 1;
[0106] each J is independently selected from the group consisting
of --H, --OH, and --F, provided that when a first and second J are
bound to a C and said first J is --OH, said second J is --H;
[0107] m is 0, 1, or 2;
[0108] T is --Ar.sub.3, --OH, --CF.sub.3, --CO--CO.sub.2H,
--CO.sub.2H or any bioisosteric replacement for --CO.sub.2H;
[0109] R.sub.1 is selected from the group consisting of the
following formulae, in which any ring may optionally be singly or
multiply substituted at any carbon by Q.sub.1, at any nitrogen by
R.sub.5, or at any atom by .dbd.O, --OH, --CO.sub.2H, or halogen,
and in which any saturated ring may optionally be unsaturated at
one or two bonds:
##STR00005## ##STR00006## ##STR00007##
[0110] R.sub.20 is selected from the group consisting of:
##STR00008## ##STR00009##
[0111] wherein each ring C is independently chosen from the group
consisting of benzo, pyrido, thieno, pyrrolo, furano, thiazolo,
isothiazolo, oxazolo, isoxazolo, pyrimido, imidazolo, cyclopentyl,
and cyclohexyl;
[0112] R.sub.3 is
[0113] --CN,
[0114] --CH.dbd.CH--R.sub.9,
[0115] --CH.dbd.N--O--R.sub.9,
[0116] --(CH.sub.2).sub.1-3-T.sub.1-R.sub.9,
[0117] --CJ.sub.2-R.sub.9,
[0118] --CO--R.sub.13, or
##STR00010##
[0119] each R.sub.4 is independently selected from the group
consisting of:
[0120] --H,
[0121] --Ar.sub.1,
[0122] --R.sub.9,
[0123] -T.sub.1-R.sub.9, and
[0124] --(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9,
[0125] each T.sub.1 is independently selected from the group
consisting of:
[0126] --CH.dbd.CH--,
[0127] --O--,
[0128] --S--,
[0129] --SO--,
[0130] --SO.sub.2--,
[0131] --NR.sub.10--,
[0132] --NR.sub.10--CO--,
[0133] --CO--,
[0134] --O--CO--,
[0135] --CO--O--,
[0136] --CO--NR.sub.10--,
[0137] --O--CO--NR.sub.10--,
[0138] --NR.sub.10--CO--O--,
[0139] --NR.sub.10--CO--NR.sub.10--,
[0140] --SO.sub.2--NR.sub.10--,
[0141] --NR.sub.10--SO.sub.2--, and
[0142] --NR.sub.10--SO.sub.2--NR.sub.10--,
[0143] each R.sub.5 is independently selected from the group
consisting of:
[0144] --H,
[0145] --Ar.sub.1,
[0146] --CO--Ar.sub.1,
[0147] --SO.sub.2--Ar.sub.1,
[0148] --R.sub.9,
[0149] --CO--R.sub.9,
[0150] --CO--O--R.sub.9,
[0151] --SO.sub.2--R.sub.9,
##STR00011##
[0152] R.sub.6 and R.sub.7 taken together form a saturated 4-8
member carbocyclic ring or heterocyclic ring containing --O--,
--S--, or --NH--, or
[0153] R.sub.7 is --H and R.sub.6 is
[0154] --H
[0155] --Ar.sub.1,
[0156] --R.sub.9, or
[0157] --(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9;
[0158] each R.sub.9 is a C.sub.1-6 straight or branched alkyl group
optionally singly or multiply substituted by --OH, --F, or .dbd.O
and optionally substituted with one or two Ar.sub.1 groups;
[0159] each R.sub.10 is independently selected from the group
consisting of --H or a C.sub.1-6 straight or branched alkyl
group;
[0160] each R.sub.13 is independently selected from the group
consisting of --Ar.sub.2 and --R.sub.4;
[0161] each Ar.sub.1 is a cyclic group independently selected from
the set consisting of an aryl group which contains 6, 10, 12, or 14
carbon atoms and between 1 and 3 rings, a cycloalkyl group which
contains between 3 and 15 carbon atoms and between 1 and 3 rings,
said cycloalkyl group being optionally benzofused, and a
heterocycle group containing between 5 and 15 ring atoms and
between 1 and 3 rings, said heterocycle group containing at least
one heteroatom group selected from --O--, --S--, --SO--,
--SO.sub.2--, .dbd.N--, and --NH--, said heterocycle group
optionally containing one or more double bonds, said heterocycle
group optionally comprising one or more aromatic rings, and said
cyclic group optionally being singly or multiply substituted by
.dbd.O, --OH, perfluoro C.sub.1-3 alkyl, or -Q.sub.1;
[0162] each Ar.sub.2 is independently selected from the following
group, in which any ring may optionally be substituted by
-Q.sub.1:
##STR00012##
[0163] Ar.sub.3 is a cyclic group selected from the set consisting
of a phenyl ring, a 5-membered heteroaromatic ring, and a
6-membered heteroaromatic ring, said heteroaromatic rings
comprising 1-3 heteroatom groups selected from --O--, --S--,
--SO--, --SO.sub.2--, .dbd.N--, and --NH--, said cyclic group
optionally being singly or multiply substituted with .dbd.O, --OH,
halogen, perfluoro C.sub.1-3 alkyl, or --CO.sub.2H;
[0164] each Q.sub.1 is independently selected from the group
consisting of:
[0165] --Ar.sub.1
[0166] --R.sub.9,
[0167] -T.sub.1-R.sub.9, and
[0168] --(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9,
[0169] provided that when --Ar.sub.1 is substituted with a Q.sub.1
group which comprises one or more additional --Ar.sub.1 groups,
said additional --Ar.sub.1 groups are not substituted with
Q.sub.1;
[0170] each X is independently selected from the group consisting
of .dbd.N-- and .dbd.CH--;
[0171] each X.sub.2 is independently selected from the group
consisting of --O--, --CH.sub.2--, --NH--, --S--, --SO--, and
--SO.sub.2;
[0172] each X.sub.3 is independently selected from the group
consisting of --CH.sub.2--, --S--, --SO--, and --SO.sub.2--;
[0173] each X.sub.4 is independently selected from the group
consisting of --CH.sub.2-- and --NH--;
[0174] each X.sub.5 is independently selected from the group
consisting of
##STR00013##
[0175] X.sub.6 is CH or N, provided that when X.sub.6 is N in the
R.sub.1 group labeled (o) and X.sub.5 is CH and X.sub.2 is CH.sub.2
the ring of the R.sub.1 group labeled (o) must be substituted by
Q.sub.1 or benzofused;
[0176] each Y is independently selected from the group consisting
of --O-- and --S--;
[0177] each Z is independently CO or SO.sub.2,
[0178] each a is independently 0 or 1,
[0179] each c is independently 1 or 2,
[0180] each d is independently 0, 1, or 2, and
[0181] each e is independently 0, 1, 2, or 3.
[0182] The ICE inhibitors of another embodiment (B) of this
invention are those of formula .alpha.:
##STR00014##
[0183] wherein:
[0184] X.sub.1 is --CH;
[0185] g is 0 or 1;
[0186] each J is independently selected from the group consisting
of --H, --OH, and --F, provided that when a first and second J are
bound to a C and said first J is --OH, said second J is --H;
[0187] m is 0, 1, or 2;
[0188] T is --OH, --CO--CO.sub.2H, --CO.sub.2H or any bioisosteric
replacement for --CO.sub.2H;
[0189] R.sub.1 is selected from the group consisting of the
following formulae, in which any ring may optionally be singly or
multiply substituted at any carbon by Q.sub.1, at any nitrogen by
R.sub.5, or at any atom by .dbd.O, --OH, --CO.sub.2H, or halogen,
any saturated ring may optionally be unsaturated at one or two
bonds; and wherein R.sub.1 (e) and R.sub.1 (y) are optionally
benzofused;
##STR00015## ##STR00016## ##STR00017##
[0190] R.sub.20 is selected from the group consisting of:
##STR00018## ##STR00019##
[0191] wherein each ring C is independently chosen from the group
consisting of benzo, pyrido, thieno, pyrrolo, furano, thiazolo,
isothiazolo, oxazolo, isoxazolo, pyrimido, imidazolo, cyclopentyl,
and cyclohexyl;
[0192] R.sub.3 is
[0193] --CN,
[0194] --CH.dbd.CH--R.sub.9,
[0195] --CH.dbd.N--O--R.sub.9,
[0196] --(CH.sub.2).sub.1-3-T.sub.1-R.sub.9,
[0197] --CJ.sub.2-R.sub.9,
[0198] --CO--R.sub.13, or
##STR00020##
[0199] each R.sub.4 is independently selected from the group
consisting of:
[0200] --H,
[0201] --Ar.sub.1,
[0202] --R.sub.9,
[0203] -T.sub.1-R.sub.9, and
[0204] --(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9,
[0205] each T.sub.1 is independently selected from the group
consisting of:
[0206] --CH.dbd.CH--,
[0207] --O--,
[0208] --S--,
[0209] --SO--,
[0210] --SO.sub.2--,
[0211] --NR.sub.10--,
[0212] --NR.sub.10--CO--,
[0213] --CO--,
[0214] --O--CO--,
[0215] --CO---O--,
[0216] --CO--NR.sub.10--,
[0217] --O--CO--NR.sub.10--,
[0218] --NR.sub.10--CO--O--,
[0219] --NR.sub.10--CO--NR.sub.10--,
[0220] --SO.sub.2--NR.sub.10--,
[0221] --NR.sub.10--SO.sub.2--, and
[0222] --NR.sub.10--SO.sub.2--NR.sub.10--, [0223] each R.sub.5 is
independently selected from the group consisting of:
[0224] --H,
[0225] --Ar.sub.1,
[0226] --CO--Ar.sub.1,
[0227] --SO.sub.2--Ar.sub.1,
[0228] --CO--NH.sub.2,
[0229] --SO.sub.2--NH.sub.2,
[0230] --R.sub.9,
[0231] --CO--R.sub.9,
[0232] --CO--O--R.sub.9,
[0233] --SO.sub.2--R.sub.9,
##STR00021##
[0234] R.sub.6 and R.sub.7 taken together form a saturated 4-8
member carbocyclic ring or heterocyclic ring containing --O--,
--S--, or --NH--; or
[0235] R.sub.7 is --H and R.sub.6 is:
[0236] --H,
[0237] --Ar.sub.1,
[0238] --R.sub.9,
[0239] --(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9, or [0240] an
.alpha.-amino acid side chain residue;
[0241] each R.sub.9 is a C.sub.1-6 straight or branched alkyl group
optionally singly or multiply substituted by --OH, --F, or .dbd.O
and optionally substituted with one or two Ar.sub.1 groups;
[0242] each R.sub.10 is independently selected from the group
consisting of --H or a C.sub.1-6 straight or branched alkyl
group;
[0243] each R.sub.13 is independently selected from the
##STR00022##
[0244] group consisting of --Ar.sub.2, --R.sub.4 and
[0245] each Ar.sub.1 is a cyclic group independently selected from
the set consisting of an aryl group which contains 6, 10, 12, or 14
carbon atoms and between 1 and 3 rings, a cycloalkyl group which
contains between 3 and 15 carbon atoms and between 1 and 3 rings,
said cycloalkyl group being optionally benzofused, and a
heterocycle group containing between 5 and 15 ring atoms and
between 1 and 3 rings, said heterocycle group containing at least
one heteroatom group selected from --O--, --S--, --SO--,
--SO.sub.2--, .dbd.N--, and --NH--, said heterocycle group
optionally containing one or more double bonds, said heterocycle
group optionally comprising one or more aromatic rings, and said
cyclic group optionally being singly or multiply substituted by
--NH.sub.2, --CO.sub.2H, --Cl, --F, --Br, --I, --NO.sub.2, --CN,
.dbd.O, --OH, perfluoro C.sub.1-3 alkyl,
##STR00023##
[0246] each Ar.sub.2 is independently selected from the following
group, in which any ring may optionally be singly or multiply
substituted by -Q.sub.1 and -Q.sub.2:
##STR00024##
[0247] each Q.sub.1 is independently selected from the group
consisting of --Ar.sub.1
[0248] --O--Ar.sub.1--R.sub.9,
[0249] -T.sub.1-R.sub.9, and
[0250] --(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9;
[0251] each Q.sub.2 is independently selected from the group
consisting of --OH, --NH.sub.2, --CO.sub.2H, --Cl, --F, --Br, --I,
--NO.sub.2, --CN , --CF.sub.3 and
##STR00025##
[0252] provided that when --Ar.sub.1 is substituted with a Q.sub.1
group which comprises one or more additional --Ar.sub.1 groups,
said additional --Ar.sub.1 groups are not substituted with
Q.sub.1;
[0253] each X is independently selected from the group consisting
of .dbd.N-- and .dbd.CH--;
[0254] each X.sub.2 is independently selected from the group
consisting of --O--, --CH.sub.2--, --NH--, --S--, --SO--, and
--SO.sub.2--;
[0255] each X.sub.3 is independently selected from the group
consisting of --CH.sub.2--, --S--, --SO--, and --SO.sub.2--;
[0256] each X.sub.4 is independently selected from the group
consisting of --CH.sub.2-- and --NH--;
[0257] each X.sub.5 is independently selected from the group
consisting of
##STR00026##
[0258] X.sub.6 is CH or N, provided that when X.sub.6 is N in the
R.sub.1 group labeled (o) and X.sub.5 is CH and X.sub.2 is CH.sub.2
the ring of the R.sub.1 group labeled (o) must be substituted by
Q.sub.1 or benzofused;
[0259] each Y is independently selected from the group consisting
of --O-- and --S--, and --NH;
[0260] each Z is independently CO or SO.sub.2,
[0261] each a is independently 0 or 1,
[0262] each c is independently 1 or 2,
[0263] each d is independently 0, 1, or 2, and
[0264] each e is independently 0, 1, 2, or 3,
[0265] provided that when [0266] R.sub.1 is (f), [0267] R.sub.6 is
an .alpha.-amino acid side chain residue, and [0268] R.sub.7 is
--H,
[0269] then (aa1) and (aa2) must be substituted with Q.sub.1;
[0270] also provided that when [0271] R.sub.1 is (O), [0272] g is
0, [0273] J is --H, [0274] m is 1, [0275] R.sub.6 is an
.alpha.-amino acid side chain residue, [0276] R.sub.7 is --H,
[0277] X.sub.2 is --CH.sub.2--, [0278] X.sub.5 is
[0278] ##STR00027## [0279] X.sub.6 is
##STR00028##
[0279] and [0280] R.sub.3 is
##STR00029##
[0280] or --CO--R.sub.13, when [0281] R.sub.13 is: [0282]
--CH.sub.2--O--CO--Ar.sub.1, [0283] --CH.sub.2--S--CO--Ar.sub.1,
[0284] --CH.sub.2--O--Ar.sub.1, [0285] --CH.sub.2--S--Ar.sub.1, or
[0286] --R.sub.4 when --R.sub.4 is --H;
[0287] then the ring of the R.sub.1(o) group must be substituted
with Q.sub.1 or benzofused; and
[0288] provided that when [0289] R.sub.1 is (w), [0290] g is 0,
[0291] J is --H, [0292] m is 1, [0293] T is --CO.sub.2H or
--CO--NH--OH, [0294] X.sub.2 is O, [0295] R.sub.5 is
benzyloxycarbonyl, and [0296] ring C is benzo, [0297] then R.sub.3
cannot be --CO--R.sub.13 when: [0298] R.sub.13 is
--CH.sub.2--O--Ar.sub.1 and [0299] Ar.sub.1 is 1-phenyl-3-chloro-
or [0300] 3-trifluoromethyl-pyrazole-5-yl; [0301] or when [0302]
R.sub.13 is --CH.sub.2--O--CO--Ar.sub.1 and [0303] Ar.sub.1 is
2,6-dichlorophenyl.
[0304] Preferred forms of the R.sub.1 group (a) for embodiments A
and B are:
##STR00030##
[0305] Preferred forms of the R.sub.1 group (b) are:
##STR00031##
[0306] Preferred forms of the R.sub.1 group (c) are:
##STR00032## [0307] provided that when R1 is (c1), [0308] g is 0,
[0309] J is --H, [0310] m is 1, [0311] T is --CO.sub.2H, [0312] X
is N, [0313] R.sub.5 is benzyloxycarbonyl, and [0314] R.sub.6 is
--H, [0315] then R.sub.3 cannot be --CO--R.sub.13 when [0316]
R.sub.13 is --CH.sub.2--O--Ar.sub.1 and [0317] Ar.sub.1 is a
chloro-substituted 1-phenyl-3-trifluoromethyl-pyrazole-5-yl, or
when [0318] R.sub.13 is --CH.sub.2--O--CO--Ar.sub.1 and [0319]
Ar.sub.1 is 2,6-dichlorophenyl, [0320] and when the 2-position of
the scaffold ring is substituted with para-fluoro-phenyl;
[0321] Preferred forms of the R.sub.1 group (d) are:
##STR00033## [0322] Preferred forms of the R.sub.1 group (e)
are:
##STR00034##
[0323] which is optionally benzofused;
##STR00035##
[0324] provided that when R.sub.1 is (e4), [0325] g is 0, [0326] J
is --H, [0327] m is 1, [0328] T is --CO.sub.2H, [0329] R.sub.5 is
benzyloxycarbonyl, and [0330] c is 1,
[0331] then R.sub.3 cannot be --CO--R.sub.13 when [0332] R.sub.13
is --CH.sub.2--O--Ar.sub.1 and [0333] Ar.sub.1 is
1-phenyl-3-trifluoromethyl-pyrazole-5-yl, wherein the phenyl is
optionally substituted with a chlorine atom; or when [0334]
R.sub.13 is --CH.sub.2--O--CO--Ar.sub.1 and [0335] Ar.sub.1 is
2,6-dichlorophenyl, [0336] and when the 2-position of the scaffold
ring is substituted with para-fluoro-phenyl; and [0337] also
provided that when
[0338] R.sub.1 is (e7),
[0339] g is 0, [0340] J is --H, [0341] m is 1, [0342] T is
--CO.sub.2H or --CO--NH--OH, [0343] R.sub.5 is a protective group
for the N atom of an amino acid side chain residue, and [0344] each
c is 1, [0345] then R.sub.3 cannot be --CO--R.sub.13 when [0346]
R.sub.13 is: [0347] --CH.sub.2--O--CO--Ar.sub.1, [0348]
--CH.sub.2--S--CO--Ar.sub.1, [0349] --CH.sub.2--O--Ar.sub.1, or
[0350] --CH.sub.2--S--Ar.sub.1.
[0351] Preferred forms of the R.sub.1 group (g) are:
##STR00036##
[0352] Preferred forms of the R.sub.1 group (h) are:
##STR00037##
[0353] Preferred forms of the R.sub.1 group (i) are:
##STR00038##
[0354] Preferred forms of the R.sub.1 group (j) are:
##STR00039##
[0355] Preferred forms of the R.sub.1 group (k) are:
##STR00040##
[0356] Preferred forms of the R.sub.1 group (1) are:
##STR00041##
[0357] Preferred forms of the R.sub.1 group (m) are:
##STR00042##
[0358] Preferred forms of the R.sub.1 group (n) are:
##STR00043##
[0359] Preferred forms of the R.sub.1 group (o) are:
##STR00044##
[0360] Preferred forms of the R.sub.1 group (o) of embodiment B
is:
##STR00045##
[0361] wherein X.sub.2 is --O--, --S--, --SO.sub.2--, or
--NH--.
[0362] For embodiments A and B, preferred forms of the R.sub.1
group (p) are:
##STR00046##
[0363] Preferred forms of the R.sub.1 group (q) are:
##STR00047##
[0364] Preferred forms of the R.sub.1 group (r) are:
##STR00048##
[0365] Preferred forms of the R.sub.1 group (s) are:
##STR00049##
[0366] Preferred forms of the R.sub.1 group (t) are:
##STR00050##
[0367] Preferred forms of the R.sub.1 group (v) are:
##STR00051##
[0368] A preferred form of the R.sub.1 group (w) of embodiment B
is:
##STR00052##
[0369] wherein X.sub.2 is --O--, --S--, --SO.sub.2-- or --NH--.
[0370] The preferred compounds of embodiments A and B of this
invention are those which employ formula .alpha., wherein:
[0371] X.sub.1 is CH;
[0372] g is O;
[0373] J is --H;
[0374] m is 0 or 1 and T is --Ar.sub.3, --CO--CO.sub.2H,
--CO.sub.2H or any bioisosteric replacement for --CO.sub.2H, or
[0375] m is 1 or 2 and T is --OH, --CF.sub.3, or --CO.sub.2H;
[0376] more preferably m is 1 and T is --CO.sub.2H;
[0377] R.sub.1 is
##STR00053##
wherein ring C is benzo;
[0378] R.sub.3 is
[0379] --CO--R.sub.13, or
##STR00054##
[0380] most preferably R.sub.3 is any one of 1), 2) or 3) as
follows: 1) --CO--Ar.sub.2, 2) --CO--R.sub.9 where R.sub.9 is
C.sub.3-6 alkyl substituted with two Ar.sub.1 groups or one
Ar.sub.1 group itself substituted with an Ar.sub.1 group,
--C.sub.1-2--Ar.sub.1, --Cl, --CH.sub.3, or --CF.sub.3, or 3)
--(CH.sub.2).sub.1,2-T.sub.1-R.sub.9 where T.sub.1 is --O-- or
--S-- and R.sub.9 is C.sub.1-2 alkyl substituted with two Ar.sub.1
groups or one Ar.sub.1 group itself substituted with an Ar.sub.1
group, C.sub.1-2--Ar.sub.1, --Cl, --CH.sub.3, or --CF.sub.3;
[0381] R.sub.4 is --H or --R.sub.9;
[0382] T.sub.1 is [0383] --O--, [0384] --S--, [0385] --CO--, [0386]
--O--CO--, or [0387] --SO.sub.2--;
[0388] when R.sub.1 is (a), (b), (k), or (m), R.sub.5 is preferably
--Ar.sub.1 or C.sub.1-4--Ar.sub.1;
[0389] when R.sub.1 is (c), (e), (f), (o), or (r), R.sub.5 is
preferably --SO.sub.2--Ar.sub.1, --SO.sub.2--R.sub.9, or
--CO--C.sub.1-4--Ar.sub.1;
[0390] R.sub.7 is --H and R.sub.6 is C.sub.1-4--Ar.sub.1;
[0391] R.sub.10 is --H or a C.sub.1-3 straight or branched alkyl
group;
[0392] R.sub.13 is --Ar.sub.2;
[0393] Ar.sub.1 is phenyl, naphthyl, pyridyl, benzothiazolyl,
thienyl, benzothienyl, benzoxazolyl, 2-indanyl, or indolyl;
[0394] Ar.sub.2 is preferably substituted with --Ar.sub.1, or
--C.sub.1-4--Ar.sub.1;
[0395] Ar.sub.3 is phenyl, thiophene, thiazole, pyridine, or
oxazole; and
[0396] Q.sub.1 is --R.sub.9 or
--(CH.sub.2).sub.1,2-T.sub.1-(CH.sub.2).sub.1-3--Ar.sub.1 where
T.sub.1 is --O-- or --S--.
[0397] In connection with this continuation-in-part, we now prefer
the compounds of embodiment B of this invention which employ
formula .alpha., wherein:
[0398] X.sub.1 is --CH;
[0399] g is O;
[0400] J is --H;
[0401] m is 0 or 1 and T is --CO--CO.sub.2H, or any bioisosteric
replacement for --CO.sub.2H; or
[0402] m is 1 and T is --CO.sub.2H;
[0403] R.sub.1 is selected from the group consisting of the
following formulae, in which any ring may optionally be singly or
multiply substituted at any carbon by Q.sub.1, at any nitrogen by
R.sub.5, or at any atom by .dbd.O, --OH, --CO.sub.2H, or halogen,
and wherein (e) is optionally benzofused:
##STR00055## ##STR00056##
[0404] and c is 1;
[0405] ring C is benzo optionally substituted with --C.sub.1-3
alkyl, --O--C.sub.1-3 alkyl, --Cl, --F or --CF.sub.3;
[0406] R.sub.3 is: [0407] --CO--R.sub.13, or
##STR00057##
[0408] more preferably R.sub.3 is any one of 1), 2) or 3) as
follows: 1) --CO--Ar.sub.2; 2) --CO--R.sub.9 where R.sub.9 is
C.sub.1-5 alkyl substituted with an Ar.sub.1; or 3)
--CH.sub.2-T.sub.1-R.sub.9 where T.sub.1 is --O-- or --S-- and
R.sub.9 is C.sub.1-2 alkyl substituted with one Ar.sub.1 group;
[0409] R.sub.4 is --H or --R.sub.9;
[0410] T.sub.1 is: [0411] --O--, [0412] --S--, [0413] --CO--,
[0414] --O--CO--, or [0415] --SO.sub.2--;
[0416] when R.sub.1 is (a) or (b), R.sub.5 is preferably --H,
and
[0417] when R.sub.1 is (c), (e), (f), (o), (r), (w), (x) or (y),
R.sub.5 is preferably: [0418] --CO--Ar.sub.1 [0419]
--SO.sub.2--Ar.sub.1, [0420] --CO--NH.sub.2, [0421]
--CO--NH--Ar.sub.1 [0422] --CO--R.sub.9, [0423] --CO--O--R.sub.9,
[0424] --SO.sub.2--R.sub.9, or [0425] --CO--NH--R.sub.9,
[0426] R.sub.7 is --H and R.sub.6 is [0427] --H, [0428] --R.sub.9
or [0429] --Ar.sub.1;
[0430] R.sub.9 is C.sub.1-6 straight or branched alkyl group
optionally substituted with .dbd.O and optionally substituted with
--Ar.sub.1;
[0431] R.sub.10 is --H or a C.sub.1-3 straight or branched alkyl
group;
[0432] R.sub.13 is: [0433] --H, [0434] --R.sub.9, [0435]
--Ar.sub.2, or [0436] --CH.sub.2-T.sub.1-R.sub.9,
[0437] more preferably where --Ar.sub.2 is (hh) and where (hh) is
optionally substituted singly or multiply with --C.sub.1-6 alkyl,
--O--C.sub.1-6 alkyl, --NH--C.sub.1-6 alkyl,
--N--(C.sub.1-6 alkyl).sub.2, --S--C.sub.1-6 alkyl, --Cl,
--F, --CF.sub.3, or
##STR00058##
[0439] Ar.sub.1 is phenyl, naphthyl, pyridyl, benzothiazolyl,
thienyl, benzothienyl, benzoxazolyl, 2-indanyl, or indolyl
optionally being singly or multiply substituted with --O--C.sub.1-3
alkyl, --NH--C.sub.1-3 alkyl,
--N--(C.sub.1-3 alkyl).sub.2, --Cl, --F, --CF.sub.3, --C.sub.1-3
alkyl, or
##STR00059##
[0440] preferably where Ar.sub.2 is:
##STR00060##
[0441] each X is independently selected from the group consisting
of .dbd.N-- and .dbd.CH--;
[0442] each X.sub.2 is independently selected from the group
consisting of --O--, --CH.sub.2--, --NH--, --S--, --SO--, and
--SO.sub.2--;
[0443] each X.sub.5 is independently selected from the group
consisting of
##STR00061##
[0444] X.sub.6 is
##STR00062##
and
[0445] Z is C.dbd.O;
[0446] provided that when [0447] R.sub.1 is (f), [0448] R.sub.6 is
an .alpha.-amino acid side chain residue, and [0449] R.sub.7 is
--H,
[0450] then (aa1) and (aa2) must be substituted with Q.sub.1;
[0451] also provided that when [0452] R.sub.1 is (o), [0453] g is
0, [0454] J is --H, [0455] m is 1, [0456] R.sub.6 is an
.alpha.-amino acid side chain residue, [0457] R.sub.7 is --H,
[0458] X.sub.2 is --CH.sub.2--, [0459] X.sub.5 is
[0459] ##STR00063## [0460] X.sub.6 is
##STR00064##
[0460] and [0461] R.sub.3 is
##STR00065##
[0461] or --CO--R.sub.13, when [0462] R.sub.13 is: [0463]
--CH.sub.2--O--CO--Ar.sub.1, [0464] --CH.sub.2--S--CO--Ar.sub.1,
[0465] --CH.sub.2--O--Ar.sub.1, [0466] --CH.sub.2--S--Ar.sub.1, or
[0467] --R.sub.4 when --R.sub.4 is --H;
[0468] then the ring of the R.sub.1(o) group must be substituted
with Q.sub.1 or benzofused; and
[0469] provided that when [0470] R.sub.1 is (w), [0471] g is 0,
[0472] J is --H, [0473] m is 1, [0474] T is --CO.sub.2H, [0475]
X.sub.2 is O, [0476] R.sub.5 is benzyloxycarbonyl, and ring C is
benzo,
[0477] then R.sub.3 cannot be --CO--R.sub.13 when: [0478] R.sub.13
is --CH.sub.2--O--Ar.sub.1 and [0479] Ar.sub.1 is
1-phenyl-3-trifluoromethyl-pyrazole-5-yl, wherein the phenyl is
optionally substituted with a chlorine atom; [0480] or when
R.sub.13 is --CH.sub.2--O--CO--Ar.sub.1, wherein
[0481] Ar.sub.1 is 2,6-dichlorophenyl.
[0482] A preferred form of R.sub.13 is --CH.sub.2--O--R.sub.9,
wherein R.sub.9 is a C.sub.1-6 straight or branched alkyl group
optionally substituted with .dbd.O and optionally substituted with
Ar.sub.1;
[0483] another preferred form of R.sub.13 is CH.sub.2--S--R.sub.9,
wherein R.sub.9 is a C.sub.1-6 straight or branched alkyl group
optionally substituted with Ar.sub.1;
[0484] another preferred form of R.sub.13 is CH.sub.2--O--R.sub.9
wherein R.sub.9 is a C.sub.1-6 straight or branched alkyl group
optionally substituted with Ar.sub.1;
[0485] another preferred form of R.sub.13 is H.
[0486] A more preferred form of the R.sub.1 group (a) is:
##STR00066##
[0487] optionally substituted with Q.sub.1, wherein
[0488] R.sub.5 is --H;
[0489] R.sub.7 is --H; and
[0490] Z is C.dbd.O;
[0491] a more preferred form of the R.sub.1 group (b) is:
##STR00067##
[0492] optionally substituted with Q.sub.1, wherein
[0493] R.sub.5 is --H;
[0494] R.sub.7 is --H; and
[0495] Z is C.dbd.O;
[0496] more preferred forms of the R.sub.1 group (c) are:
##STR00068##
[0497] provided that when R.sub.1 is (c1), [0498] g is 0, [0499] J
is --H, [0500] m is 1, [0501] T is --CO.sub.2H, [0502] X is N,
[0503] R.sub.5 is benzyloxycarbonyl, and [0504] R.sub.6 is --H,
[0505] then R.sub.3 cannot be --CO--R.sub.13 when [0506] R.sub.13
is --CH.sub.2--O--Ar.sub.1 and [0507] Ar.sub.1 is
1-phenyl-3-trifluoromethyl-pyrazole-5-yl wherein the phenyl is
optionally substituted with a chlorine atom; or when [0508]
R.sub.13 is --CH.sub.2--O--CO--Ar.sub.1, wherein [0509] Ar.sub.1 is
2,6-dichlorophenyl, and wherein the 2-position of the scaffold ring
is substituted with para-fluoro-phenyl;
[0510] more preferred forms of the R.sub.1 group (e) are:
##STR00069##
[0511] wherein c is 2; and
##STR00070##
[0512] which is optionally benzofused,
[0513] wherein c is 1 or 2;
[0514] provided that when R.sub.1 is (e4), [0515] g is 0, [0516] J
is --H, [0517] m is 1, [0518] T is --CO.sub.2H, [0519] R.sub.5 is
benzyloxycarbonyl, and [0520] c is 1,
[0521] then R.sub.3 cannot be --CO--R.sub.13 when [0522] R.sub.13
is --CH.sub.2--O--Ar.sub.1 and [0523] Ar.sub.1 is
1-phenyl-3-trifluoromethyl-pyrazole-5-yl wherein the phenyl is
optionally substituted with a chlorine atom; or when [0524]
R.sub.13 is --CH.sub.2--O--CO--Ar.sub.1, wherein [0525] Ar.sub.1 is
2,6-dichlorophenyl,
[0526] and wherein the 2-position of the scaffold ring is
substituted with para-fluoro-phenyl; and
[0527] also provided that when [0528] R.sub.1 is (e7), [0529] g is
0, [0530] J is --H, [0531] m is 1, [0532] T is --CO.sub.2H,
--CO--NH--OH, or a bioisosteric replacement for --CO.sub.2H, [0533]
R.sub.5 is a protective group for the N atom of an .alpha.-amino
acid side chain residue, and [0534] each c is 1, [0535] then
R.sub.3 cannot be --CO--R.sub.13 when R.sub.13 is: [0536]
--CH.sub.2--O--CO--Ar.sub.1, [0537] --CH.sub.2--S--CO--Ar.sub.1,
[0538] --CH.sub.2--O--Ar.sub.1, or [0539] --CH.sub.2--S--Ar.sub.1.
[0540] a more preferred form of the R.sub.1 group (f) is
[0540] ##STR00071## [0541] a more preferred form of the R.sub.1
group (g) is:
##STR00072##
[0541] wherein
[0542] R.sub.20 is (aa1) optionally substituted singly or multiply
with Q.sub.1; and
[0543] Z is C.dbd.O;
[0544] a more preferred form of the R.sub.1 group (h) is:
##STR00073##
wherein
[0545] R.sub.20 is (aa1) optionally substituted singly or multiply
with Q.sub.1; and
[0546] Z is C.dbd.O;
[0547] more preferred forms of the R.sub.1 group (o) are:
##STR00074## [0548] wherein d is 1 or 2; and
[0548] ##STR00075## [0549] more preferred forms of the R.sub.1
group (r) are:
[0549] ##STR00076## [0550] optionally substituted with Q.sub.1;
[0551] a more preferred form of the R.sub.1 group (w) is:
##STR00077##
[0551] wherein [0552] X.sub.2 is: [0553] --NH--, [0554] --S--,
[0555] --O--, or [0556] --SO.sub.2--; [0557] optionally substituted
with R.sub.5 or Q.sub.1 at X.sub.2 when X.sub.2 is --N--; and
[0558] ring C is benzo substituted with --C.sub.1-3 alkyl,
--O--C.sub.1-3 alkyl, --Cl, --F or --CF.sub.3.
[0559] When R.sub.1 is:
##STR00078##
[0560] preferred compounds of this invention include but are not
limited to:
##STR00079##
[0561] A preferred compound of embodiment B of this invention
employs formula .alpha., wherein the R.sub.1 is:
##STR00080##
[0562] Preferred compounds of this embodiment include but are not
limited to:
##STR00081## ##STR00082## ##STR00083##
[0563] When R.sub.1 is:
##STR00084##
preferred compounds of this invention include but are not limited
to:
##STR00085##
[0564] A preferred compound of embodiment B of this invention
employs formula .alpha., wherein: [0565] R.sub.1 is:
##STR00086##
[0566] and c is 2; [0567] m is 1; [0568] T is --CO.sub.2H; and
[0569] R.sub.3 is --CO--R.sub.13.
[0570] Preferred compounds of this embodiment include but are not
limited to:
##STR00087## ##STR00088##
[0571] When R.sub.1 is:
##STR00089##
preferred compounds of this invention include but are not limited
to:
##STR00090##
[0572] When R.sub.1 is:
##STR00091##
preferred compounds of this invention include but are not limited
to:
##STR00092##
[0573] When R.sub.1 is:
##STR00093##
preferred compounds of this invention include but are not limited
to:
##STR00094##
[0574] A preferred compound of embodiment B of this invention
employs formula .alpha., wherein:
[0575] R.sub.1 is:
##STR00095##
[0576] X.sub.2 is --NH--;
[0577] m is 1;
[0578] T is --CO.sub.2H;
[0579] R.sub.3 is --CO--R.sub.13.
[0580] Preferred compounds of this embodiment include but are not
limited to:
##STR00096##
[0581] optionally substituted with Q.sub.1;
preferred compounds of embodiment B of this invention include but
are not limited to:
##STR00097##
[0582] When R.sub.1 is:
##STR00098##
preferred compounds of this invention include but are not limited
to:
##STR00099##
[0583] The ICE inhibitors of another embodiment (C) of this
invention are represented by the formula .alpha.:
##STR00100##
[0584] wherein the ring is optionally substituted with one or more
R groups, preferably 0, 1 or 2; and wherein:
[0585] R.sub.1 is R.sub.5-(A).sub.p-;
[0586] R.sub.5 is selected from the group consisting of: [0587]
--H, [0588] --Ar.sub.1, [0589] --CO--Ar.sub.1, [0590]
--SO.sub.2--Ar.sub.1, [0591] --R.sub.9, [0592] --CO--R.sub.9,
[0593] --CO--O--R.sub.9, [0594] --SO.sub.2--R.sub.9,
##STR00101##
[0595] each A is independently selected from the group consisting
of any .alpha.-amino acid;
[0596] p is 0, 1, 2, 3 or 4;
[0597] Y is: [0598] --O--, [0599] --S-- or [0600] --NH;
[0601] R is: [0602] --H, [0603] --O--C.sub.1-6 alkyl, [0604]
--NH(C.sub.1-6 alkyl), [0605] --N(C.sub.1-6 alkyl).sub.2, [0606]
--S--C.sub.1-6 alkyl, [0607] --C.sub.1-6 alkyl, or [0608]
-Q.sub.2;
[0609] each R.sub.9 is a C.sub.1-6 straight or branched alkyl group
optionally singly or multiply substituted by --OH or --F and
optionally substituted with one or two Ar.sub.1 groups;
[0610] each R.sub.10 is independently selected from the group
consisting of --H or a C.sub.1-6 straight or branched alkyl
group;
[0611] each T.sub.1 is independently selected from the group
consisting of: [0612] --CH.dbd.CH--, [0613] --O--, [0614] --S--,
[0615] --SO--, [0616] --SO.sub.2--, [0617] --NR.sub.10--, [0618]
--NR.sub.10--CO--, [0619] --CO--, [0620] --O--CO--, [0621]
--CO---O--, [0622] --CO--NR.sub.10--, [0623] --O--CO--NR.sub.10--,
[0624] --NR.sub.10--CO--O--, [0625] --NR.sub.10--CO--NR.sub.10--,
[0626] --SO.sub.2--NR.sub.10--, [0627] --NR.sub.10--SO.sub.2--, and
[0628] --NR.sub.10--SO.sub.2--NR.sub.10--,
[0629] each Ar.sub.1 is a cyclic group independently selected from
the set consisting of an aryl group which contains 6, 10, 12, or 14
carbon atoms and between 1 and 3 rings, a cycloalkyl group which
contains between 3 and 15 carbon atoms and between 1 and 3 rings,
said cycloalkyl group being optionally benzofused, and a
heterocycle group containing between 5 and 15 ring atoms and
between 1 and 3 rings, said heterocycle group containing at least
one heteroatom group selected from --O--, --S--, --SO--,
--SO.sub.2--, .dbd.N--, and --NH--, said heterocycle group
optionally containing one or more double bonds, said heterocycle
group optionally comprising one or more aromatic rings, and said
cyclic group optionally being singly or multiply substituted by:
--NH.sub.2, --CO.sub.2H, --Cl, --F, --Br, --I, --NO.sub.2,
--CN, .dbd.O, --OH, -perfluoro C.sub.1-3 alkyl,
##STR00102##
or -Q.sub.1;
[0630] each Q.sub.1 is independently selected from the group
consisting of: [0631] --Ar.sub.1 [0632] --R.sub.9, [0633]
-T.sub.1-R.sub.9, and [0634] --(CH.sub.2)
1,2,3-T.sub.1-R.sub.9;
[0635] each Q.sub.2 is independently selected from the group
consisting of --OH, --NH.sub.2, --CO.sub.2H, --Cl, --F, --Br, --I,
--NO.sub.2, --CN, --CF.sub.3, and
##STR00103##
[0636] provided that when --Ar.sub.1 is substituted with a Q.sub.1
group which comprises one or more additional --Ar.sub.1 groups,
said additional --Ar.sub.1 groups are not substituted with
Q.sub.1.
[0637] Preferred compounds of embodiment C of this invention
include but are not limited to:
##STR00104##
[0638] Preferred compounds of embodiment C of this invention are
also those in which each A is independently selected from the group
consisting of the .alpha.-amino acids:
[0639] alanine,
[0640] histidine,
[0641] lysine,
[0642] phenylalanine,
[0643] proline,
[0644] tyrosine,
[0645] valine,
[0646] leucine,
[0647] isoleucine,
[0648] glutamine,
[0649] methionine,
[0650] homoproline,
[0651] 3-(2-thienyl) alanine, and
[0652] 3-(3-thienyl) alanine.
[0653] The ICE inhibitors of another embodiment (D) of this
invention are represented by the formula n:
##STR00105##
[0654] wherein:
[0655] R.sub.1 is R.sub.5--(A).sub.p-;
[0656] each T.sub.1 is independently selected from the group
consisting of: [0657] --CH.dbd.CH--, [0658] --O--, [0659] --S--,
[0660] --SO--, [0661] --SO.sub.2--, [0662] --NR.sub.10--, [0663]
--NR.sub.10--CO--, [0664] --CO--, [0665] --O--CO--, [0666]
--CO---O--, [0667] --CO--NR.sub.10--, [0668] --O--CO--NR.sub.10--,
[0669] --NR.sub.10--CO--O--, [0670] --NR.sub.10--CO--NR.sub.10--,
[0671] --SO.sub.2--NR.sub.10--, [0672] --NR.sub.10--SO.sub.2--, and
[0673] --NR.sub.10--SO.sub.2--NR.sub.10--;
[0674] R.sub.5 is selected from the group consisting of: [0675]
--H, [0676] --Ar.sub.1, [0677] --CO--Ar.sub.1, [0678]
--SO.sub.2--Ar.sub.1, [0679] --R.sub.9, [0680] --CO--R.sub.9,
[0681] --CO--O--R.sub.9, [0682] --SO.sub.2--R.sub.9,
##STR00106##
[0683] each A is independently selected from the group consisting
of any .alpha.-amino acid;
[0684] p is 0, 1, 2, 3 or 4;
[0685] each R.sub.9 is a C.sub.1-6 straight or branched alkyl group
optionally singly or multiply substituted by --OH, --F, or .dbd.O
and optionally substituted with an Ar.sub.1 group;
[0686] each R.sub.10 is independently selected from the group
consisting of --H or a C.sub.1-6 straight or branched alkyl
group;
[0687] Ar.sub.1 is a cyclic group independently selected from the
set consisting of an aryl group which contains 6, 10, 12, or 14
carbon atoms and between 1 and 3 rings, a cycloalkyl group which
contains between 3 and 15 carbon atoms and between 1 and 3 rings,
said cycloalkyl group being optionally benzofused, and a
heterocycle group containing between 5 and 15 ring atoms and
between 1 and 3 rings, said heterocycle group containing at least
one heteroatom group selected from --O--, --S--, --SO--,
--SO.sub.2--, .dbd.N--, and --NH--, said heterocycle group
optionally containing one or more double bonds, said heterocycle
group optionally comprising one or more aromatic rings, and said
cyclic group optionally being singly or multiply substituted by
--NH.sub.2, --CO.sub.2H, --Cl, --F, --Br, --I, --NO.sub.2, --CH,
.dbd.O, --OH, -perfluoro C.sub.1-3 alkyl, or
##STR00107##
[0688] Preferred compounds of embodiment D of this invention are
those in which R.sub.9 is a C.sub.1-4 straight or branched alkyl
substituted with Ar.sub.1 when Ar.sub.1 is phenyl.
[0689] Preferred compounds of embodiment D of this invention
include but are not limited to:
##STR00108##
[0690] Preferred compounds of embodiment D of this invention are
also those in which A is independently selected from the group
consisting of the .alpha.-amino acids:
[0691] alanine,
[0692] histidine,
[0693] lysine,
[0694] phenylalanine,
[0695] proline,
[0696] tyrosine,
[0697] valine,
[0698] leucine,
[0699] isoleucine,
[0700] glutamine,
[0701] methionine,
[0702] homoproline,
[0703] 3-(2-thienyl) alanine, and
[0704] 3-(3-thienyl) alanine.
[0705] The ICE inhibitors of another embodiment (E) of this
invention are represented by formula .gamma.:
##STR00109##
wherein:
[0706] m is 0, 1, or 2;
[0707] T is --CO.sub.2H, or any bioisosteric replacement for
[0708] --CO.sub.2H,
[0709] R.sub.3 is
[0710] --CN,
[0711] --COR.sub.13, or
##STR00110##
[0712] R.sub.5 is selected from the group consisting of: [0713]
--H, [0714] --Ar.sub.1, [0715] --CO--Ar.sub.1, [0716]
--SO.sub.2--Ar.sub.1, [0717] --R.sub.9, [0718] --CO--R.sub.9,
[0719] --CO--O--R.sub.9, [0720] --SO.sub.2--R.sub.9,
##STR00111##
[0721] each A is independently selected from the group consisting
of any .alpha.-amino acid;
[0722] p is 2 or 3;
[0723] each R.sub.9 is a C.sub.1-6 straight or branched alkyl group
optionally singly or multiply substituted by --OH, --F, or .dbd.O
and optionally substituted with an Ar.sub.1 group;
[0724] each T.sub.1 is independently selected from the group
consisting of: [0725] --CH.dbd.CH--, [0726] --O--, [0727] --S--,
[0728] --SO--, [0729] --SO.sub.2--, [0730] --NR.sub.10--, [0731]
--NR.sub.10--CO--, [0732] --CO--, [0733] --O--CO--, [0734]
--CO---O--, [0735] --CO--NR.sub.10--, [0736] --O--CO--NR.sub.10--,
[0737] --NR.sub.10--CO--O--, [0738] --NR.sub.10--CO--NR.sub.10--,
[0739] --SO.sub.2--NR.sub.10--, [0740] --NR.sub.10--SO.sub.2--, and
[0741] --NR.sub.10--SO.sub.2--NR.sub.10--;
[0742] each R.sub.10 is independently selected from the group
consisting of --H or a --C.sub.1-6 straight or branched alkyl
group;
[0743] each R.sub.13 is independently selected from the group
consisting of H, R.sub.9, Ar.sub.2, and CH.sub.2T.sub.1R.sub.9;
[0744] each Ar.sub.1 is a cyclic group independently selected from
the set consisting of an aryl group which contains 6, 10, 12, or 14
carbon atoms and between 1 and 3 rings, a cycloalkyl group which
contains between 3 and 15 carbon atoms and between 1 and 3 rings,
said cycloalkyl group being optionally benzofused, and a
heterocycle group containing between 5 and 15 ring atoms and
between 1 and 3 rings, said heterocycle group containing at least
one heteroatom group selected from --O--, --S--, --SO--,
--SO.sub.2--, .dbd.N--, and --NH--, said heterocycle group
optionally containing one or more double bonds, said heterocycle
group optionally comprising one or more aromatic rings, and said
cyclic group optionally being singly or multiply substituted by
--NH.sub.2, --CO.sub.2H, --Cl, --F, --Br, --I, --NO.sub.2, --CN,
.dbd.O, --OH,
-perfluoro C.sub.1-3 alkyl,
##STR00112##
or -Q.sub.1; and
[0745] each Ar.sub.2 e is independently selected from the following
group, in which any ring may optionally be singly or multiply
substituted by -Q.sub.1 and -Q.sub.2:
##STR00113## [0746] X is N or CH; [0747] Y is O or S; [0748] each
Q.sub.1 is independently selected from the group consisting of:
[0749] --Ar.sub.1 [0750] --O--Ar.sub.1 [0751] --R.sub.9, [0752]
-T.sub.1-R.sub.9, and [0753]
--(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9;
[0754] each Q.sub.2 is independently selected from the group
consisting of --OH, --NH.sub.2, --CO.sub.2H, --Cl, --F, --Br, --I,
--NO.sub.2, --CN, --CF.sub.3, and
##STR00114##
[0755] provided that when --Ar.sub.1 is substituted with a Q.sub.1
group which comprises one or more additional --Ar.sub.1 groups,
said additional --Ar.sub.1 groups are not substituted with
Q.sub.1.
[0756] Preferred compounds of embodiment E of this invention
include but are not limited to:
##STR00115## ##STR00116##
[0757] Preferred compounds of embodiment E of this invention are
also those in which A is independently selected from the group
consisting the .alpha.-amino acids:
[0758] alanine,
[0759] histidine,
[0760] lysine,
[0761] phenylalanine,
[0762] proline,
[0763] tyrosine,
[0764] valine,
[0765] leucine,
[0766] isoleucine,
[0767] glutamine,
[0768] methionine,
[0769] homoproline,
[0770] 3-(2-thienyl) alanine, and
[0771] 3-(3-thienyl) alanine.
[0772] The ICE inhibitors of another embodiment (F) of this
invention are represented by formula .delta.:
##STR00117##
wherein:
[0773] R.sub.1 is R.sub.5-(A).sub.p-;
[0774] R.sub.5 is selected from the group consisting of: [0775]
--H, [0776] --Ar.sub.1, [0777] --CO--Ar.sub.1, [0778]
--SO.sub.2--Ar.sub.1, [0779] --R.sub.9, [0780] --CO--R.sub.9,
[0781] --CO--O--R.sub.9, [0782] --SO.sub.2--R.sub.9,
##STR00118##
[0783] each A is independently selected from the group consisting
of any .alpha.-amino acid;
[0784] p is 0, 1, 2, 3 or 4;
[0785] each R.sub.9 is a C.sub.1-6 straight or branched alkyl group
optionally singly or multiply substituted by --OH, --F, or .dbd.O
and optionally substituted with an Ar.sub.1 group;
[0786] each R.sub.10 is independently selected from the group
consisting of --H or a C.sub.1-6 straight or branched alkyl
group;
[0787] each T.sub.1 is independently selected from the group
consisting of: [0788] --CH.dbd.CH--, [0789] --O--, [0790] --S--,
[0791] --SO--,
[0792] each Ar.sub.1 is a cyclic group independently selected from
the set consisting of an aryl group which contains 6, 10, 12, or 14
carbon atoms and between 1 and 3 rings, a cycloalkyl group which
contains between 3 and 15 carbon atoms and between 1 and 3 rings,
said cycloalkyl group being optionally benzofused, and a
heterocycle group containing between 5 and 15 ring atoms and
between 1 and 3 rings, said heterocycle group containing at least
one heteroatom group selected from --O--, --S--, --SO--,
--SO.sub.2--, .dbd.N--, and --NH--, said heterocycle group
optionally containing one or more double bonds, said heterocycle
group optionally comprising one or more aromatic rings, and said
cyclic group optionally being singly or multiply substituted by
--NH.sub.2, --CO.sub.2H, --Cl, --F, --Br, --I, --NO.sub.2, --CN,
.dbd.O, --OH,
-perfluoro C.sub.1-3 alkyl,
##STR00119##
[0793] each Ar.sub.2 is independently selected from the following
group, in which any ring may optionally be singly or multiply
substituted by -Q.sub.1 and -Q.sub.2:
##STR00120##
[0794] each Q.sub.1 is independently selected from the group
consisting of:
[0795] --Ar.sub.1
[0796] --O--Ar.sub.1
[0797] --R.sub.9
[0798] -T.sub.1-R.sub.9, and
[0799] --(CH.sub.2).sub.1,2,3-T.sub.1-R.sub.9;
[0800] each Q.sub.2 is independently selected from the group
consisting of --OH, --NH.sub.2, --CO.sub.2H, --Cl, --F, --Br, --I,
--NO.sub.2, --CN, --CF.sub.3, and
##STR00121##
[0801] provided that when --Ar.sub.1 is substituted with a Q.sub.1
group which comprises one or more additional --Ar.sub.1 groups,
said additional --Ar.sub.1 groups are not substituted with
Q.sub.1;
[0802] each X is independently selected from the group consisting
of .dbd.N--, and .dbd.CH--; and
[0803] each Y is independently selected from the group consisting
of --O--, --S--, and --NH.
[0804] Preferred compounds of embodiment F of this invention
include but are not limited to:
##STR00122## ##STR00123##
[0805] Preferred compounds of embodiment F of this invention are
also those in which A is independently selected from the group
consisting the .alpha.-amino acids:
[0806] alanine,
[0807] histidine,
[0808] lysine,
[0809] phenylalanine,
[0810] proline,
[0811] tyrosine,
[0812] valine,
[0813] leucine,
[0814] isoleucine,
[0815] glutamine,
[0816] methionine,
[0817] homoproline,
[0818] 3-(2-thienyl) alanine, and
[0819] 3-(3-thienyl) alanine.
[0820] The compounds of this invention having a molecular weight of
less than or equal to about 700 Daltons, and more preferably
between about 400 and 600 Daltons, are preferred. These preferred
compounds may be readily absorbed by the bloodstream of patients
upon oral administration. This oral availability makes such
compounds excellent agents for orally-administered treatment and
prevention regimens against IL-1 mediated diseases.
[0821] The ICE inhibitors of this invention may be synthesized
using conventional techniques. Advantageously, these compounds are
conveniently synthesized from readily available starting
materials.
[0822] The compounds of this invention are among the most readily
synthesized ICE inhibitors known. Previously described ICE
inhibitors often contain four or more chiral centers and numerous
peptide linkages. The relative ease with which the compounds of
this invention can be synthesized represents an enormous advantage
in the large scale production of these compounds.
[0823] It should be understood that the compounds of this invention
may exist in various equilibrium forms, depending on conditions
including choice of solvent, pH, and others known to the
practitioner skilled in the art. All such forms of these compounds
are expressly included in the present invention. In particular,
many of the compounds of this invention, especially those which
contain aldehyde or ketone groups in R.sub.3 and carboxylic acid
groups in T, may take hemi-ketal (or hemi-acetal) or hydrated
forms, as depicted below:
##STR00124##
[0824] Depending on the choice of solvent and other conditions
known to the practitioner skilled in the art, compounds of this
invention may also take acyloxy ketal, acyloxy acetal, ketal or
acetal form:
##STR00125##
[0825] In addition, it should be understood that the equilibrium
forms of the compounds of this invention may include tautomeric
forms. All such forms of these compounds are expressly included in
the present invention.
[0826] It should be understood that the compounds of this invention
may be modified by appropriate functionalities to enhance selective
biological properties. Such modifications are known in the art and
include those which increase biological penetration into a given
biological system (e.g., blood, lymphatic system, central nervous
system), increase oral availability, increase solubility to allow
administration by injection, alter metabolism and alter rate of
excretion. In addition, the compounds may be altered to pro-drug
form such that the desired compound is created in the body of the
patient as the result of the action of metabolic or other
biochemical processes on the pro-drug. Some examples of pro-drug
forms include ketal, acetal, oxime, and hydrazone forms of
compounds which contain ketone or aldehyde groups, especially where
they occur in the R.sub.3 group of the compounds of this
invention.
[0827] The compounds of this invention are excellent ligands for
ICE. Accordingly, these compounds are capable of targeting and
inhibiting events in IL-1 mediated diseases, such as the conversion
of precursor IL-1.beta. to mature IL-1.beta. and, thus, the
ultimate activity of that protein in inflammatory diseases,
autoimmune diseases and neurodegenerative diseases. For example,
the compounds of this invention inhibit the conversion of precursor
IL-1.beta. to mature IL-1.beta. by inhibiting ICE. Because ICE is
essential for the production of mature IL-1, inhibition of that
enzyme effectively blocks initiation of IL-1 mediated physiological
effects and symptoms, such as inflammation, by inhibiting the
production of mature IL-1. Thus, by inhibiting IL-1.beta. precursor
activity, the compounds of this invention effectively function as
IL-1 inhibitors.
[0828] The compounds of this invention may be employed in a
conventional manner for the treatment of diseases which are
mediated by IL-1. Such methods of treatment, their dosage levels
and requirements may be selected by those of ordinary skill in the
art from available methods and techniques. For example, a compound
of this invention may be combined with a pharmaceutically
acceptable adjuvant for administration to a patient suffering from
an IL-1 mediated disease in a pharmaceutically acceptable manner
and in an amount effective to lessen the severity of that
disease.
[0829] Alternatively, the compounds of this invention may be used
in compositions and methods for treating or protecting individuals
against IL-1 mediated diseases over extended periods of time. The
compounds may be employed in such compositions either alone or
together with other compounds of this invention in a manner
consistent with the conventional utilization of ICE inhibitors in
pharmaceutical compositions. For example, a compound of this
invention may be combined with pharmaceutically acceptable
adjuvants conventionally employed in vaccines and administered in
prophylactically effective amounts to protect individuals over an
extended period time against IL-1 mediated diseases.
[0830] The compounds of this invention may also be co-administered
with other ICE inhibitors to increase the effect of therapy or
prophylaxis against various IL-1-mediated diseases.
[0831] In addition, the compounds of this invention may be used in
combination either conventional anti-inflammatory agents or with
matrix metalloprotease inhibitors, lipoxygenase inhibitors and
antagonists of cytokines other than IL-1.beta..
[0832] The compounds of this invention can also be administered in
combination with immunomodulators (e.g., bropirimine, anti-human
alpha interferon antibody, IL-2, GM-CSF, methionine enkephalin,
interferon alpha, diethyldithiocarbamate, tumor necrosis factor,
naltrexone and rEPO) or with prostaglandins, to prevent or combat
IL-1-mediated disease symptoms such as inflammation.
[0833] When the compounds of this invention are administered in
combination therapies with other agents, they may be administered
sequentially or concurrently to the patient. Alternatively,
pharmaceutical or prophylactic compositions according to this
invention may be comprised of a combination of an ICE inhibitor of
this invention and another therapeutic or prophylactic agent.
[0834] Pharmaceutical compositions of this invention comprise any
of the compounds of the present invention, and pharmaceutically
acceptable salts thereof, with any pharmaceutically acceptable
carrier, adjuvant or vehicle. Pharmaceutically acceptable carriers,
adjuvants and vehicles that may be used in the pharmaceutical
compositions of this invention include, but are not limited to, ion
exchangers, alumina, aluminum stearate, lecithin, serum proteins,
such as human serum albumin, buffer substances such as phosphates,
glycine, sorbic acid, potassium sorbate, partial glyceride mixtures
of saturated vegetable fatty acids, water, salts or electrolytes,
such as protamine sulfate, disodium hydrogen phosphate, potassium
hydrogen phosphate, sodium chloride, zinc salts, colloidal silica,
magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based
substances, polyethylene glycol, sodium carboxymethylcellulose,
polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers,
polyethylene glycol and wool fat.
[0835] The pharmaceutical compositions of this invention may be
administered orally, parenterally, by inhalation spray, topically,
rectally, nasally, buccally, vaginally or via an implanted
reservoir. We prefer oral administration. The pharmaceutical
compositions of this invention may contain any conventional
non-toxic pharmaceutically-acceptable carriers, adjuvants or
vehicles. The term parenteral as used herein includes subcutaneous,
intracutaneous, intravenous, intramuscular, intra-articular,
intrasynovial, intrasternal, intrathecal, intralesional and
intracranial injection or infusion techniques.
[0836] The pharmaceutical compositions may be in the form of a
sterile injectable preparation, for example, as a sterile
injectable aqueous or oleaginous suspension. This suspension may be
formulated according to techniques known in the art using suitable
dispersing or wetting agents (such as, for example, Tween 80) and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution or suspension in a non-toxic
parenterally-acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are mannitol, water, Ringer's
solution and isotonic sodium chloride solution. In addition,
sterile, fixed oils are conventionally employed as a solvent or
suspending medium. For this purpose, any bland fixed oil may be
employed including synthetic mono- or diglycerides. Fatty acids,
such as oleic acid and its glyceride derivatives are useful in the
preparation of injectables, as are natural
pharmaceutically-acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil solutions
or suspensions may also contain a long-chain alcohol diluent or
dispersant such as those described in Pharmacopeia Helvetica, Ph.
Helv, or a similar alcohol.
[0837] The pharmaceutical compositions of this invention may be
orally administered in any orally acceptable dosage form including,
but not limited to, capsules, tablets, and aqueous suspensions and
solutions. In the case of tablets for oral use, carriers which are
commonly used include lactose and corn starch. Lubricating agents,
such as magnesium stearate, are also typically added. For oral
administration in a capsule form, useful diluents include lactose
and dried corn starch. When aqueous suspensions are administered
orally, the active ingredient is combined with emulsifying and
suspending agents. If desired, certain sweetening and/or flavoring
and/or coloring agents may be added.
[0838] The pharmaceutical compositions of this invention may also
be administered in the form of suppositories for rectal
administration. These compositions can be prepared by mixing a
compound of this invention with a suitable non-irritating excipient
which is solid at room temperature but liquid at the rectal
temperature and therefore will melt in the rectum to release the
active components. Such materials include, but are not limited to,
cocoa butter, beeswax and polyethylene glycols.
[0839] Topical administration of the pharmaceutical compositions of
this invention is especially useful when the desired treatment
involves areas or organs readily accessible by topical application.
For application topically to the skin, the pharmaceutical
composition should be formulated with a suitable ointment
containing the active components suspended or dissolved in a
carrier. Carriers for topical administration of the compounds of
this invention include, but are not limited to, mineral oil, liquid
petroleum, white petroleum, propylene glycol, polyoxy-ethylene
polyoxypropylene compound, emulsifying wax and water.
Alternatively, the pharmaceutical composition can be formulated
with a suitable lotion or cream containing the active compound
suspended or dissolved in a carrier. Suitable carriers include, but
are not limited to, mineral oil, sorbitan monostearate, polysorbate
60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl
alcohol and water. The pharmaceutical compositions of this
invention may also be topically applied to the lower intestinal
tract by rectal suppository formulation or in a suitable enema
formulation. Topically-transdermal patches are also included in
this invention.
[0840] The pharmaceutical compositions of this invention may be
administered by nasal aerosol or inhalation. Such compositions are
prepared according to techniques well-known in the art of
pharmaceutical formulation and may be prepared as solutions in
saline, employing benzyl alcohol or other suitable preservatives,
absorption promoters to enhance bioavailability, fluorocarbons,
and/or other solubilizing or dispersing agents known in the
art.
[0841] The IL-1 mediated diseases which may be treated or prevented
by the compounds of this invention include, but are not limited to,
inflammatory diseases, autoimmune diseases and neurodegenerative
diseases.
[0842] Inflammatory diseases which may be treated or prevented
include, for example, septic shock, septicemia, and adult
respiratory distress syndrome. Target autoimmune diseases include,
for example, rheumatoid, arthritis, systemic lupus erythematosus,
scleroderma, chronic thyroiditis, Graves' disease, autoimmune
gastritis, insulin-dependent diabetes mellitus, autoimmune
hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic
active hepatitis, myasthenia gravis and multiple sclerosis. And
target neurodegenerative diseases include, for example, amyotrophic
lateral sclerosis, Alzheimer's disease, Parkinson's disease, and
primary lateral sclerosis. The ICE inhibitors of this invention may
also be used to promote wound healing. And the ICE inhibitors of
this invention may be used to treat infectious diseases.
[0843] Although this invention focuses on the use of the compounds
disclosed herein for preventing and treating IL-1-mediated
diseases, the compounds of this invention can also be used as
inhibitory agents for other cysteine proteases.
[0844] The compounds of this invention are also useful as
commercial reagents which effectively bind to ICE or other cysteine
proteases. As commercial reagents, the compounds of this invention,
and their derivatives, may be used to block proteolysis of a target
peptide or may be derivatized to bind to a stable resin as a
tethered substrate for affinity chromatography applications. These
and other uses which characterize commercial cysteine protease
inhibitors will be evident to those of ordinary skill in the
art.
[0845] In order that this invention be more fully understood, the
following examples are set forth. These examples are for the
purpose of illustration only and are not to be construed as
limiting the scope of the invention in any way.
Example 1
[0846] The following example demonstrates a process of drug design
which embodies the present invention: [0847] Step 1) Pick 2
hydrogen bonding moieties of ICE, here, the backbone C.dbd.O and
N--H of Arg-341. [0848] Step 2) Pick a scaffold, here, a pyridone
derivative, and confirm that the hydrogen bonding moieties of the
scaffold are capable of forming satisfactory hydrogen bonds with
the hydrogen bonding moieties selected in step 1. This confirmation
is performed by using molecular mechanics techniques to minimize
the scaffold fragment in the context of the active site of ICE.
[0848] ##STR00126## [0849] Step 3) Pick a hydrophobic pocket, here,
S2, as next target and a hydrophobic moiety, here, benzene.
Minimize the benzene group within the S2 pocket to assure that
substantial hydrophobic overlap is obtained.
[0849] ##STR00127## [0850] Step 4) Pick another hydrophobic pocket,
here, S4, as the next target and a hydrophobic moiety, here,
benzene. Minimize the benzene group within the S4 pocket to ensure
that substantial hydrophobic overlap is obtained.
[0850] ##STR00128## [0851] Step 5) Fill the S1 polar pocket with an
electronegative moiety, here, a carboxylate sidechain provided by
aspartic acid in which the C-terminus has been reduced to an
aldehyde. Minimize to ensure that the carboxylate sidechain retains
a favorable electrostatic interaction with the S1 polar pocket.
[0851] ##STR00129## [0852] Step 6) Link the scaffold with the
moieties from steps 3, 4, and 5, preferably using the minimum
number of bonds consistent with a chemically reasonable structure.
Minimize the entire composite molecule in the active site of
ICE.
[0852] ##STR00130## [0853] Step 7) Evaluate the energy of the
molecule when it has the conformation necessary for binding to ICE.
Then minimize and reevaluate the energy--this is the free
conformation energy. The strain energy for binding of the potential
inhibitor to ICE is the difference between the free conformation
energy and the bound conformation energy. The strain energy should
be less than about 10 kcal/mol. In this case the bound conformation
energy is -1.6 kcal/mol and the free conformation energy is -11.7
kcal/mol, for a strain energy of 10.1 kcal/mol. [0854] Step 8) The
inhibitor designed using the above steps has been made and has been
show to have a K.sub.i of 150 nM.
Example 2
[0855] We obtained inhibition constants (K.sub.i) and IC.sub.50
values for several compounds of this invention using the three
methods described below:
1. Enzyme Assay with UV-Visible Substrate
[0856] This assay is run using an
Succinyl-Tyr-Val-Ala-Asp-pNitroanilide substrate. Synthesis of
analogous substrates is described by L. A. Reiter (Int. J. Peptide
Protein Res. 43, 87-96 (1994)). The assay mixture contains:
TABLE-US-00002 65 .mu.l buffer (10 mM Tris, 1 mM DTT, 0.1% CHAPS
@pH 8.1) 10 .mu.l ICE (50 nM final concentration to give a rate of
~1 mOD/min) 5 .mu.l DMSO/Inhibitor mixture 20 .mu.l 400 .mu.M
Substrate (80 .mu.M final concentration) 100 .mu.l total reaction
volume
[0857] The visible ICE assay is run in a 96-well microtiter plate.
Buffer, ICE and DMSO (if inhibitor is present) are added to the
wells in the order listed. The components are left to incubate at
room temperature for 15 minutes starting at the time that all
components are present in all wells. The microtiter plate reader is
set to incubate at 37.degree. C. After the 15 minute incubation,
substrate is added directly to the wells and the reaction is
monitored by following the release of the chromophore (pNA) at
405-603 nm at 37.degree. C. for 20 minutes. A linear fit of the
data is performed and the rate is calculated in mOD/min. DMSO is
only present during experiments involving inhibitors, buffer is
used to make up the volume to 100 .mu.l in the other
experiments.
2. Enzyme Assay with Fluorescent Substrate
[0858] This assay is run essentially according to Thornberry et al.
(Nature 356: 768-774 (1992)), using substrate 17 referenced in that
article. The substrate is:
Acetyl-Tyr-Val-Ala-Asp-amino-4-methylcoumarin (AMC). The following
components are mixed:
TABLE-US-00003 65 .mu.l buffer (10 mM Tris, 1 mM DTT, 0.1% CHAPS
@pH 8.1) 10 .mu.l ICE (2-10 nM final concentration) 5 .mu.l
DMSO/inhibitor solution 20 .mu.l 150 .mu.M Substrate (30 .mu.M
final) 100 .mu.l total reaction volume
[0859] The assay is run in a 96 well microtiter plate. Buffer and
ICE are added to the wells. The components are left to incubate at
37.degree. C. for 15 minutes in a temperature-controlled wellplate.
After the 15 minute incubation, the reaction is started by adding
substrate directly to the wells and the reaction is monitored
@37.degree. C. for 30 minutes by following the release of the AMC
fluorophore using an excitation wavelength for 380 nm and an
emission wavelength of 460 nm. A linear fit of the data for each
well is performed and a rate is determined in fluorescence units
per second.
[0860] For determination of enzyme inhibition constants (K.sub.i)
or the mode of inhibition (competitive, uncompetitive or
noncompetitive), the rate data determined in the enzyme assays at
varying inhibitor concentrations are computer-fit to standard
enzyme kinetic equations (see I. H. Segel, Enzyme Kinetics,
Wiley-Interscience, 1975).
3. Cell Assay
[0861] IL-1.beta. Assay with a Mixed Population of Human Peripheral
Blood Mononuclear Cells (PBMC) or Enriched Adherent Mononuclear
Cells
[0862] Processing of pre-IL-1S by ICE can be measured in cell
culture using a variety of cell sources. Human PBMC obtained from
healthy donors provides a mixed population of lymphocyte subtypes
and mononuclear cells that produce a spectrum of interleukins and
cytokines in response to many classes of physiological stimulators.
Adherent mononuclear cells from PBMC provides an enriched source of
normal monocytes for selective studies of cytokine production by
activated cells.
Experimental Procedure
[0863] An initial dilution series of test compound in DMSO or
ethanol is prepared, with a subsequent dilution into RPMI-10% FBS
media (containing 2 mM L-glutamine, 10 mM HEPES, 50 U and 50 ug/ml
pen/strep) respectively to yield drugs at 4.times. the final test
concentration containing 0.4% DMSO or 0.4% ethanol. The final
concentration of DMSO is 0.1% for all drug dilutions. A
concentration titration which brackets the apparent K.sub.i for a
test compound determined in an ICE inhibition assay is generally
used for the primary compound screen.
[0864] We generally test 5-6 compound dilutions and have performed
the cellular component of the assay in duplicate, with duplicate
ELISA determinations on each cell culture supernatant.
PBMC Isolation and IL-1 Assay
[0865] Buffy coat cells isolated from one pint human blood
(yielding 40-45 ml final volume plasma plus cells) are diluted with
media to 80 ml and LeukoPREP separation tubes (Becton Dickinson)
are each overlaid with 10 ml of cell suspension. After 15 min
centrifugation at 1500-1800.times.g, the plasma/media layer is
aspirated and then the mononuclear cell layer is collected with a
Pasteur pipette and transferred to a 15 ml conical centrifuge tube
(Corning). Media is added to bring the volume to 15 ml, gently mix
the cells by inversion and centrifuge at 300.times.g for 15 min.
Resuspend the PBMC pellet in a small volume of media, count cells
and adjust to 6.times.10.sup.6 cells/ml.
[0866] For the cellular assay, add 1.0 ml of the cell suspension to
each well of a 24-well flat bottom tissue culture plate (Corning),
0.5 ml test compound dilution and 0.5 ml LPS solution (Sigma
#L-3012; 20 ng/ml solution prepared in complete RPMI media; final
LPS concentration 5 ng/ml). The 0.5 ml additions of test compound
and LPS are usually sufficient to mix the contents of the wells.
Three control mixtures are run per experiment, with either LPS
alone, solvent vehicle control, and/or additional media to adjust
the final culture volume to 2.0 ml. The cell cultures are incubated
for 16-18 hr at 37.degree. C. in the presence of 5% CO.sub.2.
[0867] At the end of the incubation period, cells are harvested and
transferred to 15 ml conical centrifuge tubes. After centrifugation
for 10 min at 200.times.g, supernatants are harvested and
transferred to 1.5 ml Eppendorf tubes. It may be noted that the
cell pellet may be utilized for a biochemical evaluation of
pre-IL-1S and/or mature IL-1.beta. content in cytosol extracts by
western blotting or ELISA with pre-IL-1.beta. specific
antisera.
Isolation of Adherent Mononuclear Cells
[0868] PBMC are isolated and prepared as described above. Media
(1.0 ml) is first added to wells followed by 0.5 ml of the PBMC
suspension. After a one hour incubation, plates are gently shaken
and nonadherent cells aspirated from each well. Wells are then
gently washed three times with 1.0 ml of media and final
resuspended in 1.0 ml media. The enrichment for adherent cells
generally yields 2.5-3.0.times.10.sup.5 cells per well. The
addition of test compounds, LPS, cell incubation conditions and
processing of supernatants proceeds as described above.
ELISA
[0869] We have used Quantikine kits (R&D Systems) for
measurement of mature IL-1.beta.. Assays are performed according to
the manufacturer's directions. Mature IL-1.beta. levels of about
1-3 ng/ml in both PBMC and adherent mononuclear cell positive
controls are observed. ELISA assays are performed on 1:5, 1:10 and
1:20 dilutions of supernatants from LPS-positive controls to select
the optimal dilution for supernatants in the test panel.
[0870] The inhibitory potency of the compounds can be represented
by an IC.sub.50 value, which is the concentration of inhibitor at
which 50% of mature IL-1.beta. is detected in the supernatant as
compared to the positive controls.
[0871] The following K.sub.i and IC.sub.50 values were determined
for compounds A through N using the indicated assays. Structures
for compounds A through N follow this table.
TABLE-US-00004 K.sub.i (.mu.M), by indicated assay: UV-visible
Fluorescence Cell Compound K.sub.i (.mu.M) K.sub.i (.mu.M)
IC.sub.50 (.mu.M) A 5.5 25.0 B 8.6 20.0 C 10 >30 D 4.7 E 3.2 F
0.15 2-4 G 4.8 H 0.023 0.0047 6-11 I 0.0072 0.0052 2.6 J 0.012
0.0039 5-7 K 0.010 0.002 2-11 L 0.014 M 0.15 N 0.95 Structures of
compounds A through N: A ##STR00131## B ##STR00132## C ##STR00133##
D ##STR00134## E ##STR00135## F ##STR00136## G ##STR00137## H
##STR00138## I ##STR00139## J ##STR00140## K ##STR00141## L
##STR00142## M ##STR00143## N ##STR00144##
Example 3
[0872] Compounds of Example 2 were synthesized as follows:
H. N-(N-Acetyl-tyrosinyl-valinyl-pipecolyl)-3-amino-4-oxobutanoic
acid
Step A.
N-(N-tert-Butoxycarbonylpipecolyl)-4-amino-5-benzyloxy-2-oxotetrah-
ydrofuran.
[0873] Reaction of N-tert-butoxycarbonylpipecolic acid (460 mg, 2.0
mmol) and
N-allyloxycarbonyl-4-amino-5-benzyloxy-2-oxotetrahydrofuran (530
mg, 1.82 mmol) was carried out by a method analogous to that
reported by Chapman (Bioorg. & Med. Chem. Lett. 1992, 2,
613-618.) to give 654 mg of the title compound.
[0874] .sup.1H NMR (500 MHz, CDCl.sub.3 (existing as rotamers))
.delta. 7.35 (m, 5H), 6.88 (br. s, 1H), 4.9-4.45 (m, 4H), 3.95 (br.
m, 2H), 3.06 (m, 1H), 2.9 (m, 1H), 2.7 (br. m, 1H), 2.45 (m, 1H),
2.2 (m, 1H), 1.7-1.5 (m, 3H), 1.45 (two s, 9H).
Step B. N-Pipecolyl-4-amino-5-benzyloxy-2-oxotetrahydrofuran
[0875]
N-(N-tert-Butoxycarbonylpipecolyl)-4-amino-5-benzyloxy-2-oxo-tetrah-
ydrofuran (654 mg) was dissolved in 15 ml of 25% trifluoroacetic
acid in dichloromethane and stirred at room temperature. The
mixture was concentrated to give a gummy residue. The residue was
dissolved in dichloromethane and washed with 10% sodium
bicarbonate. The organic layer was dried over anhydrous sodium
sulfate, filtered, and concentrated to give 422 mg of the title
compound as a beige solid.
[0876] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 7.38 (m, 5H), 7.15
(d, 1H), 5.55 (d, 1H), 4.95-4.8 (m, 1H), 4.78 (m, 1H), 4.65 (d,
1H), 4.45 (m, 1H), 3.2 (m, 0.5H), 3.05 (m, 0.5H), 2.95 (m, 0.5H),
2.85 (m, 0.5H), 2.65 (m, 1H), 2.55-2.38 (m, 1H), 1.95 (m, 1H), 1.8
(m, 1H), 1.6 (m, 2H), 1.38 (m, 2H).
Step C.
N-(N-Acetyl-tyrosinyl-valinyl-pipecolyl)-4-amino-5-benzyloxy-2-oxo-
tetrahydrofuran
[0877] N-Acetyl-tyrosinyl-valine (464 mg, 1.44 mmol) and
N-Pipecolyl-4-amino-5-benzyloxy-2-oxotetrahydrofuran (412 mg, 1.3
mmol) were dissolved in 5 ml each of dimethylformamide and
dichloromethane and cooled to 0.degree. C. To the cooled solution
was added 1-hydroxybenzotriazole (HOBT; 210 mg, 1.56 mmol) followed
by the addition of 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide
hydrochloride (EDC; 326 mg, 1.7 mmol). After stirring for 18 hours,
the mixture was diluted with ethyl acetate and washed with water,
10% sodium hydrogen sulfate, 10% sodium bicarbonate, and water. The
organic layer was concentrated to give a crude solid that was
purified by flash chromatography (SiO.sub.2) eluting with 94:6:1
(dichloromethane:isopropanol: pyridine) to give 370 mg of the title
compound.
[0878] .sup.1H NMR (500 MHz, CD.sub.3OD (existing as diastereomers
as well as rotamers)) .delta. 7.35 (m, 5H), 7.05 (m, 2H), 6.68 (m,
2H), 5.65 & 5.25 (m, 1H), 4.9-3.95 (m, 8H), 3.4-2.6 (m, 4H),
2.5-2.1 (m, 1H), 1.98 (s, 1H), 1.9 (s, 1H), 1.85 (s, 1H), 1.8-1.6
(m, 2H), 1.55-1.3 (m, 4H), 0.95-0.85 (m, 6H).
Step D.
N-(N-Acetyl-tyrosinyl-valinyl-pipecolyl)-3-amino-4-oxobutanoic
acid
[0879] To a solution of 100 mg of
N-(N-Acetyl-tyrosinyl-valinyl-pipecolyl)-4-amino-5-benzyloxy-2-oxotetrahy-
drofuran in 10 ml of methanol was added 60 mg of Pd(OH).sub.2 on
carbon and the mixture placed under an atmosphere of hydrogen via a
balloon. The mixture was filtered through Celite and concentrated
providing a white solid. This crude solid was dissolved in 2 ml of
methanol and triturated with diethyl ether affording 26 mg of the
title compound.
[0880] .sup.1H NMR (500 MHz, CD.sub.3OD (existing as diastereomers
as well as rotamers)) .delta. 7.1 (m, 2H), 6.7 (m, 2H), 5.2 (br. m,
1H), 4.8-3.6 (m, 6H), 3.2-2.5 (m, 4H), 2.5-2.1 (m, 1H), 1.95 (three
s, 3H), 1.9-1.3 (m, 6H), 1.1-0.7 (m, 6H).
The following compounds were prepared by a method analogous to that
reported for H:
J.
N-[N-Acetyl-tyrosinyl-valinyl-(4-hydroxyprolinyl)]-3-amino-4-oxobutanoi-
c acid
[0881] Substitute N-tert-butoxycarbonyl-4-benzyloxyproline for
N-tert-butoxycarbonylpipecolic acid.
L.
N-[2-(N-Acetyl-tyrosinyl-valinyl)-(S)-1,2,3,4-tetrahydroisoquinoline-3--
carbonyl]-3-amino-oxobutanoic acid
[0882] Substitute
(S)-N-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic
acid for N-tert-butoxycarbonylpipecolic acid.
I.
N-(N-Acetyl-tyrosinyl-valinyl-(4-phenoxyprolinyl))-3-amino-4-oxobutanoi-
c acid
Step A. N-tert-Butoxycarbonyl-4-phenoxyproline methyl ester.
[0883] To a cooled solution (0.degree. C.) of
N-tert-butoxy-cis-4-hydroxyproline (2-0 g, 8.15 mmol), phenol (0.77
g, 8.15 mmol), and triphenylphosphine (2.14 g, 8.15 mmol) in 20 ml
of tetrahydrofuran was added diethyl azodicarboxylate (1.4 ml, 9
mmol) dropwise over 30 minutes. The reaction was stirred at room
temperature for 16 hrs. then concentrated to give a viscous
residue. The crude residue was purified by flash chromatography
(SiO.sub.2) eluting with 3:7 (ethyl acetate:hexane) to give 1.89 g
of the title compound.
[0884] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 7.3 (m, 2H), 6.95
(m, 1H), 6.85 (d, 2H), 4.9 (m br., 1H), 4.55-4.15 (m, 2H),
3.88-3.65 (m, 1H), 3.70 (s, 3H), 2.58 (m, 1H), 2.22 (m, 1H), 1.4
(3.times.s, 9H).
Step B. 4-Phenoxyproline methyl ester hydrochloride
[0885] To a cooled solution (ice bath) of
N-tert-Butoxycarbonyl-4-phenoxyproline methyl ester (0.6 g) in 20
ml of ethyl acetate was bubbled anhydrous hydrogen chloride until
saturated. The mixture was warmed to room temperature and stirred
for 3 hrs. then concentrated to give 480 mg of the title
compound.
[0886] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 7.22 (m, 2H), 6.95
(m 1H), 6.83 (m, 2H), 5.1 (br., 1H), 4.6 (br. m, 1H), 4.06 (br. m,
1H), 3.75 (s, 3H), 3.55 (br. m, 1H), 2.58 (m, 2H).
Step C. N-Acetyl-tyrosinyl-valinyl-(4-phenoxy)proline methyl
ester
[0887] N-Acetyl-tyrosinyl-valine (0.524 g, 1.63 mmol) and
4-phenoxyproline methyl ester (0.381 g, 1.48 mmol) were dissolved
in 4 ml each of dimethylformamide and dichloromethane and cooled to
0.degree. C. To the cooled solution was added diisopropylethylamine
(258 ul, 1.86 mmol), HOBT (0.24 g, 1.78 mmol), and EDC (0.37 g,
1.92 mmol) and the reaction was stirred for 18 hrs. The mixture was
diluted with 400 ml of ethyl acetate and washed with water, 10%
sodium hydrogen sulfate, 10% sodium bicarbonate, and water. The
organic layer was concentrated to give a residue that was purified
by flash chromatography (SiO.sub.2) eluting with 94:6:1
(CH.sub.2Cl.sub.2:i-PrOH:Pyridine) to afford 360 mg of the title
compound.
[0888] .sup.1H NMR (500 MHz, CDCl.sub.3 (existing as rotamers))
.delta. 7.3 (m, 2H), 7.05 (m, 1H), 6.95 (d, 2H), 6.9-6.2
(4.times.d, 4H), 5.05 (br. s, 1H), 4.7-3.94 (m, 5H), 2.93 (m, 1H),
2.82 (m, 1H), 2.65 (m, 1H), 2.2 (m, 1H), 2.05 (m, 1H), 1.95 (s,
3H), 1.86, (m, 1H), 0.98 (d, 3H), 0.88 (d, 3H).
Step D. N-Acetyl-tyrosinyl-valinyl-(4-phenoxy)proline
[0889] Lithium hydroxide (57 mg, 1.37 mmol) was added to a solution
of N-Acetyl-tyrosinyl-valinyl-(4-phenoxy)proline methyl ester (360
mg, 0.685 mmol) dissolved in 8 ml of tetrahydrofuran/water (1:1)
and stirred at room temperature for 1 hour. The mixture was
acidified with 10% hydrochloric acid giving a white precipitate
that was collected to give 175 mg of the title compound.
[0890] .sup.1H NMR (500 MHz, DMSO-d6) .delta. 9.2 (br. s, 1H),
8.05-7.95 (m, 2H), 7.3 (m, 1H), 7.0-6.9 (m, 4H), 6.65 (d, 2H), 4.42
(m, 1H), 4.35 (m, 1H), 4.05-3.95 (m, 2H), 3.3 (br. s, 2H), 2.75 (m,
1H), 2.55-2.38 (m, 2H), 2.2 (m, 1H), 2.0 (m, 1H), 1.7 (s, 3H), 0.95
(d, 3H), 0.85 (d, 3H).
Step E.
N-[N-Acetyl-tyrosinyl-valinyl-(4-phenoxy)prolinyl]-4-amino-5-benzy-
loxy-2-oxotetrahydrofuran
[0891] The title compound was prepared by the method reported for
compound H, step A, by reaction of
N-acetyl-tyrosinyl-valinyl-(4-phenoxy)proline and
N-allyloxycarbonyl-4-amino-5-benzyloxytetrahydrofuran.
[0892] .sup.1H NMR (500 MHz, CDCl.sub.3 (existing as a 1:1
diastereomer mixture of the hemiacetal)) .delta. 7.8-6.3 (m, 17H),
5.6 (d, 1H), 5.1-4.15 (m, 5H), 4.15-3.75 (m, 2H), 2.95-2.15 (m,
5H), 2.15-1.95 (m, 1H), 1.9-1.85 (2.times.s, 3H), 1.1-0.75 (m,
6H).
Step F.
N-[N-Acetyl-tyrosinyl-valinyl-(4-phenoxy)prolinyl]-3-amino-4-oxobu-
tanoic acid
[0893] The title compound was prepared by the hydrogenolysis
procedure reported for compound H, step D.
[0894] .sup.1H NMR (500 MHz, CD.sub.3OD (existing as a 1:1
diastereomer mixture of the hemiacetal)) .delta. 7.25 (m, 2H),
7.10-6.85 (m, 5H), 6.65 (d, 2H), 5.1 (br. m, 1H), 4.65-4.05 (m,
5H), 4.0-3.40 (m, 2H), 2.95-2.35 (m, 5H), 2.25 (m, 1H), 2.05 (m,
1H), 1.85 (s, 3H), 1.0 (d, 3H), 0.95 (d, 3H).
K.
N-[N-Acetyl-tyrosinyl-valinyl-(4-benzyloxy)prolinyl]-3-amino-4-oxobutan-
oic acid
Step A.
N-(N-Allyloxycarbonyl-4-benzyloxy)prolinyl)-3-amino-4-oxobutanoic
acid tert-butyl ester semicarbazone
[0895] The title compound was prepared by the reaction of
N-allyloxycarbonyl-4-benzyloxyproline and 3-amino-4-oxobutanoic
acid tert-butyl ester semicarbazone (T. L. Graybill et. al.,
Abstracts of papers, 206th National Meeting of the American
Chemical Society, Abstract MEDI-235. Chicago, Ill. (1993)) under
similar peptide coupling conditions as reported above (compound H;
Step C).
[0896] .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. 9.05 (br. s, 1H),
7.85 (br. m, 1H), 7.4-7.2 (m, 5H), 7.15 (br. s, 1H), 6.55 (br. s,
1H), 5.9 (m, 1H), 5.1-4.9 (br. m, 2H), 4.65-4.4 (m, 4H), 4.2 (br.
m, 1H), 3.75-3.5 (m, 2H), 2.75-2.55 (m, 2H), 2.5 (br. m, 1H), 2.25
(br. m, 1H) 1.4 (s, 9H).
Step B.
N-(N-Acetyl-tyrosinyl-valinyl-(4-benzyloxyprolinyl))-3-amino-4-oxo-
butanoic acid tert-butyl ester semicarbazone
[0897] The title compound was prepared by reaction of
N-acetyl-tyrosinyl-valine and
N-(N-allyloxycarbonyl-4-benzyloxyprolinyl)-3-amino-4-oxobutanoic
acid tert-butyl ester semicarbazone by reaction conditions reported
for compound H, step A.
[0898] .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 7.35-7.2 (m, 6H),
7.0 (d, 2H), 6.65 (d, 2H), 4.85 (m, 1H), 4.6-4.45 (m, 4H), 4.3 (br.
m, 1H), 4.15 (m, 1H), 3.7 (m, 1H), 2.95 (m, 1H), 2.75-2.6 (m, 3H),
2.35 (m, 1H), 2.1 (m, 1H), 1.9 (s, 3H), 1.4 (s, 9H), 0.95 (d, 3H),
0.90 (s, 3H).
Step C.
N-(N-Acetyl-tyrosinyl-valinyl-(4-benzyloxyprolinyl))-3-amino-4-oxo-
butanoic acid
[0899]
N-(N-Acetyl-tyrosinyl-valinyl-(4-benzyloxyprolinyl))-3-amino-4-oxob-
utanoic acid tert-butyl ester semicarbazone (270 mg) was dissolved
into 10 ml of 25% trifluoroacetic acid in dichloromethane and
stirred at room temperature for 3 hours. The mixture was
concentrated to give a solid residue. The residue was dissolved
into a 10 ml mixture of methanol:acetic acid:37% formaldehyde
(3:1:1) and stirred at room temperature for 1 hour. The mixture was
concentrated and the resulting residue purified by flash
chromatography (SiO.sub.2) eluting with
dichloromethane/methanol/formic acid (100:5:0.5) to give 37 mg of
the title compound.
[0900] .sup.1H NMR (500 MHz, CD.sub.3OD (existing as a 1:1 mixture
of diastereomers of the hemiacetal)) .delta. 7.4-7.25 (m, 5H), 7.0
(d, 2H), 6.65 (d, 2H), 4.65-4.05 (m, 7H), 3.75-3.4 (m, 2H),
3.05-2.3 (m, 5H), 2.2-1.95 (m, 2H), 1.90 (s, 3H), 1.0 (d, 3H), 0.95
(d, 3H).
Example 4
[0901] We obtained inhibition constants (K.sub.i) and IC.sub.50
values for several compounds of this invention using enzyme assays
with UV-visible substrate and cell assays as described in Example
2. The following K.sub.i and IC.sub.50 values were determined for
compounds 7a, 7b, 20a-d, 21c-f, 22e, 25, 28,33a-c, 36a, 36b, 39,
43, 47a, 47b, 54a-1, 63, 69a, 69b, 84a and 84b using the indicated
assays. Corresponding lettered compound designations are indicated
parenthetically. The compound structures are shown in Examples 2
and 5.
TABLE-US-00005 Assay UV-visible Cell Compound K.sub.i (.mu.M)
IC.sub.50 (.mu.M) 7a 35 7b 1.2 20a (=E) 3.2 20b 0.85 16.4 20c (=N)
0.95 20d 0.1 6.2 21c 0.64 21d 0.24 4.8 21e 0.22 2.9 21f 0.17 2.9
22e 0.19 25 6.2 28 12.0 33a (=A) 5.5 25.0 33b (=C) 10.0 >30.0
33c (=B) 8.6 20.0 36a (=D) 4.7 36b 0.8 17.0 39 2.5 43 20.0 47a
0.019 2.1 47b 0.027 1.8 54a (=F) 0.15 2.7 54b (=M) 0.15 9.1 54c 1.2
>19.0 54d 1.0 54e 3.5 54f 0.9 54g (=G) 4.8 >20.0 54h 0.97 54i
0.054 2.4 54j 0.28 54k 0.085 54l 0.215 7.0 63 (=Q) 0.85 4.1 69a
(=R) 0.011 0.735 69b (=S) 0.050 0.745 84a (=V) 0.100 3.3 84b (=W)
0.019 0.50
Example 5
[0902] Compounds of Example 4 were synthesized as follows:
##STR00145##
3-Benzoylamino-4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-6-carbox-
ylic acid methyl ester (3). A mixture of
(4S)-2-amino-1-pyrroline-5-carboxylic acid ethyl ester
hydrochloride (1, 0.44 g, 2.38 mmol; prepared in an analogous
fashion as the methyl ester as described by Lee and Lown, J. Org.
Chem., 52, 5717-21 (1987));
4-ethoxymethylene-2-phenyl-2-oxazolin-5-one (2, 0.50 g, 2.31 mmol)
and sodium methoxide (0.12 g, 2.22 mmol) in ethanol (10 ml) was
refluxed for 2 h. The reaction was allowed to cool to room
temperature and concentrated in vacuo. The residue was suspended in
water and 1N sulfuric acid was added until pH 1 was reached. The
aqueous mixture was extracted with dichloromethane, the organic
layer was separated and concentrated in vacuo to yield 0.6 g of a
orange solid. Chromatography (flash, SiO.sub.2, 60% ethyl
acetate/hexane increased to 100% ethyl acetate stepwise gradient,
then 10% methanol/dichloromethane) to give 0.5 g of an orange
solid. A mixture of the orange solid and potassium cyanide (0.03 g,
0.5 mmol) in methanol (10 ml) was refluxed overnight. The cooled
reaction was concentrated in vacuo to give a yellow solid.
Chromatography (flash, SiO.sub.2, 40% ethyl acetate/hexane to 100%
ethyl acetate stepwise gradient) afforded 0.22 g (31.6%) of the
title compound: .sup.1H NMR (d.sub.6-DMSO) .delta. 2.25 (m, 1H),
2.65 (m, 1H), 3.15 (m, 2H), 3.75 (s, 3H), 5.15 (dd, 1H), 7.5 (t,
2H), 7.6 (t, 1H), 7.95 (d, 2H), 8.6 (s, 1H), 9.5 (s, 1H).
(3S)-[(3-benzoylamino-4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-6-
-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester
semicarbazone (5a and 5b). A mixture of
3-benzoylamino-4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-6-carbox-
ylic acid ethyl ester (3, 0.22 g 0.70 mmol) and lithium hydroxide
hydrate (0.032 g, 0.76 mmol) in methanol (5 ml) and tetrahydrofuran
(5 ml) and was stirred 18 h at room temperature. The reaction was
concentrated to give
3-benzoylamino-4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pryrimidine-6--
carboxylic acid lithium salt (4) as a white solid. This was used
without further purification in the subsequent reaction.
[0903] A 0.degree. C. mixture of (3S)-amino-4-oxo-butanoic acid
tert-butyl ester semicarbazone (0.163 g, 0.71 mmol; Graybill et
al., Int. J. Protein Res., 44, pp. 173-82 (1994)) and
3-benzoylamino-4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-6-carbox-
ylic acid lithium salt (4) in dimethylformamide (5 ml) and
dichloromethane (5 ml) was treated with hydroxybenzotriazole (0.104
g, 0.77 mmol) and 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide
hydrogen chloride (0.148 g. 0.37 mmol). The reaction was allowed to
warm to room temperature and stirred 18 hr. The reaction was poured
onto water (50 ml) and extracted with ethyl acetate (2.times.50
mL). The combined organic layers were washed with aqueous 1M sodium
hydrogen sulfate solution, dilute aqueous sodium hydrogen carbonate
(50 mL) and saturated aqueous sodium chloride. The organic layer
was concentrated in vacuo to yield 0.43 g of a yellow solid.
Chromatography (flash, SiO.sub.2, ammonium
hydroxide/methanol/di-chloromethane (1:1:99 to 1:10:90 stepwise
gradient)) gave 0.11 g (30.9%) of the higher Rf diastereomer (5a):
.sup.1H NMR (CD.sub.3OD) .delta. 1.45 (s, 9H), 2.29-2.35 (m, 1H),
2.6-2.7 (m, 2H), 2.8 (dd, 1H), 3.1-3.15 (m, 1H), 3.2-3.3 (m, 1H),
4.9-4.95 (m, 1H), 5.2 (dd, 1H), 7.25 (d, 1H), 7.5-7.55 (m, 2H),
7.55-7.6 (m, 1H), 7.95 (d, 2H), 8.9 (s, 1H) and 0.11 g (30.9%) of
the lower Rf diastereomer (5b): .sup.1H NMR (CD.sub.3OD) .delta.
1.45 (s, 9H), 2.3-2.4 (m, 1H), 2.6-2.7 (m, 1H), 2.7-2.8 (m, 2H),
3.1-3.15 (m, 1H), 3.2-3.3 (m, 1H), 4.85-4.95 (m, 1H), 5.15 (dd,
1H), 7.25 (d, 1H), 7.55 (t, 2H), 7.6 (t, 1H), 7.95 (d, 2H), 8.9 (s,
1H). Diastereomer 5a and diastereomer 5b were taken on
separately.
(3S)-[(3-benzoylamino-4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-6-
-carbonyl)-amino]-4-oxo-butanoic acid (7a). A suspension of
(3S)-[(3-benzoylamino-4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-6-
-carbonyl)-amino]-4-oxo-butanoic acid tert-butyl ester
semicarbazone (5a, 0.11 g, 0.22 mmol) in dichloromethane (7.5 ml)
and trifluoroacetic acid (2.5 ml) was stirred for 5 h. The reaction
was concentrated in vacuo, the residue was taken up in
dichloromethane, concentrated in vacuo, suspended in toluene and
concentrated in vacuo to give 0.07 g of
(3S)-[(3-benzoylamino-4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-6-
-carbonyl)-amino]-4-oxo-butanoic acid semicarbazone (6a) as a white
solid. The solid was suspended in a mixture of 37% aqueous
formaldehyde/acetic acid/methanol (1:1:5) and stirred at room
temperature for 18 hr. The reaction was concentrated in vacuo, the
residue was suspended in acetonitrile and concentrated in vacuo to
give 0.1 g of a white solid. Chromatography (HPLC, reverse phase
C18, 1% to 75% acetonitrile/water (buffered with 0.1%
trifluoroacetic acid) gradient elution) to give 0.05 g (60%) of 7a
as a white solid: RT=7.9 min (HPLC, C18 reverse phase, 1 to 100%
acetonitrile/water (0.1% trifluoroacetic acid buffer); 20 min
gradient elution); .sup.1H NMR (CD.sub.3OD (existing as a 1:1
mixture of anomers of the hemi-acyloxy acetal form)) .delta.
2.25-2.4 (m, 1H), 2.45-2.8 (m, 4H), 3.05-3.15 (m, 1H), 4.25-4.35
(m, 1H), 4.55-4.6 (m, 1H), 5.1-5.2 (m, 1H), 7.45-7.65 (m, 3H),
7.9-8.0 (m, 2H), 8.9 (s, 1H).
(3S)-[(3-benzoylamino-4-oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-6-
-carbonyl)-amino]-4-oxo-butanoic acid (7b) was prepared as
described for diastereomer 7a to give 0.03 g (35%) of 7b as a white
solid: RT=8.1 min (HPLC, C18 reverse phase, 1 to 100%
acetonitrile/water (0.1% trifluoroacetic acid buffer); 20 min
gradient elution); .sup.1H NMR (d.sub.6-DMSO (existing as a 1:1
mixture of anomers of the hemi-acyloxy acetal form)) .delta.
2.1-2.2 (m, 1H), 2.4 (d, 1H), 2.7-2.8 (m, 1H), 3.0-3.2 (m, 3H), 5.0
(dd, 1H), 5.1-5.2 (m, 1H), 5.5 (s, 1H), 5.7-5.8 (m, 1H), 7.55 (t,
2H), 7.67 (t, 1H), 7.95 (d, 2H), 8.55 (s, 1H), 9.0-9.15 (m, 1H),
9.4-9.5 (m, 1H).25198387.sub.--1 2003
##STR00146##
Imidazole-2-carboxylic acids 13 were prepared using modifications
of described procedures (Yamanaka et al., Chem. Pharm. Bull., 31,
pp. 4549-53 (1983)); Suzuki et al., J. Org. Chem., 38, pp. 3571-75
(1973)); and Oliver et al. (J. Org. Chem., 38, pp. 1437-38 (1973)).
Imidazole-2-carboxylic acid (13a) was prepared according to Curtis
and Brown, J. Org. Chem., 45, pp. 4038-40 (1980).
4-Benzylimidazole-2-carboxylic acid (13b), was isolated as an
off-white solid: mp. 153-155.degree. C.; IR (KBr) 3026-2624, 1630,
1515, 1498, 1438, 1405; .sup.1H NMR (d.sub.6-DMSO) .delta. 7.31
(5H, m), 7.14 (1H, s), 3.95 (2H, s).
4-(2-Phenylethyl)imidazole-2-carboxylic acid (13c), was isolated as
a pale yellow solid: mp. 151-153.degree. C.; IR (KBr) 3054-2617,
1637, 1497, 1376; .sup.1H NMR (d.sub.6-DMSO) .delta. 7.27 (5H, m),
7.11 (1H, s), 2.92 (4H, s).
4-(3-Phenylpropyl)imidazole-2-carboxylic acid (13d), was isolated
as a pale yellow solid: mp. 148-150.degree. C.; IR (KBr) 3020-2615,
1636, 1509, 1498, 1383; .sup.1H NMR (d.sub.6-DMSO) .delta.
7.35-7.22 (5H, m), 7.01 (1H, s), 2.62 (4H, m), 1.94 (2H, m).
4-[3-(4-Methoxyphenyl)propyl]imidazole-2-carboxylic acid (13e), was
isolated as a white crystalline solid: mp. 155-156.degree. C.
(decomp.); IR (KBr) 3300-2300, 1633, 1513, 1376, 1244; .sup.1H NMR
(d.sub.6-DMSO) .delta. 9.50-7.50 (2H, bs), 7.15 (1H, s), 7.11 (2H,
d, J=8.5), 6.84 (2H, d, J=8.5), 3.71 (3H, s), 2.60-2.50 (4H, m),
1.86 (2H, m). Anal. Calcd for C.sub.14H.sub.16N.sub.2O.sub.3: C,
64.60; H, 6.20; N, 10.76. Found: C, 64.45; H, 6.21; N, 10.70.
4-[3-(4-Hydroxyphenyl)propyl]imidazole-2-carboxylic acid (13f). A
solution of the ethyl ester of 13e (1.15 g, 4.0 mmol) in dry
dichloromethane (50 ml) was treated with boron tribromide (16 ml,
1.0M solution in CH.sub.2Cl.sub.2, 16.0 mmol) at 0.degree. C. After
15 min at 0.degree. C., the mixture was warmed to 25.degree. C. and
stirred for 16 h. The reaction mixture was cooled in an ice bath
and quenched with a dropwise addition of water (20 ml). The
resulting mixture was briefly stirred at 25.degree. C. then
filtered. The filtrate was carefully neutralised by the addition of
solid NaHCO.sub.3 to afford 13f (700 mg, 71%) as a white solid:
m.p. 186-187.degree. C. (decomp.) (recrystallised from MeOH); IR
(KBr) 3500-2400, 2935, 1640, 1516, 1396, 1232; .sup.1H NMR
(d.sub.6-DMSO) .delta. 9.83 (3H, bs), 7.16 (1H, s), 6.98 (2H, d,
J=8.2), 6.66 (2H, d, J=8.2), 2.60-2.40 (4H, m), 1.84 (2H, m). Anal.
Calcd for C.sub.13H.sub.14N.sub.2O.sub.3: C, 63.40; H, 5.73; N,
11.38. Found: C, 62.96; H, 5.70; N, 11.27.
(2R,S,3S)N.sup.2-Tert-butoxycarbonyl-N-(tetrahydro-2-benzyloxy-5-oxo-3-fu-
ranyl)-L-alaninamide (14). Tri-n-butyl tin hydride (4.0 ml, 14.9
mmol) was added dropwise to a solution of
(2R,S,3S)3-(N-allyloxycarbonyl)amino-2-benzyloxy-5-oxotetrahydrofuran
(Chapman, Biorg. Med. Chem. Lett., 2, pp. 613-18 (1992); (2.91 g,
10 mmol)), N-tert-butoxycarbonyl-L-alanine (2.08 g, 11 mmol) and
bis(triphenylphosphine)palladium (II) chloride (150 mg) in
dichloromethane (75 ml) until the colour of the solution turned
dark orange. Hydroxybenzotriazole (2.70 g, 20 mmol) was added, and
the mixture cooled to 0.degree. C.
1-(3-dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (2.30
g, 12 mmol) was added then the mixture was allowed to warm slowly
to room temperature during 4 h. The mixture was diluted with ethyl
acetate (250 ml) and washed with 1N hydrochloric acid (3.times.150
ml), saturated aqueous sodium bicarbonate (3.times.150 ml) and
brine (2.times.150 ml), then dried (MgSO.sub.4), filtered and
concentrated. The crude product was purified by column
chromatography (50-70% ethyl acetate/hexane) to afford 3.17 g (84%)
of a mixture of diastereomers. Recrystallization (ethyl
acetate-hexane) gave colorless crystals: mp. 132-145.degree. C.; IR
(KBr) 3357, 3345, 1781, 1688, 1661, 1535, 1517, 1165; .sup.1H NMR
(d.sub.6-DMSO) .delta. 8.49 (d, J=6.8), 8.23 (d, J=7.4), 7.40 (5H,
m), 7.01 (1H, m), 5.68 (d, J=5.0), 4.75 (m), 4.31 (m), 3.97 (1H,
m), 2.82 (m), 3.11 (m), 2.82 (m), 2.59 (m), 2.45 (m), 1.40 (9H, 5),
1.20 (d, J=7.2), 1.16 (d, J=7.2). Anal. Calcd for
C.sub.19H.sub.26N.sub.2O.sub.6: C, 60.31; H, 6.92; N, 7.40. Found
C, 60.30; H, 6.91; N, 7.38.
(2R,S,3S)tert-Butoxycarbonyl-N-(tetrahydro-2-benzyloxy-5-oxo-3-furanyl)-L-
-prolinamide (15), was prepared by the method described for 14 to
afford 1.64 g (81%) of a colorless glass. IR (KBr) 3317, 2978,
1797, 1697, 1670, 1546, 1400, 1366, 1164, 1121; .sup.1H NMR
(CDCl.sub.3) .delta. 7.68 (1H, brm), 7.35 (5H, m); 5.53 (d, J=5.2),
5.43 (s), 4.93-4.61 (m), 4.44 (m), 4.25 (brm), 3.39 (2H, brm),
3.10-2.81 (1H, m), 2.44 (1H, m), 2.32 (brm), 1.88 (brm), 1.67
(brm), 1.42 (9H, s).
[0904]
(2R,S,3S)N-(N-tert-Butoxycarbonyl-(4(R)-phenoxy-L-prolinyl)-3-amino-
-2-benzyloxy-5-oxotetrahydrofuran (16) was prepared by the method
described for 14 to afford 530 mg (84%) of a colorless amorphous
solid: .sup.1H NMR (CDCl.sub.3) .delta. 7.65 (1H, m), 7.4-7.2 (7H,
m), 6.95 (1H, m), 6.85 (1H, m), 5.55 (1H, d), 4.95 (1H, d), 4.8-4.7
(1H, brm), 4.65 (1H, d), 4.55-4.45 (1H, brm), 4.4-4.3 (0.5H, brm),
3.95-3.85 (0.5H, brm), 3.75-3.58 (2H, m), 2.95-2.8 (1H, m),
2.7-2.55 (1H, m), 2.54-2.4 (1H, m), 2.35-2.2 (1H, m), 1.4
(9H,s).
(2R,S,3S)N.sup.2-[4-(3-Phenylpropyl)imidazole-2-carbonyl]-N-(tetrahydro-2-
-benzyloxy-5-oxo-3-furanyl)-L-alaninamide (17d). Trifluoroacetic
acid (7 ml) was added to a solution of
(2R,S,3S)N.sup.2-tert-butoxycarbonyl-N-(tetrahydro-2-benzyloxy-5-oxo-3-fu-
ranyl)-L-alaninamide (14) (1.00 g, 2.64 mmol) in dichloromethane (7
ml) at 0.degree. C. The mixture was stirred at 0.degree. C. for 75
min. The mixture was concentrated, and the residue treated with
diethyl ether then the ether was removed under vacuum. This
procedure was repeated twice to yield a pale yellow glass. The
solid was dissolved in DMF (20 ml). Diisopropylethylamine (1.38 ml,
7.92 mmol) followed by 4-(3-phenylpropyl) imidazole-2-carboxylic
acid (13d) (0.67 g, 290 mmol), 1-(3-dimethylaminopropyl)-3-ethyl
carbodiimide hydrochloride (0.56 g, 2.90 mmol) and
hydroxybenzotriazole (0.71 g, 5.28 mmol) were then added to this
solution. The mixture was stirred at room temperature for 20 h then
poured into brine. The mixture was extracted with ethyl acetate
(3.times.50 ml). The combined organic extracts were washed with
saturated aqueous sodium bicarbonate (2.times.100 ml) then brine
(2.times.100 ml), dried (MgSO.sub.4), filtered and concentrated.
The residue was purified by column chromatography (ethyl acetate)
to afford 0.99 g (76%) of 17d as a mixture of diastereomers: IR
(KBr) 3293, 3064, 2937, 1793, 1650, 1530, 1451, 1446, 1119; .sup.1H
NMR (CDCl.sub.3) .delta. 7.96 (brm), 7.62 (brd), 7.36-7.10 (10H,
m), 6.88 (s), 6.86 (s), 5.53 (d, J=5.2), 5.48 (s), 4.87-4.52 (4H,
m), 3.11-2.38 (2H, m), 2.65 (4H, m), 1.99 (2H, m), 1.47 (d, J=6.9),
1.46 (d, J=7.0). The following compounds were prepared in a similar
manner:
(2R,S,3S)N.sup.2-(Imidazole-2-carbonyl)-N-(tetrahydro-2-benzyloxy-5-oxo-3-
-furanyl)-L-alaninamide (17a), was isolated (74%) as a pale yellow
solid: IR (KBr) 3289, 3056, 2937, 1793, 1664, 1642, 1528, 1453,
1440, 1124; .sup.1H NMR (d.sub.6-DMSO) .delta. 13.13 (1H, brs),
8.67 (d, J=7.0), 8.48 (d, J=7.8), 8.29 (d, J=6.8), 8.25 (d, J=7.6),
7.40-7.34 (6H, m), 7.11 (1H, s), 5.69 (d, J=5.0), 5.49 (d, J=0.8),
4.85-4.31 (4H, m), 3.19-2.42 (2H, m), 1.38 (d, J=7.4), 1.34 (d,
J=7.4).
(2R,S,3S)N.sup.2-(4-Benzylimidazole-2-carbonyl)-N-(tetrahydro-2-benzyloxy-
-5-oxo-3-furanyl)-L-alaninamide (17b), was isolated (75%) as a pale
yellow glass: IR (KBr) 3294, 3031, 2937, 1792, 1650, 1530, 1453,
1444, 1119; .sup.1H NMR (CDCl.sub.3) .delta. 7.99 (brm), 7.75
(brd), 7.36-7.11 (10H, m), 6.81 (1H, s), 5.51, 5.45 (d, s, J=5.3),
4.85-4.47 (4H, m), 3.95 (2H, s), 3.04-2.72 (1H, m), 2.48-2.35 (1H,
m), 1.44 (d, J=6.9), 1.43 (d, J=7.1).
(2R,S,3S)N.sup.2-[4-(2-Phenylethyl)imidazole-2-carbonyl]-N-(tetra-
hydro-2-benzyloxy-5-oxo-3-furanyl)-L-alaninamide (17c), was
isolated (79%) as a pale yellow glass: IR (KBr) 3292, 3029, 2936,
1793, 1650, 1530, 1453, 1444, 1119; .sup.1H NMR (CDCl.sub.3)
.delta. 8.06 (brm), 7.70 (brs), 7.39-7.15 (10H, m), 6.82 (s), 6.81
(s), 5.53 (d, J=5.2), 5.48 (s), 4.87-4.53 (4H, m), 2.95 (4H, m),
3.11-2.37 (2H, m), 1.48 (d, J=5.6), 1.45 (d, J=6.7).
(2R,S,3S)1-[4-(2-Phenylethyl)imidazole-2-carbonyl]-N-(tetrahydro-2-benzyl-
oxy-5-oxo-3-furanyl)-L-prolinamide (18c), was isolated (79%) as a
pale yellow glass: IR (CH.sub.2Cl.sub.2) 3422, 2959, 1795, 1685,
1611, 1497, 1116; .sup.1H NMR (d.sub.6-DMSO) .delta. 12.78-12.59
(1H, m), 8.61-8.34 (1H, m), 7.39-7.22 (10H, m), 6.99-6.61 (1H, m),
5.71-5.26 (1H, m), 4.85-4.02 (4H, m), 3.63 (1H, m), 3.18-1.74 (11H,
m).
(2R,S,3S)1-[4-(3-Phenylpropyl)imidazole-2-carbonyl]-N-(tetrahydro-2-benzy-
l-oxy-5-oxo-3-furanyl)-L-prolinamide (18d), was isolated (87%) as a
colorless glass: IR(CH.sub.2Cl.sub.2) 3422, 3214, 2945, 1794, 1685,
1604, 1496, 1117; .sup.1H NMR (d.sub.6-DMSO) .delta. 12.71 (1H,
brm), 8.61-8.34 (1H, m), 7.45-7.18 (10H, m), 7.05-6.64 (1H, m),
5.70-5.28 (1H, m), 4.85-4.02 (4H, m), 3.62 (1H, m) 3.18-1.71 (13H,
m).
(2R,S,3S)1-{4-[3-(4-Methoxyphenyl)propyl]imidazole-2-carbonyl}-N-(tetra-h-
ydro-2-benzyloxy-5-oxo-3-furanyl)-L-prolinamide (18e), was isolated
(72%) as a white glassy solid: mp. 62-65.degree. C.; IR (KBr) 3213,
2937, 1793, 1680, 1606, 1606, 1512, 1245; .sup.1H NMR
(d.sub.6-DMSO) .delta. 12.71, 12.67, 12.58 (1H, 3.times.bs),
8.60-8.30 (1H, m), 7.40-7.20 (5H, m), 7.15-6.55 (5H, m), 5.66-5.20
(1H, m), 4.81-4.59 (2H, m), 4.55-4.05 (2H, m), 3.71 (3H, s),
3.65-3.45 (1H, m), 3.15-1.50 (13H, m). FABSMS m/e 547 (M.sup.+,
100%), 439, 412, 340, 312, 243, 177, 154.
(2R,S,3S)1-{4-[3-(4-Hydroxyphenyl)propyl]imidazole-2-carbonyl}-N-(tetra-h-
ydro-2-benzyloxy-5-oxo-3-furanyl)-L-prolinamide (18f), was isolated
(70%) as a light yellow glassy solid: mp. 86-90.degree. C.; IR
(KBr) 3298, 1790, 1669, 1606, 1515, 1242; .sup.1H NMR
(d.sub.6-DMSO) .delta. 12.66, 12.56 (1H, 2.times.bs), 9.14 (1H, s),
8.57-8.30 (1H, m), 7.36-7.30 (5H, m), 7.02-6.83 (3H, m), 6.70-6.57
(2H, m), 5.65-5.28 (1H, m), 4.80-4.49 (2H, m), 4.50-4.05 (2H, m),
3.65-3.45 (1H, m), 3.15-1.55 (13H, m). FABMS m/e 533 (M.sup.+,
100%), 425, 298, 229, 176, 154.
1-{5-[3-(4-Methoxyphenyl)propyl]-1H-imidazole-2-carbonyl}-4(R)-phenoxypyr-
rolidine-2(S)-carbonyl-(tetrahydro-2(R,S)-benzyloxy-5-oxofuran-3(S)-yl)ami-
de (19e) was isolated (77%) as a clear colorless amorphous solid.
.sup.1H NMR (CDCl.sub.3) .delta. 9.95-9.75 (1H, m), 7.95 (1H, brs),
7.40-7.2 (7H, m), 7.2-6.78 (7H, m), 5.65-5.6 (1H, m), 5.55-5.45
(1H, m), 5.3-5.2 (1H, m), 5.15-5.0 (1H, m), 4.95-4.75 (1H, m),
4.7-4.6 (1H, m), 4.5-4.4 (1H, m), 4.35-4.4.25 (1H, m), 3.8 (3H, s),
3.05-1.75 (10H, m).
(3S)3-{N-[4-(3-Phenylpropyl)imidazole-2-carbonyl]-L-alaninyl}amino-4-oxo--
butanoic acid (20d). A mixture of
(2R,S,3S)N.sup.2-[4-(3-Phenylpropyl)imidazole-2-carbonyl]-N-(tetrahydro-2-
-benzyloxy-5-oxo-3-furanyl)-L-alaninamide (0.93 g, 1.90 mmol) and
10% palladium on activated carbon (0.93 g) in methanol (100 ml) was
stirred under a hydrogen atmosphere for 5 h. The resulting mixture
was filtered and concentrated to yield a colorless glass.
Recrystallization from methanol-diethyl ether afforded 401 mg (53%)
of 20d as a colorless solid: mp. 94-96.degree. C.;
[.alpha.].sub.D.sup.27+16.4.degree. (c 0.5, MeOH); IR (KBr) 3300,
3287, 1786, 1732, 1659, 1651, 1532, 1451; .sup.1H NMR (CD.sub.3OD)
.delta. 7.19 (5H, m), 6.91 (1H, s), 4.60-4.46 (2H, m), 4.27 (1H,
m), 2.63 (4H, m), 2.75-2.40 (2H, m), 1.96 (2H, m), 1.44 (3H, d,
J=7.0). The following compounds were prepared in a similar manner:
(3S)3-[N-(Imidazole-2-carbonyl)-L-alaninyl]amino-4-oxobutanoic acid
(20a; E), was isolated (83%) as a colorless solid: mp. 115.degree.
C.; [.alpha.].sub.D.sup.25+4.4.degree. (c 0.5, MeOH); IR (KBr)
3303, 1782, 1658, 1650, 1563, 1521, 1454; .sup.1H NMR (CD.sub.3OD)
.delta. 7.18 (2H, s), 4.55 (2H, m), 4.27 (1H, m), 2.56 (2H, m),
1.45 (d, J=7.1), 1.44 (d, J=7.0).
(3S)3-[N-(4-Benzylimidazole-2-carbonyl)-L-alaninyl]amino-4-oxobut-
anoic acid (20b), was isolated (56%) as a colorless solid: mp.
113-115.degree. C.; [.alpha.].sub.D.sup.29+18.2.degree. (c 0.5
MeOH). IR (KBr) 3301, 3288, 1783, 1727, 1650, 1531, 1452; .sup.1H
NMR (CD.sub.3OD) .delta. 7.25 (5H, m), 6.90 (1H, s), 4.59-4.45 (2H,
m), 4.26 (1H, m), 3.95 (2H, s), 2.74-2.39 (2H, m), 1.42 (3H, d,
J=7.0). Anal. Calcd for C.sub.18H.sub.20N.sub.4O.sub.5: C, 56.69;
H, 5.55; N, 14.69. Found: C, 57.06; H, 5.54; N, 14.41.
(3S)3-{N-[4-(2-Phenylethyl)imidazole-2-carbonyl]-L-alaninyl}amino-4-oxobu-
tanoic acid (20c; N), was isolated (53%) as a colorless solid: mp.
102-104.degree. C.; [.alpha.].sub.D.sup.27+13.7.degree. (c 0.5,
MeOH); IR (KBr) 3299, 3289, 1785, 1732, 1650, 1531, 1452; .sup.1H
NMR (CD.sub.3OD) .delta. 7.20 (5H, m), 6.82 (1H, s), 4.60-4.46 (2H,
m), 4.29 (1H, m), 2.92 (4H, s), 2.76-2.41 (2H, m), 1.44 (3H,
2.times.d, J=7.1). Anal. Calcd for
C.sub.19H.sub.22N.sub.4O.sub.5H.sub.2O: C, 56.43; H, 5.98; N,
13.85. Found: C, 56.65; H, 5.84; N, 13.91.
(3S)3{N-[4-(2-Phenylethyl)imidazole-2-carbonyl]-L-prolinyl}amino-4-oxobut-
anoic acid (21c), was isolated (85%) as a colorless glass: mp.
101-103.degree. C. (methanol-diethyl ether);
[.alpha.].sub.D.sup.27-63.8.degree. (c 0.25, MeOH); IR (KBr) 3275,
1784, 1728, 1664, 1606, 1498, 1429; .sup.1H NMR (CD.sub.3OD)
.delta. 7.24 (5H, m), 6.83 (s), 6.79 (s), 4.58-4.14 (3H, m), 3.69
(1H, m), 2.93 (4H, brs), 2.75-1.99 (6H, m). Anal. Calcd for
C.sub.21H.sub.24N.sub.4O.sub.5H.sub.2O: C, 58.60; H, 6.09; N,
13.02. Found: C, 58.34; H, 5.96; N, 12.67.
(3S)3-{N-[4-(3-Phenylpropyl)imidazole-2-carbonyl]-L-prolinyl}amino-4-oxo--
butanoic acid (21d), was isolated (81%) as a colorless glass: mp.
91-94.degree. C.; (methanol-diethyl ether);
[.alpha.].sub.D.sup.25-68.degree. (c 0.25, MeOH); IR (KBr) 3277,
2939, 1784, 1727, 1662, 1606, 1498, 1429; .sup.1H NMR (CD.sub.3OD)
.delta. 7.29-7.16 (5H, m), 6.92 (s), 6.86 (s), 4.58-4.16 (3H, m),
3.71 (1H, m), 2.75-1.92 (13H, m). Anal. Calcd for
C.sub.22H.sub.26N.sub.4O.sub.5H.sub.2O: C, 59.45; H, 6.35; N,
12.60. Found: C, 59.75; H, 6.21; N, 12.41.
(3S)3-{N-[4-[3-(4-Methoxyphenyl)propyl]imidazole-2-carbonyl]-L-prolinyl}a-
mino-4-oxobutanoic acid (21e), was isolated (65%) as a white glassy
solid: mp. 101-105.degree. C.; [.alpha.].sub.D.sup.23-60.6 (c 0.05,
MeOH); IR (KBr) 3231, 1784, 1726, 1611, 1512, 1245; .sup.1H NMR
(CD.sub.3OD) .delta. 7.09 (2H, d, J=8.6), 6.92, 6.85 (1H,
2.times.s), 6.81 (2H, d, J=8.6), 5.45-5.30 (1H, m), 4.64-4.46 (1H,
m), 4.28-4.10 (2H, m), 3.75 (3H, s), 3.74-3.66 (1H, m), 2.67-1.84
(13H, m). Anal. Calcd for C.sub.23H.sub.28N.sub.4O.sub.6H.sub.2O:
C, 58.22; H, 6.37; N, 11.81. Found: C, 58.39; H, 6.34; N, 11.45;
FABMS m/e 457 (M.sup.+), 405, 312, 243, 215, 176, 154 (100%).
(3S)3-{N-[4-[3-(4-Hydroxyphenyl)propyl]imidazole-2-carbonyl]-L-prolinyl}a-
mino-4-oxobutanoic acid (21f), was isolated (43%) as a white glassy
solid: mp. 114-118.degree. C.; [.alpha.].sub.D.sup.25-55.7.degree.
(c 0.05, MeOH); IR (KBr) 3288, 2935, 1780, 1715, 1662, 1610, 1515,
1441; .sup.1H NMR (CD.sub.3OD) .delta. 6.99 (2H, d, J=8.5), 6.91,
6.85 (1H, 2.times.s), 6.68 (2H, d, J=8.5), 5.45-5.30 (1H, m),
4.60-4.47 (1H, m), 4.30-4.10 (2H, m), 3.80-3.55 (1H, m), 2.70-1.80
(13H, m). Anal. Calcd for C.sub.22H.sub.26N.sub.4O.sub.6H.sub.2O:
C, 57.38; H, 6.13; N, 12.17. Found: C, 57.68; H, 6.25; N, 11.66.
FABMS m/e 443 (M.sup.+), 298, 229, 154 (100%).
3(S)-[(1-{5-[3-(4-Methoxyphenyl)propyl]-1H-imidazole-2-carbonyl}-4(R)-phe-
noxy pyrrolidine-2(S)-carbonyl)amino]-4-oxobutanoic acid (22e) was
isolated (43%) as a beige solid: .sup.1H NMR (CD.sub.3OD) .delta.
7.35-7.2 (3H, m), 7.15-7.0 (2H, m), 6.98-6.85 (3H, m), 6.83-6.77
(2H, d), 5.4-5.1 (1H, m), 4.65-4.5 (1H, m), 4.35-4.2 (2H, m),
4.15-3.90 (1H, m), 3.78 (3H, s), 3.62-3.48 (1H, m), 2.78-2.25 (8H,
m), 2.02-1.9 (2H, m).
##STR00147##
{Phenethyl-[5-(3-propyl)-1H-imidazole-2-carbonyl]amino}acetic acid
tert-butyl ester (23). A 0.degree. C. solution of
4-(3-phenylpropyl)-imidazole-2-carboxylic (13d) (150 mg, 0.65 mmol)
and N-(2-phenethyl)glycine tert-butyl ester (140 mg, 0.59 mmol) in
5 ml of anhydrous dimethylformamide was treated with
diisopropylethylamine (154 .mu.l, 0.89 mmol), hydroxy-benzotriazole
(160 mg, 1.18 mmol), and 1-(3-dimethylaminopropyl)-3-ethyl
carbodiimide hydrochloride (136 mg, 0.71 mmol). After stirring for
36 h, the reaction was poured onto saturated aqueous sodium
chloride and extracted with ethyl acetate (3.times.50 ml) The
combined organic extracts were washed twice with saturated aqueous
sodium bicarbonate (2.times.) and saturated aqueous sodium chloride
(1.times.), dried (Na.sub.2SO.sub.4), filtered, and concentrated in
vacuo to give a brown oil. Chromatography (flash, SiO.sub.2, 30%
ethyl acetate/hexane) to give 160 mg (61%) of 23 as a white solid:
.sup.1H NMR (CDCl.sub.3) .delta. 7.38-7.14 (10H, m), 6.85-6.8 (1H,
m), 4.84-4.76 (1H, d), 4.5-4.42 (1H, m), 4.07-4.0 (1H, d),
3.78-3.72 (1H, m), 3.12-2.94 (2H, 2.times.m), 2.75-2.55 (4H, m),
2.1-1.95 (2H, m), 1.5-1.45 (9H, 3.times.s).
(3S)-(2-Phenethyl-[5-(3-phenylpropyl)-1H-imidazole-2-carbonyl]amino}acety-
l amino) 4-oxobutanoic acid tert-butyl ester semicarbazone (24).
The ester 23 (160 mg, 0.357 mmol) was treated with 25%
trifluoroacetic acid/dichloromethane (7 ml) for 4 h. The reaction
was concentrated in vacuo to afford 180 mg of the acid. The acid
(180 mg, 0.357 mmol) was coupled to (3S)-3-amino-4-oxobutanoic acid
tert-butyl ester semicarbazone (161 mg, 0.357 mmol) as describe for
the preparation of 5a and 5b to give 86 mg (33%) of 24 (one
diastereomer) as a white solid: .sup.1H NMR (CDCl.sub.3) .delta.
10.9-10.3 (1H, 2 d), 10.08-9.78 (1H, 2 d), 9.25-9.15 (1H, m),
8.35-8.10 (1H, 2 m), 7.9-7.85 (1H, 2 s), 7.40-7.05 (10H, m),
6.9-6.75 (1H, m), 6.3-5.8 (1H, br s), 5.2-4.65 (2H, m), 4.35-3.5
(3H, m), 3.25-3.0 (2H, m), 2.9-2.45 (6H, m), 2.05-1.8 (2H, m), 1.4
(9H,s).
(3S)-(2-{Phenethyl-[5-(3-phenylpropyl)-1H-imidazole-2-carbonyl]amino}acet-
ylamino)-4-oxobutanoic acid trifluoroacetic acid salt (25) was
prepared by the method described for 7a to afford 32 mg (82%) as a
white solid: .sup.1H NMR (CD.sub.3OD) .delta. 7.05-7.35 (m, 11H),
4.65 (m, 1H), 4.4 (m, 1H), 4.3 (s, 2H), 3.6-4.0 (m, 2H), 2.5-2.95
(m, 8H), 2.05 (m, 2H).
7-[5-(3-Phenylpropyl)-1H-imidazole-2-carbonyl]-1,4-dithia-7-azaspiro[4.4]-
nonane-8(S)-carboxylic acid methyl ester (26).
4-(3-Phenylpropyl)imidazole-2-carboxylic acid (13d) was coupled to
1,4-dithia-7-azaspiro[4.4]nonane-8(S)-carboxylic acid methyl ester
hydrobromide (Smith et. al., J. Med. Chem., 31, pp. 875-85 (1988))
by the method described for 23 to afford 140 mg (65%) as a yellow
gum: .sup.1H NMR (CDCl.sub.3) .delta. 7.34-7.15 (5H, m), 6.98-6.8
(1H, 3 s), 5.7-5.65 (0.5H, m), 5.2-5.1 (1H, m), 4.82-4.75 (0.5H,
m), 4.4-4.35 (1H, m), 4.05 (1H, d), 3.75-3.7 (3H, 2 s), 3.4-3.3
(4H, m), 2.95-2.45 (8H, m), 2.05-1.95 (2H, m).
(3S)-({7-[5-(3-Phenylpropyl)-1H-imidazole-2-carbonyl]-1,4-dithia-7-azaspi-
ro[4.4]nonane-8(S)-carbonyl}-amino)-4-oxobutanoic acid tert-butyl
ester semicarbazone (27). Following the procedure described for 4,
the ester 26 was converted to its acid which was subsequently
coupled to (3S)-3-amino-4-oxobutanoic acid tert-butyl ester
semicarbazone as described for 24 to give 70 mg (33%) as a brown
solid: .sup.1H NMR (CD.sub.3OD) .delta. 7.28-7.10 (5H, m), 6.90
(1H, br s), 4.94 (1H, m), 3.96-3.86 (2H, q), 3.35-3.25 (4H, d), 3.0
(2H, s), 2.73-2.59 (6H, m), 2.0-1.92 (2H, m),1.44 (9H,s).
(3S)-({7-[5-(3-Phenylpropyl)-1H-imidazole-2-carbonyl]-1,4-dithia-7-azaspi-
ro[4.4]nonane-8(S)-carbonyl}-amino)-4-oxobutanoic acid (28) was
prepared by the method described for 7a to afford 17 mg (26%) as a
light brown solid: .sup.1H NMR (CD.sub.3OD) .delta. 7.4 (s, 1H),
7.1-7.25 (m, 5H), 4.9 (m, 1H), 4.6 (m, 1H), 4.3 (m, 1H), 3.95 (s,
2H), 3.25-3.4 (m, 4H), 3.0 (d, 2H), 2.6-2.8 (m, 5H), 2.45 (m, 1H),
2.05 (m, 2H).
##STR00148##
4,5-Dihydroimidazole-4-carboxylic esters (29) were prepared by a
modification of the procedure described by Jones et al.,
Tetrahedron Lett., 29, pp. 3853-56 (1988). (4R,S)Methyl
2-(2-phenylethyl)-4,5-dihydroimidazole-4-carboxylate (29a). Dry
hydrogen chloride was bubbled into a solution of
hydrocinnamonitrile (3.28 ml, 25 mmol) in methanol (125 ml) at
0.degree. C. for 45 mins. The solvents were removed to give the
imidate salt which was dissolved in methanol (125 ml) along with
methyl 2,3-diaminopropionate (25 mmol) (Jones et al., supra). The
mixture was kept at room temperature for 2.5 h, then concentrated
to a yellow oil. The crude product was purified by column
chromatography (10-20% methanol/dichloromethane) to afford 3.52 g
(61%) of a colorless glass: .sup.1H NMR (CDCl.sub.3) .delta.
7.30-7.15 (5H, m), 4.63 (1H, t, J=9.7), 3.96 (2H, d, J=9.7), 3.72
(3H, s), 3.10 (4H, m), .sup.13C NMR (CDCl.sub.3) .delta. 171.3,
168.8, 138.3, 128.4, 128.2, 126.6, 57.3, 53.0, 47.7, 31.7, 27.9.
(4R,S) Methyl
2-[2-(4-trifluoromethylphenyl)ethyl]-4,5-dihydroimidazole-4-carboxylate
(29b), was prepared by the method described for 29a to yield 6.80 g
(78%) of a colorless solid: mp. 136-141.degree. C.; .sup.1H NMR
(CDCl.sub.3) .delta. 7.45 (4H, s), 4.71 (1H, dd, J=8.6, 10.8), 4.02
(2H, m), 3.73 (3H, s), 3.19 (4H, m). Imidazole-4-carboxylic esters
30 were prepared by a modification of the procedure described by
Martin et al., J. Org. Chem., 33, pp. 3758-61 (1968). Methyl
2-(2-phenylethyl)imidazole-4-carboxylate (30a). A mixture of
(4R,Syl 2-(2-phenylethyl)-4,5-dihydroimidazole-4-carboxylate (29a)
(3.40 g, 14.64 mmol), chloroform (75 ml) and manganese (IV) oxide
(13.0 g, 150 mmol) was heated under reflux for 21 h then filtered
hot. The solids were washed with chloroform and methanol. The
combined filtrates were concentrated to leave a yellow-brown solid,
which was purified by column chromatography (2-5%
methanol/dichloromethane) to afford 1.46 g (43%) of a pale yellow
solid: mp. 151-155.degree. C.; IR (KBr) 3028, 2946, 1720, 1533,
1433, 1348, 1195, 1166; .sup.1H NMR (CDCl.sub.3) .delta. 7.62 (1H,
s), 7.26-7.02 (5H, m), 3.82 (3H, s), 3.03 (4H, brs), .sup.13C NMR
(CDCl.sub.3) .delta. 162.9, 150.2, 140.3, 128.5, 128.2, 126.3,
51.5, 34.5, 30.4. Anal. Calcd for C.sub.13H.sub.14N.sub.2O.sub.2:
C, 67.81; H, 6.13; N, 12.16. Found: C, 67.70; H, 6.15; N, 12.16.
Methyl 2-[2-(4-trifluoromethylphenyl)ethyl]imidazole-4-carboxylate
(30b), was prepared by the method described for 30a. It was
recrystallised from ethyl acetate to afford 1.88 g (33%) of cream
crystals: mp. 225-26.degree. C.; IR (KBr) 3239, 2951, 1715, 1532,
1331, 1158, 1105, 1068; .sup.1H NMR (CDCl.sub.3) .delta. 7.61 (1H,
s), 7.54 (2H, d, J=8.1), 7.26 (2H, d, J=8.1), 3.89 (3H, s), 3.10
(4H, m). Anal. Calcd for C.sub.14H.sub.13F.sub.3N.sub.2O.sub.2: C,
56.38; H, 4.39; N, 9.39; F, 19.11. Found: C, 56.23; H, 4.44; N,
9.33; F, 19.08. 2-(2-Phenylethyl)imidazole-4-carboxylic acid (31a).
A mixture of methyl 2-(2-phenylethyl)imidazole-4-carboxylate (30a)
(1.38 g, 6 mmol), methanol (30 ml) and 1M aqueous sodium hydroxide
(30 ml) was heated under reflux for 16 h. The methanol was removed
under reduced pressure, and the resulting aqueous solution was
neutralized with 4M hydrochloric acid, whereupon a pale yellow
solid precipitated. The precipitate was collected, washed with
water, and dried to afford 1.18 g (91%) of a pale yellow solid: mp.
117-120.degree. C.; IR (KBr) 3375, 3131, 2616, 2472, 1638, 1592,
1551, 1421, 1388, 1360; .sup.1H NMR (d.sub.6-DMSO) .delta. 7.59
(1H, s), 7.26 (5H, m), 2.99 (4H, m). Anal. Calcd for
C.sub.12H.sub.12N.sub.2O.sub.2 0.25H.sub.2O: C, 65.29; H, 5.71; N,
12.69. Found: C, 65.00; H, 5.64; N, 12.58.
2-[2-(4-Trifluoromethylphenyl)ethyl]imidazole-4-carboxylic acid
(31b), was prepared by the method described for 31a to afford 1.09
g (76%) of a pale yellow solid: mp. 126-130.degree. C.; IR (KBr)
3339, 2640-2467, 1638, 1589, 1545, 1383, 1323; .sup.1H NMR
(d.sub.6-DMSO) .delta. 7.69 (2H, d, J=8.0), 7.59 (1H, s), 7.47 (2H,
d, J=8.0), 3.06 (4H, m).
(2R,S,3S)N.sup.2-[2-(2-Phenylethyl)imidazole-4-carbonyl]-N-(tetrahydro-2--
benzyl-oxy-5-oxo-3-furanyl)-L-alaninamide (32a). To a solution of
(2R,S,3S)N.sup.2-tert-butoxycarbonyl-N-(tetrahydro-2-benzyloxy-5-oxo-3-fu-
ranyl)-L-alaninamide (14) (1.59 g, 4.20 mmol; Chapman, Biorg. Med.
Chem. Lett., 2, pp. 613-18 (1992)) in dichloromethane (15 ml),
cooled to 0.degree. C., was added trifluoroacetic acid (15 ml). The
mixture was stirred at 0.degree. C. for 1 h and then concentrated.
The residue was treated with ether and then the ether was removed
under vacuum. This procedure was repeated twice to yield a pale
yellow glass. The solid was dissolved in DMF (20 ml), then
diisopropylethylamine (2.19 ml, 12.6 mmol),
2-(2-phenylethyl)imidazole-4-carboxylic acid (31a) (1.0 g, 4.62
mmol), 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride
(0.89 g, 4.62 mmol) and hydroxybenzotriazole (1.14 g, 8.40 mmol)
were added to the solution. The reaction mixture was stirred at
room temperature for 20 h then poured into brine. The mixture was
extracted with ethyl acetate (3.times.50 ml). The combined organic
extracts were washed with saturated aqueous sodium bicarbonate
(3.times.100 ml) then brine (3.times.100 ml), dried (MgSO.sub.4)
and concentrated. The residue was purified by column chromatography
(2-10% isopropanol in dichloromethane then 0-6% isopropanol in
ethyl acetate) to yield 1.10 g (55%) of 32a as a mixture of
diastereomers: IR (KBr) 3278, 3065, 1790, 1641, 1577, 1545, 1499,
1454, 1120; .sup.1H NMR (CDCl.sub.3) .delta. 10.26 (1H, s), 8.14
(1H, s), 7.66 (d, J=7.0), 7.56 (d, J=7.0), 7.43 (1H, s), 7.31-7.11
(10H, m), 5.49 (d, J=5.6), 5.48 (s), 4.83-4.41 (4H, m), 3.04-2.41
(2H, m), 2.99 (4H, s), 1.45 (d, J=7.0), 1.44 (d, J=7.0).
(2R,S,3S)N.sup.2-{2-[2-(4-Trifluoromethylphenyl)ethyl]imidazole-4-carbony-
l}-N-(tetrahydro-2-benzyloxy-5-oxo-3-furanyl)-L-alaninamide (32b),
was prepared by the method described for 32a to afford 1.08 g (62%)
of a pale yellow glass: IR (KBr) 3376, 3284, 3070, 2938, 1791,
1642, 1578, 1546, 1327, 1165, 1122, 1068; .sup.1H NMR (CDCl.sub.3)
.delta. 7.95 (0.5H, m), 7.55-7.25 (11.5H, m), 5.53 (s), 5.49 (d,
J=5.3), 4.88-4.48 (4H, m), 3.11-2.96 (4H, m), 2.91 (1H, m), 2.51
(1H, m), 1.47 (3H, d, J=7.1).
(2R,S,3S)N.sup.2-(2-Benzylimidazole-4-carbonyl)-N-(tetrahydro-2-benzyloxy-
-5-oxo-3-furanyl)-L-alaninamide (32c), was prepared by the method
described for 32a from 2-benzylimidazole-4-carboxylic acid (Ger.
Offen. DE 3427136) to afford 1.13 g (83%) of a yellow glass:
IR(CH.sub.2Cl.sub.2) 3433, 3062, 2990, 1803, 1693, 1584, 1504,
1429, 1285, 1258; .sup.1H NMR (CDCl.sub.3) .delta. 9.50 (s), 9.37
(s), 7.86 (0.5H, d, J=6.1), 7.56-7.21 (10.5H, m), 7.48 (1H, s),
5.51 (d, J=5.2), 5.48 (s), 4.87-4.41 (4H, m), 4.08 (s), 4.07 (s),
3.03-2.39 (2H, m), 1.46 (3H, d, J=7.0).
(3S)3-{N-[2-(2-Phenylethyl)imidazole-4-carbonyl]-L-alaninyl}amino-4-oxobu-
tanoic acid (33a; A). A mixture of
(2R,S,3S)N.sup.2-[2-(2-phenylethyl)imidazole-4-carbonyl]-N-(tetrahydro-2--
benzyloxy-5-oxo-3-furanyl)-L-alaninamide (32a) (1.0 g, 2.10 mmol)
and 10% palladium on activated carbon (1.0 g) in methanol (50 ml)
was stirred under a hydrogen atmosphere for 4.5 h. The resulting
mixture was filtered and concentrated to yield a colorless glass.
Recrystallization from methanol-diethyl ether afforded 510 mg (63%)
of a colorless solid: mp. 127.degree. C.; IR (KBr) 3360, 3279,
2981, 1781, 1732, 1646, 1577, 1547; .sup.1H NMR (CD.sub.3OD)
.delta. 7.54 (1H, s), 7.29-7.12 (5H, m), 4.60-4.47 (2H, m), 4.28
(1H, m), 3.01 (4H, s), 2.76-2.39 (2H, m), 1.43 (3H, 2.times.d,
J=7.0, J=7.0), .sup.13C NMR (CD.sub.3OD) .delta. 176.2, 176.0,
174.7, 174.6, 164.4, 164.3, 150.5, 141.9, 134.8, 129.5, 129.3,
127.3, 122.3, 98.8, 98.4, 52.3, 52.0, 50.3, 35.6, 31.2, 18.8, 18.7.
Anal. Calcd for C.sub.19H.sub.22N.sub.4O.sub.5H.sub.2O: C, 56.43;
H, 5.98; N, 13.85. Found: C, 56.78; H, 5.70; N, 13.77.
(3S)3-{N-[2-(2-[4-Trifluoromethylphenyl]ethyl)
imidazole-4-carbonyl]-L-alaninyl}-amino-4-oxobutanoic acid (33b;
C), was prepared by the method described for 33a to afford 612 mg
(73%) of a colorless solid: mp. 120-124.degree. C.;
[.alpha.].sub.D.sup.23+14.3.degree. (c 0.5, MeOH); IR (KBr) 3287,
2985, 2937, 1782, 1732, 1646, 1579, 1547, 1327; .sup.1H NMR
(CD.sub.3OD) .delta. 7.56 (2H, d, J=8.0), 7.54 (1H, s), 7.36 (2H,
d, J=8.0), 4.60-4.48 (2H, m), 4.28 (1H, m), 3.08 (4H, m), 2.75-2.41
(2H, m), 1.43 (3H, d, J=7.0). Anal. Calcd for
C.sub.20H.sub.21F.sub.3N.sub.4O.sub.5. 0.5H.sub.2O:C, 51.84; H,
4.78; N, 12.09; F, 12.30. Found: C, 51.83; H, 4.72; N, 12.14; F,
12.36.
(3S)3-[N-(2-Benzylimidazole-4-carbonyl)-L-alaninyl]amino-4-oxobutanoic
acid (33c; B), was prepared by the method described for 33a to
afford 426 mg (64%) of a colorless solid:
[.alpha.].sub.D.sup.23+13.4.degree. (c 0.407, MeOH). IR (KBr) 3260,
3150, 2980, 1779, 1727, 1649, 1573, 1547; .sup.1H NMR (CD.sub.3OD)
.delta. 7.58 (1H, s), 7.34-7.22 (5H, m), 4.59-4.47 (2H, m), 4.28
(1H, m), 4.07 (2H, s), 2.74-2.41 (2H, m), 1.42 (3H, d, J=6.7);
.sup.13C NMR (CD.sub.3OD) .delta. 175.6, 175.5, 175.0, 164.6,
164.5, 150.1, 138.7, 135.3, 130.0, 129.9, 128.2, 122.9, 98.9, 98.5,
52.5, 52.2, 35.5, 35.1, 35.0, 19.0, 18.9. Anal. Calcd for
C.sub.18H.sub.20N.sub.4O.sub.5H.sub.2O: C, 55.37; H, 5.68; N,
14.35. Found C, 55.83; H, 5.75; N, 13.96. MS (FAB, m/z): 373
((M.sup.+), 228, 185, 91.
##STR00149##
5-Benzylpyrrole-2-carboxylic acid (34b). A mixture of Ethyl
5-benzylpyrrole-2-carboxylate (0.7 g, 3.05 mmol; Elder et al.,
Synthetic Communications, 19, 763-767 (1989)), ethanol (20 ml) and
1M sodium hydroxide (9.2 ml, 9.2 mmol) was stirred and heated under
reflux for 3 h. The major part of the ethanol was removed and the
remaining liquid was diluted with water, washed with ether, cooled
in ice and acidified with concentrated hydrochloric acid. The
mixture was extracted with ether. The combined extracts were washed
with brine, dried (Na.sub.2SO.sub.4) and concentrated to afford
0.567 g (92%) of an off white solid: mp. 130-134.degree. C.;
.sup.1H NMR (CDCl.sub.3) .delta. 8.87 (1H, brs), 7.37-6.95 (5H, m),
6.97 (1H, m), 6.07 (1H, m), 4.00 (2H, s).
(2R,S,3S)N.sup.2-(Pyrrole-2-carbonyl)-N-(tetrahydro-2-benzyloxy-5-oxo-3-f-
uranyl)-L-alaninamide (35a). A solution of
(2R,S,3S)N.sup.2-tert-butoxycarbonyl-N-(tetrahydro-2-benzyloxy-5-oxo-3-fu-
ranyl)-L-alaninamide (14) (756 mg, 2.0 mmol) in dry dichloromethane
(8 ml) at 0.degree. C. was treated with trifluoroacetic acid (8 ml)
for 1 h and then evaporated to dryness. Dry ether was added to the
residue and the mixture concentrated to give a viscous oil. The oil
was dissolved in dry DMF (10 ml). Pyrrole-2-carboxylic acid (34a)
(244 mg, 2.2 mmol) was added and the solution was cooled in an ice
bath before the addition of N,N-diisopropylamine (0.78 g, 6.0
mmol), 1-hydroxybenzotriazole (0.54 g, 4.0 mmol) and ethyl
dimethylaminopropyl carbodiimide hydrochloride (0.42 g, 2.2 mmol).
The resulting mixture was stirred at 25.degree. C. for 17 h and
then saturated aqueous sodium chloride (30 ml) was added. The
mixture was extracted with ethyl acetate (3.times.20 ml) and the
combined organic extracts were washed with 5% aqueous sodium
bicarbonate (3.times.10 ml) and brine (10 ml), dried (MgSO.sub.4)
and concentrated. Flash chromatography (25% hexane-ethyl acetate)
afforded 557 mg (75%) of a 1:1 mixture of diastereomers as a white
glassy solid: mp. 85-90.degree. C.; IR (KBr) 3288, 1789, 1665,
1629, 1557 and 1122; .sup.1H NMR (d.sub.6-DMSO) .delta. 11.46 (1H,
bs), 8.55 (0.5H, d, J=7.0), 8.30 (0.5H, d, J=7.6), 8.06 (0.5H, d,
J=7.0), 8.04 (0.5H, d, J=7.6), 7.36-7.30 (5H, m), 6.88-6.85 (2H,
m), 6.10-6.07 (1H, m), 5.63 (0.5H, d, J=5.0), 5.42 (0.5H, s), 4.72
(2H, q, J=12.2), 4.74-4.25 (2H, m), 3.14-2.35 (2H, m), 1.29, 1.25
(3H, 2.times.d, J=7.2).
(2R,S,3S)N.sup.2-(5-Benzylpyrrole-2-carbonyl)-N-(tetrahydro-2-benzyloxy-5-
-oxo-3-furanyl)-L-alaninamide (35b), was prepared from
5-benzylpyrrole-2-carboxylic acid (34b) by the method described for
compound 35a (65%). Data is given for a single diastereomer.
.sup.1H NMR (d.sub.6-DMSO) .delta. 11.37 (1H, brs,), 8.27 (1H, d,
J=7.4), 7.93 (1H, d, J=7.6), 7.33-7.16 (10H, m), 6.76 (1H, m), 5.82
(1H, m), 5.62 (1H, d, J=5.2), 4.76 (1H, d, J=12.0), 4.65 (1H, m),
4.62 (1H, d, J=12.2), 4.47 (1H, m), 3.88 (2H, s), 2.77 (1H, dd,
J=9.0, 18.0), 2.5 (dd), 1.23 (3H, d, J=7.0).
(3S)3-[N-(Pyrrole-2-carbonyl)-L-alaninyl]amino-4-oxobutanoic acid
(36a; D). A mixture of (35a) (612 mg; 1.65 mmol), methanol (40 ml)
and 10% palladium on carbon (500 mg) was vigorously stirred under
an atmosphere of hydrogen for 4 h. The mixture was filtered through
a 0.2 .mu.M nylon membrane then concentrated. The residue was
purified by flash chromatography (5-10% methanol in methylene
chloride) to afford the hemihydrate of (36a) (223 mg, 48%) as a
white solid after precipitation from an ethyl acetate-ether
mixture. There were traces of solvent in the product: mp.
96-100.degree. C.; IR (KBr) 3381, 1774, 1729 (EtOAc), 1632, 1558,
1523, 1123; .sup.1H NMR (CD.sub.3OD) .delta. 6.94-6.85 (2H, m),
6.17 (1H, dd, J=3.8 and 2.6), 4.58 (0.5H, d, J=3.94), 4.56 (0.5H,
d, J=4.24), 4.51 (1H, q, J=7.16), 4.35-4.20 (1H, m), 2.74-2.40 (2H,
m), 1.42 and 1.41 (3H, 2.times.d, J=7.13).
(3S)3-[N-(5-Benzylpyrrole-2-carbonyl)-L-alaninyl]amino-4-oxobutanoic
acid (36b), was prepared (41%) from 35b by the method described for
compound 36a, to afford an off white solid: mp. 109-112.degree. C.;
[.alpha.].sub.D.sup.25+6.3.degree. (c 0.3, methanol); IR (KBr)
3368, 1724, 1630, 1530, 1453, 1414, 1233, 1049; .sup.1H NMR
(d.sub.4 methanol) .delta. 7.25-7.11 (5H, m), 6.76 (1H, d, J=3.5),
5.84 (1H, d, J=3.5), 4.51 (1H, m), 4.43 (1H, q, J=7.1), 4.23 (1H,
m), 2.5 (2H, m), 1.35 (3H, d, J=7.0). Anal. Calcd for
C.sub.19H.sub.21N.sub.3O.sub.5. 1.75H.sub.2O: C, 56.64; H, 6.13; N,
10.43. Found: C, 56.34; H, 5.72; N, 10.00.
##STR00150##
(2R,S,3S)1-(Indole-2-carbonyl)-N-(tetrahydro-2-benzyloxy-5-oxo-3-furanyl)-
-L-prolinamide (38). Trifluoroacetic acid (4 ml) was added to a
solution of
(2R,S,3S)1-tert-butoxycarbonyl-N-(tetrahydro-2-benzyloxy-5-oxo-3-furan-
yl)-L-prolinamide (15) (0.607 g, 1.5 mmol) in dichloromethane (4
ml) at 0.degree. C. The mixture was stirred at 0.degree. C. for 75
min. The mixture was concentrated, and the residue treated with
diethyl ether, then the ether was removed under vacuum. This
procedure was repeated twice to yield a yellow oil, which was
dissolved in DMF (12 ml). Diisopropyl-ethylamine (0.78 ml, 4.5
mmol) followed by indole-2-carboxylic acid (266 mg, 1.65 mmol),
1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (316
mg, 1.65 mmol) and hydroxybenzotriazole (405 mg, 3 mmol) were then
added to the solution. The mixture was stirred at room temperature
for 20 h then poured into brine. The mixture was extracted with
ethyl acetate (3.times.30 ml). The combined organic extracts were
washed with saturated aqueous sodium bicarbonate (2.times.60 ml)
then brine (2.times.60 ml), dried (MgSO.sub.4), filtered and
concentrated. The residue was purified by column chromatography
(ethyl acetate) to afford 518 mg (77%) of a mixture of
diastereomers: IR (KBr) 3314, 1780, 1677, 1609, 1524, 1435, 1406,
1344; .sup.1H NMR (d.sub.6-DMSO), .delta. 11.58 (1H, m), 8.81-8.41
(1H, m), 7.71-6.67 (10H, m), 5.70 (d, J=5.2), 5.48 (s), 4.89-4.29
(4H, m), 3.99-3.74 (2H, m), 3.20-2.44 (2H, m), 2.39-1.77 (4H, m).
(3S)3-[1-(Indole-2-carbonyl)-L-prolinyl]amino-4-oxobutanoic acid
(39). A mixture of
(2R,S,3S)1-(indole-2-carbonyl)-N-(tetrahydro-2-benzyloxy-5-oxo-3-furanyl)-
-L-prolinamide (38) (478 mg, 1.07 mmol) and 10% palladium on carbon
(475 mg) and methanol (150 ml) was stirred under a hydrogen
atmosphere for 6 h. The resulting mixture was filtered and
concentrated to yield a colorless glass. Recrystallization from a
mixture of methanol and diethyl ether afforded 202 mg (53%) of a
colorless solid: mp. 135-138.degree. C.;
[.alpha.].sub.D.sup.24-44.degree. (c 0.25, CH.sub.3OH); IR (KBr)
3287, 2977, 2879, 1781, 1725, 1716, 1667, 1662, 1600, 1529, 1441,
1346;
[0905] .sup.1H NMR (CD.sub.3OD) .delta. 7.65 (1H, d, J=8.0), 7.44
(1H, d, J=8.4), 7.22 (1H, m), 7.09-6.84 (2H, m), 4.62 (2H, m), 4.29
(1H, m), 4.15-3.73 (2H, m), 2.74-1.72 (6H, m).
##STR00151##
Methyl 2-(3,5-dihydro-7-methyl-4-oxo-4H-pyrrolo
[3,2-d]pyrimidin-3-yl)acetate (40). Freshly prepared methyl
glycinate (1.25 g, 14 mmol) was added to a stirred solution of
ethyl
3-[N-(dimethylamino)methylene]amino-4-methylpyrrole-2-carboxylate
(1.56 g, 7.0 mmol; Lim et al., J. Org. Chem., 44, pp. 3826-29
(1979)) in dry methanol (60 ml). The resulting mixture was kept at
70.degree. C. Two further batches of methyl glycinate (1.25, 14.0
mmol) were added after 18 h and 42 h heating. The mixture was
cooled and filtered 24 h after the final addition. The filtrate was
concentrated and the residue purified by flash chromatography (2-5%
methanol/chloroform) to afford 0.54 g (35%) of a white crystalline
solid: mp. 233-235.degree. C. (recrystallized from ethyl acetate);
IR (KBr) 3135, 2958, 1745, 1675, 1254; .sup.1H NMR (d.sub.6-DMSO)
.delta. 11.90 (1H, s), 8.07 (1H, s), 7.23 (1H, s), 4.83 (2H, s),
3.69 (3H, s), 2.16 (3H, s). Anal. Calcd for
C.sub.10H.sub.11N.sub.3O.sub.3 0.1H.sub.2O: C, 53.85; H, 5.07; N,
18.84. Found: C, 53.85; H, 4.96; N, 18.81; MS (70 eVE.I.) m/e 222,
221 (M.sup.+, 100%), 189, 162, 133, 105.
2-(3,5-Dihydro-7-methyl-4-oxo-4H-pyrrolo[3,2-d]pyrimidin-3-yl)acetic
acid, sodium salt (41). A suspension of 40 (354 mg, 1.6 mmol) in
methanol (15 ml) was treated with 0.5N sodium hydroxide (4.8 ml)
and the resulting mixture was stirred at 25.degree. C. for 1 h. The
reaction mixture was filtered to afford the hemihydrate of 41 (354
mg, 97%) as a white crystalline solid: mp. >340.degree. C.
(recrystallized from methanol); IR (KBr) 3461, 3143, 1676, 1666,
1605, 1415; .sup.1H NMR (d.sub.6 DMSO) .delta. 11.63 (1H, s), 7.83
(1H, s), 7.11 (1H, d, J=2.0), 4.24 (2H, s), 2.14 (3H, s). Anal.
Calcd for C.sub.9H.sub.8N.sub.3O.sub.3Na. 0.5H.sub.2O: C, 45.39; H,
3.81; N, 17.64. Found: C, 45.57; H, 4.05; N, 17.39.
(2R,S,3S)2-(3,5-Dihydro-7-methyl-4-oxo-4H-pyrrolo[3,2-d]pyrimidin--
3-yl)-N-(tetrahydro-2-benzyloxy-5-oxo-3-furanyl)acetamide (42). A
suspension of the sodium salt 41 (344 mg, 1.5 mmol) in dry DMF (15
ml) was treated with ethyl dimethylaminopropyl carbodiimide
hydrochloride (373 mg, 1.95 mmol) and 1-hydroxybenzo-triazole (405
mg, 3.0 mmol). The mixture was kept at 25.degree. C. for 1 h then
(2R,S,3S)N-allyloxycarbonyl-3-amino-2-benzyloxy-5-oxotetrahydrofuran
(437 mg, 1.5 mmol; Chapman, Biorg. Med. Chem. Lett., 2, pp. 613-18
(1992)) and (Ph.sub.3P).sub.2PdCl.sub.2 (25 mg) were added followed
by the dropwise addition of n-tributyltin hydride (0.6 ml, 2.25
mmol). The resulting mixture was stirred at 25.degree. C. for 1 h
then water (20 ml) was added. The mixture was extracted with ethyl
acetate (3.times.15 ml), and the combined organic extracts were
washed with water (5 ml), dried (MgSO.sub.4), and concentrated to
afford a mixture of diastereomers.
[0906] Evaporation of the aqueous phase and purification of the
residue by flash chromatography (5% methanol/chloroform) gave an
additional quantity affording a total 182 mg of 42 (31%): m.p.
240-244.degree. C.; IR (KBr) 3274, 1772, 1691, 1664, 1562; .sup.1H
NMR (d.sub.6-DMSO) .delta. 11.81 (1H, s), 8.85 (0.6H, d, J=6.6),
8.72 (0.4H, d, J=7.4), 7.98 (0.6H, s), 7.95 (0.4H, s), 7.40-7.30
(5H, m), 7.20 (1H, d, J=2.2), 5.61 (0.4H, d, J=5.0), 5.46 (s),
4.85-4.60 (m), 4.28 (m), 3.20-2.35 (2H, m), 2.16 (3H, s).
(3S)-3-[2-(3,5-Dihydro-7-methyl-4-oxo-4H-pyrrolo[3,2-d]pyrimidin-3-yl)-1--
oxo-ethylamino]-4-oxobutanoic acid (43). A mixture of 42 (131 mg,
0.33 mmol), in methanol (50 ml) and 10% palladium on carbon (100
mg) was stirred vigorously under an atmosphere of hydrogen for 2 h.
An additional quantity of catalyst (100 mg) was added and the
mixture hydrogenated for a further 2 h. The mixture was filtered
through a 0.2 .mu.M nylon membrane, and concentrated. The residue
was recrystallized from methanol/diethyl ether to afford 79 mg
(78%) of 43 as a hygroscopic white solid: mp. 222-226.degree. C.;
(decomp.); [.alpha.].sub.D.sup.32+0.5 (c 0.02, MeOH); IR (KBr)
3282, 1680, 1558, 1425 1275; .sup.1H NMR (CD.sub.3OD) .delta. 8.03
(1H, s), 7.18 (1H, d, J=0.7), 4.79-4.74 (2H, m), 4.63-4.59 (1H,
2.times.d, J=3.6), 4.36-4.25 (1H, m), 2.78-2.39 (2H, m), 2.24 (3H,
d, J=0.7). Anal. Calcd for C.sub.13H.sub.14N.sub.4O.sub.5.
1.4H.sub.2O: C, 47.10; H, 5.12; N, 16.90. Found: C, 47.00; H, 4.79;
N, 16.59. FABMS m/e 307, 306 (M.sup.+), 244, 207, 190, 152, 115
(100%).
##STR00152##
(1S,9S) t-Butyl
6,10-dioxo-octahydro-9-(3-phenylpropionylamino)-6H-pyridazino[1,2-a][1,2]-
diazepine-1-carboxylate (44a). To a solution of (1S,9S).sub.t-butyl
9-amino-6,10-dioxo-octahydro-6H-pyridazino
[1,2-a][1,2]diazepine-1-carboxylate (690 mg; 2.32 mmol; GB 2128984)
in dioxane (16 ml) and water (4 ml) at 0.degree. C. was added solid
sodium bicarbonate (292 mg; 3.48 mmol) followed by dropwise
addition of 3-phenylpropionyl chloride (470 mg; 2.78 mmol). The
mixture was stirred at room temperature for 2 h then more sodium
bicarbonate (200 mg; 2.38 mmol) and 3-phenylpropionyl chloride (100
mg; 0.6 mmol) was added. The mixture was stirred for a further 2 h
at room temperature, diluted with ethyl acetate (50 ml), washed
with saturated sodium bicarbonate (2.times.25 ml) then dried
(MgSO.sub.4) and concentrated. The residue was purified by flash
chromatography (0-50% ethyl acetate/chloroform) and finally
crystallized by trituration with ether to afford 860 mg (86%) of a
white solid: mp. 137-138.degree. C.;
[.alpha.].sub.D.sup.23-95.1.degree. (c 0.549, CH.sub.2Cl.sub.2); IR
(KBr) 3327, 1736, 1677, 1664, 1536, 1422, 1156; .sup.1H NMR
(CDCl.sub.3) .delta. 7.24 (5H, m), 6.50 (1H, d, J=7.5), 5.24 (1H,
m), 4.90 (1H, m), 4.60 (1H, m), 3.44 (1H, m), 2.93 (2H, m), 2.84
(1H, m), 2.64 (1H, m), 2.54 (2H, m), 2.26 (2H, m), 1.70 (4H, m),
1.70 (9H, s). MS (FAB, m/z): 430 (M.sup.++1), 374, 242, 105, 91.
(1S,9S)t-Butyl
octahydro-10-oxo-9-(3-phenylpropionylamino)-6H-pyridazino-[1,2-a][1,2]dia-
zepine-1-carboxylate (44b), was prepared from (1S,9S)-t-butyl
9-amino-octahydro-10-oxo-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylate
(Attwood et al., J. Chem. Soc. Perkin 1, pp. 1011-19 (1986)) as for
44a, to afford 810 mg (81%) of a colorless oil:
[.alpha.].sub.D.sup.23-33.5.degree. (c 0.545, CH.sub.2Cl.sub.2); IR
(film) 3334, 2935, 1737, 1728, 1659, 1642; .sup.1H NMR (CDCl.sub.3)
.delta. 7.24 (5H, m), 6.75 (1H, d, J=6.7), 5.27 (1H, m), 4.92 (1H,
m), 3.39 (1H, m), 3.03 (4H, m), 2.55 (3H, m), 2.33 (1H, m), 2.17
(1H, m), 1.80 (5H, m), 1.47 (9H, s), 1.39 (1H, m). MS (FAB, m/z):
416 (M.sup.++1), 360, 211, 143, 97. (1S,9S)
6,10-Dioxo-octahydro-9-(3-phenylpropionylamino)-6H-pyridazino[1,2-a][1,2]-
diazepine-1-carboxylic acid (45a). To a solution of (1S,9S) t-butyl
6,10-dioxo-octahydro-9-(3-phenylpropionylamino)-6H-pyridazino[1,2-a][1,2]-
diazepine-1-carboxylate (44a) (800 mg; 1.863 mmol) in dry
dichloromethane (5 ml) at 0.degree. C. was added trifluoroacetic
acid (5 ml). The solution was stirred at room temperature for 3 h
then concentrated. Dry ether (10 ml) was added to the residue then
removed under vacuum. This process was repeated three times to
afford a crystalline solid. The solid was triturated with ether and
filtered to afford 590 mg (85%) of a white crystalline solid: mp.
196-197.5.degree. C.; [.alpha.].sub.D.sup.23-129.5.degree. (c 0.2,
CH.sub.3OH); IR (KBr) 3237, 1729, 1688, 1660, 1633, 1574, 1432,
1285, 1205; .sup.1H NMR (CD.sub.3OD) .delta. 8.28 (1H, d, J=7.4),
7.22 (5H, m), 5.32 (1H, dd, J=5.9, 2.9), 4.75 (1H, m), 4.51 (1H,
m), 3.50 (1H, m), 3.01 (1H, m), 2.91 (2H, m), 2.55 (2H, m), 2.29
(3H, m), 1.95 (2H, m), 1.71 (2H, m). Anal. Calcd for
C.sub.19H.sub.23N.sub.3O.sub.5: C, 61.12; H, 6.21; N, 11.25. Found:
C, 60.80; H, 6.28; N, 10.97. MS (FAB, m/z) 374 (M.sup.++1), 242,
105, 91. (1S,9S)
Octahydro-10-oxo-9-(3-phenylpropionylamino)-6H-pyridazino[1,2-a]--
[1,2]diazepine-1-carboxylic acid (45b), was prepared from (1S,9S)
t-butyl
octahydro-10-oxo-9-(3-phenylpropionylamino)-6H-pyridazino[1,2-a][1,2]diaz-
epine-1-carboxylate (44b) by the method described for compound 45a
to afford 657 mg (96%) of 45b as a crystalline solid: mp.
198-202.degree. C.; [.alpha.].sub.D.sup.23-86.2.degree. (c 0.5,
CH.sub.3OH); IR (KBr) 3294, 2939, 1729, 1645, 1620, 1574, 1453,
1214; .sup.1H NMR (CD.sub.3OD) .delta. 7.92 (1H, d, J=7.9), 7.20
(5H, m), 5.29 (1H, m), 4.90 (1H, m), 3.47 (1H, m), 3.08 (2H, m),
2.90 (2H, m), 2.55 (3H, m), 2.36 (1H, m), 1.81 (5H, m), 1.43 (2H,
m). MS (FAB, m/z) 360 (M.sup.++1), 211, 143, 91. [3S,
2R,S,(1S,9S)]N-(2-Benzyloxy-5-oxotetrahydrofuran-3-yl)-6,10-dioxo-oc-
tahydro-9-(3-phenylpropionylamino)-6H-pyridazino[1,2-a][1,2]diazepine-1-ca-
rboxamide (46a). To a solution of (1S,9S)
6,10-dioxo-octahydro-9-(3-phenyl-propionylamino)-6H-pyridazino[1,2-a][1,2-
]diazepine-1-carboxylic acid (45a) (662 mg; 1.773 mmol) in dry
dichloromethane (9 ml) and dry dimethyl formamide (3 ml) at room
temperature was added bis(triphenylphosphine)palladium chloride (30
mg) and
(3S,2R,S)-3-allyloxycarbonylamino-2-benzyloxy-5-oxotetrahydrofuran
(Chapman, Biorg. Med. Chem. Lett., 2, pp. 613-18 (1992)) (568 mg;
1.95 mmol) followed by dropwise addition of tri-n-butyltin hydride
(1.19 g; 4.09 mmol). 1-Hydroxy-benzotriazole (479 mg; 3.546 mmol)
was added to the mixture and the mixture was cooled to 0.degree. C.
before addition of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride (408 mg; 2.128 mmol). The mixture was stirred at room
temperature for 3.25 h then diluted with ethyl acetate (50 ml),
washed twice with dilute hydrochloric acid (20 ml), twice with
saturated sodium bicarbonate (20 ml), once with brine then dried
(MgSO.sub.4) and concentrated. The resulting oil was purified by
flash chromatography (0-100% ethyl acetate/chloroform) to afford
810 mg (81%) of 46a as a mixture of anomers: mp. 92-94.degree. C.;
IR (KBr) 3311, 1791, 1659, 1651, 1536; .sup.1H NMR (CDCl.sub.3)
.delta. 7.49, 6.56 (1H, 2d, J=6.7, 7.8), 7.29 (10H, m), 6.37, 6.18
(1H, 2d, J=7.7, 7.6), 5.56, 5.34 (1H, d, s, J=5.2), 5.08-4.47 (6H),
3.18-2.80 (5H), 2.62-2.28 (5H), 2.04-1.53 (5H). MS (FAB, m/z), 563
(M.sup.++1), 328, 149, 91. [3S,
2R,S,(1S,9S)]N-(2-Benzyloxy-5-oxotetrahydrofuran-3-yl)-octahydro-10-oxo-9-
-(3-phenylpropionylamino)-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxamide
(46b), was prepared from 45b by the method described for 46a to
yield 790 mg (96%) of a glass: m.p. 58-60.degree. C.; IR (KBr)
3316, 2940, 1793, 1678, 1641, 1523, 1453, 1120; .sup.1H NMR
(CDCl.sub.3) .delta. 7.28 (10H, m), 6.52, 6.42 (1H, 2d, J=7.2,
7.1), 5.53, 5.44 (1H, d, s, J=5.2), 5.35 (1H, m), 4.6-4.9, 4.34
(4H, m), 3.1-2.8 (6H, m), 2.6-2.1 (7H), 1.95-1.05 (5H). MS (FAB,
m/z), 549 (M.sup.++1), 400, 310, 279, 91. [3S,
(1S,9S)]3-(6,10-Dioxo-octahydro-9-(3-phenylpropionylamino)-6H-pyridazino[-
1,2-a][1,2]diazepine-1-carboxamido)-4-oxobutanoic acid (47a). A
mixture of [3S,
2R,S,(1S,9S)]N-(2-benzyloxy-5-oxotetrahydrofuran-3-yl)-6,10-dioxo-oc-
tahydro-9-(3-phenylpropionylamino)-6H-pyridazino[1,2-a][1,2]diazepine-1-ca-
rboxamide (46a) (205 mg; 0.364 mmol), 10% palladium on carbon (200
mg) and methanol (20 ml) was stirred under hydrogen at atmospheric
pressure for 5 h. The mixture was filtered then concentrated to
yield 154 mg (90%) of a glass: mp. 116-118.degree. C.;
[.alpha.].sub.D.sup.23-140.degree. (c 0.1, CH.sub.3OH); IR (KBr)
3323 (br), 1783, 1731, 1658, 1539, 1455, 1425; .sup.1H NMR
(CD.sub.3OD) .delta. 7.21 (5H, m), 5.17 (1H, m), 4.73 (1H, m), 4.50
(2H, m), 4.23 (1H, m), 3.38 (1H, m), 3.06 (1H, m), 2.91 (2H, m),
2.73-2.18 (6H, m) and 2.01-1.59 (5H, m). Anal. Calcd for
C.sub.23H.sub.27N.sub.4O.sub.7+H.sub.2O: C, 56.32; H, 6.16; N,
11.42. Found: C, 56.29; H, 6.11; N, 11.25. MS (FAB, m/z) 473
(M.sup.++1), 176, 149, 105, 91.
[3S,(1S,9S)]3-(Octahydro-10-oxo-9-(3-phenylpropionylamino)-6H-pyridazino--
[1,2-a][1,2]diazepine-1-carboxamido)-4-oxobutanoic acid (47b), was
prepared from 46b by the method described for 47a. The residue was
purified by flash chromatography (0-10% methanol/chloroform) to
afford 65 mg (52%) of a glass; m.p. 87-90.degree. C.;
[.alpha.].sub.D.sup.23-167.0.degree. (c. 0.1, methanol); IR (KBr)
3329, 2936, 1786, 1727, 1637; .sup.1H NMR (CD.sub.3OD) .delta. 7.23
(5H, m), 5.29 (1H, m), 4.83 (1H, m), 4.59 (1H, d, J=3.6), 4.29 (1H,
m), 3.3-3.0 (3H, m), 2.91 (2H, m), 2.70-2.34 (5H, m), 2.19 (2H, m),
1.75 (4H, m), 1.36 (2H, m). Anal. Calcd for
C.sub.23H.sub.30N.sub.4O.sub.6+0.5H.sub.2O: C, 59.09; H, 6.68; N,
11.98. Found: C, 58.97; H, 6.68; N, 11.73. MS (FAB, m/z) 459
(M.sup.++1), 310, 149, 105, 91.
TABLE-US-00006 ##STR00153## ##STR00154## R.sub.1 R.sub.2 R.sub.3
(a) PhCH.sub.2 H (S)Me (b) PhCH.sub.2 CH.sub.2Ph H (c) PhCH.sub.2
(CH.sub.2).sub.2Ph H (d) PhCH.sub.2 nBu H (e) PhCH.sub.2 Me H (f)
PhCH.sub.2 Ph H (g) PhCH.sub.2 H H (h) PhCH.sub.2 CH.sub.2Ph (S)-Me
(i) Ph(CH.sub.2).sub.2 CH.sub.2 H
Pyridones 48 were prepared by the method described by Damewood et
al., J. Med. Chem., 37, pp. 3303-12 (1994)). Compound 48d is
new.
[0907] 3-Benzyloxycarbonylamino-6-butyl-pyrid-2-one (48d), was
isolated as a cream solid: mp. 158-160.degree. C.; IR (KBr) 3382,
2953, 2930, 2866, 1729, 1643, 1524, 1468, 1202, 1044; .sup.1H NMR
(d.sub.6-DMSO) .delta. 8.26 (1H, s), 7.72 (1H, d), 7.39 (5H, m),
6.00 (1H, d), 5.14 (2H, s), 2.41 (2H, t), 1.52 (2H, m), 1.24 (2H,
m), 0.87 (3H, t). Anal. Calcd for C.sub.17H.sub.20N.sub.2O.sub.3:
C, 67.98; H, 6.71; N, 9.33. Found: C, 67.69; H, 6.68; N, 9.20. MS
CI M.sup.+=300 (m))28%.
(2S) Methyl
2-[3-benzyoxycarbonylamino-1,2-dihydro-2-oxo-1-pyridyl]propionate
(49a). Sodium hydride (80% oil dispersion) (0.35 g, 11.64 mmole)
was added to a stirred mixture of
3-(benzyloxycarbonylamino)pyrid-2-one (48a) (2.58 g, 10.58 mmol)
and tetrahydrofuran (100 ml) at room temperature. The mixture was
stirred for 10 mins. The resulting solution was added to a solution
of 2(Ryl-2((trifluoromethane) sulphonyloxy)propionate (2.5 g, 10.58
mmole; Feenstra et al., Tetrahedron Lett., 28, pp. 1215-18 (1987))
in tetrahydrofuran (5 ml) at room temperature during 10 mins. The
mixture was stirred at room temperature for 80 mins then poured
into ethyl acetate. The mixture was washed twice with 1M HCl, twice
with aqueous sodium bicarbonate then brine. It was dried
(MgSO.sub.4) and concentrated. The residue was purified by flash
chromatography (30% ethyl acetate/hexane) to afford 2.945 g (84%)
of a colorless solid: mp. 96-7.degree.; [.alpha.].sub.D.sup.20
71.36 (c 2.5, CHCl.sub.2); IR (KBr) 3370, 1764, 1729, 1648, 1602,
1564, 1523, 1515, 1503, 1449, 1359, 1203, 1064; .sup.1H NMR
(CDCl.sub.3) .delta. 8.04 (1H, d, J=7.2), 7.86 (1H, s), 7.36 (5H,
m), 6.98 (1H, dd, J=7.1, J=1.7), 6.30 (1H, t, J=7.2), 5.46 (1H, q,
J=7.4), 5.20 (2H, s), 3.74 (3H, s), 1.66 (3H, d, J=7.4). Anal.
Calcd for C.sub.17H.sub.18N.sub.2O.sub.5: C, 61.81; H, 5.49; N,
8.48. Found: C, 61.49; H, 5.51; N, 8.41. MS (FAB, m/z) 331
(M.sup.++1), 299, 223, 196, 163, 91. Methyl
[6-benzyl-3-benzyloxycarbonylamino-1,2-dihydro-2-oxo-1-pyridyl]-acetate
(49b). Sodium hydride (80% oil dispersion) (0.65 g, 26.2 mmole) was
added to a stirred mixture of 6-benzyl-3(benzyloxycarbonylamino)
pyrid-2-one (48b) (7.3 g, 2.18 mmol) and tetrahydrofuran (150 ml)
at room temperature. The mixture was stirred for 10 mins, treated
with methyl bromoacetate (2.5 ml, 26.2 mmol) and kept for 3 h. The
resulting mixture was poured onto a mixture of ice and 1M HCl. The
resulting solid was filtered off then dissolved in dichloromethane.
The resulting solution was dried (MgSO.sub.4), decolourized with
charcoal and concentrated. The residue was purified by
chromatography (2-5% ethyl acetate/dichloromethane) to afford 7.2 g
(81%) of colorless crystals: mp. 117-9.degree.; IR (KBr) 3375,
1753, 1730, 1651, 1605, 1513, 1384, 1223, 1185, 1071; .sup.1H NMR
(CDCl.sub.3) .delta. 8.02 (1H, d, J=7.5), 7.78 (1H, s), 7.31 (8H,
m), 7.10 (2H, m), 6.15 (1H, d, J=7.5), 5.20 (2H, s), 4.70 (2H, s),
3.88 (2H, s), 3.66 (3H, s). The following compounds were prepared
in a similar manner: Methyl
[3-benzyloxycarbonylamino-1,2-dihydro-2-oxo-6-phenethyl-1-pyridyl]-acetat-
e (49c). 97% yield: m.p. 102-4.degree. C. IR (KBr) 3245, 3232,
1741, 1725, 1648, 1600, 1526, 1216; .sup.1H NMR (d.sub.6-DMSO)
.delta. 8.45 (1H, s), 7.76 (1H, d, J=7.6), 7.35 (10H, m), 6.15 (1H,
d, J=7.6), 5.15 (2H, s), 4.85 (2H, s), 3.68 (3H, s), 2.86 (4H, s).
Methyl
[3-benzyloxycarbonylamino-6-butyl-1,2-dihydro-2-oxo-1-pyridyl]-acetate
(49d). 90% yield: mp. 111-112.degree. C.; IR (KBr) 3393, 1738,
1731, 1645, 1598, 1517, 1225, 1208; .sup.1H NMR (d.sub.6-DMSO)
.delta. 8.39 (1H, s), 7.78 (1H, d, J=7.7), 7.35 (5H, m), 6.17 (1H,
d, J=7.7), 5.15 (2H, s), 4.80 (2H, s), 3.67 (3H, s), 1.38 (6H, m),
0.89 (3H, t). Methyl
[3-benzyloxycarbonylamino-1,2-dihydro-6-methyl-2-oxo-1-pyridyl]-acetate
(49e). 84% yield as a colorless solid: mp. 115-6.degree. C.; IR
(KBr) 3246, 1740, 1725, 1649, 1598, 1573, 1535, 1417, 1365, 1259,
1219, 1193, 1090, 1068, 1006; .sup.1H NMR (d.sub.6-DMSO) .delta.
8.40 (1H, s), 7.75 (1H, d, J=7.6), 7.38 (5H, m), 6.20 (1H, d,
J=7.6), 5.15 (2H, s), 4.85 (2H, s), 3.68 (3H, s), 2.26 (3H, s).
Methyl
[3-benzyloxycarbonylamino-1,2-dihydro-6-phenyl-1-pyridyl]-acetate
(49f). 67% yield as a colorless oil: IR (KBr) 3266, 1739, 1727,
1646, 1606, 1566, 1517, 1490, 1365, 1213, 1163, 1075; .sup.1H NMR
(CDCl.sub.3) .delta. 8.15 (1H, d), 7.85 (1H, s), 7.39 (10H, m),
6.22 (1H, d), 5.22 (2H, s), 4.57 (2H, s), 3.74 (3H, s). Methyl
[3-benzyloxycarbonylamino-1,2-dihydro-2-oxo-1-pyridyl]-acetate (49
g). 80% yield as a colorless crystalline solid: m.p.
110-111.degree. C. IR (KBr) 3385, 1745, 1726, 1650, 1601, 1512,
1502, 1378, 1369, 1358, 1215, 1195, 1162, 1067; .sup.1H NMR
(CDCl.sub.3) .delta. 8.06 (1H, d), 7.84 (1H, s), 7.36 (5H, m), 6.88
(1H, dd), 6.27 (1H, t), 5.20 (2H, s), 4.68 (2H, s), 3.78 (3H, s).
Anal. Calcd for C.sub.16H.sub.16N.sub.2O.sub.5: C, 60.75; H, 5.10;
N, 8.85. Found: C, 60.65; H, 5.15; N, 8.85. MS FAB (+)M+=317 (M+1).
2(S)Methyl
2-methyl-[6-benzyl-(3-benzyloxycarbonyl-amino)-1,2-dihydro-2-oxo-1-pyridy-
l]-acetate (49 h), was prepared by the method used in the
preparation of compound 49a to afford (58%) an oil;
[.alpha.].sub.D.sup.25-25.0.degree. (c 1, CH.sub.2Cl.sub.2); IR
(KBr) 3381, 1736, 1650, 1604, 1513, 1218, 1190, 1068; .sup.1H NMR
(CDCl.sub.3) .delta. 7.97 (1H, d), 7.78 (1H, s), 7.4-7.14 (10H, m),
6.17 (1H, d), 5.19 (2H, s), 4.64 (1H, q), 3.98 (2H, s), 3.62 (3H,
s), 1.31 (3H, d). Methyl
[6-benzyl-1,2-dihydro-2-oxo-3-(2-phenylethoxy)-carbonylamino-1-pyridyl]ac-
etate (49i), was isolated (88%) as a colorless solid: mp.
130-133.degree. C.; IR (KBr) 3363, 1746, 1732, 1651, 1604, 1515,
1368, 1231, 1212, 1185; .sup.1H NMR (CDCl.sub.3) .delta. 8.00 (1H,
d, J=7.0), 7.68 (1H, s), 7.36-7.10 (10H, m), 6.15 (1H, d, J=7.6),
4.7 (2H, s), 4.38 (2H, t, J=7.0), 3.88 (2H, s), 3.67 (3H, s), 2.98
(2H, t, J=7).
##STR00155##
2(S)Methyl 2[3-amino-1,2-dihydro-2-oxo-1-pyridyl]propionate (50a).
A mixture of
2(S)methyl-2[3-benzyloxycarbonylamino-1,2-dihydro-2-oxo-1-pyridyl)propion-
ate (49a) (2.75 g, 8.33 mmol), methanol (100 ml), and 10% palladium
on carbon (300 mg) was stirred under an atmosphere of hydrogen for
30 min. The mixture was filtered and concentrated to afford 1.63 g
(100%) of a colorless solid: .sup.1H NMR (d.sub.6-DMSO) .delta.
8.35 (1H, brs), 7.46 (1H, d), 7.22 (1H, d), 6.29 (1H, t), 5.22 (1H,
q), 3.63 (3H, s), 1.55 (3H, d). The following compounds were
prepared in a similar manner: Methyl
[3-amino-6-benzyl-1,2-dihydro-2-oxo-1-pyridyl]acetate (50b). 100%
yield as a grey solid: mp. 134-6.degree. C.; IR (KBr) 3418, 3312,
1723, 1658, 1596, 1548, 1435, 1290, 1245, 1011; .sup.1H NMR
(d.sub.6-DMSO) .delta. 7.25 (5H, m), 6.45 (1H, d, J=7.4), 5.92 (1H,
d, J=7.4), 5.00 (2H, s), 4.63 (2H, s), 3.88 (2H, s), 3.51 (3H, s).
Methyl [3-amino-1,2-dihydro-2-oxo-6-phenethyl-1-pyridyl]acetate
(50c). 99% yield as a viscous oil: IR (KBr) 3456, 341, 2953, 1745,
1649, 1600, 1548, 1219; .sup.1H NMR (CDCl.sub.3) .delta. 7.25 (5H,
m), 6.51 (1H, d, J=7.4), 5.92 (1H, d, J=7.4), 4.79 (2H, s), 3.77
(3H, s), 2.80 (4H, m).
Methyl[3-amino-6-butyl-1,2-dihydro-2-oxo-1-pyridyl]acetate (50d).
97% as a brown solid: mp. 75-7.degree. C.; IR (KBr) 3437, 3342,
2955, 1745, 1655, 1609, 1550, 1432, 1301, 1222, 1200; .sup.1H NMR
(CDCl.sub.3) .delta. 6.53 (1H, d, J=6.8), 5.93 (1H, d, J=6.8), 4.81
(2H, s), 3.77 (3H, s), 2.44 (2H, t), 1.45 (4H, m), 0.93 (3H, t).
Methyl[3-amino-1,2-dihydro-6-methyl-2-oxo-1-pyridyl]acetate (50e),
was isolated (100%) as a colorless crystalline solid: mp.
87-9.degree. C.; IR (KBr) 3442, 3326, 1735, 1647, 1600, 1549, 1434,
1407, 1383, 1366, 1225, 1209; .sup.1H NMR (d.sub.6-DMSO) .delta.
6.40 (1H, d, J=7.3), 5.93 (1H, d, J=7.3), 4.86 (2H, s), 4.79 (2H,
s), 3.67 (3H, s), 2.15 (3H, s).
Methyl[3-amino-1,2-dihydro-2-oxo-6-phenyl-1-pyridyl]acetate (50f),
was isolated (86%) as a grey solid: mp. 207-9.degree. C.; IR (KBr)
3473, 3345, 1750, 1644, 1600, 1536, 1443, 1366, 1309, 1212, 1184,
1156; .sup.1H NMR (d.sub.6-DMSO) .delta. 7.30 (5H, m), 6.54 (1H,
d), 6.03 (1H, d), 5.25 (2H, s), 4.49 (2H, s), 3.61 (3H, s).
Methyl[3-amino-1,2-dihydro-2-oxo-1-pyridyl]acetate (50 g), was
obtained as a colorless oil and used immediately in the next
step.
[0908] 2(S)Methyl
2-methyl-D-amino-6-benzyl-1,2-dihydro-2-oxo-1-pyridyl]acetate (50
h), was isolated (69%) as a colorless oil: IR (film) 3354, 1743,
1646, 1600, 1548, 1494, 1455, 1309, 1268, 1227, 113; .sup.1H
NMR(C.sub.6D.sub.6) .delta. 7.29-6.76 (5H, m), 5.86 (1H, d, J=7.2),
5.51 (1H, d, J=7.2), 4.43 (1H, q, J=6.7), 3.69 (2H, s), 3.41 (2H,
s), 3.36 (3H, s), 1.43 (3H, d, J=6.7).
TABLE-US-00007 ##STR00156## ##STR00157## R.sub.1 R.sub.2 R.sub.3
(a) Ph(CH.sub.2).sub.2CO H (S)Me (b) Ph(CH.sub.2).sub.2CO
CH.sub.2Ph H (c) Ph(CH.sub.2).sub.2CO (CH.sub.2).sub.2Ph H (d)
Ph(CH.sub.2).sub.2CO nBu H (e) Ph(CH.sub.2).sub.2CO Me H (f)
Ph(CH.sub.2).sub.2CO Ph H (g) Ph(CH.sub.2).sub.2CO H H (h)
Ph(CH.sub.2).sub.2CO CH.sub.2Ph (S)-Me or (R,S)-Me (i) AcTyr
CH.sub.2Ph H (j) Ph(CH.sub.2).sub.2SO.sub.2 CH.sub.2Ph H (k)
Ph(CH.sub.2).sub.2OCO CH.sub.2Ph H (l) Ph(CH.sub.2).sub.3CO
CH.sub.2Ph H
[0909] 2(S)Methyl
2-[1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-propionate
(51a). 3-Phenylpropionyl chloride (1.5 g, 9 mmol) was added
dropwise to a stirred mixture of 2S
methyl-2-[3-amino-1,2-dihydro-2-oxo-1-pyridyl]propionate (50a)
(1.63 g, 8.33 mmol), dioxane (60 ml), water (15 ml) and sodium
bicarbonate (1.54 g, 16.7 mmol). The mixture was kept for 1 h then
extracted with ethyl acetate. The extracts were washed with aqueous
sodium bicarbonate, dried (MgSO.sub.4) and concentrated. The
resulting red oil was purified by flash chromatography to afford
2.54 g (93%) of an oil: [.alpha.].sub.D.sup.20-68.degree. C. (1,
CH.sub.2Cl.sub.2); IR(CH.sub.2Cl.sub.2) 3369, 1747, 1690, 1650,
1602, 1512, 1267, 1260, 1217; .sup.1H NMR (CDCl.sub.3) .delta. 8.41
(1H, dd), 8.36 (1H, s), 7.24 (5H, m), 7.02 (1H, dd), 6.32 (1H, t),
5.44 (1H, q), 3.75 (3H, s), 3.03 (2H, t), 2.70 (2H, t), 1.66 (3H,
d). FAB M.sup.+=329 (M+1), 197, 165, 131, 110, 91.
The following compounds were prepared in a similar manner: Methyl
[6-benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-acetate
(51b), was isolated (93%) as crystals: mp. 95-7.degree. C.; IR
(KBr) 3265, 1747, 1686, 1642, 1590, 1563, 1511, 1454, 1401, 1220,
1183, 1133; .sup.1H NMR (CDCl.sub.3) .delta. 8.39 (1H, d, J=7.7),
8.27 (1H, s), 7.21 (10H, m), 6.17 (1H, d, J=7.7), 4.70 (2H, s),
3.89 (2H, s), 3.67 (3H, s), 3.02 (2H, m), 2.70 (2H, m). Methyl
[1,2-dihydro-2-oxo-6-phenethyl-3-(3-phenylpropionyl)amino-1-pyridyl]-acet-
ate (51c), was isolated (81%) as colorless crystals: mp.
105-8.degree. C.; IR (KBr) 3378, 1746, 1680, 1646, 1597, 1517,
1221; .sup.1H NMR (CDCl.sub.3) .delta. 8.34 (1H, d, J=7.7), 8.25
(1H, s), 7.23 (10H, m), 6.11 (1H, d, J=7.7), 4.77 (2H, s), 3.78
(3H, s), 2.88 (8H, m). Methyl
[6-butyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-acetate
(51d), was isolated (88%) as colorless crystals: mp. 84-5.degree.
C.; IR (KBr) 3345, 2958, 2930, 1756, 1693, 1650, 1602, 1510, 7.7),
8.22 (1H, s), 7.26 (5H, m), 6.12 (1H, d, J=7.7), 4.80 (2H, s), 3.79
(3H, s), 3.03 (2H, t), 2.68 (2H, t), 2.50 (2H, t), 1.46 (4H, m),
0.95 (3H, t).
Methyl[1,2-dihydro-6-methyl-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-a-
cetate (51e), was isolated (100%) as a pale yellow oil: IR (film)
3264, 1745, 1691, 1644, 1587, 1566, 1518, 1495, 1400, 1215, 1183,
1136; .sup.1H NMR (CDCl.sub.3) .delta. 8.33 (1H, d, J=7.6), 7.26
(5H, m), 6.13 (1H, d, J=7.6), 4.83 (2H, s), 3.79 (3H, s), 3.03 (2H,
m), 2.69 (2H, m), 2.28 (3H, s).
Methyl[1,2-dihydro-2-oxo-6-phenyl-3-(3-phenylpropionyl)amino-1-pyridy-
l]-acetate (51f), was isolated (99%) as a pale yellow oil: IR
(film) 3365, 3299, 1751, 1689, 1643, 1600, 1563, 1519, 1493, 1419,
1370, 1224; .sup.1H NMR (CDCl.sub.3) .delta. 8.46 (1H, d, J=7.7),
8.32 (1H, s), 7.32 (10H, m), 6.24 (2H, d, J=7.7), 4.57 (2H, s),
3.73 (3H, s), 3.06 (2H, m), 2.72 (2H, m). Methyl
[1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-acetate
(51 g), was isolated (81%) as an oil: IR (film) 3330, 1753, 1689,
1650, 1600, 1560, 1517, 1374, 1225, 1208; .sup.1H NMR (CDCl.sub.3)
.delta. 8.43 (1H, dd, J=7.4, 1.7), 8.33 (1H, s), 7.28 (5H, m), 6.92
(1H, dd, J=6.9, 1.7), 6.29 (1H, t), 4.67 (2H, s), 3.79 (3H, s),
3.04 (2H, m), 2.70 (2H, m). MS FAB (+) M.sup.+=315 (M+1).
2(S)Methyl
2-methyl-[6-benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl-
]-acetate (51 h), was isolated (93%) as a colorless oil;
[.alpha.].sub.D.sup.30-19.degree. (c 1, 1645, 1600, 1567, 1514,
1454, 1225; .sup.1H NMR (CDCl.sub.3) .delta. 8.35 (1H, d, J=7.5),
8.26 (1H, s), 7.27 (10H, m), 6.20 (1H, d, J=7.5), 4.65 (1H, q,
J=6.8), 3.99 (2H, s), 3.71 (3H, s), 3.03 (2H, m), 2.68 (2H, m),
1.31 (3H, d, J=6.8). Methyl
[3-(N-acetyl-O-benzyl-L-tyrosine)amino-6-benzyl-1,2-dihydro-2-oxo-pyridyl-
]acetate (51i). A stirred mixture of methyl
[3-amino-6-benzyl-1,2-dihydro-2-oxo-1-pyridyl]acetate (100 mg,
0.367 mmol), Boc-Tyr(Bn)--OH (136 mg, 0.367 mmol),
dimethylformamide (1 ml), diisopropylethylamine (0.25 ml, 1.468
mmol) and 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (118 mg, 0.367 mmol) was kept overnight at room
temperature. The mixture was diluted with ethyl acetate, washed
twice with 1M hydrochloric acid, twice with aqueous sodium
bicarbonate, once with brine, then dried (MgSO.sub.4) and
concentrated. The residue was purified by flash chromatography (10%
ethyl acetate/dichloromethane) to afford a 162 mg (70%) of a
colorless oil. The oil (160 mg, 0.255 mmol) was dissolved in
dichloromethane (1 ml) and treated with trifluoroacetic acid (1 ml)
at 0.degree. C. The resulting solution was allowed to reach room
temperature during 40 min then evaporated to dryness at 30.degree.
C. The residue was dissolved in dichloromethane then evaporated to
dryness again. This procedure was repeated three times. The residue
was dissolved in pyridine (0.5 ml) and treated with acetic
anhydride (0.03 ml, 0.3 mmol) at 0.degree. C. The resulting mixture
was allowed to reach room temperature and kept for 3.5 h. It was
diluted with ethyl acetate, washed twice with 1M hydrochloric acid,
twice with aqueous sodium bicarbonate, dried (MgSO.sub.4) and
concentrated to afford 128 mg (86%) of a colorless oil: IR (film)
3290, 1751, 1649, 1602, 1568, 1513, 1455, 1438, 1375, 1224, 1179;
.sup.1H NMR (CDCl.sub.3) .delta. 8.78 (1H, s), 8.33 (1H, d, J=7.6),
7.33 (8H, m), 7.11 (4H, m), 6.86 (2H, d, J=8.5), 6.47 (1H, d,
J=7.6), 6.12 (1H, d, J=7.6), 4.99 (2H, s), 4.85 (1H, m), 4.69 (2H,
s), 3.87 (2H, s), 3.62 (3H, s), 3.08 (2H, m), 1.96 (3H, s).
[0910]
Methyl[6-benzyl-1,2-dihydro-2-oxo-3-(2-phenylethanesulphonyl)amino--
1-pyridyl]-acetate (51j). 2-Phenylethanesulphonyl chloride (Zhong
et al., J. Am. Chem. Soc., 113, pp. 2259-63 (1991)) was added to a
stirred mixture of methyl
[3-amino-6-benzyl-2-oxo-1,2-dihydro-1-pyridyl]-acetate (49b) (1.0
g, 3.67 mmol), dichloromethane (15 ml) and triethylamine (1.0 ml,
7.34 mmol). The mixture was kept overnight then poured into ethyl
acetate. The resulting mixture was washed twice with aqueous sodium
bicarbonate, three times with 1M hydrochloric acid, then brine. It
was dried (MgSO.sub.4) and concentrated. The resulting pale brown
solid was purified by flash chromatography (10% ethyl
acetate/dichloromethane) to afford 1.25 g (77%) of a pale yellow
solid: m.p. 92-4.degree. C.; IR (KBr) 3181, 1737, 1646, 1595, 1565,
1454, 1241, 1220, 1150; .sup.1H NMR (CDCl.sub.3) .delta. 7.53 (1H,
d, J=7.5), 7.29 (10H, m), 6.10 (1H, d, J=7.5), 4.75 (2H, s), 3.89
(2H, s), 3.67 (3H, s), 3.34 (2H, m), 3.14 (2H, m).
Methyl
[6-benzyl-1,2-dihydro-2-oxo-3-(4-phenylbutyryl)amino-1-pyridyl]-ac-
etate (511), was isolated (74%) as colorless crystals: mp.
93-95.degree. C.; IR (KBr) 3285, 1747, 1683, 1642, 1591, 1563,
1512, 1455, 1220, 1181; .sup.1H NMR (CDCl.sub.3) .delta. 8.39 (1H,
d, J=7.6), 8.24 (1H, s), 7.2 (10H, m), 6.18 (1H, d, J=7.6), 4.7
(2H, s), 3.90 (2H, s), 3.67 (3H, s), 2.69 (2H, t), 2.40 (2H, t),
2.04 (2H, m).
##STR00158##
2(S)2-[1,2-Dihydro-2-oxo-3-(3-phenylpropionyl)amino)-1-pyridyl]propionic
acid (52a). 1M Sodium hydroxide (15 ml, 15 mmol) was added to a
stirred solution of 2(S) methyl
2-[1,2-dihydro-2-oxo-3(3-phenylpropionyl)amino-1-pyridyl]propionate
(51a) (2.39 g, 7.3 mmol) in methanol (30 ml) at 0.degree. C. The
mixture was kept at this temperature for 2 h, acidified with 1M
hydrochloric acid (15.1 ml) and extracted with ethyl acetate. The
extracts were washed with brine, dried (MgSO.sub.4) and
concentrated to afford 1.98 g (87%) of a colorless solid:
[.alpha.].sub.D.sup.20-75.degree. (1, CH.sub.2Cl.sub.2); IR (KBr)
3301, 1724, 1693, 1637, 1563, 1523, 1453, 1233, 1216, 765; .sup.1H
NMR (CDCl.sub.3) .delta. 8.47 (2H, m), 7.20 (5H, m), 7.03 (1H, d),
6.36 (1H, t), 5.35 (1H, q), 3.01 (2H, m), 2.70 (2H, m), 1.69 (3H,
m). The following compounds were prepared in a similar manner:
[6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]acetic
acid (52b), was isolated (100%) as a pale amber oil: IR (film)
3291, 1738, 1686, 1644, 1591, 1554, 1519, 1496, 1454, 1403, 1215,
1182; .sup.1H NMR (CDCl.sub.3) .delta. 8.44 (1H, d, J=7.8), 8.4
(1H, s), 7.21 (10H, m), 6.19 (1H, d, J=7.8), 4.71 (2H, s), 3.90
(2H, s), 2.99 (2H, m), 2.71 (2H, m).
[1,2-Dihydro-2-oxo-6-phenethyl-3-(3-phenylpropionyl)amino-1-pyridyl]a-
cetic acid (52c), was isolated (94%) as a beige solid: mp.
214-6.degree. C.; IR (KBr) 3289, 1740, 1680, 1640; .sup.1H NMR
(d.sub.6-DMSO) .delta. 9.24 (1H, s), 8.14 (1H, d, J=7.7), 7.22
(10H, m), 6.11 (1H, d, J=7.8), 4.78 (2H, s), 2.81 (8H, m).
[0911]
[6-Butyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]ace-
tic acid (52d), was isolated (99%) as a pale brown solid: mp.
132-4.degree. C.; IR (KBr) 3286, 1739, 1676, 1641, 1584, 1555,
1535, 1455, 1414, 1249, 1227, 1204; .sup.1H NMR (CDCl.sub.3)
.delta. 8.42 (1H, d, J=7.8), 8.37 (1H, s), 7.24 (5H, m), 6.19 (1H,
d, J=7.8), 4.82 (2H, s), 3.55 (1H, s), 3.00 (2H, t), 2.67 (2H, t),
2.53 (2H, t), 1.41 (4H, m), 0.94 (3H, t).
[1,2-Dihydro-6-methyl-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]acetic
acid (52e), was isolated as a solid (100%): mp. 159-61.degree. C.;
IR (KBr) 3335, 1731, 1686, 1642, 1536, 1516, 1430, 1420, 1401,
1222, 1195; .sup.1H NMR (d.sub.6.sup.-DMSO) .delta. 9.21 (1H, s),
8.13 (1H, d, J=7.6), 7.20 (5H, m), 6.15 (1H, d, J=7.6), 4.77 (2H,
s), 2.87 (2H, m), 2.70 (2H, m), 2.25 (3H, s).
[1,2-Dihydro-2-oxo-6-phenyl-3-(3-phenylpropionyl)amino-1-pyridyl]acetic
acid (52f), was isolated (100%) as a pale yellow foam: IR (KBr)
3271, 1747, 1683, 1634, 1580, 1536, 1490, 1406, 1392, 1365, 1235,
1219; .sup.1H NMR (CDCl.sub.3) .delta. 8.52 (1H, d, J=7.7), 7.31
(10H, m), 6.48 (2H, s), 6.30 (1H, d, J 7.7), 4.60 (2H, s), 3.03
(2H, m), 2.71 (2H, m).
[1,2-Dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]acetic acid
(52 g), was isolated (94%) as a colorless solid: mp. 195-7.degree.
C.; IR (KBr) 3324, 1724, 1693, 1644, 1569, 1555, 1512, 1427, 1370,
1240; .sup.1H NMR (d.sub.6-DMSO) .delta. 9.31 (1H, s), 8.23 (1H, d,
J=6.8), 7.36 (1H, dd, J=6.8, 1.71), 7.25 (5H, m), 6.25 (1H, t),
4.66 (2H, s), 2.84 (4H, m).
2(R,S)2-[6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-
-propionic acid (52 h), was prepared by hydrolysis of compound 51 h
in aqueous tetrahydrofuran during 5 h at 40.degree. C. to afford
(95%) as a yellow oil: IR (film) 3330, 1734, 1686, 1643, 1600,
1587, 1553, 1524, 1498, 1208; .sup.1H NMR (d.sub.6-DMSO) .delta.
9.29 (1H, s), 8.18 (1H, d, J=7.6), 7.21 (10H, m), 6.22 (1H, d,
J=7.6), 4.82 (1H, q, J=6.6), 4.08 (2H, m), 2.76 (4H, m), 1.05 (3H,
d, J=6.6).
3-(Acetyl-Tyr(Bn))amino-6-benzyl-1,2-dihydro-2-oxo-1-pyridyl]acetic
acid (52i), was isolated (93%) as a foam: IR (KBr) 3302, 1731,
1646, 1603, 1562, 1512, 1454, 1428, 1379, 1231, 1178; .sup.1H NMR
(CDCl.sub.3) .delta. 9.48 (1H, s), 8.36 (1H, d, J=7.6), 7.30 (8H,
m), 7.10 (2H, m), 6.85 (2H, d, J=8.3), 6.91 (2H, d, J=8.3), 6.71
(1H, d, J 7.6), 4.95 (1H, m), 4.90 (2H, s), 4.68 (2H, s), 3.92 (2H,
s), 3.17-2.83 (2H, m), 1.92 (3H, s).
[6-Benzyl-1,2-dihydro-2-oxo-3-(2-phenylethanesulphonyl)amino-1-p-
yridyl]acetic acid (52j), was isolated (100%) as a colorless solid:
mp. 165-7.degree. C.; IR (KBr) 3174, 1760, 1646, 1593, 1567, 1497,
1453, 1424, 1326, 1225, 1140, 1127; .sup.1H NMR (d.sub.6-DMSO)
.delta. 13.09 (1H, s), 9.08 (1H, s), 7.30 (11H, m), 6.02 (1H, d),
4.68 (2H, s), 4.99 (2H, s), 3.29 (2H, m), 3.03 (2H, m).
[6-Benzyl-1,2-dihydro-2-oxo-3-(2-phenylethoxy)
carbonylamino-1-pyridyl]acetic acid (52k), was prepared (70%) by
hydrolysis of compound 49i during 1 h at 60.degree. C.:
IR(CH.sub.2Cl.sub.2) 1797, 1689, 1649, 1601, 1512, 734; .sup.1H NMR
(CDCl.sub.3) .delta. 8.39 (1H, s), 8.03 (1H, d), 7.81 (1H, s),
7.33-7.07 (10H, m), 6.13 (1H, d, J=7.8), 4.72 (2H, s), 4.33 (2H, t,
J=7.0), 3.86 (2H, s), 2.93 (2H, t, J=7.0).
[6-Benzyl-1,2-dihydro-2-oxo-3-(4-phenylbutyryl)amino-1-pyridyl]acetic
acid (521), was isolated (100%) as a white foam: m.p.
159-161.degree. C.; IR (KBr) 3373-3310, 1787, 1726, 1691, 1649,
1599, 1567, 1517, 1367, 1215; .sup.1H NMR (CDCl.sub.3) .delta. 8.43
(1H, d, J=7.7), 8.25 (1H, s), 7.37-7.09 (10H, m), 6.21 (1H, d,
J=7.7), 4.73 (2H, s), 4.15 (3H, s), 3.91 (2H, s), 2.67 (2H, t),
2.39 (2H, t), 2.02 (2H, m).
##STR00159##
2(S),
N-3(S)2-[1,2-Dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-N--
(2-benzyloxy-5-oxotetrahydrofuran-3-yl)propionamide (53a).
Tri-n-butyltin hydride (1.7 ml, 6.3 mmol) was added dropwise to a
stirred mixture of
2(S)-2-[1,2-dihydro-2-oxo-3(3-phenylpropionyl)amino-1-pyridyl]propionic
acid (52a) (1.1 g, 3.49 mmol), 3(S),
2(R,S)3-allyloxycarbonylamino-2-benzyloxy-5-oxotetrahydrofuran
(1.02 g, 3.49 mmol; Chapman, Biorg. Med. Chem. Lett., 2, pp. 613-18
(1992)), bis(triphenylphosphine)palladium (II) chloride (55 mg),
dichloromethane (35 ml) and dimethylformamide (1 ml). The resulting
mixture was stirred for 5 min. then 1-hydroxybenzotriazole (946 mg,
7 mmol) was added. The mixture was cooled to 0.degree. C. before
the addition of 1-(3-dimethylaminopropyl)-2-ethylcarbodiimide
hydrochloride (740 mg, 3.84 mmol). The mixture was kept overnight
at room temperature then poured into ethyl acetate. The mixture was
washed twice with 1M hydrochloric acid, twice with aqueous sodium
bicarbonate, then brine. The mixture was dried (MgSO.sub.4) and
concentrated. The residue was triturated with pentane. The
remaining solid was purified by flash chromatography (40-60% ethyl
acetate/hexane) to afford 1.28 g (73%) of colorless solid: IR (KBr)
1796, 1692, 1647, 1595, 1557, 1512, 1119; .sup.1H NMR
(d.sub.6-DMSO) .delta. 9.28, 9.26 (1H, 2.times.s), 8.77, 8.69 (1H,
2.times.d), 8.24, 8.20 (1H, 2.times.dd), 7.20 (11H, m), 6.31, 6.26
(1H, 2.times.t), 5.65 (0.5H, d), 5.46 (0.5H, d), 5.41, 5.28 (1H,
2.times.q), 4.7 (2.5H, m), 4.24 (0.5H, t), 3.24 (2H, m), 2.80 (4H,
m), 1.51, 1.46 (3H, 2.times.d). The following compounds were
prepared in a similar manner:
N(3(S))2[6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-
-N-(2-benzyloxy-5-oxotetrahydrofuran-3-yl)acetamide (53b), was
obtained (86%) as a foam: IR (KBr) 3345, 3297, 1807, 1791, 1688,
1679, 1650, 1602, 1554, 1525, 1497, 1453, 1372, 1257, 1119; .sup.1H
NMR (d.sub.6-DMSO) .delta. 9.25 (0.5H, s), 9.23 (0.5H, s), 8.75
(0.5H, d, J=6.5), 8.67 (0.5H, d, J=7.4), 8.18 (1H, 2d), 7.21 (15H,
m), 6.07 (1H, 2d), 5.65 (0.5H, d, J=5.0), 5.38 (0.5H, s), 4.83-4.45
(4.5H, m), 4.19 (0.5H, m), 3.94, 3.83 (2H, m), 3.10-2.31 (6H, m).
N(3(S))2[1,2-Dihydro-2-oxo-6-phenethyl-3-(3-phenylpropionyl)amino-1-pyrid-
yl]-N-(2-benzyloxy-5-oxotetrahydrofuran-4-yl)acetamide (53c), was
obtained (74%) as a mixture of anomers: .sup.1H NMR (d.sub.6-DMSO)
.delta. 9.71 (1H, d), 9.41 (0.5H, d), 9.25 (0.5H, d), 8.64 (1H, d,
J=7.7), 7.75 (15H, m), 6.61 (1H, 2d), 6.11 (0.5H, d), 5.93 (0.5H,
s), 5.17 (5H, m), 4.77 (0.5H, m), 3.68-2.94 (2H, m), 3.32 (8H, m).
N(3(S))2[6-Butyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]--
N-(2-benzyloxy-5-oxotetrahydrofuran-3-yl)acetamide (53d), was
obtained (74%) as a mixture of anomers: IR (KBr) 3300, 1791, 1689,
1645, 1597, 1566, 1546, 1514, 1454, 1417, 1378; .sup.1H NMR
(CDCl.sub.3) .delta. 8.38 (1H, d, J=7.7), 8.13 (1H, s), 7.30 (10H,
m), 6.18 (1H, t), 5.47 (0.5H, d, J=5.2), 5.43 (0.5H, s), 4.75
(4.5H, m), 4.38 (0.5H, m), 3.08-2.35 (8H, m), 1.43 (4H, m), 0.95
(3H, t).
N(3(S))2[1,2-Dihydro-6-methyl-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-
-N-(2-benzyloxy-5-oxotetrahydrofuran-3-yl)acetamide (53e), was
obtained (67%) as a mixture of anomers: IR (KBr) 3282, 1774, 1667,
1651, 1596, 1561, 1556, 1498, 1265, 1254, 1236, 1199, 1143; .sup.1H
NMR (d.sub.6-DMSO) .delta. 9.17 and 9.15 (1H, 2.times.s), 8.89
(0.5H, d, J=6.5), 8.73 (0.5H, d, J=7.4), 7.25 (10H, m), 6.13 (1H,
t), 5.64 (0.5H, d, J=5.0), 5.45 (0.5H, s), 4.89-4.61 (4.5H, m),
4.26 (0.5H, m), 3.17-2.36 (6H, m), 2.23 and 2.15 (3H, 2s).
N(3(S))2-[1,2-Dihydro-2-oxo-6-phenyl-3(3-phenylpropionyl)amino-1-pyridyl]-
-N-(2-benzyloxy-5-oxotetrahydrofuran-3-yl)acetamide (53f), was
obtained (73%) as a mixture of anomers: IR (KBr) 3296, 1792, 1691,
1643, 1595, 1561, 1514, 1489, 1453, 1420, 1373, 1230, 1118; .sup.1H
NMR (d.sub.6-DMSO) .delta. 9.40, 9.36 (1H, 2s), 8.70 (0.5H, d,
J=7.6), 8.52 (0.5H, d, J=7.5), 8.29 (1H, dd), 7.25 (15H, m), 6.20
(1H, d, J=7.6), 5.61 (0.5H, d, J=5.0), 5.28 (0.5H, s), 4.78-4.20
(5H, m), 3.12-2.24 (6H, m).
N(3(S))2-[1,2-Dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-N-(2-be-
nzyloxy-5-oxotetrahydrofuran-3-yl)acetamide (53 g), was obtained
(70%) as a mixture of anomers: IR (KBr) 3336, 3290, 1791, 1691,
1646, 1595, 1582, 1556, 1518, 1454, 1376, 1351, 1150, 1122; .sup.1H
NMR (d.sub.6-DMSO) .delta. 9.26 (1H, 2s), 8.86 (0.5H, d, J=6.4),
8.67 (0.5H, d, J=7.5), 8.23 (1H, m), 7.40-7.13 (11H, m), 6.24 (1H,
2t, J=7.2), 5.61 (0.5H, d, J=5.0), 5.44 (0.5H, s), 4.83-4.59 (2.5H,
m), 4.25 (0.5H, m), 3.15-2.34 (2H, m), 2.91-2.70 (4H, m). Anal.
Calc. for C.sub.27H.sub.27N.sub.3O.sub.6H.sub.2O: C, 63.90; H,
5.76; N, 8.28. Found: C, 63.70; H, 5.68; N, 8.22. MS FAB
M.sup.+=490 (M+1). 2(R,S),
N(3(S))2-[6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl-
]-N(2-benzyloxy-5-oxotetrahydrofuran-3-yl)propionamide (53 h), was
obtained (89%) as a mixture of diastereomers. Data is given for a
single diastereomer: IR (film) 3356, 1788, 1677, 1645, 1602, 1517,
1455, 1377, 1203, 1167, 1120; .sup.1H NMR (CDCl.sub.3) .delta. 8.34
(1H, d, J=7.6), 8.19 (1H, s), 7.38-7.13 (10H, m), 6.26 (1H, d,
J=7.6), 5.58 (1H, t), 5.31, 5.24 (1H, 2.times.s), 4.62 (2H, 2q),
4.60 (1H, m), 4.27 (1H, m), 2.98, 2.68 (4H, 2m), 3.0-2.0 (2H, m),
1.42 (3H, d).
N(3(S))2-[6-Benzyl-1,2-dihydro-2-oxo-3-(N-acetyl-O-benzyltyrosinyl)amino--
1-pyridyl]-N-(2-benzyloxy-5-oxotetrahydrofuran-3-yl)acetamide
(53i), was obtained (76%) as a mixture of anomers: IR (KBr) 1794,
1698, 1651, 1612, 1514, 1454, 1374, 1247, 1177, 1126; .sup.1H NMR
(d.sub.6-DMSO) .delta. 9.34, 9.31 (2.times.0.5H, 2s), 8.71 (1H,
2d), 8.38 (1H, m), 8.17 (1H, d), 7.48-6.88 (19H, m), 6.08 (1H, 2d),
5.65 (0.5H, d, J=5.0), 5.40 (0.5H, s), 5.04 (2H, s), 4.68 (5.5H,
m), 4.15 (0.5H, m), 3.95, 3.84 (2H, s+abq), 3.20-2.40 (4H, m), 1.78
(3H, s).
N(3(S))2-[6-Benzyl-1,2-dihydro-2-oxo-3-(2-phenylethanesulphonyl)amino-1-p-
yridyl]-N-(2-benzyloxy-5-oxotetrahydrofuran-3-yl)acetamide (53j),
was obtained (78%) as a mixture of anomers: IR (KBr) 3344, 1792,
1691, 1647, 1599, 1566, 1454, 1365, 1150, 1121, 973; .sup.1H NMR
(d.sub.6-DMSO) .delta. 9.02, 8.99 (1H, 2s), 8.80 (0.5H, d, J=6.4),
8.70 (0.5H, d, J=7.4), 7.26 (15H, m), 6.00 (1H, dd), 5.63 (0.5H, d,
J=5.0), 5.39 (0.5H, s), 4.68 (4.5H, m), 4.18 (0.5H, m), 3.90 (2H,
m), 3.30-2.30 (6H, m).
N(3(S))2-[6-Benzyl-1,2-dihydro-2-oxo-3-(2-phenylethoxy)carbonylamino-1-py-
ridyl]-N-(2-benzyloxy-5-oxotetrahydrofuran-3-yl)acetamide (53k),
was obtained (78%) as a mixture of anomers: IR (KBr) 3386, 1794,
1726, 1650, 1603, 1518, 1366, 1214, 699; .sup.1H NMR (CDCl.sub.3)
.delta. 8.03 (1H, bd), 7.63, 7.61 (1H, 2.times.s), 7.34-7.04 (15H,
m), 6.21, 6.18 (1H, 2d), 5.44 (0.5H, d, J=5.4), 5.37 (0.5H, s),
4.85, 4.83 (1H, 2d, J=11.6, 11.5), 4.61-4.48, 4.32 (4H, 2m), 4.4
(2H, t), 4.08, 4.03 (2H, 2bs), 3.07-2.78 (3H, m), 2.47-2.30 (1H,
m).
N(3(S))2-[6-Benzyl-1,2-dihydro-2-oxo-3-(4-phenylbutyryl)amino-1-pyridyl]--
N-(2-benzyloxy-5-oxotetrahydrofuran-3-yl)acetamide (531), was
obtained (86%) as a colorless oil: IR(CH.sub.2Cl.sub.2) 1797, 1689,
1649, 1601, 1512, 734; .sup.1H NMR (CDCl.sub.3) .delta. 8.42, 8.40
(1H, 2d, J=7.6), 7.35-7.07 (15H, m), 6.21, 6.19 (1H, 2d, J=7.6),
5.44 (0.5H, d), 5.37 (0.5H, s), 4.84, 4.81 (1H, 2d, J=11.7, 11.4),
4.73-4.48, 4.34 (4H, 2m), 4.05 (2H, m), 3.05-2.63, 2.46-2.30 (6H,
2m), 2.01 (2H, m).
TABLE-US-00008 ##STR00160## ##STR00161## R.sub.1 R.sub.2 R.sub.3
(a) Ph(CH.sub.2).sub.2CO H (S)Me (b) Ph(CH.sub.2).sub.2CO
CH.sub.2Ph H (c) Ph(CH.sub.2).sub.2CO (CH.sub.2).sub.2 Ph H (d)
Ph(CH.sub.2).sub.2CO nBu H (e) Ph(CH.sub.2).sub.2CO Me H (f)
Ph(CH.sub.2).sub.2CO Ph H (g) Ph(CH.sub.2).sub.2CO H H (h)
Ph(CH.sub.2).sub.2CO CH.sub.2Ph (R,S)-Me (i) AcTyr CH.sub.2Ph H (j)
Ph(CH.sub.2).sub.2SO.sub.2 CH.sub.2Ph H (k) Ph(CH.sub.2).sub.2OCO
CH.sub.2Ph H (l) Ph(CH.sub.2).sub.3CO CH.sub.2Ph H
3(S),
N(2(S))3-(2-(1,2-Dihydro-2-oxo-3-(3-phenylpropionylamino-1-pyridyl)-
-propionylamino)-4-oxo-butanoic acid (54a; F). A mixture of 2(S),
N(3(S))2-[1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl]-N(2-ben-
zyloxy-5-oxotetrahydro-furan-3-yl)propionamide 53a (1.28 g, 2.5
mmol), methanol (140 ml) ethyl acetate (60 ml) and 10% palladium on
carbon (1.4 g) was stirred under an atmosphere of hydrogen. After
2.5 h more catalyst (300 mg) was added and hydrogenation continued
for 1 h. The mixture was filtered through Celite.TM. and then
refiltered through 0.2 .mu.M nylon filter and concentrated. The
residual oil triturated with a mixture of methanol and ether to
afford 916 mg (87%) of colorless crystals: mp. 198-200.degree. C.;
[.alpha.].sub.D.sup.28-120.degree. (0.1, CH.sub.3OH); IR (KBr)
3330, 1794, 1688, 1644, 1583, 1556, 1515, 1427; .sup.1H NMR
(CD.sub.3OD) .delta. 8.28 (1H, d), 7.35 (1H, d), 7.20 (5H, m), 6.36
(1H, t), 5.49 (1H, q), 4.59 (1H, t), 4.25 (1H, m), 2.98, 2.74
(2.times.2H, 2.times.m), 2.59 (2H, m), 1.57 (3H, d). Anal. Calcd
for C.sub.21H.sub.23N.sub.3O.sub.6 0.75H.sub.2O: C, 59.08; H, 5.78;
N, 9.84. Found: C, 59.24; H, 5.96; N, 9.84. FAB M.sup.+=414 (M+1),
297, 165, 91. The following compounds were prepared in a similar
manner:
3(S)3-(6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl)ac-
etylamino-4-oxobutanoic acid, (54b; M), was isolated (59%) as
colorless crystals: mp. 115.degree. C. (decomp);. IR (KBr) 3440,
3297, 1718, 1646, 1598, 1565, 1526, 1496, 1260; .sup.1H NMR
(CD.sub.3OD) 8.25 (1H, d, J=7.7), 7.25 (10H, m), 6.15 (1H, 2d, each
J=7.7), 4.73 (2H, 2q), 4.59 (1H, m), 4.30 (1H, m), 3.95 (2H, s),
2.98 (2H, m), 2.75 (2H, m), 2.8-2.42 (2H, m). Anal. Calcd for
C.sub.27H.sub.27N.sub.3O.sub.6. 0.7H.sub.2O: C, 64.58; H, 5.70; N,
8.37. Found: C, 64.51; H, 5.63; N, 8.38. MS FAB+M.sup.+=490 (M+1).
3(S)3-(1,2-Dihydro-2-oxo-6-phenethyl-3(3-phenyl-propionyl)amino-1-pyridyl-
)acetylamino-4-oxobutanoic acid (54c), was isolated (46%) as a
white solid: IR (KBr) 3375, 1694, 1643, 1586, 1561, 1515, 1377,
1254, 1188, 1070; .sup.1H NMR (CD.sub.3OD) 8.18 (1H, d, J=7.8),
7.22 (10H, m), 6.15 (1H, d, J=7.8), 4.75 (2H, s), 4.58 (1H, m),
4.30 (1H, m), 3.01-2.28 (10H, m); MS FAB+M.sup.+=504 (M+1).
3(S)3-(6-Butyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl)ace-
tylamino-4-oxobutanoic acid (54d), was isolated (90%) as colorless
crystals: m.p. 120-5.degree. C.; IR (KBr) 3315, 1784, 1679, 1644,
1589, 1561, 1556, 1520, 1415, 1379, 1186; .sup.1H NMR (CD.sub.3OD)
8.22 (1H, d, J=7.8), 7.24 (5H, m), 6.22 (1H, d, J=7.8), 4.80 (2H,
m), 4.60 (1H, s), 4.28 (1H, m), 2.98 (2H, m), 2.72 (2H, m), 2.58
(4H, m), 1.48 (4H, m), 0.97 (3H, t, J=7.1). Anal. Calcd for
C.sub.24H.sub.29N.sub.3O.sub.6 0.5H.sub.2O. C, 62.06; H, 6.51; N,
9.05. Found: C, 62.08; H, 6.43; N, 9.01. MS FAB+M.sup.+=456 (M+1).
3(S)3-(1,2-Dihydro-6-methyl-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl)ac-
etylamino-4-oxobutanoic acid (54e), was isolated (85%) as a
colorless solid: mp. 129-138.degree. C.; IR (KBr) 327, 3294, 1710,
1695, 1682, 1554, 1525, 1379, 1272, 1240; .sup.1H NMR (CD.sub.3OD)
.delta. 8.19 (1H, d, J=7.6), 7.19 (5H, m), 6.21 (1H, d, J=7.6),
4.80 (2H, m), 4.59 (1H, m), 4.30 (1H, m), 2.98 (2H, m), 2.72 (2H,
m), 2.80-2.40 (2H, m), 2.30 (3H, s). Anal. Calcd for
C.sub.21H.sub.22N.sub.3O.sub.6. H.sub.2O: C, 58.46; H, 5.84; N,
9.74. Found C, 58.82; H, 60.5; N, 9.42.
3(S)3-(1,2-Dihydro-2-oxo-6-phenyl-3-(3-phenyl-propionyl)amino-1-pyridyl)a-
cetylamino-4-oxobutanoic acid (54H), 73% as an off-white solid:
m.p. 140.degree. C. (decomp). [.alpha.].sub.D.sup.24=-8.5.degree.
(c 0.1, MeOH). IR (KBr) 3302, 1796, 1726, 1679, 1643, 1590, 1560,
1516, 1490, 1449, 1420, 1398, 1376, 1231; .sup.1H NMR (CD.sub.3OD)
.delta. 8.36 (1H, d), 7.49-7.14 (10H, m), 6.27 (1H, dd), 4.54 (3H,
m), 4.30 (1H, m), 3.0, 2.73 (2.times.2H, 2.times.m), 2.7-2.29 (2H,
m).
3(S)3-(1,2-Dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl)acetylamino-
-4-oxobutanoic acid (54 g; G), was isolated (73%) as a foam: mp.
140-5.degree. C. (decomp); IR (KBr) 3352, 3314, 1719, 1700, 1668,
1649, 1600, 1559, 1514, 1379, 1261; .sup.1H NMR (CD.sub.3OD)
.delta. 8.32 (1H, d, J=7.5), 7.19 (6H, m), 6.34 (1H, t), 5.1-4.6
(3H, m), 4.32 (1H, m), 2.7 (6H, m). Anal. Calcd for
C.sub.20H.sub.21N.sub.3O.sub.6. 0.6H.sub.2O: C, 58.50, H, 5.45; N,
10.24. Found: C, 58.43, H, 5.35, N. 9.85. MS FAB+M+=400 (M+1).
3(S),
N(2(R,S))3-(2-(6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-py-
ridyl)propionylamino)-4-oxobutanoic acid (54 h), was obtained (69%)
as a colorless foam: m.p. 120.degree. C.;
[.alpha.].sub.D.sup.20-16.0.degree. (c, 0.11, CH.sub.2Cl.sub.2). IR
(KBr) 3315, 1783, 1727, 1666, 1644, 1599, 1564, 1517, 1454, 1379;
.sup.1H NMR (CD.sub.3OD) .delta. 8.23 (1H, m), 7.27 (10H, m), 6.28
(1H, m), 4.84 (1H, m), 4.53 (1H, m), 4.22 (1H, m), 4.10 (2H, m),
2.96 (2H, m), 2.72 (2H, m), 2.39 (2H, m), 1.21 (3H, m). Anal. Calcd
for C.sub.28H.sub.29N.sub.3O.sub.6. 1.25H.sub.2O: C, 63.93, H,
6.03; N, 7.99. Found: C, 63.98, H, 5.85; N, 7.86. MS FAB (+)
M.sup.+=504 (M+1).
3(S)3-(3-(2-Acetyl-L-tyrosinyl)amino-6-benzyl-1,2-dihydro-2-oxo-1-pyridyl-
)acetylamino-4-oxobutanoic acid (54i), was isolated (79%) as
colorless crystals: mp. 193-6.degree. C. (decomp.); IR (KBr) 3284,
1644, 1599, 1565, 1519, 1455, 1429, 1407, 1375, 1267, 1251; .sup.1H
NMR (d.sub.6.sup.-DMSO/CDCl.sub.3) .delta. 8.16 (1H, d, J=7.7),
7.26 (5H, m), 7.03 (2H, d, J=8.4), 6.61 (2H, d, J=8.4), 6.03 (1H,
d, J=7.7), 4.58 (3H, m), 4.44 (1H, m), 4.13 (1H, m), 3.84 (2H, s),
3.07-2.30 (4H, m). Anal. Calcd for C.sub.29H.sub.30N.sub.4O.sub.8.
2H.sub.2O: C, 58.19; H, 5.72; N, 9.36. Found: C, 58.11; H, 5.63; N,
9.29. MS FAB+M.sup.+=563 (M+1).
3(S)3-(6-Benzyl-1,2-dihydro-2-oxo-3-(2-phenylethane-sulphonyl)amino-1-pyd-
ridyl)acetylamino-4-oxobutanoic acid (54j), was isolated (85%) as a
colorless solid: mp. 102-5.degree. C.;
[.alpha.].sub.D.sup.23-9.9.degree. (c 0.1, MeOH); IR (KBr) 3452,
3328, 3155, 1719, 1679, 1645, 1594, 1567, 1453, 1425, 1357, 1307,
1225, 1148, 1132; .sup.1H NMR (CD.sub.3OD) .delta. 7.52 (1H, d,
J=7.6), 7.33 (10H, m), 6.12 (1H, d, J=7.6), 4.73 (2H, m), 4.58 (1H,
d, J=3.7), 4.34 (1H, m), 3.97 (2H, s), 3.29 (2H, m), 3.08 (2H, m),
2.75-2.37 (2H, m). Anal. Calcd for C.sub.26H.sub.27N.sub.3O.sub.7S.
1.7H.sub.2O: C, 56.14; H, 5.51; N, 7.55. Found: C, 56.20; H, 5.49;
N, 7.29. MS FAB+M.sup.+=526 (M+1).
3(S)3-(6-Benzyl-1,2-dihydro-2-oxo-3-(2-phenylethoxy)carbonylamino-1-pyrid-
yl)acetylamino-4-oxobutanoic acid (54k), was isolated (54%) as an
off-white solid: mp. 84-86.degree. C.; IR (KBr) 3373-3310, 1787,
1726, 1691, 1649, 1599, 1567, 1517, 1367, 1215; .sup.1H NMR
(CD.sub.3OD) .delta. 7.93 (1H, bd, J=7.4), 7.37-7.18 (10H, m), 6.15
(1H, d, J=7.4), 4.77 (1H, d, J=3.7), 4.67 and 4.58 (2H, 2m), 4.35
(2H, t, J=6.9), 4.35 (1H, m), 3.94 (2H, s), 2.98 (2H, t, J=6.9),
2.76-2.39 (2H, m).
3(S)3-(6-Benzyl-1,2-dihydro-2-oxo-3-(4-phenylbutyryl)carbonylamino-1-pyri-
dyl)acetylamino-4-oxobutanoic acid (541), was isolated (50%) as a
white solid: mp. 89-93.degree. C.; IR (KBr) 3369-3302, 1678, 1645,
1594, 1565, 1517, 1379, 1258; .sup.1H NMR (d.sub.4-methanol)
.delta. 8.25 (1H, d, J=7.6), 7.37-7.18 (10H, m), 6.15 (1H, d,
J=7.4), 4.74 (2H, m), 4.60 (1H, m), 4.30 (1H, m), 3.97 (2H, s),
2.76-2.37 (2H, m), 2.67 (2H, t), 2.45 (2H, t), 1.98 (2H, m). Anal.
Calcd for C.sub.28H.sub.29N.sub.3O.sub.6. 1.5H.sub.2O: C, 63.39; H,
6.08; N, 7.92. Found C, 63.69; H, 5.74; N, 7.83.
TABLE-US-00009 ##STR00162## ##STR00163## R.sub.1 R.sub.2 R.sub.3
(a) ##STR00164## H H (b) ##STR00165## --CH.sub.2--Ph H
t-Butyl
N-2-(3-benzyloxycarbonylamino-1,2-dihydro-2-oxo-1-pyridyl)acetyl--
3-amino-5-(2,6-dichloro-benzoyloxy)-4-oxo-pentanoate (56a). The
acetic acid (55a) (WO 93 21213) in THF (2 ml) was stirred at room
temperature and treated with 1-hydroxybenzotriazole (60 mg, 0.448
mmol) and dimethylaminopropyl-3-ethylcarbodiimide hydrochloride (47
mg, 0.246 mmol). After 5 mins water (2 drops) was added and
stirring continued for 20 minutes. Bis(triphenylphosphine)
palladium II chloride (6 mg) was added followed by a solution of
t-butyl
3-(allyloxycarbonylamino)-4-oxo-5-(2,6-dichlorobenzoyl-oxy)pentanoate
(WO 93 16710) (103 mg, 0.224 mmol) in THF (1 ml). Tributyltin
hydride (0.09 ml, 0.336 mmol) was added dropwise over 1 hour at
room temperature. The mixture was stirred for a further 3 hours and
poured onto ethyl acetate, washed with 1M HCl, aqueous NaHCO.sub.3,
brine, dried over MgSO.sub.4 and concentrated in vacuo. The residue
was triturated with pentane and the supernatant discarded. The
remaining solid was purified by flash chromatography (50% ethyl
acetate/hexane) to afford the title compound 92 mg (63%) as a
colorless oil: [.alpha.].sub.D.sup.26-29.6.degree. (c 1.1,
CH.sub.2Cl.sub.2); IR (film) 3377, 3365, 3332, 3312, 1733, 1691,
1650, 1599, 1515, 1366, 1261, 1153, 1068, 747; .sup.1H NMR
(CDCl.sub.3) .delta. 8.09 (1H, d, J=6.8), 7.84 (1H, s), 7.58 (1H,
d, J=8.3), 7.33 (8H, m), 7.02 (1H, dd, J=6.9, 1.7), 6.33 (1H, t,
J=7.2), 5.20 (2H, s), 5.12 (2H, m), 4.89 (1H, dt), 4.65 (2H, m),
2.80 (2H, m), 1.38 (9H, s). t-Butyl
N-2-(6-benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl)acet-
yl-3-amino-5-(2,6-dichlorobenzyloxy)-4-oxo-pentanoate (56b), was
prepared by the method described for (56a) which afforded the title
compound (66%) as a colorless oil: IR (film) 3364, 3313, 1738,
1688, 1648, 1600, 1566, 1514, 1433, 1369, 1254, 1152; .sup.1H NMR
(CDCl.sub.3) .delta. 8.40 (1H, d, J 7.6), 8.30 (1H, s), 7.28 (13H,
m), 6.20 (1H, d, J=7.6), 5.12 (2H, q), 4.86 (1H, m), 4.65 (2H, q),
4.06 (2H, s), 3.07-2.61 (6H, m), 1.39 (9H, s).
TABLE-US-00010 ##STR00166## ##STR00167## R.sup.1 R.sup.2 R.sup.3
(a) ##STR00168## H H (b) ##STR00169## --CH.sub.2--Ph H
N-2(3-Benzyloxycarbonylamino-1,2-dihydro-2-oxo-1-pyridyl)acetyl-3-amino-5-
-(2,6-dichlorobenzoyloxy)-4-oxo-pentanoic acid (57a; O). The ester
(56a) (210 mg, 0.356 mmol) in dichloromethane (0.5 ml) was cooled
to 0.degree. C. and treated with trifluoroacetic acid (0.5 ml),
stirred and warmed to 20.degree. C. over 30 minutes. The solution
was evaporated to dryness under reduced pressure, redissolved in
dichloromethane and concentrated (.times.3). The residue was
triturated with ethyl acetate and diluted with ether to afford the
title compound 162 mg (85%) as a colorless solid: m.p.
165-8.degree. C. (decomposition);
[.alpha.].sub.D.sup.23-38.8.degree. (c 0.1, CH.sub.3OH); IR (KBr)
3332, 3275, 1723, 1658, 1649, 1597, 1581, 1562, 1526, 1432, 1385,
1258, 1218, 1206; .sup.1H NMR (d.sub.6-DMSO) .delta. 8.96 (1H, d,
J=7.3), 8.34 (1H, s), 7.85 (1H, dd, J=7.3), 7.58 (3H, m), 7.35 (5H,
m), 6.29 (1H, t, J=7.3), 5.26 (2H, m), 5.15 (2H, s), 4.69 (3H, m),
2.75 (2H, m). Anal. Calcd. C.sub.27H.sub.23N.sub.3O.sub.9Cl.sub.2:
C, 53.66; H, 3.84; N, 6.95. Found: C, 53.36; H, 3.90; N, 6.81. M.
S. (+FAB); 604 (M.sup.++1), 285, 241, 195, 173, 149, 91.
N-2-(6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl)acet-
yl-3-amino-5-(2,6-dichloro-benzoyloxy)-4-oxo-pentanoic acid (57b;
P), was prepared by the method described for 57a which afforded the
title compound (78%) as colorless crystals: m.p. 116-120.degree. C.
(decomposition); [.alpha.].sub.D.sup.26-41.1.degree. (c 0.1,
CH.sub.3OH); IR (KBr) 3299, 1739, 1715, 1689, 1666, 1645, 1598,
1563, 1518, 1432, 1209, 1151; .sup.1H NMR (d.sub.6-DMSO) .delta.
9.24 (1H, s), 8.88 (1H, d, J=7.6), 8.18 (1H, d, J=7.7), 7.60 (3H,
m), 7.26 (10H, m), 6.06 (1H, d, J=7.7), 5.23 (2H, ABq), 4.69 (3H,
m), 3.93 (2H, s), 2.78 (6H, m). Anal. Calcd. for
C.sub.35H.sub.31N.sub.3O.sub.8Cl.sub.2. H.sub.2O: C, 59.16; H,
4.68; N, 5.91. Found: C, 59.38; H, 4.53; N, 5.84. M.S. (+FAB); 694,
(Cl=35, 37), (M.sup.++1); 692 (Cl=35, 35), (M.sup.++1).
##STR00170##
(3S,4R ,S) t-Butyl
N-(benzyloxycarbonyl)-3-amino-4-(2-benzoxazolyl)-4-hydroxy-butanoate
(59). To a stirred solution of benzoxazole (250.2 mg, 2.1 mmol) in
anhydrous THF (10.5 ml) at -78.degree. C. under N.sub.2 was added
2.3M n-butyl lithium in hexanes (0.96 ml, 2.2 mmol) dropwise. After
stirring at -78.degree. C. for 20 min, dry MgBr.sub.2OEt.sub.2
(594.0 mg, 2.3 mmol) was added as a solid. The resulting
heterogeneous mixture was warmed to -45.degree. C. and stirred for
15 min. The reaction mixture was then recooled to -78.quadrature.C
and a solution of aldehyde 58 (Graybill et al., Int. J. Peptide
Protein Res., 44, pp. 173-182 (1993)) (644.6 mg, 2.1 mmol) in THF
(10.5 ml) was added dropwise. The reaction was stirred at
-78.degree. C. for 30 min, warmed to 0.degree. C. for 1 h, and then
stirred at room temperature for 16 h. The reaction was quenched
with 5% sodium bicarbonate (2.0 ml) and the THF was removed in
vacuo. The resulting aqueous residue was extracted four times with
methylene chloride. The combined extracts were washed with brine,
dried (MgSO.sub.4), filtered and reduced in vacuo to give 880.0 mg
of crude product. Flash chromatography (45:55 ethyl acetate/hexane)
afforded 567.2 mg (630) of the title compound, an oil, as a mixture
of diastereoisomers at C-4. IR (film) 3324, 2976, 1726, 1517, 1455,
1368, 1243, 1159, 1048, 747; .sup.1H NMR (CDCl.sub.3) .delta.
7.71-7.64 (1H, m), 7.52-7.48 (1H, m), 7.37-7.20 (7H, m), 5.91 (1H,
brd, J=9.0), 5.79 (1H, d, J=9.0), 5.41-4.78 (4H, m), 4.75-4.54 (1H,
m), 2.91-2.51 (2H, m), 1.42 (9H, s), 1.37 (9H, s). (3S,4R,S) t-Buty
3-amino-4-(2-benzoxazolyl)-4-hydroxybutanoate (60). A solution of
the ester 59 (189.0 mg, 0.44 mmol) in ethanol (5.0 ml) was treated
with 10% Palladium on carbon (20.5 mg) and stirred under an
atmosphere of H.sub.2 for 21 h. The mixture was filtered through
Celite.RTM., and the solvent was evaporated to afford 125.0 mg
(98%) of crude amine 60 as an oil. This was used without further
purification. .sup.1H NMR (CDCl.sub.3) .delta. 7.73-7.64 (1H, m),
7.51-7.42 (1H, m), 7.35-7.22 (2H, m), 6.48 (3H, brs), 5.58 (1H, d,
J=3.0), 5.27 (1H, d, J=6.5), 4.23-4.05 (1H, m), 2.92-2.63 (2H, m),
1.36 (9H, s), 1.33 (9H, s). (3S,4R,S) t-Butyl
N-(N-benzyloxycarbonyl-(S)-valinyl-(S)-alaninyl)-3-amino-4-(2-benzoxazoly-
l)-4-hydroxybutanoate (61). A solution of the amine 60 (261.4 mg,
0.89 mmol), Z-Val-Ala-OH (286.9 mg, 0.89 mmol) (prepared by
standard peptide synthetic procedures) and hydroxybenzotriazole
(120.3 mg, 0.89 mmol) in DMF (3.0 ml) at 0.degree. C. was treated
with 1-ethyl-3-[3-(dimethylamino) propyl]carbodiimide hydrochloride
(179.2 mg, 0.93 mmol). The reaction was warmed to room temperature
and stirred for 16 h. The reaction was diluted with ethyl acetate
and washed twice with 1M sodium hydrogensulphate, twice with
saturated sodium bicarbonate, then water, and brine. The organic
layer was dried (MgSO.sub.4), filtered and reduced in vacuo to
afford 494.8 mg of crude product. Flash chromatography (95:5
methylene chloride/methanol) gave 480.9 mg (91%) of the title
compound as a yellow solid: mp. 81-83.degree. C.; IR (KBr) 3312,
2974, 1723, 1709, 1529, 1455, 1368, 1243, 1156, 747; .sup.1H NMR
(CDCl.sub.3) .delta. 7.79 (0.5H, d, J=8.0), 7.73-7.20 (9.5H, m),
6.15 (1H, t, J=8.5), 5.74 (0.5H, brd, J=5.5), 5.45 (1H, brd,
J=7.5), 5.28-5.20 (0.5H, m), 4.82-4.11 (3.5H, m), 4.78-4.55 (1H,
m), 4.40-4.22 (1H, m), 2.95-2.51 (2H, m), 2.12-1.95 (1H, m),
1.45-1.32 (12H, m), 1.11-0.81 (6H, m), .sup.13C NMR (CDCl.sub.3)
.delta. 173.14, 172.94, 171.82, 171.03, 170.78, 165.98, 165.45,
157.29, 157.17, 151.23, 151.10, 140.92, 140.82, 136.83, 136.79,
128.91, 128.52, 125.75, 124.97, 120.60, 120.40, 111.38, 81.82,
81.68, 70.27, 68.97, 67.44, 60.43, 50.74, 50.55, 49.18, 49.07,
36.87, 36.57, 32.37, 28.51, 19.88, 19.80, 18.53. Anal. Calcd. for
C.sub.31H.sub.40N.sub.4O.sub.8. H.sub.2O: C, 60.57; H, 6.89; N,
9.11. Found: C, 60.84; H, 6.64; N, 9.09. M.S. (+FAB); 597
(M.sup.++1); 541, 91. (3S)t-Butyl
N-(N-benzyloxycarbonyl-(S)-valinyl-(S)-alaninyl)-3-amino-4-(2-benzoxazoly-
l)-4-oxobutanoate (62). The alcohol 61 (100.3 mg, 0.17 mmol) was
dissolved in methylene chloride (2.0 ml) and Dess-Martin reagent
(142.6 mg, 0.34 mmol) was added (Ireland et al., J. Org. Chem., 58,
p. 2899 (1993); Dess et al., J. Org. Chem., 48, pp. 4155-4156
(1983)). The resulting mixture was stirred for 22 min and then
partitioned between saturated sodium thiosulphate: saturated sodium
bicarbonate (1:1, 10 ml), and ethyl acetate (10 ml). The resulting
organic phase was washed with saturated sodium thiosulphate,
saturated sodium bicarbonate (1:1), saturated sodium bicarbonate,
and brine. The organic phase was dried (MgSO.sub.4), filtered and
reduced in vacuo to give 111.3 mg of crude product. Flash
chromatography (95:5 methylene chloride/methanol) afforded 97.3 mg
(96%) of the title compound as an oil:
[.alpha.].sub.D.sup.23-11.74.degree. (c 0.95, CH.sub.2Cl.sub.2);
IR(CH.sub.2Cl.sub.2) 3419, 2974, 1721, 1677, 1501, 1369, 1221,
1156; .sup.1H NMR (CDCl.sub.3) .delta. 7.89-7.84 (1H, m), 7.73-7.22
(10H, m), 5.98 (1H, d, J=9.0), 5.72 (1H, m), 5.10 (2H, q, J=12.5),
4.73 (2H, m), 4.20 (1H, dd, J=7.0, 8.5), 3.30 (1H, dd, J=5.0,
16.5), 3.03 (1H, dd, J=5.5, 16.5), 2.18-1.97 (1H, m), 1.39 (3H, d,
J=7.0), 1.34 (9H, s), 0.93 (3H, d, J=6.0), 0.90 (3H, d, J=6.0),
.sup.13C NMR (CDCl.sub.3) .delta. 186.46, 172.73, 171.90, 170.13,
157.17, 156.28, 151.16, 140.99, 136.99, 129.39, 129.08, 128.66,
128.59, 126.49, 123.06, 112.55, 82.73, 67.60, 60.84, 53.75, 49.41,
38.58, 32.05, 28.52, 19.85, 19.32, 18.51. M.S. (+FAB); 595
(M.sup.++1); 539, 91.
(3S)N-(N-Benzyloxycarbonyl-(S)-valinyl-(S)-alaninyl)-3-amino-4-(2-benzoxa-
zolyl)-4-oxobutanoate (63; Q). A solution of the ester 62 (95.0 mg,
0.16 mmol) in a 1:1 mixture of methylene chloride and
trifluoroacetic acid (10.0 ml) was stirred for 1 h under a dry
atmosphere of N.sub.2. The solution was then reduced in vacuo,
taken up in ether and reduced again. This process was repeated six
times to afford the crude product as an off white solid. Flash
chromatography (95:5 methylene chloride/methanol) gave 60.0 mg
(69%) of the title compound as a white solid. The product existed
as a mixture of three isomers in CD.sub.3OD, consisting of the
ketone form (one isomer, c 44%), and its acyloxy ketal form (two
isomers at C-4, c. 56%): m.p. 156-159.degree. C.
[.alpha.].sub.D.sup.26-45.6.degree. (c 0.13, methanol); IR (KBr)
3440, 2967, 1713, 1703, 1638, 1531, 1427; .sup.1H NMR (CD.sub.3OD)
.delta. 7.93-7.24 (9H, m), 5.59 (1H, brt), 5.16-5.00 (2H, m),
5.0-4.78 (1H, m), 4.50-4.22 (1H, m), 3.95-3.81 (1H, m), 3.11 (2H,
d, J=6.5), 3.05-2.92 (1H, m), 2.70-2.39 (1H, m), 2.08-1.89 (1H, m),
1.19-0.78 (9H, m). Anal. Calcd. for C.sub.27H.sub.30N.sub.4O.sub.8.
0.5H.sub.2O: C, 59.22; H, 5.71; N, 10.23. Found: C, 59.48, H, 5.36;
N, 10.17. M.S. (+FAB); 539 (M.sup.++1), 91.
##STR00171## ##STR00172##
7-Methoxybenzoxazole (65a). A mixture of 2-nitro-6-methoxyphenol
(2.62 g, 15.5 mmol) (EP 333176) and 100 (50.0 ml) was stirred under
an atmosphere of H.sub.2 for 75 min. The mixture was filtered
through Celite.RTM. then immediately treated with
p-toluenesulphonic acid (32.0 mg) and triethylorthoformate (6.45
ml, 38.8 mmol) then heated under reflux under an atmosphere of
N.sub.2. After 20 h p-toluenesulphonic acid (30.0 mg) and
triethylorthoformate (6.45 ml, 38.8 mmol) were added. After a total
of 44 h heating, the reaction was allowed to cool and reduced in
vacuo. The resulting residue was purified by flash chromatography
(25:75 ethyl acetate/hexane) to give 1.97 g (85%) of the title
compound as a yellow solid: m.p. 28-31.degree. C.; IR (film) 1629,
1497, 1434, 1285, 1097; .sup.1H NMR (CDCl.sub.3) .delta. 8.09 (1H,
s), 7.40 (1H, d, J=8.0), 7.28 (1H, t, J=8.0), 6.89 (1H, d, J=8.0),
4.02 (3H, s); .sup.13C NMR (CDCl.sub.3) .delta. 152.84, 145.82,
142.50, 139.99, 125.75, 113.42, 108.80, 56.97. Anal. Calcd. for
C.sub.8H.sub.7N.sub.1O.sub.2. 0.1H.sub.2O: C, 63.65; H, 4.81; N,
9.29. Found: C, 63.43, H, 4.88; N, 9.05. M.S. (+FAB); 150
(M.sup.++1). 4-Methoxybenzoxazole (65b). To a suspension of
4-hydroxybenzoxazole (2.00 g, 14.8 mmol) (Musser et al., J. Med.
Chem., 30, pp. 62-67 (1987)) in acetone (80.0 ml) was added dried
K.sub.2CO.sub.3 (2.25 g, 16.3 mmol) followed by iodomethane (1.38
ml, 22.2 mmol). The reaction was heated under reflux under N.sub.2
for 4.5 h, then filtered and reduced in vacuo to afford the crude
product. The resulting residue was purified by flash chromatography
(25:75 ethyl acetate/hexane) to give 2.0 g (91%) of the title
compound as a white crystalline solid: m.p. 72-74.degree. C.; IR
(KBr) 3089, 1619, 1610, 1503, 1496, 1322, 1275, 1090, 1071, 780,
741; .sup.1H NMR (CDCl.sub.3) .delta. 8.02 (1H, s), 7.32 (1H, t,
J=8.0), 7.18 (1H, d, J=8.0), 6.81 (1H, d, J=8.0), 4.04 (3H, s).
Anal. Calcd. for C.sub.8H.sub.7NO.sub.2: C, 64.42; H, 4.73; N,
9.39. Found: C, 64.40; H, 4.84; N, 9.31; m/z (EI) 149 (M.sup.++1,
1000). (3S,4R,S) t-Butyl
N-(allyloxycarbonyl)-3-amino-4-hydroxy-4-(2-(7-methoxybenzoxazolyl))butan-
oate (66a). To a stirred solution of 7-methoxybenzoxazole 65a
(548.6 mg, 3.68 mmol) in anhydrous THF (18.5 ml) at -78.degree. C.
under N.sub.2 was added 1.56M n-butyl lithium in hexanes (2.47 ml,
3.86 mmol) dropwise, to produce a yellow colored solution. After
stirring at -78.degree. C. for 20 min, dry MgBr.sub.2OEt.sub.2
(1.045 g, 4.05 mmol) was added as a solid. The resulting
heterogeneous mixture was warmed to -45.quadrature.C and stirred
for 15 min. The reaction mixture was then recooled to
-78.quadrature.C and a solution of (S)-Alloc-Asp(t-Bu)H.sup.1b
(946.4 mg, 3.68 mmol) in THF (18.5 ml) was added dropwise. The
reaction was stirred at -78.degree. C. for 30 min, warmed to
0.degree. C. and stirred for 1 h. The resulting homogeneous
reaction was warmed to room temperature and stirred for 16 h. The
reaction was quenched with 5% sodium bicarbonate (3.5 ml) then THF
was removed in vacuo. The resulting aqueous residue was extracted
with methylene chloride (.times.6). The combined extracts were
washed with brine, dried (MgSO.sub.4), filtered and reduced in
vacuo to give 1.8 g of crude product. Flash chromatography (40:60
ethyl acetate/hexane) gave 1.21 g (81%) of the title compound, an
oil, as a mixture of diastereoisomers at C-4: IR(CH.sub.2Cl.sub.2)
3425, 2983, 1725, 1504, 1290, 1157, 1101; .sup.1H NMR (CDCl.sub.3)
.delta. 7.35-7.19 (2H, m), 6.89-6.81 (1H, m), 6.00-5.57 (2H, m),
5.32-5.05 (3H, m), 4.68-4.35 (3H, m), 4.01 (3H, s), 2.86-2.59 (2H,
m), 1.45 (9H, s), 1.41 (9H, s); .sup.13C NMR (CDCl.sub.3) .delta.
171.18, 171.09, 165.80, 165.30, 156.71, 156.60, 145.65, 142.76,
142.71, 140.82, 140.72, 133.23, 125.81, 125.72, 118.41, 118.21,
113.07, 112.87, 108.95, 82.16, 70.28, 69.98, 66.52, 66.39, 57.03,
52.57, 52.29, 37.83, 36.86, 28.65. Anal. Calcd. for
C.sub.20H.sub.26N.sub.2O.sub.7. 0.6H.sub.2O: C, 57.57; H, 6.57; N,
6.72. Found: C, 57.49, H, 6.34; N, 6.60. M.S. (+FAB); 407
(M.sup.++1); 351, 307, 154. (3S,4R,S) t-Butyl
N-(allyloxycarbonyl)-3-amino-4-hydroxy-4-(2-(4-methoxybenzoxazolyl))butan-
oate (66b), was prepared according to the method described for 66a
which afforded 1.29 g (26%, 68% based on recovered starting
material) of the title compound as an oil and as a mixture of
diastereoisomers at C-4: IR(CH.sub.2Cl.sub.2) 3400, 1725, 1625,
1505, 1369, 1354, 1281, 1263, 1226, 1158, 1092, 1048; .sup.1H NMR
(CDCl.sub.3) .delta. 7.34-7.24 (1H, m), 7.16 (1H, d, J=8.2), 6.79
(1H, d, J=7.9), 6.00-5.50 (2H, m), 5.30-5.05 (3H, m), 4.70-4.35
(4H, m), 4.02 (3H, s), 2.90-2.45 (2H, m), 1.45-1.41 (9H,
2.times.s). Anal. Calcd. for C.sub.20H.sub.26N.sub.2O.sub.7.
0.4H.sub.2O: C, 58.07; H, 6.53; N, 6.77. Found: C, 58.09; H, 6.41;
N, 6.63. M.S. (+FAB); 407 (M.sup.++1, 88%); 351 (100). (3S,4R,S)
t-Butyl
N-(N-acetyl-(S)-(O-tert-butyl-tyrosinyl)-(S)-valinyl-(S)-alaninyl)-3-amin-
o-4-hydroxy-4-(2-(7-methoxybenzoxazolyl))butanoate (67a). To a
stirred solution of the benzoxazole 66a (481.9 mg, 1.19 mmol) and
Ac-Tyr(.sup.tBu)-Val-Ala-OH (586.3 mg, 1.30 mmol) in methylene
chloride (3.5 ml) and DMF (3.5 ml) was added
bis(triphenylphosphine) palladium (II) chloride (18.0 mg), followed
by tributyltinhydride (0.80 ml, 2.96 mmol) dropwise.
Hydroxybenzotriazole (320.4 mg, 2.37 mmol) was added and the
mixture cooled to 0.degree. C.
1-Ethyl-3-[3-(dimethylamino)propyl]carbodiimide hydrochloride
(278.2 mg, 1.42 mmol) was added and the mixture was allowed to warm
to room temperature and stirred for 16.5 h. The reaction was
diluted with ethyl acetate and washed twice with 1M sodium
hydrogensulphate, twice with saturated sodium bicarbonate, water,
and brine. The organic layer was dried (MgSO.sub.4), filtered and
reduced in vacuo to yield 2.0 g of crude product. Flash
chromatography (95:5 methylene chloride/methanol) gave 844.0 mg
(94%) of the title compound as a white solid: m.p. 205.degree. C.;
IR (KBr) 3399, 3304, 2977, 1729, 1643, 1506, 1367, 1290, 1161;
.sup.1H NMR (d.sub.6-DMSO) .delta. 8.24-7.78 (4H, m), 7.43-7.32
(2H, m), 7.23 (2H, d, J=8.5), 7.16-7.07 (1H, m), 6.93 (2H, d,
J=8.5), 6.52, 6.40 (1H, 2.times.d, J=5.5, J=5.0), 5.03, 4.78-4.49,
4.45-4.16 (5H, brt, 2.times.m), 4.05, 4.04 (3H, 2.times.s),
3.08-2.35 (14H, m), 2.11-1.89 (1H, m), 1.83 (3H, s), 1.49-1.32,
1.15, 1.0-0.81 (27H, s, 2.times.m, J=7.0); .sup.13C NMR
(d.sub.6-DMSO) .delta. 175.55, 175.18, 173.88, 173.75, 173.05,
169.23, 157.28, 148.55, 146.16, 143.21, 136.63, 133.55, 128.87,
127.17, 115.78, 111.92, 84.02, 81.50, 71.40, 61.15, 60.05, 57.79,
53.39, 51.62, 43.76, 40.52, 34.58, 32.52, 31.60, 26.35, 23.11,
22.71, 21.76. Anal. Calcd. for C.sub.39H.sub.55N.sub.5O.sub.10.
0.5H.sub.2O: C, 61.40; H, 7.40; N, 9.18. Found: C, 61.43; H, 7.31;
N, 9.07. M.S. (+FAB); 754 (M.sup.++1); 698, 338, 267. (3S,4R,S)
t-Butyl
N-(N-acetyl-(S)-(O-tert-butyl-tyrosinyl)-(S)-valinyl-(S)-alaninyl)-3-amin-
o-4-hydroxy-4-(2-(4-methoxybenzoxazolyl))butanoate (67b), was
prepared according to the method described for 67a which afforded
1.05 g (94%) of the title compound as a fine white powder: m.p.
210-213.degree. C. (dec); IR (KBr) 3284, 2977, 1736, 1691, 1632,
1536, 1505, 1452, 1392, 1367, 1258, 1236, 1161, 1091; .sup.1H NMR
(d.sub.6-DMSO) .delta. 8.20-7.75 (4H, m), 7.40-7.10 (4H, m),
7.00-6.80 (3H, m), 6.45, 6.34 (1H, 2.times.d, J=5.3, J=5.0),
5.00-4.10 (5H, m), 4.00, 3.99 (3H, 2.times.s), 3.00-2.25 (4H, m),
1.95 (1H, m), 1.78 (3H, s), 1.39-0.80 (27H, m). Anal. Calcd. for
C.sub.39H.sub.55N.sub.5O.sub.10. 0.5H.sub.2O: C, 61.40; H, 7.40; N,
9.18. Found: C, 61.58; H, 7.38; N, 8.91. M.S. (+FAB); 754
(M.sup.++1, 30%); 72 (100). (3S)t-Butyl
N-(N-acetyl-(S)-(O-tert-butyl-tyrosinyl)-(S)-valinyl-(S)-alaninyl)-3-amin-
o-4-(2-(7-methoxybenzoxazolyl))-4-oxobutanoate (68a). The
Dess-Martin reagent (1.082 g, 2.55 mmol) (Ireland et al., J. Org.
Chem., 58, p. 2899 (1993); Dess et al., J. Org. Chem., 48, pp.
4155-4156 (1983)) was added to a stirred suspension of the alcohol
67a (641.0 mg, 0.85 mmol) in methylene chloride (46.0 ml). The
resulting mixture was stirred for 1 h before being partitioned
between saturated sodium thiosulphate: saturated sodium bicarbonate
(1:1, 86.0 ml) and ethyl acetate (86.0 ml). The resultant organic
phase was washed in turn with saturated sodium thiosulphate:
saturated sodium bicarbonate (1:1), saturated sodium bicarbonate,
and brine. The organic phase was dried (MgSO.sub.4), filtered and
reduced in vacuo to give 660.0 mg of crude product. Flash
chromatography (94:6 methylene chloride/methanol) gave 636.0 mg
(100%) of the title compound as a white solid: m.p. 209.degree. C.;
[.alpha.].sub.D.sup.24-21.8.degree. (c 0.16, methanol); IR (KBr)
3395, 3294, 2977, 1722, 1641, 1535, 1505, 1161; .sup.1H NMR
(CDCl.sub.3) .delta. 8.43-8.16 (1H, m), 7.97-7.62 (2H, m),
7.49-7.14 (3H, m), 7.08-6.95 (3H, m), 6.89-6.73 (2H, m), 5.81-5.68
(1H, m), 5.16-4.86 (2H, m), 4.53 (1H, brt), 4.03 (3H, s), 3.16-2.84
(4H, m), 2.11-1.84 (4H, m), 1.46-1.14 (21H, m), 0.92-0.78 (6H, m);
.sup.13C NMR (CDCl.sub.3) .delta. 186.28, 173.39, 171.90, 171.19,
171.03, 169.89, 156.43, 154.75, 146.32, 142.88, 140.98, 132.31,
130.54, 126.98, 124.73, 114.95, 111.42, 82.44, 78.71, 58.92, 57.20,
54.91, 53.47, 48.77, 39.43, 38.15, 32.79, 29.44, 28.60, 23.55,
20.27, 19.70, 19.34. M.S. (+FAB); 752 (M.sup.++1); 696, 336, 265.
(3S)t-Butyl
N-(N-acetyl-(S)-(O)-tert-butyl-tyrosinyl)-(S)-valinyl-(S)-alaninyl)-3-ami-
no-4-(2-(4-methoxybenzoxazolyl))-4-oxobutanoate (68b), was prepared
according to the method described for the ketone 68a which afforded
420 mg (55%) of the title compound as a white solid: m.p.
211-213.quadrature.C (dec); [.alpha.].sub.D.sup.24-23.9.degree. (c
0.82, methanol); IR (KBr) 3277, 3075, 1723, 1690, 1632, 1530, 1506,
1392, 1366, 1269, 1234, 1160, 1094; .sup.1H NMR (CDCl.sub.3)
.delta. 8.15 (1H, brs), 7.7 (2H, brs), 7.46 (1H, t, J=8.3), 7.24
(2H, d, J=8.3), 7.10 (1H, brs), 7.03 (2H, d, J=8.3), 6.83 (3H, m),
5.74 (1H, q, J=6.9), 5.00 (2H, m), 4.51 (1H, t, J=7.0), 4.07 (3H,
s), 3.20-2.95 (4H, m), 2.00 (4H, m), 1.42 (3H, d, J=6.8), 1.35 (9H,
s), 1.23 (9H, s), 0.86 (6H, d, J=6.7). M.S. (+FAB); 752 (M.sup.++1,
7%); 72 (100).
(3S)N-(N-Acetyl-(S)-tyrosinyl-(S)-valinyl-(S)-alaninyl)-3-amino-4-(2-(7-m-
ethoxybenzoxazolyl))-4-oxobutanoate (69a; R). A solution of the
ester 68a (600.0 mg, 0.80 mmol) in a 1:1 mixture of methylene
chloride and trifluoroacetic acid (65.0 ml) was stirred for 1 h
under a dry atmosphere of N.sub.2. The solution was then reduced in
vacuo, taken up in ether and reduced again. This process was
repeated six times to afford the crude product as an off white
solid. Flash chromatography (gradient 95:5 to 80:20 methylene
chloride/methanol) gave 420.8 mg (83%) of the title compound as a
hygroscopic white solid. The product existed as a mixture of three
isomers in CD.sub.3OD, consisting of the keto form (c 50%), and its
acyloxy keto form (two isomers at C-4, c 50%): m.p. decomposes
above 150.degree. C.; [.alpha.].sub.D.sup.24-33.2.degree. (c 0.17,
methanol); IR (KBr) 3300, 1715, 1658, 1650, 1531, 1517, 1204;
.sup.1H NMR (CD.sub.3OD) .delta. 7.46-7.19 (2H, m), 7.16-6.91 (3H,
m), 6.70-6.59 (2H, m), 5.62-5.49 (1H, m), 5.00-4.72 (1H, obscurred
m), 4.69-4.51 (1H, m), 4.49-4.08 (2H, m), 4.05-3.89 (3H, m),
3.16-2.47 (4H, m), 2.05-1.78 (4H, m), 1.41-1.11, 1.05-0.70 (9H,
2.times.m). Anal. Calcd. for C.sub.31H.sub.37N.sub.5O.sub.10.
3H.sub.2O: C, 53.67; H, 6.25; N, 10.10. Found: C, 53.76; H, 5.56;
N, 10.28. M.S. (+FAB); 640 (M.sup.++1); 435, 147. (3S)t-Butyl
N-(N-acetyl-(S)-tyrosinyl-(S)-valinyl-(S)-alaninyl)-3-amino-4-(2-(4-metho-
xybenzoxazolyl))-4-oxobutanoate (69b; S), was prepared according to
the method described for the acid 69a which afforded the
hygroscopic title compound 252 mg (96%). The product existed as a
mixture of three isomers in CD.sub.3OD, consisting of the keto
form, and its acyloxy ketal form (two isomers at C-4). The product
existed as a single isomer in d-6 DMSO: m.p. 200-203.degree. C.
(dec.); [.alpha.].sub.D.sup.24-38.0.degree. (c 0.23, methanol); IR
(KBr) 3289, 2968, 1718, 1713, 1658, 1634, 1548, 1517, 1506, 1461,
1453, 1393, 1369, 1268, 1228, 1174, 1092; .sup.1H NMR
(d.sub.6-DMSO) .delta. 9.20 (1H, brs), 8.71 (1H, d, J=6.2), 8.10
(2H, m), 7.83 (1H, d, J=8.7), 7.61 (1H, t, J=8.2), 7.46 (1H, d,
J=8.2), 7.08 (3H, m), 6.65 (2H, d, J=8.3), 5.50 (1H, q, J=6.5),
4.50 (1H, m), 4.37 (1H, m), 4.20 (1H, m), 4.05 (3H, s), 3.09-2.77
(4H, m), 1.94 (1H, m), 1.79 (3H, s), 1.23 (3H, d, J=7.0), 0.82 (6H,
m). Anal. Calcd. for C.sub.31H.sub.37N.sub.5O.sub.10. 1.5H.sub.2O:
C, 55.85; H, 6.05; N, 10.51. Found: C, 55.21; H, 5.69; N, 10.13.
M.S. (+FAB); 640 (M.sup.++1, 22%); 107 (100).
##STR00173##
3S)t-Butyl
N-(allyloxycarbonyl)-3-amino-4-oxo-5-(1,2-dioxo-2-phenylethyloxy)-pentano-
ate (80). Potassium fluoride (792 mg, 13.6 mmol) and then benzoyl
formic acid (1.02 g, 6.82 mmol) were added to a stirred solution of
(3S)t-butyl N-(allyloxycarbonyl)-3-amino-5-bromo-4-oxo-pentanoate
(WO 93 16710) (2.17 g, 6.20 mmol) in dimethylformamide (30 ml). The
mixture was stirred for 140 mins, quenched with water (50 ml) and
extracted with ethyl acetate (2.times.50 ml). The combined organic
extracts were washed with water (4.times.50 ml) then brine (50 ml).
They were dried (MgSO.sub.4) and concentrated to afford an oil
which was purified by flash chromatography (20-45% ethyl acetate in
hexane) to afford 2.44 g (94%) of a colorless oil:
[.alpha.].sub.D.sup.20-35.0.degree. (c 1.41, CH.sub.2Cl.sub.2); IR
(film) 3359, 2981, 2938, 1752, 1740, 1726, 1712, 1512, 1369, 1285,
1177, 1053, 991, 939, 688; .sup.1H NMR (CDCl.sub.3) .delta. 8.15
(2H, m), 7.66 (1H, m), 7.53 (2H, m), 5.90 (2H, m), 5.33 (2H, m),
5.31 (1H, d, J=16.9), 5.18 (1H, d, J=16.9), 4.63 (3H, m), 3.03 (1H,
dd, J=17.3, 4.6), 2.74 (1H, dd, J=17.3, 4.9), 1.44 (9H, s). MS
(C.I.) 420 (M.sup.++1 20%); 364 (100). (3S)t-Butyl
N-(allyloxycarbonyl)-3-amino-5-hydroxy-4-oxo-pentanoate (81). A
mixture of the ester 80 (2.40 g, 5.71 mmol), tetrahydrofuran (200
ml) and 1M aqueous potassium bicarbonate (200 ml) was vigorously
stirred at room temperature for 18 h. The layers were separated and
the aqueous portion extracted with ethyl acetate (100 ml). The
combined organic extracts were washed with brine (100 ml), dried
(MgSO.sub.4) and concentrated. The residue was purified by flash
chromatography (10-60% ethyl acetate in hexane) to afford 1.48 g
(90%) of pale yellow oil: [.alpha.].sub.D.sup.20-5.9.degree. (c
1.06, CH.sub.2Cl.sub.2); IR (film) 3345, 2981, 2936, 1739, 1725,
1712, 1692, 1515, 1368, 1259, 1158, 1051; .sup.1H NMR (CDCl.sub.3)
.delta. 5.92 (2H, m), 5.30 (2H, m), 4.36-4.69 (5H, m), 3.05 (1H,
dd, J=17.4, 4.3), 2.93 (1H, t), 2.70 (1H, dd, J=17.4, 4.9), 1.43
(9H, s). Anal. Calcd for C.sub.18H.sub.21N.sub.1O.sub.6.
0.25H.sub.2O: C, 53.51; H, 7.43; N, 4.80. Found: C, 53.61; H, 7.18;
N, 4.71. MS (C.I.)280 (M.sup.++1, 87%); 232 (100). (3S)t-Butyl
N-(allyloxycarbonyl)-3-amino-5-(2,6-dichlorophenyl-methoxy)-4-oxo-pentano-
ate (82). A stirred mixture of alcohol 81 (1.44 g, 5.01 mmol),
2,6-dichlorobenzyl iodide (Abraham et al., J. Chem. Soc., pp.
1605-1607 (1936)) (4.31 g, 15.0 mmol), silver oxide (2.32 g, 10.0
mmol) and dichloromethane (25 ml) was heated under reflux for 45 h.
The mixture was allowed to cool to room temperature then diluted
with water (50 ml) then extracted with ethyl acetate (50 ml, 25
ml). The organic layer was washed with water (50 ml) then brine (50
ml), dried (MgSO.sub.4), and concentrated. The residue was purified
by flash chromatography (10-100% ethyl acetate in hexane) to afford
1.65 g (74%) of a colorless oil: [.alpha.].sub.D.sup.20+8.8.degree.
(c 1.13, CH.sub.2Cl.sub.2); IR (film) 3339, 2980, 2935, 1724, 1712,
1503, 1438, 1368, 1246, 1156, 1106, 770; .sup.1H NMR (CDCl.sub.3)
.delta. 7.33 (2H, m), 7.22 (1H, dd), 5.92 (2H, m), 5.28 (2H, m),
4.87 (2H, m), 4.67 (1H, m), 4.58 (2H, br d), 4.56 (1H, d, J=16.9),
4.31 (1H, d, J=16.9), 3.04 (1H, dd, J=16.7, 4.5), 2.77 (1H, dd,
J=16.7, 4.9), 1.40 (9H, s). Anal. Calcd. for
C.sub.20H.sub.25Cl.sub.2N.sub.1O.sub.6. 0.25H.sub.2O: C, 53.28; H,
5.70; N, 3.11. Found: C, 53.15; H, 5.52; N, 2.98. M.S. (C.I.); 446
(M.sup.+, 27%); 390 (100). (3R,S)t-Butyl
N-[N-phenylmethyloxycarbonylvalaninyl-alaninyl]-3-amino-5-(2,6-dichloroph-
enylmethyloxy)-4-oxo-pentanoate (83a).
1-(3-Dimethylamino-propyl)-3-ethylcarbodiimide hydrochloride (379
g, 1.98 mmol) and 1-hydroxybenzotriazole (486 mg, 3.60 mmol) were
added to a stirred solution of
N-phenyl-methyloxycarbonylvalinyl-alanine (637 mg, 1.98 mmol) in
tetrahydrofuran (40 ml) and water (1 ml). The mixture was stirred
for 15 mins and then the ether 82 (802 mg, 1.80 mmol) and
bis(triphenyl-phosphine)palladium (II) chloride (ca 5 mg) were
added. Tributyltin hydride (785 mg, 725 1, 2.70 mmol) was then
added dropwise during 20 mins and the resulting solution was
stirred for 3.75 h and then quenched with 1M hydrochloric acid (50
ml). The mixture was extracted twice with ethyl acetate. The
combined organic extracts were washed with 1M hydrochloric acid,
twice with aqueous sodium bicarbonate, water and then brine, dried
(MgSO.sub.4) and concentrated. The residue was purified by flash
chromatography (10-30% ethyl acetate -dichloromethane) to afford
941 mg (79%) of pale yellow solid: m.p. 148-52.degree. C.; IR (KBr)
3287, 3070, 1730, 1691, 1641, 1536, 1369, 1289, 1247, 1156; .sup.1H
NMR (CDCl.sub.3) .delta. 7.33 (8H, m), 7.23 (1H, dd), 6.61 (1H, br,
d), 5.42 (1H, br, d), 5.11 (2H, s), 4.85 (3H, m), 4.50 (1H, m),
4.40 (1H, d, J=16.9), 4.26 (1H, d, J=16.9), 4.02 (1H, m), 2.99 (1H,
dd, J=16.8, 4.7), 2.73 (1H, dd, J=16.8, 5.0), 2.09 (1H, m), 1.37
(12H, m), 0.96 (3H, d, J=6.9), 0.91 (3H, d, J=6.8). Anal. Calcd.
for C.sub.32H.sub.41Cl.sub.2N.sub.3O.sub.8. 0.25H.sub.2O: C, 57.25;
H, 6.23; Cl, 10.57; N, 6.26. Found: C, 57.18; H, 6.23; Cl, 10.58;
N, 5.95. M.S. (+FAB); 667 (M.sup.+ 1, 1%); 666 (3), 159 (25), 91
(100). (3R,S)t-Butyl
N-[(N-acetyl-O-t-butyltyrosinyl)-valaninyl-alaninyl]-3-amino-5-(2,6-dichl-
orophenylmethyloxy)-4-oxo-pentanoate (83b), was prepared by the
method described for 83a to afford 554 mg (64%) of colorless solid:
m.p. 184-6.degree. C.; IR (KBr) 3282, 3075, 1736, 1690, 1633, 1536,
1508, 1366, 1236, 1161; .sup.1H NMR (d.sub.6-DMSO) .delta. 8.49
(1H, d), 8.14 (1H, d), 8.08 (1H, d), 7.84 (1H, d), 7.43 (3H, m),
7.14 (2H, d), 6.83 (2H, d), 4.71 (2H, s), 4.51 (2H, m), 4.36 (2H,
dd), 4.17 (2H, m), 2.93 (1H, m), 2.73 (1H, m), 1.94 (1H, m), 1.74
(3H, s), 1.37 (9H, s), 1.23 (12H, m), 0.83 (6H, m). M.S. (+FAB);
793 (M.sup.+ 1, 4%); 737 (5), 681 (1), 178 (40), 159 (45), 136
(100), 107 (40). M.S. (-FAB); 792 (20), 791 (40), 447 (100).
(R,S)N-[N-(Phenylmethyloxy)carbonyl-valinyl-alaninyl]-3-amino-5-(2,6-dich-
lorophenylmethyloxy)-4-oxo-pentanoic acid (84a; V). Trifluoroacetic
acid (5 ml) was added to a stirred solution of the ester 83a, (918
mg, 1.38 mmol) in dichloromethane (20 ml). The mixture was stirred
for 2.5 h then evaporated to dryness. The residue was treated with
ether (25 ml) and evaporated to dryness. This procedure was
repeated three times. The resulting product was triturated with
ether (10 ml) and then dried to afford 730 mg (87%) of light brown
powder: m.p. 156-60.degree. C.; IR (KBr) 3282, 2965, 1702, 1694,
1642, 1536, 1438, 1246, 1230; .sup.1H NMR (d.sub.6-DMSO) .delta.
8.48 (1H, d), 8.09 (1H, d), 7.47 (9H, m), 5.02 (2H, s), 4.70 (2H,
s), 4.49 (1H, m), 4.37 (2H, dd), 4.27 (1H, m), 3.88 (1H, m), 2.75
(1H, dd), 2.54 (1H, dd), 1.96 (1H, m), 1.19 (3H, s), 0.84 (6H, m).
Anal. Calcd. for C.sub.28H.sub.33Cl.sub.2N.sub.3O.sub.8.
0.5H.sub.2O: C, 54.27; H, 5.53; Cl, 11.45; N, 6.78. Found: C,
54.49; H, 5.39; Cl, 11.33; N, 6.73. M.S. (+FAB); 610 (M.sup.+ 1,
10%); 91 (100).
(R,S)N-[N-(Acetyl)tyrosinyl-valinyl-alaninyl]-3-amino-5-(2,6-dichlorophen-
ylmethyloxy)-4-oxo-pentanoic acid (84b; W), was obtained as a
colorless powder (95%) by the method used for 84a. m.p.
165-8.degree. C.: IR (KBr) 3295, 2968, 1733, 1642, 1517, 1438,
1231, 1105; .sup.1H NMR (d.sub.6-DMSO) 9.2 (1H, br, s), 8.48 (1H,
br, d), 8.14 (1H, br, d), 8.02 (1H, br, d), 7.81 (1H, br, d), 7.45
(3H, m), 7.02 (2H, d), 6.62 (2H, d), 4.70 (2H, s), 4.12-4.53 (3H,
m), 3.60 (3H, m), 2.51-2.92 (4H, m), 1.96 (1H, m), 1.75 (3H, s),
1.21 (3H, d), 0.83 (6H, m). Anal. Calcd. for
C.sub.31H.sub.38Cl.sub.2N.sub.4O.sub.9. H.sub.2O: C, 53.22; H,
5.76; Cl, 10.14; N, 8.09. Found: C, 53.33; H, 5.54; Cl, 10.02; N,
7.85. M.S. (+FAB); 682 (M.sup.+2, 30%); 681 (67), 158 (100).
(-FAB); 680 (45), 679 (100).
Example 6
[0912] We obtained inhibition constants (K.sub.i) and IC.sub.50
values for several compounds of this invention using enzyme assays
with UV-visible substrate, fluorescent substrate, and cell assays
as described in Example 2. The following K.sub.i and IC.sub.50
values were determined for compounds 22e, 54b, 54j, 54k, 57b, 85,
86, 87, 88, 89, 90, 91, 92, 98, 102a-c, 106a-c, 108a-c, 114a, 114b,
115, 121, 125a, 125b, 126, 127, 128, 129, 130, 131, 132a, 132b,
133, 135a, 135b, 136, 137, 138, 139, 140, 141, 142, 144, 145, 146,
147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159,
160, 161, 162, and 163 using the indicated assays. The structures
of compounds 22e, 54b, 54j, 54k, and 57b are shown in Example 5.
The other compound structures are shown in Example 7.
TABLE-US-00011 Assay UV-visible Cell Compound K.sub.i (.mu.M)
IC.sub.50 (.mu.M) 22e 0.19 >20 54b 20 54j 10 54k 6.6 57b 2.2 85
0.0035 9.8 86 0.175 4.0 87 7.2 35.0 88 0.9 89 0.018 90 0.42 6.2 91
0.26 >25 92 3.8 98 0.535 4.0 102a 4.0 102b 0.29 1.75 102c 0.68
106a 2.3 30.0 106b 0.2 2.9 106c 3.8 >30.0 108a 17.5 108b 0.4
25.0 108c 0.43 114a 0.12 3.8 114b 3.7 115 0.345 6.0 121 4.3 125a
0.39 >30.0 125b 0.060 0.30 126 0.45 1.5 127 0.39 8.0 128 0.04
7.5 129 0.59 25.0 130 1.20 131 12.0 30.0 132a 5.0 >30.0 132b
12.5 133 50.0 >30.0 135a 0.090 0.90 135b 0.32 0.95 136 1.0 137
0.04 0.25 138 0.375 139 0.350 2.0 140 0.87 >30.0 141 0.670 142
1.75 144 0.32 >20.0 145 0.34 8.5 146 0.16 3.8 147 0.26 8.5 148
6.3 30.0 149 14.0 >30.0 150 10.0 30.0 151 13.0 30.0 152 8.8 153
0.24 154 0.042 2.4 155 0.023 156 0.001 2.7 157 0.26 158 1.1 159
0.0017 8.0 160 0.145 2.25 161 0.011 162 0.0025 163 0.0028 1.2
Example 7
[0913] Compounds 126, 127, 128, 129, 135a, 135b, 137 144, 145, 146,
147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 159, 160,
162, and 163 were synthesized by a method similar to the method
used in the synthesis of 69a.
##STR00174## ##STR00175## ##STR00176## ##STR00177##
[0914] Compound 158 was synthesized by a method similar to the
method used in the synthesis of (K).
##STR00178##
[0915] Compound 130 was synthesized by a method similar to the
method used in the synthesis of 56b.
##STR00179##
[0916] Compounds 131, 136, 138, and 142 were synthesized by a
method similar to the method used in the synthesis of 57b.
##STR00180##
[0917] Compounds 132a, 132b, 139, 140, and 141 were synthesized by
a method similar to the method used in the synthesis of 47a. The
starting material for compound 140 was obtained as described in:
Robl, et al., J. Am. Chem. Soc., 116, pp. 2348-2355 (1994). The
starting material for compound 141 was obtained as described in:
Wyvratt, et al., Pept. Struct: Funct. Proc. (8th Am. Pept. Symp.),
(1983) or U.S. Pat. No. 4,415,496.
##STR00181##
[0918] Compound 133 was synthesized by a method similar to the
method used in the synthesis of 47b.
##STR00182##
[0919] Compound 161 was synthesized by a method similar to the
method used in the synthesis of 125a.
##STR00183##
[0920] Compounds 22e, 54b, 54j, 54k, and 57b were synthesized as
described in example 5.
[0921] Compounds 85, 86, 87, 88, 89, 90, 91, 92, 98, 102a, 102b,
102c, 106a, 106b, 106c, 108a, 108b, 108c, 114a, 114b, 115, 121,
125a, and 125b were synthesized as follows.
##STR00184##
N-(N-Acetyl-tyrosinyl-valinyl-(4(R)-allyloxy
prolinyl))-3(S)-amino-4-oxobutanoic acid (85). Step A.
N-tert-Butoxycarbonyl-4(R)-allyloxyproline.
N-tert-Butoxycarbonyl(4R)-hydroxyproline (9.25 g, 40 mmol) was
added to a solution of 60% sodium hydride (3.36 g, 84 mmol) in 100
ml of anhydrous tetrahydrofuran and stirred for 2 hours at room
temperature. Allyl bromide (6.9 ml, 80 mmol) was added to the
mixture and refluxed for 6 hours. The mixture was quenched with the
addition of ice chips, then additional water was added and the
mixture was washed with hexane. The aqueous layer was acidified
with 10% sodium hydrogen sulfate and extracted with ethyl acetate
(2.times.150 ml). The combined extracts were dried over anhydrous
sodium sulfate, filtered and evaporated to give 5 g of the title
product with no further purification. .sup.1H NMR (CDCl.sub.3;
exist as rotamers) .delta. 5.92-5.82 (1H, m), 5.3-5.14 (2H, m)
4.5-4.31 (1H, m), 4.16-4.05 (1H, m), 4.04-3.9 (1H, m), 3.79-3.5
(3H, m), 2.43-2.2 (1.5H, m), 2.15-2.10 (0.5H, m), 1.45 (4.5H, s),
1.35 (4.5H, s). Step B. 4(R)-Allyloxyproline methyl ester
hydrochloride. N-tert-Butoxycarbonyl-4(R)-allyloxyproline (5 g,
18.4 mmol) was refluxed in 50 ml of saturated methanolic hydrogen
chloride for 6 hours. The mixture was evaporated in vacuo to give
3.78 g of a yellow gum as the title compound: .sup.1H NMR
(CDCl.sub.3) .delta. 5.83-5.72 (1H, m), 5.24-5.14 (1H, d),
5.13-5.08 (1H, d), 4.55-4.3 (3H, m), 4.25-4.15 (1H, m), 3.9 (1.5H,
s), 3.78 (1.5H, s), 3.7-3.28 (3H, m), 2.45-2.32 (1H, m), 2.2-2.05
(1H, m). Step C. N-Acetyl-tyrosinyl-valinyl-(4(R)-allyloxyprolineyl
ester. 4(R)-Allyloxyproline methyl ester hydrochloride (1.05 g,
4.75 mmol) and N-acetyl-Tyr-Val-OH (1.68 g, 5.21 mmol) were
dissolved in 10 ml of a 1:1 mixture of dichloromethane and
dimethylformamide and cooled to 0.degree. C. Diisopropylethylamine
(1 ml, 5.93 mmol) was added to the cooled mixture followed by the
addition of N-hydroxybenzotriazole (0.769 g, 5.69 mmol) and
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.18
g, 6.2 mmol). After stirring for 2 hours, the mixture was warmed to
room temperature and stirred for 16 hours. The reaction was poured
into 150 ml of ethyl acetate and washed with 50 ml each of water,
10% sodium hydrogen sulfate, and 10% sodium bicarbonate. The
organic layer was dried over sodium sulfate, filtered, and
evaporated to give a light yellow solid. This was purified by flash
chromatography eluting with dichloromethane/methanol/pyridine
(100:3:0.5) to give 780 mg of the title compound. .sup.1H NMR
(CD.sub.3OD) .delta. 7.02-6.96 (2H, d), 6.67-6.63 (2H, d),
5.95-5.85 (1H, m), 5.34-5.27 (1H, d), 5.16-5.13 (1H, d), 4.53-4.38
(3H, m), 4.28-4.22 (1H, m), 4.12-3.97 (3H, m), 3.82-3.73 (1H, m),
3.72 (3H, s), 3.04-2.88 (2H, m), 2.85-2.72 (2H, m), 2.45-2.34 (1H,
m), 2.08-1.95 (2H, m), 1.92 (3H, s), 1.00-0.92 (6H, 2.times.d).
Step D.
N-(N-Acetyl-tyrosinyl-valinyl-(4(R)-allyloxyprolinyl))-3(S)-amino-4-oxobu-
tanoic acid tert-butyl ester semicarbazone.
N-Acetyl-tyrosinyl-valinyl-(4-allyloxyproline)methyl ester (770 mg,
1.57 mmol) was dissolved in 20 ml of tetrahydrofuran and 4 ml of
methanol. Lithium hydroxide (145 mg, 3.46 mmol) was added to the
mixture and stirred at room temperature. After two hours, 1 ml of
10% hydrogen chloride was added and the mixture evaporated in vacuo
to give a solid residue then partitioned between 5 ml of water and
50 ml of ethyl acetate and the organic layer separated and
evaporated in vacuo to give 430 mg of the acid that was used
immediately in the next step.
N-Acetyl-tyrosinyl-valinyl-4-allyloxyproline (420 mg, 0.88 mmol)
and 3-amino-4-oxobutyric acid tert-butyl ester semicarbazone (184
mg, 0.8 mol, Graybill et al., Int. J. Protein Res., 44, pp. 173-82
(1994)) to give 100 mg (20%) of the title compound as a white
amorphous solid: .sup.1H NMR (CD.sub.3OD) .delta. 7.24-7.2 (1H, m),
7.04-6.97 (2H, d), 6.73-6.65 (2H, d), 5.98-5.86 (1H, m), 5.35-5.24
(1H, d), 5.17-5.12 (1H, m), 4.12-3.98 (2H, m), 3.72-3.67 (1H, m),
2.98-2.92 (3H, m), 2.38-2.32 (1H, m), 2.1-2.02 (2H, m), 1.92 (3H,
s), 0.98-0.89 (6H, 2.times.d). Step E.
N-(N-Acetyl-tyrosinyl-valinyl-(4(R)-allyloxyprolinyl))-3(S)-amino-4-ox-
obutanoic acid (85).
N-(N-Acetyl-tyrosinyl-valinyl-(4(R)-allyloxyprolinyl))-3(S)-amino-4-oxobu-
tanoic acid tert-butyl ester semicarbazone (100 mg) was deprotected
as described (Example 3, compound K, Step C) to give 44.2 mg (53%)
of the title compound: .sup.1H NMR (CD.sub.3OD) .delta. 7.04-6.97
(2H, d), 6.72-6.65 (2H, d), 5.97-5.86 (1H, m), 5.32-5.25 (1H, d),
5.17-5.12 (1H, d), 4.62-4.40 (3H, m), 4.30-4.13 (2H, m), 4.12-3.96
(3H, m), 3.75-3.68 (1H, m), 2.99-2.92 (1H, m), 2.78-2.70 (1H, m),
2.70-2.48 (2H, m), 2.35-2.30 (1H, m), 2.17-1.95 (2H, m), 1.92 (3H,
s), 0.98-0.88 (6H, 2.times.d). Compounds 86 and 87 were prepared by
a similar method described for the synthesis of 69a in example
5:
##STR00185##
N-Acetyl-(S)-valinyl-(4-(S)-phenoxy)prolinyl-3(S)-amino-4-(7-methoxybenzo-
xazol-2-yl)-4-oxo-butanoic acid (86).
N-Acetyl-(S)-valinyl-(S)-(4-(S)-phenoxy)proline was converted to 86
as a white powder: .sup.1H NMR (DMSO-d.sub.6) .delta. 8.75(d, 1H),
7.6-7.2 (m, 4H), 7.0-6.8 (m, 4H), 5.5 (m, 1H), 5.05 (s, 1H), 4.5
(t, 1H), 4.29 (t, 1H), 4.0 (s, 3H), 4.0-3.8 (m, 2H), 3.0-2.8 (dd,
2H), 2.3 (m, 1H), 2.09 (m, 1H), 1.95-1.8 (m, 2H), 1.78 (s, 3H),
1-0.7(dd, 6H).
##STR00186##
N-Acetyl(4-(R)-phenoxy)prolinyl-3(S)-amino-4-(7-methoxybenzoxazol-2-yl)-4-
-oxo-butanoic acid (87): N-Acetyl-(S)-(4-(S)-phenoxy)proline was
converted to 87 as a white powder: .sup.1H NMR (DMSO-d.sub.6)
.delta. 9.1(d, 1H), 8.76 (d, 1H), 7.6-7.2 (m, 4H), 7.0-6.9 (m, 4H),
5.55 (m, 1H), 5.45 (m, 1H), 5.0 (m, 2H), 4.56 (t, 1H), 4.40 (t,
1H), 4.0 (s, 3H), 3.9 (dd, 1H), 3.76 (d, 1H), 3.64 (d, 1H), 3.1-2.9
(m, 1H), 2.8 (m, 1H), 2.50 (m, 1H), 2.3-2.2 (m, 1H), 2.09 (m, 1H),
1.95 and 1.75(2.times.s, 3H, rotamers)
##STR00187##
N-2-(6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl)acet-
yl-3(S)-amino-5-hydroxy-4-oxo-pentanoic acid (88).
N-2-(6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl)acet-
yl-3(S)-amino-5-hydroxy-4-oxo-pentanoic acid tert-butyl ester was
prepared from 52b and 81 following the method described for the
synthesis of 83a to give a white solid (45%): .sup.1H NMR
(CDCl.sub.3) .delta. 8.40(d, 1H), 8.20 (s, 1H), 7.4-7.1 (m, 11H),
6.18 (s, 1H), 4.72 (m, 1H), 4.65-4.5 (q, 2H), 4.4-4.2 (dd, 2H), 4.0
(s, 2H), 3.04 (t, 2H), 2.9 (dd, 1H), 2.76 (t, 2H), 2.55 (dd, 1H),
1.39 (s, 9H). The resulting product was converted to 88 by method
described in example 5, compound 84a to give the title compound
(42%) as a white solid: .sup.1H NMR (CDCl.sub.3) .delta. 8.5(d,
1H), 8.1 (d, 1H), 8.0 (m, 1H), 7.4-7.1 (m, 11H), 6.3 (d, 1H),
4.9-4.8 (m, 2H), 4.6-4.4 (m, 2H), 4.3 (dd, 1H), 4.1 (s, 2H), 3.3
(t, 1H), 3.05 (t, 2H), 2.8-2.6 (m, 3H) Compounds 89 and 90 were
prepared by a similar method described for the preparation of 84a
in example 5.
##STR00188##
N-Acetyl-(S)-tyrosinyl-(S)-valinyl-(S)-alaninyl-3(S)-amino-5-(2-chloroben-
zyloxy)-4-oxo-pentanoic acid (89)was prepared from
Ac-Tyr-Val-Ala-OH and (3S)t-butyl
N-(allyloxycarbonyl)-3-amino-5-(2-chlorophenyl-methoxyl)-4-oxo-pentanoate
(prepared by a similar method as 82) to give a white solid: .sup.1H
NMR (DMSO-d.sub.6) .delta. 9.15(s, 1H), 8.5 (d, 1H), 7.98 (d, 1H),
7.75 (d, 1H), 7.55-7.3 (m, 4H), 7.0 (d, 1H), 6.6 (d, 2H), 4.6-4.3
(m, 6H), 4.3-4.1 (m, 2H), 2.9 (d, 1H), 2.76 (dd, 1H), 2.7-2.5 (m,
2H), 1.95 (m, 1H), 1.75 (s, 3H), 1.2 (d, 3H), 0.9-0.7(dd, 6H)
##STR00189##
N-2-(6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl)acet-
yl-3-amino-5-(2-chlorobenzyloxy)-4-oxo-pentanoic acid (90) was
prepared from 52b and (3S)t-butyl
N-(allyloxycarbonyl)-3-amino-5-(2-chlorophenyl-methoxyl)-4-oxo-pentanoate
(prepared by a similar method as 82) to give a white solid: .sup.1H
NMR(DMSO-d.sub.6) .delta. 9.2(s, 1H), 8.75 (d, 1H), 7.7-7.1 (m,
14H), 6.4 (d, 1H), 4.65 (d, 6H), 4.56 (s, 1H), 4.6-4.35 (dd, 1H),
3.9 (s, 2H), 2.9-2.6 (m, 6H)
##STR00190##
N-2-(6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionyl)amino-1-pyridyl)acet-
yl-3(S)-amino-5-(5-(2,6-dichlorophenyl)thiazol-2-yl)-4-oxo-pentanoic
acid (91) was prepared from 52b and
3-(Allyloxycarbonyl)-amino-4-[(2,6-dichloro-phenyl)-thiazol-2-yl]-4-hydro-
xy-butyric acid tert-butyl ester (99) as described for the
preparation of 69a to give an off-white powder: .sup.1H NMR
(DMSO-d.sub.6) .delta. 9.32(s, 1H), 9.05 (d, 1H), 8.27 (d, 1H),
8.18 (d, 1H), 7.7 (d, 1H), 7.6(t, 1H), 7.4-7.1 (m 11H), 6.1 (d,
1H), 5.64 (m, 1H), 4.8-4.6 (dd, 2H), 3.85 (s, 2H), 3.02 (m, 1H),
2.9-2.7 (m, 4H).
##STR00191##
3-(S)-(2-(3[3-(S)-(4-Hydroxy-phenyl)-propionylamino]-2-oxo-azepan-1-yl)-a-
cetylamino)-4-oxo-butyric acid (92) was prepared from
2-(3[3-(S)-(4-Hydroxy-phenyl)-propionylamino]-2-oxo-azepan-1-yl)-acetic
acid and
N-allyloxycarbonyl-4-amino-5-benzyloxy-2-oxotetrahydrofuran
(Chapman, Biorg. Med. Chem. Lett., 2, pp. 613-18 (1992)) by a
similar method described for the synthesis of 54a to give the title
compound as a white solid: .sup.1H NMR (DMSO-d.sub.6) .delta.
9.10-9.20 (s, 1H), 8.40 (s, 1H), 7.88 (d, 1H), 7.0 (d, 2H), 6.64
(d, 2H), 4.60 (t, 1H), 4.10 (q, 2H), 3.9-4.2 (m, 2H), 3.6 (m, 1H),
3.18 (d, 2H), 2.70 (t, 2H), 2.40 (m, 2H), 1.85-1.40 (m, 8H).
##STR00192##
4-Ethoxymethylene-2-styryl-4H-oxazol-5-one (94) was prepared
according to Cornforth, The Chemistry of Penicillin, Clarke,
Johnson, Robinson, (eds.) Princeton University Press, p. 804 (1949)
4-Oxo-3-(3-phenyl-acryloylamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimid-
ine-(6S)-carboxylic acid ethyl ester (95) was prepared from 94 by
the procedure in example 5 for compound 3 to give 4.5 g (30%) of
the title compound: .sup.1H NMR (CD.sub.3OD) .delta. 1.3 (t, 3H),
2.35 (m, 1H), 2.65 (m, 1H), 3.1 (m, 1H), 3.15 (m, 1H), 4.25 (q,
2H), 5.15 (dd, 1H), 6.95 (d, 1H), 7.4 (m, 3H), 7.6 (m, 2H), 7.65
(d, 1H), 8.95 (s, 1H).
4-Oxo-3-(3-phenyl-acryloylamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimid-
ine-(6S)-carboxylic acid (96) A mixture of
4-Oxo-3-(3-phenyl-acryloylamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimid-
ine-(6S)-carboxylic acid ethyl ester (95, 3.1 g, 8.8 mmol) and
aqueous 1N lithium hydroxide (8.8 mL, 8.8 mmol) in methanol (10 mL)
was stirred 18 h at room temperature. The reaction was diluted with
water and washed with ethyl ether (1.times.20 mL). The aqueous
layer was acidified with conc. hydrochloric acid. The solid was
collected by filtration and washed with water. The solid was dried
in a vacuum oven at 50.degree. C. for 18 h to give 2.2 g (75%) of
the title compound as a tan solid: .sup.1H NMR (CD.sub.3OD) .delta.
2.4(m 1H), 2.7 (m, 1H), 3.1 (m, 1H), 3.2 (m, 1H), 5.15 (dd, 1H),
7.0 (d, 1H), 7.4 (m, 3H), 7.6 (m, 2H), 7.65 (d, 1H), 8.95 (s, 1H)
4-Oxo-3-(3-phenyl-acryloylamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a-
]pyrimidine-(6S)-carboxylic acid
(2-benzyloxy-5-oxo-tetrahydro-furan-(3S)-yl)-amide (97) was
prepared from 96 by the method described in example 3 for compound
H, step A to give 0.52 g (75%) of the title compound as a mixture
of diastereomers: .sup.1H NMR (CDCl.sub.3) .delta. 2.3-2.7 (m, 3H),
2.9 (dd, 1H), 3.05 (m, 1H), 3.3 (m, 1H), 4.4-4.8 (m, 2H), 4.9
(2.times.d, 1H), 5.05 (m, 1H), 5.55 (2.times.s, 1H), 6.6
(2.times.d, 1H), 7.4 (m, 6H), 7.55 (m, 4H), 7.65 (2.times.d, 1H),
8.0 (m, 2H), 9.2 (s.times.2, 1H).
4-Oxo-(3S)-{[4-oxo-3-(3-phenyl-propionylamino)-4,6,7,8-tetrahydro-pyrrolo-
[1,2-a]pyrimidine-(6S)-carbonyl]-amino}-butyric acid (98) was
prepared by the procedure in example 3 for compound H, step D to
give 0.13 g (45%) of the title compound: .sup.1H NMR (CD.sub.3OD)
.delta. 2.35(m, 1H), 2.45-2.75 (m, 3H), 2.8 (t, 2H), 3.0 (t, 2H),
3.1 (m, 1H), 3.25(m, 1H), 4.3 (m, 1H), 6.65 (dd, 1H), 5.15 (m, 1H),
7.15 (m, 1H), 7.3 (m, 4H), 8.8 (a, 1H).
##STR00193##
3(S)-(Allyloxycarbonyl)-amino-4-[(2,6-dichloro-phenyl)-oxazol-2-yl]-4(R,S-
)-hydroxy-butyric acid tert-butyl ester (99). A solution of
5-(2,6-Dichlorophenyl)oxazole (2.71 g, 12.7 mmol; prepared by a
similar method described in Tet. Lett. 23, p2369 (1972)) in
tetrahydrofuran (65 mL) was cooled to -78.degree. C. under a
nitrogen atmosphere. To this solution was added n-butyl lithium
(1.5M solution in hexanes, 8.5 mL, 13.3 mmol) and stirred at
-78.degree. C. for 30 min. Magnesium bromide etherate (3.6 g, 13.9
mmol) was added and the solution was allowed to warm to -45.degree.
C. for 15 min. The reaction was cooled to -78.degree. C. and
aldehyde 58 (3.26 g, 12.7 mmol; Graybill et al., Int. J. Protein
Res., 44, pp. 173-182 (1993)) in tetrahydrofuran (65 mL) was added
dropwise. The reaction was stirred for 25 min., then allowed to
warm to -40.degree. C. and stirred for 3 h, and then at room
temperature for 1 h. The reaction was quenched with 5% NaHCO.sub.3
(12 mL) and stirred for 3 h. The tetrahydrofuran was removed in
vacuo and the resulting residue was extracted with dichloromethane.
The organic layer was washed with saturated sodium chloride
solution and dried over magnesium sulfate, filtered, and
concentrated to yield 6.14 g of the title compound. Purification
gave 4.79 g (80%) of 99: .sup.1H NMR (CDCl.sub.3) .delta. 1.45(s,
9H), 2.7-2.5 (m, 2H), 2.8 (dd, 1H), 4.2, 4.4(2.times.d, 1H),
4.7-4.5 (m, 3H), 5.35-5.1 (m, 2H), 5.6, 5.7(2.times.d, 1H), 6.0-5.8
(m, 1H), 7.2 (d, 1H), 7.3 (m, 1H), 7.4 (m, 2H).
4-Oxo-3-(3-phenyl-propionylamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimi-
dine-(6S)-carboxylic acid (100). A mixture of
4-Oxo-3-(3-phenyl-acryloylamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimid-
ine-(6S)-carboxylic acid (96; 2.1 g, 6.5 mmol) and 20% palladium
hydroxide on carbon (0.5 g) in methanol (50 mL) was stirred under a
hydrogen atmosphere for 4 h. The resulting mixture was filtered and
concentrated to yield 2.1 g (100%) of the title compound as a white
solid: .sup.1H NMR (CD.sub.3OD) .delta. 2.35(m, 1H), 2.65 (m, 1H),
2.75 (t, 2H), 3.0 (t, 2H), 3.1 (m, 1H), 3.15 (m, 1H), 5.1 (dd, 1H),
7.15 (m, 1H), 7.25 (m, 4H), 8.75 (s, 1H)
##STR00194##
2,6-Dichloro-benzoic acid
4-tert-butoxycarbonyl-2-oxo-(3S)-{[4-oxo-3-(3-phenyl-propionylamino)-4,6,-
7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-(6S)-carbonyl]-amino}-butyl
ester (101a) was prepared by the procedure in example 5 for
compound 56a to give 0.16 g (20%) of the title compound: .sup.1H
NMR (CD.sub.3OD) .delta. 1.45(s, 9H), 2.3 (m, 1H), 2.6 (m, 1H), 2.7
(m, 3H), 2.95 (m, 3H), 4.8 (m, 1H), 5.1 (m, 1H), 5.2 (q, 2H), 7.1
(m, 1H), 7.2 (m, 4H), 7.4 (m, 3H), 8.75 (s, 1H).
4-(7-methoxy-benzoxazol-2-yl)-4-oxo-(3S)-{[4-oxo-3-(3-phenyl-propionylami-
no)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-(6S)-carbonyl]-amino}-butr-
ic acid tert-butyl ester (101b).
4-Hydroxy-4-(7-methoxy-benzoxazol-2-yl)-(3S)-{[4-oxo-3-(3-phenyl-propiony-
lamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-(6S)-carbonyl]-amino}--
butyric acid tert-butyl ester was prepared from 100 and 66a by the
procedure in example 5 for compound 67a to give 0.95 g
(quantitative) of the product as a mixture of diastereomers:
.sup.1H NMR (CD.sub.3OD) .delta. 1.45(2.times.s, 9H), 2.2
(2.times.m, 1H), 2.35-3.0 (m, 9H), 4.0 (m, 3H), 4.75 (m, 1H), 4.85
(m, 1H), 5.05 (2.times.dd, 1H), 7.1 (2.times.dd, 1H), 7.15-7.3 (m,
4H), 7.5 (2.times.t, 1H), 7.8 (2.times.d, 1H), 8.55 (2.times.dd,
1H), 8.7 (2.times.s, 1H). The resulting product was converted to
101b by the procedure in example 5 for compound 68a to give 0.36 g
(50%) of the title compound: .sup.1H NMR (CD.sub.3OD) .delta.
1.4(s, 9H), 2.35 (m, 1H), 2.55 (m, 1H), 2.75 (t, 2H), 2.95 (t, 2H),
3.00 (m, 1H), 3.1 (dd, 2H), 3.15 (m, 1H), 5.15 (dd, 1H), 5.65 (t,
1H), 7.1 (m, 2H), 7.2 (m, 4H), 7.4 (m, 2H), 8.7 (s, 1H)
4-[5-(2,6-Dichloro-phenyl)-oxazol-2-yl]-4-oxo-(3S)-{[4-oxo-3-(3-phenyl-pr-
opionylamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-(6S)-carbonyl]-a-
mino}-butyric acid tert-butyl ester (101c).
4-[5-(2,6-Dichloro-phenyl)-oxazol-2-yl]-4-hydroxy-(3S)-{[4-oxo-3-(3-pheny-
l-propionylamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-(6S)-carbony-
l]-amino}-butyric acid tert-butyl ester from 100 and 99 using the
method described in example 5, compound 67a to give 0.09 g (60%) of
the product as a mixture of diastereomers: .sup.1H NMR (CD.sub.3OD)
.delta. 1.45(2.times.s, 9H), 2.2 (m, 1H), 2.5 (m, 2H), 2.7
(2.times.dd, 1H), 2.75 (t, 2H), 2.9-3.1 (m, 4H), 4.7 (m, 1H), 5.1
(m, 2H), 7.1 (m, 1H), 7.1-7.25 (m, 4H), 7.4 (t, 1H), 7.5 (t, 1H),
8.55 (d, 1H), 8.75 (s, 1H). The resulting product was converted to
101c by the method described in example 5, compound 68a to give
0.04 g (45%) of the title compound: .sup.1H NMR (CD.sub.3OD)
.delta. 1.4(s, 9H), 2.3 (m, 1H), 2.6 (m, 1H), 2.75 (t, 2H), 2.95
(t, 2H), 2.9-3.2 (m, 4H), 5.2 (dd, 1H), 5.55 (t, 1H), 7.1 (m, 1H),
7.25 (m, 4H), 7.55 (m, 3H), 8.75 (s, 1H). 2,6-Dichloro-benzoic acid
4-carboxy-2-oxo-(3S)-{[4-oxo-3-(3-phenyl-propionylamino)-4,6,7,8-tetrahyd-
ro-pyrrolo[1,2-a]pyrimidine-(6S)-carbonyl]-amino}-butyl ester
(102a) was prepared from 101a by the procedure in example 5 for
compound 57a to give 0.12 g (80%) of the title compound: .sup.1H
NMR (CD.sub.3OD) .delta. 2.35(m, 1H), 2.65 (m, 1H), 2.75 (m, 2H),
2.85 (dd, 1H), 2.95 (m, 2H), 3.0 (dd, 1H), 3.15 (m, 1H), 3.25 (m,
1H), 4.55 (dd, 1H), 5.15 (m, 1H), 5.25 (q, 2H), 7.15 (m, 1H), 7.25
(m, 4H), 7.45 (m, 1H), 8.8 (s, 1H).
4-(7-methyoxy-benzoxazol-2-yl)-4-oxo-(3S)-{[4-oxo-3-(3-phenyl-propionylam-
ino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-(6S)-carbonyl]-amino}-but-
ric acid (102b) was prepared from 101b by the procedure described
in example 5 for compound 69a to give 0.12 g (35%) of the title
compound: .sup.1H NMR (DMSO-d.sub.6) .delta. 2.1(m, 1H), 2.55 (m,
1H), 2.7-3.1 (m, 8H), 4.05 (s, 3H), 5.1 (dd, 1H), 5.55 (t, 1H), 7.2
(m, 1H), 7.25 (m, 5H), 7.5 (t, 1H), 7.55 (d, 1H), 8.7 (s, 1H), 9.2
(d, 1H), 9.4 (s, 1H), 12.7 (br, 1H).
4-[5-(2,6-Dichloro-phenyl)-oxazol-2-yl]-4-oxo-(3S)-{[4-oxo-3-(3-
-phenyl-propionylamino)-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrimidine-(6S)-c-
arbonyl]-amino}-butyric acid (102c) was prepared from 101c as
described in example 5 for compound 69a to give 0.01 g (40%) of the
title compound: .sup.1H NMR (CD.sub.3OD) .delta. 2.35(m, 1H), 2.6
(m, 1H), 2.75 (t, 2H), 2.95 (t, 2H), 3.05 (m, 1H), 3.15 (m, 3H),
5.15 (dd, 1H), 5.55 (t, 1H), 7.15 (m, 1H), 7.2 (m, 4H), 7.55 (m,
3H), 8.8 (s, 1H)
##STR00195##
(3-tert-Butoxycarbonylamino-2-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepi-
n-1-yl)acetic acid methyl ester (103). Step A.
2(S)-tert-Butoxycarbonylamino-3-(2-nitrophenyl-amino)-propionic
acid. 2-tert-Butoxycarbonylamino-3-aminopropionic acid (10 g, 49
mmol), 2-fluoronitrobenzene (5.7 ml, 54 mmol), and sodium
bicarbonate (8.25 g, 98 mmol) was taken into 130 ml of
dimethylformamide and heated at 80.degree. C. for 18 hours. The
reaction was evaporated in vacuo to give a viscous orange residue
that was dissolved in 300 ml of water and extracted with diethyl
ether (3.times.150 ml). The aqueous solution was acidified to pH 5
with 10% sodium hydrogen sulfate and extracted with ethyl acetate
(3.times.250 ml). The combined extracts were dried over anhydrous
sodium sulfate, filtered, and evaporated to give 12.64 g (83%) of
the title compound as an orange amorphous solid. .sup.1H NMR
(CD.sub.3OD) .delta. 8.15-8.10 (1H, d), 7.54-7.48 (1H, t),
7.13-7.08 (1H, d), 6.73-6.65 (1H, t), 4.45-4.35 (1H, m), 3.9-3.8
(1H, dd), 3.65-3.55 (1H, dd), 1.45 (9H, s). Step B.
2(S)-tert-Butoxycarbonylamino-3-(2-aminophenyl-amino)-propionic
acid. A mixture of
2-tert-Butoxycarbonylamino-3-(2-nitrophenylamino)propionic acid
(12.65 g, 40.5 mmol) and 0.5 g of 10% Pd/C in 100 ml of methanol
under hydrogen at 1 atmosphere was stirred for 4 hrs. The solution
was filtered through Celite 545 and the filtrate evaporated in
vacuo to afford 11.95 g of the title compound in quantitative yield
as a dark brown solid that was used without purification. .sup.1H
NMR (CD.sub.3OD) .delta. 6.75-6.70 (3H, m), 6.65-6.58 (1H, m),
4.35-4.3 1H, m), 3.6-3.38 (2H, m), 1.45 (9H, s). Step C.
3(S)-tert-Butoxycarbonylamino-1,3,4,5-tetrahydro-benzo[b][1,4]diazepin-2--
one. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(8.54 g, 44.5 mmol) was added to a cooled (0.degree. C.) solution
of 2-tert-butoxycarbonylamino-3-(2-aminophenylamino)propionic acid
(11.95 g, 40.5 mmol) in 100 ml of dimethylformamide and stirred for
18 hours. The reaction was poured into 700 ml of ethyl acetate and
washed four times with 100 ml of water. The organic layer was dried
over anhydrous sodium sulfate, filtered, and evaporated to give a
brown solid that was purified by flash chromatography eluting with
3:7 ethyl acetate/hexane to give 8 g (71%) of the title compound: H
NMR (CDCl.sub.3) .delta. 7.78 (1H, s), 7.02-6.95 (1H, m), 6.88-6.82
(1H, m), 6.82-6.78 (1H, m), 6.75-6.70 (1H, m), 5.8-5.7 (1H, d),
4.55-4.45 (1H, m), 3.95 (1H, s), 3.9-3.82 (1H, m), 3.48-3.40 (1H,
m), 1.45 (9H, s). Step D.
(3(S)-tert-Butoxycarbonylamino-2-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]diaze-
pin-1-yl)acetic acid methyl ester (103). A 1.0 M solution of
lithium bis(trimethylsilyl)amide (3.4 ml, 3.4 mmol) in THF was
added dropwise to a -78.degree. C. solution of
3-tert-butoxycarbonylamino-1,3,4,5-tetrahydrobenzo[b][1,4]diazepin-2-one
(0.94 g, 3.38 mmol) in 20 ml of anhydrous tetrahydrofuran and
stirred for 30 minutes. Methyl bromoacetate (0.44 ml, 4 mmol) was
added dropwise to the reaction mixture then warmed to room
temperature. The reaction was diluted with 100 ml of ethyl acetate
and washed with 0.3N potassium hydrogen sulfate (50 ml), water
(2.times.50 ml), and brine. The combined organics were dried over
anhydrous sodium sulfate, filtered, and evaporated to afford a gum
that was purified by flash chromatography eluting with 3:7
EtOAc/Hex. to give 0.98 g (83%) of the title compound as a white
solid. .sup.1H NMR (CDCl.sub.3) .delta. 7.15-7.07 (2H, m),
6.98-6.94 (1H, m), 6.88-6.84 (1H, d), 5.62-5.55 (1H, d), 4.71-4.65
(1H, d), 4.65-4.6 (1H, m), 4.33-4.27 (1H, d), 3.96-3.90 (1H, m),
3.78 (3H, s), 3.44-3.37 (1H, m), 1.4 (9H, s).
##STR00196##
[2-Oxo-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydro-benzo[b][1,4]diaz-
epin-1-yl]acetic acid methyl ester (104a). Anhydrous hydrogen
chloride was bubbled into a solution of
(3(S)-tert-butoxycarbonylamino-2-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diaz-
epin-1-yl)acetic acid methyl ester (103, 1 g, 2.86 mmol) in 25 ml
of ethyl acetate for 2 minutes then stirred for 1 hour at room
temperature. The reaction was evaporated to give
2-oxo-3(S)-amino-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl
acetic acid methyl ester hydrochloride as a white solid. The
hydrochloride salt and hydrocinnamic acid (0.47 g, 3.15 mmol) was
dissolved into 20 ml of dimethylformamide and cooled to 0.degree.
C. Diisopropylethylamine (1 ml, 5.72 mmol) was added to the
solution followed by the addition of N-hydroxybenzotriazole and
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride. After
stirring for 18 hours at room temperature, the mixture was diluted
with 150 ml of ethyl acetate and washed with 10% sodium hydrogen
sulfate, 10% sodium bicarbonate, and brine. The organic layer was
dried over anhydrous sodium sulfate, filtered, and evaporated to a
crude solid that was purified by flash chromatography eluting with
7:3 ethyl acetate/dichloromethane to afford 600 mg (55%) of the
title compound as a white solid. .sup.1H NMR (CDCl.sub.3) .delta.
7.3-6.85 (9H, m), 6.55-6.0 (1H, d), 4.88-4.82 (1H, m), 4.72-4.65
(1H, d), 4.28-4.22 (1H, m), 3.95-3.9 (1H, m), 3.78 (3H, s), 3.65
(1H, br. s), 3.28-3.2 (1H, m), 2.95-2.84 (2H, m), 2.55-2.4 (2H, m).
(3(S)-(3-Phenylpropionylamino)-2-oxo-2,3,4,5-tetra-hydrobenzo[b][1,4]diaz-
epin-1-yl)acetic acid (105a).
(3(S)-(3-Phenylpropionylamino)-2-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diaz-
epin-1-yl)acetic acid methyl ester (104a) was dissolved in 90%
methanol. Lithium hydroxide hydrate was added to the reaction and
the reaction was stirred at room temperature for 4 h. The reaction
was evaporated in vacuo to give a white solid. This was dissolved
in 20 ml of water and acidified to pH 5 and extracted with ethyl
acetate to afford 304 mg (88%) of the title compound as a white
solid. .sup.1H NMR (CDCl.sub.3) .delta. 7.5-6.9 (11H, m), 4.92-4.8
(1H, m), 4.7-4.58 (1H, d), 4.38-4.25 (1H, d), 3.88-3.78 (1H, m),
3.45-3.25 (1H, m), 3.05-2.85 (2H, m), 2.55-2.45 (2H, m).
4-Oxo-3(S)-{2-[2-oxo-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydro-
-benzo[b][1,4]diazepin-1-ylacetylamino}butyric acid (106a).
N-[1-(2-Benzyloxy-5-oxotetrahydrofuran-3-ylcarbamoyl-methyl)-2-oxo-2,3,4,-
5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl]-3-phenylpropionamide
was prepared from 105a by the procedure in example 3, compound H
(stepA) to afford 390 mg (93%) of the product as diastereomers.
.sup.1H NMR (CD.sub.3OD) .delta. 7.58-7.22 (14H, m), 5.78-5.73
(0.5H, d), 5.64 (0.5H, s), 5.0-4.72 (4H, m), 4.54-4.42 (2H, m),
3.82-3.76 (0.5H, m), 3.68-3.62 (0.5H, m), 3.28-3.21 (0.5H, m),
3.19-3.12 (0.5H, m), 3.07-2.98 (2H, m), 2.78-2.48 (4H, m). The
resulting product was converted to 106a by the method described in
example 3, compound H (StepD) to afford the title compound as a
white solid (17%): H NMR (CD.sub.3OD) .delta. 7.54-6.98 (9H, m),
5.58-5.44 (1H, m), 4.8-4.2 (4H, m), 3.96-3.3 (2H, m), 3.30-3.05
(1H, m), 2.98-2.25 (5H, m).
[2-Oxo-5-(3-phenylpropionyl)-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrah-
ydrobenzo[b][1,4]diazepin-1-yl]acetic acid methyl ester (104b).
Anhydrous hydrogen chloride was bubbled into a solution of
(3(S)-tert-butoxycarbonylamino-2-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diaz-
epin-1-yl)acetic acid methyl ester (103, 1 g, 2.86 mmol) in 25 ml
of ethyl acetate for 2 minutes then stirred for 1 hour at room
temperature. The reaction was evaporated to give
2-oxo-3(S)-amino-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl
acetic acid methyl ester hydrochloride as a white solid. The
hydrochloride salt was suspended into 20 ml of dichloromethane and
cooled to 0.degree. C. Triethylamine (1.6 ml, 11.5 mmol) was added
to the suspension followed by the dropwise addition of
dihydrocinnamoyl chloride (0.9 ml, 6 mmol). The mixture was warmed
to room temperature and stirred for 18 hours. The mixture was
diluted with 25 ml of dichloromethane and washed twice with 50 ml
of water and once with 50 ml of brine. The organic layer was dried
over anhydrous sodium sulfate, filtered, and evaporated to give a
viscous, yellow oil that was purified by flash chromatography
eluting with 1:1 ethyl acetate/dichloromethane to afford 1.35 g
(92%) of the title product as a white solid. .sup.1H NMR
(CDCl.sub.3) .delta. 7.45-7.02 (14H, m), 6.37-6.32 (1H, d),
4.78-4.72 (1H, m), 4.52-4.3 (3H, m), 3.82-3.77 (1H, m), 3.74 (3H,
s), 3.03-2.87 (4H, m), 2.58-2.45 (2H, m), 2.45-2.35 (1H, m),
2.25-2.16 (1H, m).
[2-Oxo-5-(3-phenylpropionyl)-3-(3(S)-phenylpropionylamino)-2,3,4,5-tetrah-
ydrobenzo[b][1,4]diazepin-1-yl]acetic acid (105b).
[2-Oxo-5-(3-phenylpropionyl)-3-(3-phenylpropionylamino)-2,3,4,5-tetrahydr-
obenzo[b][1,4]diazepin-1-yl]acetic acid methyl ester (104b; 680 mg,
1.32 mmol) was hydrolyzed by the procedure in example 105a to
afford 645 mg (98%) of the title compound as a white solid. .sup.1H
NMR (CDCl.sub.3) .delta. 7.58 (1H, br. s), 7.5-7.42 (1H, m),
7.35-6.95 (14H, m), 4.95-4.88 (1H, m), 4.64-4.55 (1H, d), 4.54-4.45
(1H, t), 4.15-4.05 (1H, d), 3.75 (1H, m), 3.05-2.75 (4H, m),
2.58-2.45 (2H, m), 2.45-2.28 (1H, m), 2.25-2.14 (1H, m).
2-Oxo-3(S)-{2-[2-oxo-5-(3-phenylpropionyl)-3(S)-(3-phenyl-propionyl-amino-
)-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl]acetylamino}butyric
acid (106b).
[2-Oxo-5-(3-phenylpropionyl)-3-(3-phenylpropionylamino)-2,3,4,5-t-
etrahydrobenzo[b][1,4]diazepin-1-yl]acetic acid and
3-amino-4-oxobutyric acid tert-butylester semicarbazone were
coupled by the procedure in example 3, compound K (step A) to give
350 mg (85%) of a white solid. .sup.1H NMR (CDCl.sub.3) .delta.
9.05 (1H, br. s), 7.58-7.55 (1H, d), 7.5-7.35 (1H, m), 7.35-6.95
(14H, m), 6.75-6.72 (1H, d), 6.25 (1H, br. s), 5.25 (1H, br. s),
4.95-4.88 (1H, m), 4.8-4.72 (1H, m), 4.55-4.4 (2H, m), 3.92-3.88
(1H, d), 3.73-3.68 (1H, m), 2.95-2.8 (4H, m), 2.8-2.72 (1H, m),
2.62-2.55 (1H, m), 2.55-2.45 (2H, m), 2.4-2.32 (1H, m), 2.2-2.12
(1H, m), 1.45 (9H, s).
4-Oxo-3-{2-[2-oxo-5-(3-phenylpropionyl)-3-(3-phenyl-propionyl
-amino)-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl]-acetyl-amino}butyri-
c acid tert-butyl ester semicarbazone was deprotected as described
in example 3, compound K (step C) to give 118 mg (47%) of the title
compound as a white solid. .sup.1H NMR (CD.sub.3OD) .delta.
7.48-6.95 (14H, m), 4.65-4.15 (6H, m), 3.5-3.4 (1H, m), 2.85-2.72
(4H, m), 2.65-2.5 (1H, m), 2.5-2.34 (3H, m), 2.34-2.15 (2H, m).
[5-Benzyl-2-oxo-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydro
-benzo[b][1,4]diazepin-1-yl]acetic acid methyl ester (104c).
[2-Oxo-3-(3-phenylpropionylamino)-2,3,4,5-tetrahydrobenzo-[b][1,4]diazepi-
n-1-yl]acetic acid methyl ester (104a; 500 mg, 1.31 mmol), calcium
carbonate (155 mg, 1.58 mmol), and benzyl bromide (170 .mu.l, 1.44
mmol) were taken into 10 ml of dimethylformamide and heated to
80.degree. C. for 8 hours. The mixture was diluted with 150 ml of
ethyl acetate and washed 4 times with 50 ml of water. The organic
layer was dried over anhydrous sodium sulfate, filtered, and
evaporated to give a viscous, yellow oil that was purified by flash
chromatography eluting with dichloromethane/ethyl acetate (8:2) to
give 460 mg (75%) of the title compound as a white solid. .sup.1H
NMR (CDCl.sub.3) .delta. 7.34-7.05 (14H, m), 6.32-6.28 (1H, d),
4.84-4.76 (1H, d), 4.76-4.70 (1H, m), 4.43-4.37 (1H, d), 4.26-4.18
(1H, d), 4.06-4.00 (1H, d), 3.79 (3H, s), 3.45-3.37 (1H, m),
3.02-2.95 (1H, m), 2.90-2.82 (2H, m), 2.5-2.34 (2H, m).
[5-Benzyl-2-oxo-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydro
-benzo[b][1,4]diazepin-1-yl]acetic acid (105c) was prepared by the
hydrolysis of the ester (102c) by the procedure reported in example
105a to give 450 mg (98%) of the title compound as a white solid:
.sup.1H NMR (CD.sub.3OD) .delta. 7.5-7.05 (14H, m), 6.4 (1H, br.
s), 4.85-4.55 (2H, m), 4.5-4.21 (2H, m), 4.12-3.92 (1H, d),
3.45-3.3 (1H, m), 3.1-2.8 (3H, m), 2.55-2.28 (3H, m).
3(S)-{2-[5-Benzyl-2-oxo-3-(3(S)-phenylpropionylamino)-2,3,4,5-tetrahydrob-
enzo[b][1, 4]diazepin-1-yl]-acetylamino}-4-oxobutyric acid (106c).
[5-Benzyl-2-oxo-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydro-benzo[b[-
1,4]diazepin-1-yl]acetic acid and 3(S)-amino-4-oxobutyric acid
tert-butylester semicarbazone were coupled by the procedure in
example 3, compound K (step A) and to afford 260 mg (85%) of a
white solid: .sup.1H NMR (CD.sub.3OD) .delta. 7.35-7.0 (15H, m),
4.94-4.88 (1H, m), 4.68-4.58 (1H, d), 4.57-4.52 (1H, m), 4.41-4.34
(1H, d), 4.3-4.23 (1H, d), 4.1-4.04 (1H, d), 3.18-3.11 (1H, m),
3.09-2.98 (1H, m), 2.78-2.72 (2H, t), 2.65-2.57 (1H, m), 2.42-2.33
(3H, m).
3(S)-{2-[5-Benzyl-2-oxo-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydrob-
enzo[b][1,4]diazepin-1-yl]-acetylamino}-4-oxobutyric acid
tert-butyl ester semicarbazone was deprotected as described in
example 3, compound K (step C) to give 168 mg (81%) of the title
compound as a white solid. .sup.1H NMR (CD.sub.3OD) .delta.
7.37-7.0 (14H, m), 4.75-4.62 (1H, m), 4.6-4.45 (2H, m), 4.4-4.21
(2H, m), 4.15-3.95 (2H, m), 3.15-3.0 (2H, m), 2.82-2.67 (2H, m),
2.65-2.52 (1H, m), 2.5-2.32 (3H, m).
##STR00197##
2,6-Dichlorobenzoic acid
4-tert-butoxycarbonyl-2-oxo-3(S)-{2-[2-oxo-5-(3-phenylpropionyl)-3(S)-(3--
phenylpropionylamino)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]acetyl-
-amino}butyl ester (107a). The resulting semicarbazone was prepared
by the coupling of compound 105b and t-butyl
3-(allyloxycarbonylamino)-4-oxo-5-(2,6-dichlorobenzoyl-oxy)pentanoate
(WO 93 16710) as described in compound 56a to give 256 mg (58%) of
the title compound as a white solid. .sup.1H NMR (CDCl.sub.3)
.delta. 7.45-7.04 (17H, m), 6.45-6.34 (2H, m), 5.28-5.21 (1H, m),
5.1-5.0 (1H, m), 4.95-4.90 (1H, m), 4.75-4.70 (1H, m), 4.55-4.44
(1H, m), 4.32-4.22 (1H, dd), 3.99-3.85 (1H, dd), 3.85-3.76 (1H, m),
3.06-2.83 (5H, m), 2.83-2.74 (1H, m), 2.6-2.44 (2H, m), 2.43-2.33
(1H, m), 2.24-2.15 (1H, m), 1.45 (9H, s). 2,6-Dichlorobenzoic acid
4-carboxy-2-oxo-3(S)-{2-[2-oxo-5-(3-phenylpropionyl)-3(S)-(3-phenylpropio-
nylamino)-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl]acetylamino}butyl
ester (108a) was prepared from 107a by the method described for
compound 57a which afforded 156 mg (68%) of the title compound as a
white solid. .sup.1H NMR (CD.sub.3OD) .delta. 7.5-6.9 (17H, m),
5.16-5.02 (1H, dd), 4.88-4.71 (2H, m), 4.62-4.44 (2H, m), 4.42-4.28
(2H, m), 4.27-4.18 (1H, m), 3.47-3.41 (1H, m), 2.90-2.60 (5H, m),
2.46-2.4 (2H, m), 2.39-2.18 (2H, m).
4-(7-Methoxybenzoxazol-2-yl)-4-oxo-3(S)-{2-[2-oxo-5-(3-phenylpro-
pionyl)-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydrobenzo[b][1,4]diaze-
pin-1-yl]-acetylamino}butyric acid tert-butyl ester (107b).
4(R,S)-Hydroxy-4-(7-methoxybenzoxazol-2-yl)-3(S)-{2-[2-oxo-5-(3-phenylpro-
pionyl)-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydro[b][1,4]diazepin-1-
-yl-acetylamino}butyric acid tert-butyl ester was prepared from
105b and 66a by the method described in example 5, compound 67 to
give 560 of a white solid: .sup.1H NMR (CDCl.sub.3) .delta.
7.72-6.78 (19H, m), 6.37-6.28 (1H, m), 5.17-5.08 (0.5H, m),
4.92-4.82 (0.5H, m), 4.81-4.6 (1H, m), 4.6-4.35 ((3H, m), 4.05-3.9
(1H, m), 3.95 (3H, s), 3.82-3.7 (1H, m), 2.96-2.05 (10H, m), 1.45
(4.5H, s), 1.38 (4.5H, s). The resulting product was converted to
107b by the method described in example 5, compound 68a to give the
title compound (56%) as a white solid. .sup.1H NMR (CD.sub.3OD)
.delta. 7.62-6.8 (17H, m), 5.64-5.58 (0.5H, t), 5.52-5.46 (0.5H,
t), 4.62-4.47 (2H, m), 4.40-4.32 (1H, m), 3.9 (1.5H, s), 3.88
(1.5H, s), 3.43-3.37 (1H, m), 3.0-2.92 (1H, m), 2.90-2.62 (6H, m),
2.5-2.4 (2H, m), 2.28-2.15 (2H, m), 1.32 (4.5H, s), 1.25 (4.5H, s).
4-(7-Methoxybenzoxazol-2-yl)-4-oxo-3(S)-{2-[2-oxo-5-(3-phenylpropionyl)-3-
(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl]-
-acetylamino}butyric acid (108b) was prepared by the method
described in example 5, compound 69a to give the title compound
(50%) as a white solid. .sup.1H NMR (CD.sub.3OD) .delta. 7.41-6.88
(17H, m), 5.6-5.55 (0.5H, t), 5.48-5.43 (0.5H, t), 4.64-4.45 (2H,
m), 4.45-4.30 (1H, m), 3.93 (1.5H, s), 3.90 (1.5H, s), 3.47-3.34
(1H, m), 3.10-2.85 (2H, m), 2.84-2.63 (5H, m), 2.6-2.4 (2H, m),
2.3-2.1 (2H, m).
4-[5-(2,6-Dichlorophenyl)oxazol-2-yl]-4-oxo-3(S)-{2-[2-oxo-5-(3-phenylpro-
pionyl)-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydrobenzo[b][1,4]diaze-
pin-1-yl]-acetylamino}butyric acid tert-butyl ester (107c).
4-[5-(2,6-Dichlorophenyl)oxazol-2-yl]-4(R,S)-hydroxy-3(S)-{2-[2-oxo-5-(3--
phenylpropionyl)-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydrobenzo[b][-
1,4]diazepin-1-yl]-acetylamino}butyric acid tert-butyl ester was
prepared from 106c and 99 by a similar method as described for
compound 67a in example 5 to give 72% of a white solid. .sup.1H NMR
(CDCl.sub.3) .delta. 7.71-7.64 (1H, m), 7.58-7.42 (2H, m),
7.42-6.92 (15H, m), 6.5-6.37 (2H, m), 5.15-5.04 (1H, m), 4.88-4.68
(2H, m), 4.57-4.37 (2H, m), 4.28-4.13 (1H, m), 3.87-3.64 (2H, m),
3.04-2.80 (4H, m), 2.76-2.68 (1H, m), 2.67-2.42 (3H, m), 2.41-2.31
(1H, m), 2.22-2.12 (1H, m), 1.45 (9H, s). The resulting product was
converted to 107c by a similar method as described for compound 68a
in example 5 to give the title compound in quantitative yield as a
white solid. .sup.1H NMR (CDCl.sub.3) .delta. 7.47-6.98 (18H, m),
6.52-6.42 (1H, d), 5.6-5.52 (1H, m), 4.78-4.71 (1H, m), 4.52-4.40
(2H, m), 4.03-3.94 (0.67H, m), 3.94-3.85 (0.33H, m), 3.85-3.75 (1H,
m), 3.45-3.33 (1H, m), 3.08-2.98 (1H, m), 2.97-2.84 (4H, m),
2.55-2.43 (2H, m), 2.43-2.32 (1H, m), 2.23-2.13 (1H, m), 1.35 (9H,
s).
4-[5-(2,6-Dichlorophenyl)oxazol-2-yl]-4-oxo-3(S)-{2-[2-oxo-5-(3-pheny-
lpropionyl)-3(S)-(3-phenylpropionylamino)-2,3,4,5-tetrahydrobenzo[b][1,4]d-
iazepin-1-yl]-acetylamino}butyric acid (108c) was prepared from
107c by a similar method as described for compound 69a in example 5
to give 72% the title compound as a white solid. .sup.1H NMR
(CD.sub.3OD) .delta. 7.58-7.0 (18H, m), 5.62-5.53 (0.67H, m),
5.52-5.47 (0.33H, m), 4.68 (3H, m), 3.54-3.42 (1H, m), 3.1-2.92
(2H, m), 2.88-2.68 (5H, m), 2.63-2.45 (2H, m) 2.40-2.22 (2H,
m).
##STR00198##
3(S)-{2(R,S)-[4-Benzyl-7-oxo-6(S)-(N-benzyloxycarbonylamino)-[1,4]diazepa-
n-1-yl]-propionylamino}-4-oxo-butyric acid trifluoroacetic acid
salt (114a): Step A. To a solution of
tert-butyl-2-N-benzyloxycarbonyl-3-N-benzyl-(S)-2,3-diaminopropionate
(110; 0.85 g, 2.2 mmol),
3-(N-tert-butoxycarbonyl)amino-2-methyl-5-oxo-pentanoic acid methyl
ester (109a; 0.65 g, 2.7 mmol), acetic acid (0.1 mL, 1.8 mmol),
sodium acetate (0.36 g, 2 mmol) and 4 .ANG. molecular sieves (1 g)
in methanol (45 mL), was added sodium cyanoborohydride (0.33 g, 5.3
mmol). The mixture was stirred overnight at 25.degree. C. then
filtered through Celite and concentrated under reduced pressure.
The residue was dissolved in 1 N NaOH and extracted with ethyl
acetate (3.times.40 mL). The organic layer was dried (MgSO.sub.4),
filtered and evaporated to give an oil. Chromatography (silica-gel,
4:1 hexane:ethyl acetate as eluent) gave 0.92 g (68% yield) of 111a
as an oil. Step B. The above material was dissolved in
dichloromethane (3 mL) cooled to 0.degree. C. and treated with a
25% solution of trifluoroacetic acid in dichloromethane (20 mL)
then allowed to warm to 25.degree. C. and stir until the reaction
was judged complete by TLC (4:1 hexane:ethyl acetate). The solvent
was removed under reduced pressure and the residue dried under
vacuum then dissolved in dichloromethane (40 mL) and treated with
4-methylmorpholine (1 mL, 9 mmol), HOBT (0.2 g, 1.5 mmol) and EDC
(0.61 g, 3.2 mmol). The resulting mixture was stirred overnight at
25.degree. C. then diluted with dichloromethane and washed with
water. The organic layer was dried (MgSO.sub.4), filtered and
evaporated to give an oil. Chromatography (silica-gel, 3:2
hexane:ethyl acetate) gave 0.49 g (74% yield) of 112a as a viscous
oil. Step C. A solution of
2(R,S)-[4-benzyl-7-oxo-6(S)--(N-benzyloxycarbonylamino)-[1,4]diazepan-1-y-
l]-propionic acid methyl ester (112a; 0.15 g, 0.32 mmol) was
dissolved in methanol and treated with 1 M LiOH (0.32 mL) and
stirred 5.5 hours at 25.degree. C. then evaporated to dryness. The
residue was azeotroped with ethanol (2.times.10 mL), acetonitrile
(2.times.10 mL), benzene (2.times.10 mL) then dried under vacuum.
The resulting residue was converted to 114a by a method similar to
that described in example 3, compound K (steps A, B, and C) and
purified by reverse phase (C18 column) HPLC using 0.1%
TFA:water/0.1% TFA:acetonitrile as eluent. to give 17 mg (10%
yield) of a viscous oil: .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.
1.15 (m, 3H), 2.30-2.70 (m, 6H), 2.72-2.95 (bm, 6H), 3.30-3.80 (m,
4H), 4.10 (m, 1H), 4.40 (m, 4H), 4.95 (m, 1H) 6.95-7.10 (bs, 5H),
and 7.12-7.20 ppm (bs, 5H).
3(S)-{2-[4-Benzyl-7-oxo-6(S)--(N-benzyloxycarbonylamino)-[1,4]diazepan-1--
yl]-acetylamino}-4-oxo-butyric acid trifluoroacetic acid salt
(114b) was prepared from 109b by a similar method described for the
synthesis of 114a to give 85 mg of viscous oil: .sup.1H NMR (500
MHz, CD.sub.3OD) .delta. 1.20 (d, J=7 Hz, 3H), 2.28 (m, 2H), 2.60
(m, 2H), 3.18 (bs, 6H), 3.35-3.45 (m, 2H), 3.60-3.95 (m, 2H), 4.15
(m, 1 H), 4.32 (m, 1H), 4.42 (m, 1H), 5.00 (bm, 2H), 7.20 (bs, 5H),
and 7.40 ppm (bs, 5H); .sup.19F NMR (470 MHz, CD.sub.3OD) .delta.
-10.72 ppm (s, 3 F).
4-Oxo-3(S)-{2(R,S)-[7-oxo-4-(3-phenyl-propionyl)-6(S)-(3-phenyl-propionyl-
amino)-[1,4]diazepan-1-yl]-propionylamino}-butyric acid (115): Step
D. A suspension of
2(R,S)-[4-benzyl-7-oxo-6(S)-(N-benzyloxycarbonylamino)-[1,4]diazepan-1-yl-
]-propionic acid methyl ester (112b; 0.22 g, 0.49 mmol) and 20%
Pd(OH).sub.2 on carbon (50 mg) in ethanol was stirred under
hydrogen atmosphere for 7 hours. The solvent was evaporated under
reduced pressure and the residue dissolved in dichloromethane (20
mL) then treated with triethylamine (1 mL) and dihydrocinnamoyl
chloride (170 mg, 1 mmol). The resulting mixture was allowed to
stir overnight then diluted with ethyl acetate and washed with 1 N
NaOH. The organic layer was dried (MgSO.sub.4), filtered and
evaporated to give an oil. Chromatography (silica-gel, 4:1
hexane:ethyl acetate) gave 0.175 g (75% yield) of 113 as an oil.
Step C. A 0.15 g sample of 113 (0.32 mmol) was dissolved in
methanol, treated with 1 M LiOH (0.32 mL), stirred at 40.degree. C.
overnight then evaporated to dryness. The residue was azeotroped
with ethanol (2.times.10 mL), acetonitrile (2.times.10 mL), benzene
(2.times.10 mL) then dried under vacuum. The resulting residue was
converted to 115 by a method similar to that described in example
3, compound K (steps A, B, and C).
##STR00199##
3-{2-[2,4-Dibenzyl-3,7-dioxo-6-(N-benzyloxycarbonylamino)-[1,4]diazepan-1-
-yl]-acetylamino}-4-oxo-butyric acid (121): Step E. A solution of
tert-butyl-2-N-carbobenzoxy-3-N-benzyl-(S)-2,3-diaminopropionate
(110; 1.77 g, 4.6 mmol),
N-allyl-N-tert-butoxycarbonyl-(S)-phenylalanine (116; 1.04 g, 4.8
mmol), HOBT (0.74 g, 5.5 mmol) and EDC (1.33 g, 6.9 mmol) in
dichloromethane (50 mL) was allowed to stir at 25.degree. C. for 16
h then diluted with dichloromethane (100 mL) and washed with water.
The organic layer was dried (MgSO.sub.4), filtered and evaporated
to give an oil. Chromatography (silica-gel, 85:15 hexane:ethyl
acetate) gave 1.34 g (43% yield) of 117 as a colorless viscous oil.
Step F. A 1.34 g sample of 117 was dissolved in dichloromethane (3
mL) and treated with a 50% solution of trifluoroacetic acid in
dichloromethane (20 mL). After 1.5 h, the solvent was removed under
reduced pressure and the residue dried under vacuum then dissolved
in dichloromethane (50 mL) and combined with 4-methylmorpholine
(0.2 mL, 2 mmol), HOBT (0.27 g, 2 mmol) and EDC (0.8 g, 4 mmol).
The mixture was stirred overnight at 25.degree. C. then diluted
with dichloromethane and washed with water. The organic layer was
dried (MgSO.sub.4), filtered and evaporated to give an oil.
Chromatography (silica-gel, 7:3 hexane:ethyl acetate) gave 0.8 g
(80% yield) of 118 as a viscous oil. Step G. A 0.8 g sample of 118
was dissolved in methanol (40 mL), cooled to -78.degree. C. and
saturated with ozone until the solution was blue in color. The
excess ozone was removed by purging with argon then dimethylsulfide
(5 mL) was added and the mixture allowed to warm to 25.degree. C.
and stir 3 h. Solvent removal and chromatography (silica-gel, 1:1
hexane:ethyl acetate) gave 0.74 g (74% yield) of 119 as a white
solid. Step H. A 0.2 g sample (0.4 mmol) of 119 was dissolved in
acetone (25 mL), cooled to 0.degree. C. and treated dropwise with a
solution of Jones reagent until the orange color persisted.
2-Propanol (5 mL) was then added to the mixture and the resulting
solution filtered through Celite and washed with acetone. Solvent
removal gave a green-white solid that was dried under vacuum to
give 120. The resulting residue was converted to 121 by a method
similar to that described in example 3, compound K (steps A, B, and
C). Chromatography (SiO.sub.2, 95:4.5: 0.5 dicholormethane:
methanol: acetic acid eluent) gave 85 mg (53% yield) of cream
colored solid which was identified as
3-{2-[2,4-d]benzyl-3,7-dioxo-6-(N-benzyloxycarbonylamino)-[1,4]diazepan-1-
-yl-acetylamino}-4-oxo-butyric acid (121) on the basis of the
following spectral data: .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.
2.38 (m, 1H), 2.45 (m, 1H), 3.21 (bs, 2H), 3.32-3.39 (bm, 6H), 3.85
(m, 1H), 4.05 (m, 1H), 4.21 (bm, 1H), 4.31 (bs, 1H), 4.45 (dm, J=11
Hz, 1H), 4.95 (bs, 4H), 7.20 (bs, 5H), and 7.33-7.45 ppm (m, 5H);
.sup.19F NMR (470 MHz, CD.sub.3OD) d-10.62 ppm (s, 3 F).
##STR00200##
t-Butyl
(3S)N-(allyloxycarbonyl)-3-amino-5-(2-chlorophenylmethylthio)-4-o-
xo-pentanoate (123). Potassium fluoride (273 mg, 4.70 mmol) and
then 2-chlorophenylmethyl thiol (373 mg, 2.35 mmol) were added to a
stirred solution of (3S)t-butyl
N-(allyloxycarbonyl)-3-amino-5-bromo-4-oxo-pentanoate (122; 749 mg,
2.14 mmol; WO 93 16710) in dimethylformamide (20 ml). The mixture
was stirred for 3.5 h, quenched with water (50 ml) and extracted
with ethyl acetate (2.times.50 ml). The combined organic extracts
were washed with water (4.times.50 ml) then brine (50 ml). They
were dried (MgSO.sub.4) and concentrated to afford an oil which was
purified by flash chromatography (10-35% ethyl acetate/hexane) to
afford 832 mg (91%) of a colourless solid: mp. 45-6.degree. C.;
[.alpha.].sub.D.sup.20-19.0.degree. (c 1.0, CH.sub.2Cl.sub.2); IR
(film) 3340, 2980, 2935, 1725, 1712, 1511, 1503, 1474, 1446, 1421,
1393, 1368, 1281, 1244, 1157, 1052, 1040, 995, 764, 739; .sup.1H
NMR (CDCl.sub.3) .delta. 7.36 (2H, m), 7.21 (2H, m), 5.91 (2H, m),
5.27 (2H, m), 4.76 (1H, m), 4.59 (2H, d), 3.78 (2H, s), 3.36 (2H,
m), 2.91 (1H, dd), 2.74 (1H, dd), 1.43 (9H, s). Anal. Calcd for
C.sub.20H.sub.26ClNO.sub.5S: C, 56.13; H, 6.12; N, 3.27; S, 7.49.
Found: C, 56.08; H, 6.11; N, 3.26; S, 7.54. MS (C.I.) 430/28
(M.sup.++1, 3%), 374/2 (100). t-Butyl
(3S)3(2(6-benzyl-1,2-dihydro-2-oxo-3(3-phenylpropionylamino)-1-pyridyl)ac-
etylamino-5-(2-chlorophenylmethylthio)-4-oxopentanoate (124a).
6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionylamino)-pyridyl
acetic acid (52b; 300 mg, 0.76 mmol) in THF (7 ml) was stirred with
1-hydroxybenzotriazole (205 mg, 1.52 mmol) and
1-(3-dimethylaminopropy-3-ethylcarbodiimide hydrochloride). After 3
min, water (12 drops) was added and the mixture stirred 10 min then
treated with t-butyl
(3S)N-(allyloxycarbonyl)-3-amino-5-(2-chlorophenylmethylthio)-4-oxopentan-
oate (123) (325 mg, 0.76 mmol), bis(triphenylphosphine) palladium
II chloride (20 mg) and tributyltin hydride (0.6 ml, 2.28 mmol).
The mixture was stirred for 5 h at room temperature, poured into
ethyl acetate and washed with aqueous 1M HCl (.times.2), aqueous
sodium bicarbonate, brine, dried (MgSO.sub.4) and concentrated. The
residue was triturated with pentane and the supernatant discarded.
Chromatography (silica gel, 50% ethyl acetate/hexane) afforded a
colourless foam (439 mg, 81%): [.alpha.].sub.D.sup.21-18.3.degree.
(c 0.5, CH.sub.2Cl.sub.2); IR (KBr) 3356, 3311, 1722, 1689, 1646,
1599, 1567, 1513, 1367, 1154; .sup.1H NMR (CDCl.sub.3) .delta. 8.39
(1H, d), 8.23 (1H, s), 7.24 (14H, m), 6.16 (1H, d), 4.95 (1H, m),
4.63 (2H, m), 4.02 (2H, s), 3.74 (2H, s), 3.27 (2H, s), 2.85 (6H,
m), 1.40 (9H, s). Anal. Calcd for
C.sub.39H.sub.42ClN.sub.3O.sub.6S: C, 65.39; H, 5.91; N, 5.87.
Found: C, 65.51; H, 5.99; N, 5.77.
t-Butyl[3S(1S,9S)]-3-(6,10-dioxo-1,2,3,4,7,8,9,10-octahydro)-9-(3-phenylp-
ropionylamino)-6H-pyridazine[1,2-a][1,2]diazepine-1-carboxamido-5-(2-chlor-
ophenylmethylthio)-4-oxopentanoate (124b) was prepared by a similar
method as 124a from the thioether 123 and
3S(1S,9S)-3-(6,10-dioxo-1,2,3,4,7,8,9,10-octahydro)-9-(3-phenylpropionyla-
mino)-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid (45a) to
afford 452 mg (50%) of colourless foam: mp 55-7.degree. C.;
[.alpha.].sub.D.sup.22-94.0.degree. (c 0.12,
CH.sub.2Cl.sub.2);.sub.IR (KBr) 3288, 2934, 1741, 1722, 1686, 1666,
1644, 1523, 1433, 1260, 1225, 1146, 757; .sup.1H NMR (CDCl.sub.3)
.delta. 7.35 (3H, m), 7.20 (7H, m), 6.46 (1H, d), 5.21 (1H, m),
4.97 (2H, m), 4.56 (1H, m), 3.75 (2H, s), 3.25 (3H, m), 2.93 (5H,
m), 2.71 (1H, dd), 2.55 (2H, m), 2.30 (1H, m), 1.92 (3H, m), 1.66
(2H, m), 1.42 (9H, s). Anal. Calcd for
C.sub.35H.sub.43ClN.sub.4O.sub.7S. 0.25H.sub.2O: C, 59.73; H, 6.23;
Cl, 5.04; N, 7.96; S, 4.56. Found: C, 59.73; H, 6.19; Cl, 5.10; N,
7.79; S, 4.58. MS (-FAB) 697 (M-1, 100).
(3S)3(2(6-Benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionylamino)-1-pyridyl)a-
cetylamino-5-(2-chlorphenylmethylthio)-4-oxopentanoic acid (125a).
t-Butyl-3(2(6-benzyl-1,2-dihydro-2-oxo-3-(3-phenylpropionylamino)-1-pyrid-
yl)acetyl-amino-5-(2-chlorophenylmethylthio)-4-oxopentanoate (124a)
(400 mg, 0.56 mmol) in dichloromethane (3 ml) at 0.degree. C. was
treated with trifluoroacetic acid (3 ml) and stirred at 0.degree.
C. for 1 h and room temperature for 0.5 h. The solution was
concentrated then redissolved in dichloromethane and
reconcentrated. This procedure was repeated three times. The
residue was stirred in ether for 1 hr and filtered to yield a
colourless solid (364 mg, 99%): mp. 165-7.degree. C.;
[.alpha.].sub.D.sup.22-27.7.degree. (c 0.2, CH.sub.2Cl.sub.2); IR
(KBr) 3289, 1712, 1682, 1657, 1645, 1593, 1562, 1527, 1497, 1416,
1203, 1182; .sup.1H NMR (CDCl.sub.3) d 8.47 (1H, d), 8.21 (1H, s),
7.70 (1H, d), 7.22 (14H, m), 6.24 (1H, d), 5.03 (1H, m), 4.65 (2H,
m), 4.06 (2H, s), 3.69 (2H, m), 3.23 (2H, m), 2.88 (6H, m).
[0922]
[3S(1S,9S)]-3-(6,10-dioxo-1,2,3,4,7,8,9,10-octahydro)-9-(3-phenylpr-
opionyl-amino)-6H-pyridazine[1,2-a][1,2]diazepine-1-carboxamido-5-(2-chlor-
ophenyl-methylthio)-4-oxopentanoic acid (125b), was prepared by a
similar method as 125a from the t-butyl ester 124b to afford 362 mg
(93%) of colourless powder: mp 76-80.degree. C.;
[.alpha.].sub.D.sup.21-134.degree. (c 0.10, MeOH); IR (KBr) 3309,
2935, 1725, 1658, 1528, 1445, 1417, 1277, 1219, 1175; .sup.1H NMR
(D.sub.6-DMSO) .delta. 8.80 (1H, d), 8.19 (1H, d), 7.31 (9H, m),
5.09 (1H, m), 4.74 (1H, m), 4.63 (1H, m), 4.35 (1H, m), 3.76 (2H,
m), 3.28 (3H, m), 2.80 (5H, m), 2.52 (4H, m), 2.16 (2H, m), 1.90
(3H, m). Anal. Calcd for C.sub.31H.sub.35Cl.sub.2N.sub.4O.sub.7S.
0.25H.sub.2O: C, 57.49; H, 5.53; N, 8.65; S, 4.95. Found: C, 57.35;
H, 5.43; N, 8.45; S, 4.88. MS (-FAB) 641 (M-1, 100).
[0923] The data of the examples above demonstrate that compounds
according to this invention display inhibitory activity towards
IL-1.beta. Converting Enzyme.
[0924] Insofar as the compounds of this invention are able to
inhibit ICE in vitro and furthermore, may be delivered orally to
mammals, they are of evident clinical utility for the treatment of
IL-1 mediated diseases. These tests are predictive of the compounds
ability to inhibit ICE in vivo.
[0925] While we have described a number of embodiments of this
invention, it is apparent that our basic con-structions may be
altered to provide other embodiments which utilize the products and
processes of this inven-tion. Therefore, it will be appreciated
that the scope of this invention is to be defined by the appended
claims, rather than by the specific embodiments which have been
presented by way of example.
* * * * *